<?xml version='1.0' encoding='UTF-8' ?><Trials_downloaded_from_ICTRP>
  <Trial>
    <Internal_Number>2452965</Internal_Number>
    <TrialID>EUCTR2004-001298-24-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis</Public_title>
    <Scientific_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd</Primary_sponsor>
    <Date_registration3>20040628</Date_registration3>
    <Date_registration>28/06/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001298-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/07/2004</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Baseline predialysis (for HD patients) Hb concentration 8-11 g/dL determined from the mean of 2 screening values with at least one day between measurements&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous therapy with recombinant human erythropoetin or any other erythropoeitc substance within 12 weeks prior to screening. If epoetin treatment has been interrupted for at least 12 weeks, the patient may be enrolled in the study. Ongoing epoetin treatment should not be discontinued to allow participation in the trial.&lt;br&gt;</Exclusion_Criteria>
    <Condition>anemia in chronic kidney patients who are in dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: cera&lt;br&gt;Product Code: RO 0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Neorecormon&lt;br&gt;Product Name: Neorecormon&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50000-&lt;br&gt;INN or Proposed INN: epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate the efficay of IV RO 0503821;Secondary Objective: - To asses time to response&lt;br&gt;- To asses the safety and tolerability of multiple doses of RO 0503821 during the correction and extension periods in this patient population&lt;br&gt;- To asses long term safety with RO 0503821 in this patient population&lt;br&gt;- To investigate the farmachokinetics and the concentration-effect relationships after IV administration of RO 0503821 in this patient population;Primary end point(s): To demonstrate the efficay of IV RO 0503821 treatment for correction of anemia in patients with kidney chronic disease who are on dialysis</Primary_outcome>
    <Secondary_ID>BA16736</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453174</Internal_Number>
    <TrialID>EUCTR2004-002160-22-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431
Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients With Type 2 DM and Chronic Renal Insufficiency</Public_title>
    <Scientific_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431
Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients With Type 2 DM and Chronic Renal Insufficiency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Merck &amp; Co., Inc.</Primary_sponsor>
    <Date_registration3>20041012</Date_registration3>
    <Date_registration>12/10/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002160-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/11/2004</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a.	Patient has type 2 diabetes mellitus (T2DM). &lt;br&gt;b.	Patient has moderate, severe, or end-stage renal insufficiency as indicated by a ‘yes’ answer to one or more of the following :&lt;br&gt;1)	Creatinine clearance =30 to &lt; 50 mL/min&lt;br&gt;2)	Creatinine clearance &lt; 30 mL/min&lt;br&gt;3)	Patient receiving dialysis&lt;br&gt;c.	Patient is =18 years of age.&lt;br&gt;d.	Patient has an understanding of the study procedures and agrees to participate in the study by giving written informed consent.&lt;br&gt;e.	Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period.&lt;br&gt;f.	Patient is a male, or a female who is highly unlikely to conceive.&lt;br&gt;g.	HbA1c =6.5% and =10% measured at, or within 2 weeks prior to, Visit 3.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a.	Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis&lt;br&gt;b.	Patient has an ALT or AST &gt;2.0-fold the Upper Limit of Normal (ULN)&lt;br&gt;c.	Patient has acute or rapidly progressive renal disease, or a history of renal transplant.&lt;br&gt;d.	Patient has any of the following disorders within the past 6 months: &lt;br&gt;•	Acute coronary syndrome (e.g., MI or unstable angina).&lt;br&gt;•	Coronary artery intervention (e.g., CABG or PTCA).&lt;br&gt;•	Worsening congestive heart failure (e.g., worsening symptoms or increase in pharmacologic therapy).&lt;br&gt;•	Stroke or transient ischemic neurological disorder.&lt;br&gt;e.	Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months.&lt;br&gt;f.	Patient has a BMI &lt;20 kg/m2 or &gt;43 kg/m2&lt;br&gt;g.	Patient has a positive urine pregnancy test&lt;br&gt;h.	Patient has any other condition or therapy which, in the opinion of the investigator or Merck medical monitor, might pose a risk to the patient or make participation not in the patient’s best interest.&lt;br&gt;i.	Patient has poor mental function or any other reason to expect that the patient may have difficulty in complying with the requirements of the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Type 2 Diabetes Mellitus

Chronic Renal Insufficiency [MedDRA classification code:  10050441] &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10045242
</Condition>
    <Intervention>&lt;br&gt;Product Name: MK-0431   25-mg Tablet&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Current Sponsor code: MK-0431&lt;br&gt;Other descriptive name: L-000224715&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Glibinese [Glipizide 5-mg scored tablets]&lt;br&gt;Product Name: Glibinese 5-mg scored tablets&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: glipizide&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: In patients with type 2 diabetes mellitus and chronic renal insufficiency with inadequate glycemic control&lt;br&gt;&lt;br&gt;Primary:  To assess the safety and tolerability of MK-0431 after 12 weeks.&lt;br&gt;;Secondary Objective: In patients with type 2 diabetes mellitus and chronic renal insufficiency with inadequate glycemic control&lt;br&gt;&lt;br&gt;To assess the safety and tolerability of MK-0431 over 54 weeks.;Primary end point(s): N/A</Primary_outcome>
    <Secondary_ID>0431-028</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453243</Internal_Number>
    <TrialID>EUCTR2004-000587-26-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids versus Cellcept combined with full-dose Neoral and steroids, in de novo adult renal transplant recipients.</Public_title>
    <Scientific_title>A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids versus Cellcept combined with full-dose Neoral and steroids, in de novo adult renal transplant recipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20041110</Date_registration3>
    <Date_registration>10/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000587-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/02/2005</Date_enrollement>
    <Target_size>690</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Partially double blinded, partially open&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a)	The patient has given written informed consent to participate in the extension study.&lt;br&gt;b)	The patient has completed the core study (through 12 months post-transplantation, either being maintained on study medication or having attended the Follow-up visits up to Month 12 after being discontinued from study medication).  &lt;br&gt;c)	Females capable of becoming pregnant are required to practice a medically approved method of birth control as long as they are on study medication and for a period of 3 months following discontinuation of study medication.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients with any medical or psychosocial condition which the investigator believes would hinder compliance with the study requirements.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prophylaxis of kidney allograft rejection in de novo adult renal transplant recipients &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Product Name: FTY720&lt;br&gt;Product Code: FTY720&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: Mycophenolate Mofetil&lt;br&gt;Product Code: RS-61443&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Neoral&lt;br&gt;Product Name: Ciclosporin for microemulsion&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this extension is to assess long-term safety and efficacy data of two doses of FTY720 (2.5 or 5.0 mg) combined with full dose Neoral and steroids versus MMF combined with full dose Neoral and steroids in de novo adult renal transplant recipients beyond 12 months post-transplantation.;Secondary Objective: To provide continued treatment for patients who have completed the 12-month core study on study medication.;Primary end point(s): Biopsy-proven acute rejection, graft loss, death or discontinuation from study</Primary_outcome>
    <Secondary_ID>CFTY720A2218E1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453302</Internal_Number>
    <TrialID>EUCTR2004-004416-22-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatment</Public_title>
    <Scientific_title>Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Karolinska Institutet, Dept of Medicine, Clinical Pharmacology Unit</Primary_sponsor>
    <Date_registration3>20041206</Date_registration3>
    <Date_registration>06/12/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004416-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/01/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Diabetes mellitus type 2&lt;br&gt;&lt;br&gt;With or without established microalbuminuria (urinary albumin excretion of 30-299 µg/mg creatinine in a spot sample) Two out of three specimens collected within a 3-6 month period should be abnormal before the diagnosis can be settled. &lt;br&gt;&lt;br&gt;Glomerular filtration rate (GFR) between 15-50 ml/min (measured the last 6 months) or GFR &gt;75ml/min. GFR will be established by 24-hour Iohexolclearence.&lt;br&gt;&lt;br&gt;Age 18-80 years&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Definite history of myocardial infarction, coronary revascularisation procedure or stroke. (i.e, a strong clinical indication for statin treatment) &lt;br&gt;&lt;br&gt;Functioning renal transplant, or living donor-related transplant planned.&lt;br&gt;&lt;br&gt;Patients on dialysis.&lt;br&gt;&lt;br&gt;Poor metabolic control, i.e HbA1c &gt; 9%&lt;br&gt;&lt;br&gt;Definite history of chronic liver disease, or abnormal liver function (i.e ALT &gt;1,5 x ULN or, if ALT not available, AST &gt; 1,5 x ULN). &lt;br&gt;&lt;br&gt;Evidence of active inflammatory muscle disease (e.g dermatomyositis, polymyositis), or CK&gt;3 x ULN&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to a statin or to ezetimibe&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to acetylsalicylic acid.&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to an ACE-inhibitor.&lt;br&gt;&lt;br&gt;Need for concomitant treatment with a strong inhibitor of CYP3A4, such as itrokonazole, ketokonazole, erythromycin, clarithromycin, HIV-protease inhibitors or nefazodone (i.e. agents that may markedly elevate simvastatin levels).&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diabetes mellitus type 2, without or with renal impairment
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zocord  R&lt;br&gt;Product Name: Zocord  R&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Simvastatin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 40-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Ezetrol&lt;br&gt;Product Name: Ezetrol  R&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: ezetimibe&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the effects of simvastatin + ezetimibe with those of simvastatin alone, on thrombogenic mechanisms, in patients with diabetes mellitus type 2.;Secondary Objective: a) Compare the effects of simvastatin alone with those of placebo (baseline data) on thrombogenic mechanisms&lt;br&gt;b) Compare the effects of simvastatin + ezetimibe with those of simvastatin alone, and simvastatin alone with placebo on inflammatory variables.&lt;br&gt;c) Assess how the treatment effects relate to renal function.  &lt;br&gt;;Primary end point(s): ADP stimulated platelet P-selectin expression (flow cytometry in whole blood).&lt;br&gt;Other flow cytometric platelet variables related to the primary end point are (a) circulating platelet-platelet aggregates, (b) circulating platelet-leukocyte aggregates, (c) single platelet counts.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DMK001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453351</Internal_Number>
    <TrialID>EUCTR2004-002032-26-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia</Public_title>
    <Scientific_title>An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd.</Primary_sponsor>
    <Date_registration3>20041112</Date_registration3>
    <Date_registration>12/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002032-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/12/2004</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Aranesp, NeoRecormon&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	1.	Written informed consent&lt;br&gt;2.	Adult patients (equal or more than 18 years old) with chronic renal anemia&lt;br&gt;3.	Continuous maintenance erythropoietic therapy with RO0503821 or a protocol-specified reference medication (epoetin alfa formulated with human albumin,  epoetin beta or darbepoetin alfa) in one of the following studies: BA16528, BA16285, BA16286, BA16736, BA16738, BA16739, BA16740, BA17283 and BA17284&lt;br&gt;4.	Hemoglobin concentration between 10.5 and 13.0 g/dL &lt;br&gt;5.	Adequate iron status defined as serum ferritin equal or more than 100 ng/mL or TSAT equal or more than 20% (or percentage of hypochromic RBCs &lt; 10%)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;6.	Poorly controlled hypertension necessitating interruption of erythropoietin treatment in the 6 months before screening&lt;br&gt;7.	Epileptic seizure in the  6 months before screening&lt;br&gt;8.	Platelets  &gt; 500 x 10 9/L&lt;br&gt;9.	Pure red cell aplasia &lt;br&gt;10.	Chronic congestive heart failure (New York Heart Association Class IV)&lt;br&gt;11.	High likelihood of early withdrawal or interruption of the study (e.g., myocardial infarction, severe or unstable coronary artery disease, stroke, severe liver disease within the 12 weeks before screening)&lt;br&gt;12.	Active malignant disease (except non-melanoma skin cancer)&lt;br&gt;13.	Life expectancy less than 12 months&lt;br&gt;14.	Pregnancy or breast-feeding&lt;br&gt;15.	Women of childbearing potential without effective contraception&lt;br&gt;16.	Administration of another investigational drug planned during the study period&lt;br&gt;17.	Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study or reference drug  formulations&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient with chronic renal anaemia</Condition>
    <Intervention>&lt;br&gt;Product Name: N/A&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: NeoRecormon&lt;br&gt;Product Name: NeoRecormon &lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50.000-&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100.000-&lt;br&gt;&lt;br&gt;Trade Name: Aranesp&lt;br&gt;Product Name: Aranesp&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;INN or Proposed INN: Da</Intervention>
    <Primary_outcome>Main Objective: To document that RO0503821 administered for prolonged periods is efficacious, safe and well tolerated in patients treated for  chronic renal anemia;Secondary Objective: N/A;Primary end point(s): Analysis of Efficacy&lt;br&gt;No formal efficacy assessment will be performed. Efficacy parameters such as hemoglobin will be reported descriptively using means, standard deviations and percentiles.&lt;br&gt;&lt;br&gt;Analysis of Safety &lt;br&gt;All patients who have received at least one dose of RO0503821 or of reference medication and a safety follow-up, whether withdrawn prematurely or not, will be included in the safety analysis. The safety parameters will be vital signs, AEs and the safety laboratory parameters. &lt;br&gt;All safety parameters will be summarized descriptively. Vital signs and laboratory data will be assessed for clinically relevant abnormalities.&lt;br&gt;Frequencies and incidence rates of AEs will be tabulated.  The goal of the statistical evaluation of AE data is a standardized tabulation of the frequencies and incidence rates of all observed AEs. These will be calculated on a per-patient basis rather than on an event basis. &lt;br&gt;Brief narratives will describe each death, each drug related SAE, premature withdrawals arising from AEs, and other significant AEs that are judged to be of special interest because of clinical importance. &lt;br&gt;All safety parameters will be summarized descriptively. Vital signs and laboratory data will be assessed for clinically relevant abnormalities.</Primary_outcome>
    <Secondary_ID>BH 18387</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453504</Internal_Number>
    <TrialID>EUCTR2004-002310-10-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism - SENSOR</Public_title>
    <Scientific_title>Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism - SENSOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Amgen Development Europe</Primary_sponsor>
    <Date_registration3>20041110</Date_registration3>
    <Date_registration>10/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002310-10                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/11/2004</Date_enrollement>
    <Target_size>800</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- CKD patients requiring dialysis (HD, HDF, HF) for at least 1 month before enrolment&lt;br&gt;- Males or females = 18 years of age at the time of informed consent. &lt;br&gt;- Men and women participating in this study must agree to use, in the opinion of the principal investigator, highly effective contraceptive measures throughout the study.  Females must have a negative serum pregnancy test (or definitive evidence to demonstrate lack of pregnancy) within 30 days before randomisation, unless there is a definite history of amenorrhoea.&lt;br&gt;- An iPTH determination within 14 days before randomisation must be = 300 pg/mL (biPTH = 150 pg/mL).  &lt;br&gt;- A serum calcium determination (corrected for calcium) within 14 days before randomisation must be = 8.4 mg/dL [2.1 mmol/L].  &lt;br&gt;- Signed the Independent Ethics Committee (IEC) approved Informed Consent document, before any study specific procedures are initiated &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Have an unstable medical condition, defined as having been hospitalised, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator.&lt;br&gt;- Are currently breast-feeding.&lt;br&gt;- Are performing peritoneal dialysis&lt;br&gt;- Have had a parathyroidectomy in the 3 months before day 1.&lt;br&gt;- Are currently enrolled in, or have not yet completed at least 30 days before day 1 other invasive investigational device or investigational drug trials, or are receiving other investigational agents (experimental dialysis machines are acceptable).&lt;br&gt;- Have a gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets.&lt;br&gt;- Have a disorder that would interfere with understanding and giving informed consent or compliance with protocol requirements&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 90-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.;Secondary Objective: To evaluate the safety of cinacalcet when co-administered with the first major meal after dialysis.&lt;br&gt;To evaluate a predefined strategy to manage nausea/vomiting during the study&lt;br&gt;;Primary end point(s): The proportion of subjects with a mean iPTH £ 300 pg/mL at weeks 11 and 13</Primary_outcome>
    <Secondary_ID>20040143</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453669</Internal_Number>
    <TrialID>EUCTR2004-004488-31-NO</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does cyclosporine A reduce the insulin secretion from the pancreas?</Public_title>
    <Scientific_title>Does cyclosporine A reduce the insulin secretion from the pancreas?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Rikshospitalet University Hospital, University of Oslo</Primary_sponsor>
    <Date_registration3>20050201</Date_registration3>
    <Date_registration>01/02/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004488-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement />
    <Target_size>16</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;Other trial design description: Therapy followed by wash out&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Dialysis patients planned to be kidney transplanted and not treated with steroids&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Age above 75 years or below 18 years&lt;br&gt;Pregnancy&lt;br&gt;Lactating mothers&lt;br&gt;Diabetes mellitus&lt;br&gt;Less than 2 months of dilayses&lt;br&gt;Coronary heart disease&lt;br&gt;Ongoing corticosteroid treatment&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney failure / dialysis patients / transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sandimmun Neoral&lt;br&gt;Product Name: Sandimmun Neoral&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Current Sponsor code: NOVARTIS&lt;br&gt;Other descriptive name: Sandimmun Neoral&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Other descriptive name: cyclosporine A&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Test the effect of cyclosporine A on insulin release;Secondary Objective: Test the effect of cyclosporine A on insulin action, endothelial function. Test the useage of pretransplant cyclosporine A pharmacokinetics detrminations for dose individualisation at the time of transplantation;Primary end point(s): Change in insulin secretion&lt;br&gt;</Primary_outcome>
    <Secondary_ID>S-02005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453918</Internal_Number>
    <TrialID>EUCTR2004-001608-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease</Public_title>
    <Scientific_title>A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Shire Pharmaceutical Development Ltd</Primary_sponsor>
    <Date_registration3>20050303</Date_registration3>
    <Date_registration>03/03/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001608-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/11/2004</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female patients greater than or equal to 18 years of age receiving haemodialysis for end stage renal disease with a level of serum phosphate&gt;5.9mg/dL (1.9mmol/L) after washout or sub-optimally treated with current phosphate binder. Patients (including those who have undergone renal transplantation in the past) must have received haemodialysis for chronic renal failure three times per week for at least the previous two months. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnant or lactating women. Patients with screening calcium below 8.8mg/dL (2.2mmol/L) or with significant abnormal laboratory values (excluding markers of pathologies associated with chronic renal failure), which in the opinion of the investigator should exclude the patient from the study. Patients with clinically significant uncontrolled concurrent illness a life threatening malignancy or current multiple myeloma or known to be HIV positive. Patients with any significant bowel obstruction, active inflammatory disease, gastrointestinal (GI) motility disorders, abnormal or irregular bowel motion or a history of major GI surgery within the last 6 mnths. Patients who have been in any other clinical trial within the last 30 days or who have previously taken lanthanum carbonate in the last year. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in Patients Receiving Haemodialysis for End Stage Renal Disease</Condition>
    <Intervention>&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Renagel 800mg Film Coated Tablets &lt;br&gt;Product Name: Renagel &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sevelamer &lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess phosphate reduction and control (3.5-5.5mg/dL [1.1-1.8mmol/L]) in patients with End Stage Renal Disease (ESRD) following administration of lanthanum carbonate or sevelamer hydrochloride;Secondary Objective: To assess: &lt;br&gt;The effects of lanthanum carbonate and sevelamer hydrochloride on serum calcium and calcium phosphate product levels&lt;br&gt;The percentage of patients achieving a reduction in serum calcium-phosphate product to less than or equal to 4.4 (mmol/L)2 (54.56mg2/dL2) following administration of lanthanum carbonate or sevelamer hydrochloride&lt;br&gt;Average daily pill burden, dose levels and compliance&lt;br&gt;The safety and tolerability of lanthanum carbonate&lt;br&gt;Patient satisfaction with treatment ;Primary end point(s): Serum phosphate reduction and control rate (defined as 3.5-5.5mg/dL [1.1-1.8 mmol/L])</Primary_outcome>
    <Secondary_ID>SPD405-310</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454519</Internal_Number>
    <TrialID>EUCTR2005-000087-12-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, en fase IV, para comparar los efectos renales del medio de contraste no iónico isosmolar, iodixanol 320 mg I/ml (VisipaqueTM), con el medio de contraste no iónico de baja osmolaridad, iopamidol 300 mg I/ml, en sujetos con insuficiencia renal y diabetes mellitus sometidos a TC helicoidal multidetector.</Public_title>
    <Scientific_title>Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, en fase IV, para comparar los efectos renales del medio de contraste no iónico isosmolar, iodixanol 320 mg I/ml (VisipaqueTM), con el medio de contraste no iónico de baja osmolaridad, iopamidol 300 mg I/ml, en sujetos con insuficiencia renal y diabetes mellitus sometidos a TC helicoidal multidetector.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Amersham Health S.A. (parte de GE Healthcare Ltd y sus filiales)</Primary_sponsor>
    <Date_registration3>20050608</Date_registration3>
    <Date_registration>08/06/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000087-12                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/08/2005</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.) The subject is at least 18 years old.&lt;br&gt;2.) The subject has diabetes mellitus (type I or II), treated with insulin or oral antidiabetic agents for at least 1 year.&lt;br&gt;3.) The subject has a pre-study serum creatinine = 1.7 mg/dl (150 µmol/l) if a man, or = 1.5 mg/dl (133 µmol/l) if a woman,&lt;br&gt;or an estimated pre-study glomerular filtration rate (eGFR) = 50 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) equation.*&lt;br&gt;The pre-study serum creatinine value must not be older than 3 months and any acute causes of impaired renal function have to be ruled out.&lt;br&gt;* the four-component MDRD equation provides estimates of GFR standardised for body surface, based on the variables serum creatinine concentration (SCr), age, race, and sex:&lt;br&gt;eGFR (mL/min/1.73m2) = 186 x SCr-1.154 x age-0.203 (x 0.742 if female) (x 1.210 if black)&lt;br&gt;Pre-study serum creatinine has to be expressed in milligrams per decilitre, age in years.&lt;br&gt;4.) The subject is referred for a contrast-enhanced MDCT examination, using a standardised CM volume of 1.5 mL per kilogram of body weight and an injection rate of 4 mL/s (in cases with inadequate venous access, a flow of 3 mL/s may be applied). For subjects with a body weight exceeding 100 kilogram, a total CM volume of 150 mL should be administered.&lt;br&gt;5.) The subject is a man, or a woman who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (with cessation of menses for more than 1 year), or, if of child-bearing potential, the result of a urine or serum ?-HCG pregnancy test conducted at screening must be known to be negative before IMP administration.&lt;br&gt;6.) The subject is able and willing to comply with study procedures.&lt;br&gt;7.) Signed and dated (i.e., date and time) written informed consent is obtained.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.) The subject is pregnant or lactating.&lt;br&gt;2.) The subject was previously included in this study.&lt;br&gt;3.) The subject has received another IMP within 30 days before or is scheduled to receive one within 7 days after IMP administration.&lt;br&gt;4.) The subject has received iodinated contrast medium within 7 days before or will receive one within 7 days after IMP administration.&lt;br&gt;5.) The subject has a history of serious hypersensitivity reaction to iodinated contrast media.&lt;br&gt;6.) The subject has non-compensated heart failure (NYHA III or IV).&lt;br&gt;7.) The subject has manifest thyrotoxicosis.&lt;br&gt;8.) The subject is in acute renal failure or in acute on chronic renal failure.&lt;br&gt;9.) The subject has undergone kidney transplantation.&lt;br&gt;10.) The subject is on haemodialysis or peritoneal dialysis.&lt;br&gt;11.) The subject has liver cirrhosis with ascites.&lt;br&gt;12.) The subject has multiple myeloma.&lt;br&gt;13.) The subject is haemodynamically unstable pre-study.&lt;br&gt;14.) The subject is scheduled for major surgery within 7 days after IMP administration.&lt;br&gt;15.) The subject has received or will receive any of the following potentially nephroprotective drugs from 3 days before until 7 days after IMP administration:&lt;br&gt;n-acetylcysteine, fenoldopam, dopamine, or hydration with sodium bicarbonate. Concurrent medication with other drugs that are potentially nephroprotective, like calcium channel blockers or theophylline, are permitted provided they are used for the subject’s underlying disease (e.g., cardiac disease, arterial hypertension, bronchial asthma).&lt;br&gt;16.) The subject has received nephrotoxic drugs within 7 days before or will receive such drugs within 7 days after IMP administration. Respective nephrotoxic drugs include antibiotics (e.g., aminoglycosides, vancomycin, amphotericin B), antineoplastic agents (e.g., methotrexate, cisplatin), and immunosuppressants (e.g., cyclosporine).&lt;br&gt;17.) The subject has received nonsteroidal anti-inflammatory drugs (NSAID) within 3 days before or will receive such drugs within 7 days after IMP administration, with the exception of low dose aspirin (up to 325 mg per day). However, subjects who are on a stable NSAID regimen may be enrolled.&lt;br&gt;18.) The subject has had or is planned to have the initiation, discontinuation, or change in dose of any of the following from 3 days before until 7 days after IMP administration: trimethoprim, cimetidine, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers.&lt;br&gt;&lt;br&gt;19.) The subject is on metformin treatment at the time of the study procedure: metformin administration has to be discontinued prior to IMP administration, according to local guidelines, withheld for at least 48 hours, and resumed only if renal function / serum creatinine did not worsen compared to the baseline values.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Subjects with a combination of diabetes mellitus (type I or II), and impaired renal function.

 &lt;br&gt;MedDRA version: 7.0
Level: Pt
Classification code 10061835
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Visipaque 320 mgI/ml &lt;br&gt;Product Name: Visipaque 320 mg I/ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iodixanol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 320 mg I/ml-&lt;br&gt;&lt;br&gt;Trade Name: Iopamiro 300 mg I/ml&lt;br&gt;Product Name: Iopamiro&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iopamidol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 300 mg I/ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate and compare the effects of two different contrast media, iodixanol 320 mg I/mL and iopamidol 300 mg I/mL, on renal function;Secondary Objective: To evaluate and compare the safety profile of iodixanol 320 mg I/mL and iopamidol 300 mg I/mL&lt;br&gt;To evaluate and compare the efficacy of iodixanol 320 mg I/mL and iopamidol 300 mg I/mL&lt;br&gt;;Primary end point(s): The primary endpoint will be the incidence rate of contrast-induced nephropathy (CIN), defined as an intra-individual increase in serum creatinine of at least 44.2 µmol/l (0.5 mg/dl) from baseline up to day 3.&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DXV406</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454536</Internal_Number>
    <TrialID>EUCTR2005-001231-29-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY 
OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENTS UNDERGOING RENAL TRANSPLANTATION
</Public_title>
    <Scientific_title>A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY 
OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENTS UNDERGOING RENAL TRANSPLANTATION
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Dept of Transplantation Surgery B 56, Karolinska University Hospital, Huddinge</Primary_sponsor>
    <Date_registration3>20050705</Date_registration3>
    <Date_registration>05/07/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001231-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/09/2005</Date_enrollement>
    <Target_size>140</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients aged 18 years or above&lt;br&gt;Recipients of first or second renal transplant&lt;br&gt;Recipients from living or cadaveric donors&lt;br&gt;Single organ recipients (kidney only)&lt;br&gt;Patients providing written informed consent&lt;br&gt;Patients cooperative and able to complete all the assessment procedures&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;HLA-identical siblings&lt;br&gt;Patients receiving immunosuppressive therapy within the preceding 28 days&lt;br&gt;PRA &gt;50% within 6 months prior to enrolment&lt;br&gt;Previous exposure to murine antibodies&lt;br&gt;History of malignancy (except localised non-melanotic skin cancer) or the presence of any active malignancy at the time of transplant&lt;br&gt;Active infection (HCV, HBV, HIV)&lt;br&gt;Pregnant or lactating females &lt;br&gt;Women of child bearing potential not willing to use reliable form of contraception                                                                                                       &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure patients who are receiving a kidney transplant.  Different immunosuppressive protocls are awailable. However, current strategies for the medical management of transplant patients are largely focused on the prevention and treatment of T-cell mediated processes. However, there is an increasing evidence that B cells may significantly contribute to post-transplant morbidity in addition to their role in acute humoral rejection.</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera&lt;br&gt;Product Name: Mabthera&lt;br&gt;Product Code: RO 45-2294/V02&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the study is to determine the effect of one dose of rituximab as induction therapy together with a conventional tacrolimus, mycophenolate mofetil, prednisolone immunosuppressive protocol on the incidence of treatment failure (biopsy-proven acute rejection, graft loss or death) at 6 months post transplant. &lt;br&gt;&lt;br&gt;;Secondary Objective: To assess the effect of rituximab induction on renal function at 6 months post transplant, measured as creatinine clearance. &lt;br&gt;&lt;br&gt;To assess the incidence and severity of  infections (CMV, BKV, fungal and bacterial) in the two groups. &lt;br&gt;Creatinine clearance determined by the iohexol technique at 6 months &lt;br&gt;Incidence of opportunistic infections (CMV, BK, fungus)&lt;br&gt;Incidence of urinary tract infections and septicemia &lt;br&gt;Incidence of rituximab-related adverse events&lt;br&gt;Incidence of malignancies &lt;br&gt;All adverse events including clinically significant abnormalities and clinical and laboratory parameters&lt;br&gt;&lt;br&gt;Additional parameters to be assessed peroperatively and at 6 months&lt;br&gt;Number of CD19+, CD20+ lymphocytes in blood &lt;br&gt;Immunoglobulin G and M levels&lt;br&gt;Anti-tetanus IgG&lt;br&gt;Anti-CMV IgG&lt;br&gt;Cystatin C &lt;br&gt;Iohexol clearance (at 6 months only)&lt;br&gt;Transplant biopsy&lt;br&gt;&lt;br&gt;&lt;br&gt;;Primary end point(s): The primary endpoint will be a composite endpoint defined as treatment failure,&lt;br&gt;including the occurrence of any of the following: biopsy-proven acute rejection, graft loss or death during the first 6 months following transplantation. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>2005-01-02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454693</Internal_Number>
    <TrialID>EUCTR2004-002973-22-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients</Public_title>
    <Scientific_title>Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>AZIENDA UNIVERSITARIA OSPEDALE POLICLINICO UMBERTO I</Primary_sponsor>
    <Date_registration3>20050801</Date_registration3>
    <Date_registration>01/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002973-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/04/2004</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Profilaxis of rejection in stable renal transplant patients &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10046694
</Condition>
    <Intervention>&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolic acid&lt;br&gt;CAS Number: 115007-34-6&lt;br&gt;Current Sponsor code: ERL080&lt;br&gt;Other descriptive name: NA&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>CERL080AIT03</Secondary_ID>
    <Secondary_Sponsor>AZIENDA POLICLINICO UMBERTO I</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2454739</Internal_Number>
    <TrialID>EUCTR2005-000855-14-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor.</Public_title>
    <Scientific_title>Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI PADOVA</Primary_sponsor>
    <Date_registration3>20050810</Date_registration3>
    <Date_registration>10/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000855-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/07/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Acute rejection prophylaxis after single-double kidney transplantation from marginal donors making use of a not nephrotoxic immunosuppressive regimen. &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Trade Name: RAPAMUNE*1MG 100 CPR&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE*2MG 30 CPR&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE*OS 60 ML 1 MG&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: THYMOGLOBULINE*IV 1F 25MG +F&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Antithymocyte immunoglobulin (rabbit)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>01-865-2005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454772</Internal_Number>
    <TrialID>EUCTR2005-002380-90-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter</Public_title>
    <Scientific_title>Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Nyremedicinsk afdeling, Aalborg Sygehus</Primary_sponsor>
    <Date_registration3>20050824</Date_registration3>
    <Date_registration>24/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002380-90                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/09/2005</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with chronic renal failure undergoing haemodialysis treatment three times a week&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Allergy to fish or egg protein. Age &lt; 18 yrs. Body Weight &lt; 50 kg. Chronic supraventricular arrhythmias. Implanted pacemaker. Myocardial infarction or stroke within the past 6 months. Tendency to significant drop in bloodpressure during haemodialysis. Ongoing infection. Other serious illness. Fasting triglycerides &gt; 3 mmol/L. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure</Condition>
    <Intervention>&lt;br&gt;Trade Name: Omegaven&lt;br&gt;Product Name: Omegaven&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the effect of intravenous infusion of an emulsion rich on n-3 polyunsaturated fatty acids on heart rate variability and the occurence of arrhythmias in relation to haemodialysis treatment;Secondary Objective: To determine the content of n-3 polyunsaturated fatty acids in plasma and cell membranes before and after infusion;Primary end point(s): The effect on heart rate variability and arrhythmias</Primary_outcome>
    <Secondary_ID>IVN3DIALYSE;N/A</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454985</Internal_Number>
    <TrialID>EUCTR2004-005002-68-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, aleatorizado, doble ciego, paralelo y de fase IV para comparar los efectos en la función renal del medio de contraste no iónico, isosmolar, iodixanol 320 mgI/ml (VisipaqueTM) con el medio de contraste no iónico, de baja osmolalidad, iopamidol 370 mgI/ml, en sujetos con función renal disminuida y diabetes mellitus sometidos a una angiografía coronaria con o sin intervención coronaria percutánea (ICP).</Public_title>
    <Scientific_title>Estudio multicéntrico, aleatorizado, doble ciego, paralelo y de fase IV para comparar los efectos en la función renal del medio de contraste no iónico, isosmolar, iodixanol 320 mgI/ml (VisipaqueTM) con el medio de contraste no iónico, de baja osmolalidad, iopamidol 370 mgI/ml, en sujetos con función renal disminuida y diabetes mellitus sometidos a una angiografía coronaria con o sin intervención coronaria percutánea (ICP).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Amersham Health SA (Parte de GE Healthcare Ltd. y sus filiales)</Primary_sponsor>
    <Date_registration3>20050922</Date_registration3>
    <Date_registration>22/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005002-68                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/11/2005</Date_enrollement>
    <Target_size>450</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;(1) The subject is over 18 years of age. &lt;br&gt;(2) The subject is referred for coronary angiography with or without PCI.&lt;br&gt;(3) The subject has diabetes mellitus I or II, treated with insulin or oral antiglycemics for at least 1 year.&lt;br&gt;(4) The subject has renal impairment of non-acute aetiology:&lt;br&gt;SCr measurement not older than 6 months ?150 µmol/L (1.7 mg/dL) for men and  ?133 µmol/L (1.5 mg/dL) for women or a creatinine clearance = 50 mL/min calculated according to Cockcroft-Gault formula. &lt;br&gt;(5) The subject is able and willing to comply with study procedures including hydration protocol and signed and dated (i.e. date and time) informed consent is obtained.&lt;br&gt;(6) The subject is male, or a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or non-lactating, or if of childbearing potential the results of a serum or urine human chorionic gonadotropin pregnancy test, performed at screening, with the result known before IMP administration, must be negative.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;(1) The subject was previously included in this study. &lt;br&gt;(2) The subject has participated in any IMP study within 30 days prior to study enrolment.&lt;br&gt;(3) The subject received iodinated contrast medium within 7 days before IMP administration or is scheduled to receive one within the study period.&lt;br&gt;(4) The subject is planned to undergo major surgery (CABG, CEA, vascular bypass) within 3 days after the IMP administration.&lt;br&gt;(5) The subject is planned to undergo selective renal angiography.&lt;br&gt;(6) The subject has a history of serious hypersensitivity reaction to iodinated contrast media.&lt;br&gt;(7) The subject has severe liver or haematologic disease, multiple myeloma or manifest thyrotoxicosis.&lt;br&gt;(8) The subject has severe heart failure requiring intravenous therapy with diuretics, inotropes, and/or vasodilators.&lt;br&gt;(9) The subject is planned to receive an intravenous diuretic or intravenous mannitol in connection to the IMP administration.&lt;br&gt;(10) The subject is haemodynamically unstable pre-study (i.e., inability to sustain systolic blood pressure above 90 mmHg within 48 hours before IMP-administration without pressor or balloon support).&lt;br&gt;(11) The subject is on haemodialysis or peritoneal dialysis, and/or is in acute renal failure. &lt;br&gt;(12) The subject has undergone kidney transplantation. &lt;br&gt;(13) The subject has received or will receive any of the following potentially nephroprotective drugs within 3 days before or 3 days after IMP administration; n-acetylcysteine, fenoldopam, dopamine or hydration with sodium bicarbonate (NaHCO3).  Potentially nephroprotective drugs such as Ca-channel blockers, theophylline etc, are allowed provided they are used for treatment of the subject’s chronic underlying disease. &lt;br&gt;(14) The subject has received or is planned to receive any of the following nephrotoxic drugs within 7 days before or 3 days after IMP administration; aminoglycosides, vancomycin, amphotericin B, cyclosporin, methotrexate, cisplatin.  &lt;br&gt;(15) The subject has received or is planned to receive nonsteroidal anti-inflammatory drugs (NSAID) within 3 days before or 3 days after IMP administration, with the exception of low dose acetyl salicylic acid (up to 325 mg per day, and at a single occasion in connection with PCI up to 500 mg).  However, subjects who are on a stable NSAID regimen may be enrolled.&lt;br&gt;(16) The subject has had or is planned to have the initiation, discontinuation, or change in dose within 3 days before or 3 days after IMP administration of any of the following: trimethoprim, cimetidine, angiotensin converting enzyme inhibitors (ACEI), or angiotensin receptor blockers (ARB).&lt;br&gt;(17) The subject is on metformin (e.g., Glucophage?) at the time of coronary angiography/intervention.  Metformin must be discontinued according to local guidelines, and stopped no later than the time of IMP administration, withheld for at least 48 hours, until the subject’s SCr has been evaluated and it is deemed safe to resume metformin.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Subjects with impaired renal function and diabetes mellitus undergoing coronary angiography.
 &lt;br&gt;MedDRA version: 8.0
Level: Pt
Classification code 10061835
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Visipaque 320 mg I/ml&lt;br&gt;Product Name: Visipaque&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iodixanol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 320 mg I/ml-&lt;br&gt;&lt;br&gt;Trade Name: Iopamiro 370 mg I/ml&lt;br&gt;Product Name: Iopamiro&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iopamidol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 370 mg I/ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate and compare the effects of two different contrast media, the iso-osmolar contrast medium (IOCM), iodixanol 320 mgI/mL, and the low-osmolar contrast medium (LOCM) iopamidol 370 mgI/mL, on renal function.;Secondary Objective: - To evaluate and compare the safety profile of iodixanol 320 mgI/mL and iopamidol 370 mgI/mL.&lt;br&gt;- To evaluate and compare the efficacy of iodixanol 320 mgI/mL and iopamidol 370 mgI/mL.&lt;br&gt;;Primary end point(s): - The peak increase in SCr from baseline up to day 3.&lt;br&gt;- The incidence of CIN, defined as number of subjects with an increase in SCr of at least 44.2 µmol/L (0.5 mg/dL) from baseline up to day 3.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DXV405</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455044</Internal_Number>
    <TrialID>EUCTR2005-002372-16-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients

Estudio multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia, la tolerabilidad, la seguridad y la farmacocinética de RAD001, en pacientes pediátricos receptores de un trasplante renal de novo - RAD351</Public_title>
    <Scientific_title>Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients

Estudio multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia, la tolerabilidad, la seguridad y la farmacocinética de RAD001, en pacientes pediátricos receptores de un trasplante renal de novo - RAD351                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Novartis Farmaceútica S.A</Primary_sponsor>
    <Date_registration3>20050906</Date_registration3>
    <Date_registration>06/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002372-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/10/2005</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a.Male and female patients ? 16 years of age.&lt;br&gt;b.Patients receiving a primary cadaveric or non-HLA identical living donor (related or unrelated) renal transplant.&lt;br&gt;c.The graft must be functional within 48 hours post transplantation. A functional graft is defined at the investigator’s determination by a 50 % fall of serum creatinine from the pre-transplant value. In the event of dialysis immediately preceding transplantation, the pre-dialysis serum creatinine value may be used.&lt;br&gt;d.Females capable of becoming pregnant must have a negative pregnancy test (qualitative dip stick test on urine) immediately prior to study entry. Females of child bearing potential must practice an approved method of birth control for the one year duration of the study and for a period of three months following discontinuation of study medication.&lt;br&gt;e.Patients who are willing and able to participate in the whole course of the study and for whom written informed consent has been obtained from the parent(s) or legal guardian.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a.Cold ischemia time &gt; 40 hours.&lt;br&gt;b.Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs.&lt;br&gt;c.Patients with non-diarrhea associated hemolytic-uremic syndrome.&lt;br&gt;d.Recipients of donor specific transfusions.&lt;br&gt;e.Patients with panel reactive T cell antibodies of 50 % or higher at the last assessment before transplantation.&lt;br&gt;f.Patients unable to undergo renal biopsies post-transplant. &lt;br&gt;g.Induction therapy with ALG, ATG and OKT3.&lt;br&gt;h.Use of anti-fungal azoles such as ketoconazole, itraconazole and fluconazole.&lt;br&gt;i.Patients requiring treatments with rifampin, carbamazepine, phenobarbital, phenytoin at the time of entry in the study.&lt;br&gt;j.The use of any investigational drug within 4 weeks prior to administration of the initial dose of study medication.&lt;br&gt;k.Patients who have received an investigational immunosuppressive agent within 4 months prior to administration of the initial dose of study medication.&lt;br&gt;l.Presence of any severe allergy (within 4 weeks prior to administration of the initial dose of study medication) requiring acute or chronic treatment; or hypersensitivity to drugs similar to RAD001 (e.g., erythromycin or other macrolide antibiotics) or to any component of the formulation.&lt;br&gt;m.Patients with any known contraindication to CsA.&lt;br&gt;n.Patients with severe or unstable medical conditions likely to affect patient safety or the objectives of this study. Other social circumstances that prevent full compliance with the protocol.&lt;br&gt;o.Patients with a history of alcohol or drug abuse, or signs of alcohol-induced organ damage, mental dysfunction or other factors limiting their ability to cooperate fully with the study.&lt;br&gt;p.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:&lt;br&gt;presence of inflammatory bowel syndrome, or gastrointestinal bleeding;&lt;br&gt;history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection (bladder augmentations and feeding tubes are acceptable).&lt;br&gt;q.Patients who are Hepatitis C positive, HIV positive, or Hepatitis B surface antigen positive. Laboratory results obtained within 6 months prior to administration of the initial dose of study medication are acceptable. Recipients of organs from donors who test positive for Hepatitis B surface antigen, Hepatitis C or HIV.&lt;br&gt;r.Evidence of liver injury as indicated by abnormal liver tests (AST or ALT &gt; 3 times ULN, total bilirubin &gt; 2 mg/dL).&lt;br&gt;s.Presence of uncontrolled hypercholesterolemia ( =350 mg/dL, = 9.1 mmol/L) or hypertriglyceridemia (= 500 mg/dL, = 5.6 mmol/L).&lt;br&gt;t.White blood cell count = 4500/mm3 or platelet count = 100,000/mm3.&lt;br&gt;u.Patients with severe systemic infections.&lt;br&gt;v.Patients with any past or present malignancy (other than excised basal cell carcinoma).&lt;br&gt;w.History of splenectomy.&lt;br&gt;x.Patients with any history of significant coagulopathy or medical condition requiring long term systemic anticoagulation after transplantation which would interfere with obtaining biopsies. Low dose aspirin is allowed.&lt;br&gt;y.Abnormal physical or laboratory findings of clinical significance which would interfere with the objectives of the study.&lt;br&gt;z.Females who are breast feeding.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>pediatric de novo renal trasplant &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10050432
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican 0.1mg fast-dispersable tablets&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001B&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.5mg/day-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0.25mg fast-dispersable tablets&lt;br&gt;Product Name: certican&lt;br&gt;Product Code: RAD001B&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.5mg/day-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1. To evaluate the safety and tolerability of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in pediatric de novo renal transplant recipients, and to provide additional safety data (quantitative protein/creatinine ratio in urine).;Primary end point(s): To evaluate the safety and tolerability of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in pediatric de novo renal transplant recipients;Secondary Objective: 1.To evaluate the efficacy of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids as measured by the incidence of biopsy proven acute allograft rejection episodes, graft loss or death at 6 and 12 months after initial dose of study medication.&lt;br&gt;2.To characterize the multiple dose pharmacokinetics of RAD001 administered b.i.d.&lt;br&gt;3.To evaluate the efficacy of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in the prevention of chronic allograft rejection (chronic graft dysfunction) at 12 months post-transplantation.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CRAD001B351</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455172</Internal_Number>
    <TrialID>EUCTR2005-001854-25-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de daclizumab y micofenolato mofetil. - ALHAMBRA</Public_title>
    <Scientific_title>Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de daclizumab y micofenolato mofetil. - ALHAMBRA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Sociedad Andaluza de Trasplante de Órganos y Tejidos</Primary_sponsor>
    <Date_registration3>20051010</Date_registration3>
    <Date_registration>10/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001854-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/12/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Pacientes de ambos sexos cuya edad sea mayor o igual a 50 años, y que sean receptores primarios de aloinjerto renal proveniente de donante mayor o igual a 55 años.&lt;br&gt;2. Pacientes que hayan otorgado su consentimiento de manera previa a su participación en el estudio.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Pacientes receptores de trasplante multiorgánico.&lt;br&gt;2. Pacientes que reciben trasplante de donante cadáver con un tiempo de isquemia fría mayos de 30 horas.&lt;br&gt;3. Pacientes con un PRA mayor del 20% en los 6 meses anteriores a la inclusión.&lt;br&gt;4. Mujeres en periodo de lactancia, embarazadas o en edad fértil, que no usen un método anticonceptivo fiable antes de comenzar la terapia con el fármaco en estudio, durante la terapia, y durante los 4 meses siguientes a la última dosis de los fármacos administrados dentro de este estudio clínico.&lt;br&gt;5. Pacientes con recuento leucocitario menor de 2,5 x 109/L, recuento de plaquetas menor de 100 x 109/L, o hemoglobina inferior a 6 g/dL en el momento de ser incluido en el estudio,&lt;br&gt;6. Pacientes con evidencia de enfermedad hepática activa.&lt;br&gt;7. Pacientes con úlcera péptica activa.&lt;br&gt;8. Pacientes con diarrea grave o cualquier otro trastorno intestinal que pudiera interferir en la capacidad de absorción de medicación oral, incluyendo pacientes diabéticos con gastroenteropatía diabética diagnosticada previamente,&lt;br&gt;9. Pacientes con evidencia de infección sistémica activa que requiera el uso continuado de antibióticos, o evidencia de infección por VIH, o presencia de hepatitis B (HBs-Ag positiva) o C crónica activa,&lt;br&gt;10. Pacientes con historia de malignidad (excepto cáncer de piel no melanocítico localizado, tratado satisfactoriamente y carcinoma “in situ” de cervix),&lt;br&gt;11. Pacientes con una historia de enfermedad, o afección psicológica, que interfiera en la capacidad del paciente para comprender los requisitos del estudio,&lt;br&gt;12. Pacientes en quienes el investigador considera necesario un tratamiento con la siguiente medicación: &lt;br&gt;a.	-Azatioprina,&lt;br&gt;b.	Metotrexato,&lt;br&gt;c.	Ciclofosfamida&lt;br&gt;d.	-Anticuerpos antilinfocitos policlonales y monoclonales (por ejemplo, OKT3, ATG), usados para la inducción en pacientes de alto riesgo inmunológico,&lt;br&gt;e.	Basiliximab,&lt;br&gt;f.	Otros fármacos en investigación,&lt;br&gt;&lt;br&gt;13. Hipersensibilidad conocida o contraindicación absoluta de cualquiera de las medicaciones administradas en el contexto del estudio, o cualquier otra sustancia presente en las medicaciones del  estudio.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años.</Condition>
    <Intervention>&lt;br&gt;Trade Name: PROGRAF&lt;br&gt;Product Name: tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE&lt;br&gt;Product Name: SIROLIMUS&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar la función renal (creatinina sérica a los 6 meses) en la entrada tardía del tratamiento con tacrolimus o rapamicina basados en regímenes con daclizumab, micofenolato mofetil y esteroides en pacientes mayores de 50 receptores de un injerto de donante mayor de 55 años.;Secondary Objective: 1. Eficacia:&lt;br&gt;Comparar los datos relativos al retraso en la función del injerto.&lt;br&gt;Comparar los datos relativos al rechazo.&lt;br&gt;Comparar la supervivencia del paciente y del injerto tras 6 meses de tratamiento.&lt;br&gt;Comparar los datos relativos al fallo de tratamiento a los 6 meses.&lt;br&gt;2. Seguridad:&lt;br&gt;Describir la incidencia de acontecimientos adversos entre ambos brazos a lo largo de 6 meses de tratamiento.;Primary end point(s): creatinina sérica a los 6 meses</Primary_outcome>
    <Secondary_ID>SATOT42005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455280</Internal_Number>
    <TrialID>EUCTR2004-000520-32-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIENTS UNDERGOING KIDNEY TRANSPLANTATION
 - SENIOR (Safety and Efficacy with kNown Immunosuppression in Older Recipients)</Public_title>
    <Scientific_title>A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIENTS UNDERGOING KIDNEY TRANSPLANTATION
 - SENIOR (Safety and Efficacy with kNown Immunosuppression in Older Recipients)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Fujisawa GmbH</Primary_sponsor>
    <Date_registration3>20051102</Date_registration3>
    <Date_registration>02/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000520-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/01/2005</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: different drug combination regimen&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1 Male or female patients minimum 60 years of age&lt;br&gt;2 Patient has end stage kidney disease and is a suitable candidate for primary renal transplantation or retransplantation&lt;br&gt;3. Patient is receiving a kidney transplant, from a cadaveric or living donor (not HLA identical) with compatible ABO blood type&lt;br&gt;4. Patient has been fully informed and has given written informed consent according to ICH-GCP. Patient unable to write and/or read but who fully understands the oral information given by the investigator (or nominated representative) has given oral informed consent witnessed by an independent person&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patient has an immunological high risk, defined as a PRA grade &gt;50% &lt;br&gt;2. Cold ischemia time of the donor kidney greater than 30 hours&lt;br&gt;3. Patient has significant liver disease, defined as having during the past 30 days continuously elevated ASAT (SGOT) and/or ALAT (SGPT) levels greater than 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor&lt;br&gt;4. Patient is allergic or intolerant to corticosteroids, macrolide antibiotics, mycophenolate mofetil, mycophenolic acid, tacrolimus, basiliximab or to the excipients of the study medication&lt;br&gt;5. Patient requires ongoing dosing with corticosteroids &lt;br&gt;6. Patient requires initial sequential or parallel therapy with immunosuppressive antibody preparation(s) or prohibited medication (see section 7.4 of protocol)&lt;br&gt;7. Patient or donor is known to be HIV positive&lt;br&gt;8. Patient with malignancy or history of malignancy, except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully&lt;br&gt;9. Patient has significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer&lt;br&gt;10. Patient is participating or has participated in another clinical trial and/or is taking or has been taking an investigational drug in the past 30 days&lt;br&gt;11. Patient has previously received or is receiving an organ transplant other than kidney&lt;br&gt;12. Patient has been previously enrolled in this study&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with end stage kidney disease who will undergo primary renal transplantion or retransplantation &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10014646
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5.0-&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: CellCept&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Mycophenolate mofetil&lt;br&gt;CAS Number: 116680-01-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;&lt;br&gt;Product Name: Simulect&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;INN or Proposed INN: Basiliximab  &lt;br&gt;CAS Number: 179045-86-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20.00-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare renal function as well as incidence of renal dysfunction, patient death, graft loss or first biopsy proven acute rejection within the first 6 months after transplantation for the two therapy regimens (Arm 1: Delayed Tacrolimus + MMF+ Basiliximab + Corticosteroids (1 week), Arm 2: Tacrolimus + MMF + Corticosteroids (3 months)). The aim is to demonstrate that Arm 1 is non-inferior to Arm 2 with regard to the primary endpoint.;Secondary Objective: To compare the efficacy and safety profiles of the two therapy regimens (Arm 1: Delayed Tacrolimus + MMF+ Basiliximab + Corticosteroids (1 week), Arm 2: Tacrolimus + MMF + Corticosteroids (3 months)). &lt;br&gt;;Primary end point(s): A two step testing strategy will be applied for the two primary endpoints. The first primary efficacy endpoint of this study will be the renal function measured by calculated creatinine clearance at month 6, determined from the serum creatine using the Cockcroft formula.&lt;br&gt;&lt;br&gt;If the result of the test for the first primary endpoint is statistically significant, then the composite endpoint can also be tested in a confirmatory way.&lt;br&gt;&lt;br&gt;The composite endpoint is the incidence of death, graft loss or acute rejection within the first 6 months after transplantation and incidence of renal dysfunction defined as a calculated creatinine clearance value of =40 ml/min/1.73 m2 at month 6. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>FG-506-02-42</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455320</Internal_Number>
    <TrialID>EUCTR2004-001270-77-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcionante con proteinuria e insuficiencia renal leve o moderada.</Public_title>
    <Scientific_title>Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcionante con proteinuria e insuficiencia renal leve o moderada.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Equipo de doctores: Dr. Amado Andrés y Dr. Manuel Praga</Primary_sponsor>
    <Date_registration3>20051103</Date_registration3>
    <Date_registration>03/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001270-77                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/03/2005</Date_enrollement>
    <Target_size>178</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Hombres y mujeres con edad entre 18 y 70 años de edad, con un trasplante renal funcionante de más de 1 año, sea cual sea la causa de la insuficiencia renal terminal que lo haya motivado (nefropatía diabética o no diabética)&lt;br&gt;2.	Insuficiencia renal leve o moderada, definida como una creatinina sérica &gt; 1,3 mg/dl en las mujeres y &gt; 1,5 mg/dl en los  varones y &lt; 3 mg/dl en ambos casos. &lt;br&gt;3.	Proteinuria &gt; 0,5 g/24 h en al menos 3 determinaciones previas al inicio del estudio y &lt; 3, 5 g /24 h.&lt;br&gt;4.	En el momento de la aleatorización y durante las 6 semanas previas a la misma, los pacientes no estarán tomando IECA o ARAII como tratamiento antihipertensivo.&lt;br&gt;5.	Se incluirá a los pacientes con estos criterios independientemente de su presión arterial, es decir, podrán ser incluidos tanto pacientes normotensos como hipertensos. No obstante, la presencia de una hipertensión de difícil control constituirá un criterio de  exclusión.&lt;br&gt;6.	No será requisito necesario la realización de biopsia renal antes del inicio del estudio. Si se hubiera realizado, los pacientes podrán ser incluidos independientemente del diagnóstico establecido (rechazo crónico, glomerulonefritis de novo o de recidiva...) siempre que cumplan los criterios de inclusión/exclusión.&lt;br&gt;&lt;br&gt;&lt;br&gt;7.	La inmunosupresión empleada en estos pacientes estará basada en Ciclosporina A y los pacientes no deben estar incluidos en ningún otro protocolo de estudio en el momento de su reclutamiento.&lt;br&gt;8.	Las mujeres potencialmente fértiles deberán presentar una prueba de embarazo negativa antes de la aleatorización y deberán practicar un método anticonceptivo probado médicamente durante todo el ensayo. &lt;br&gt;9.	El paciente ha de otorgar su consentimiento informado por escrito para participar en el estudio.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Diagnóstico de más de 2 episodios de rechazo agudo hasta el inicio del estudio.&lt;br&gt;2.	Presencia de uropatía obstructiva no resuelta.&lt;br&gt;3.	Presencia de estenosis de arteria renal del injerto no resuelta&lt;br&gt;4.	Hepatopatía severa&lt;br&gt;5.	Enfermedad sistémica o deterioro general que haga previsible la imposibilidad de su seguimiento regular.&lt;br&gt;6.	Embarazo o lactancia&lt;br&gt;7.	Alteraciones psiquiátricas&lt;br&gt;8.	Hipersensibilidad conocida a los antagonistas de receptores de angiotensina (ARAII)&lt;br&gt;9.	Potasio sérico superior a 5.5 mEq/l en ausencia de fármacos que lo justifiquen.  &lt;br&gt;10.	Creatinina sérica &gt; 3.0 mg/dl o proteinuria &gt; 3,5 g/24h.&lt;br&gt;11.	Pacientes que hayan utilizado cualquier fármaco en investigación en las 6 semanas previas.&lt;br&gt;12.	Antecedentes de abuso de alcohol o de drogas no resuelto.&lt;br&gt;13.	Pacientes receptores de trasplantes de múltiples órganos sólidos o trasplantados previamente con cualquier otro órgano.&lt;br&gt;14.	Pacientes con alguna enfermedad maligna durante los últimos 5 años, excepto carcinoma de células basales o escamosas extirpado o carcinoma de cérvix in situ tratado adecuadamente.&lt;br&gt;15.	Estar participando en el momento de inclusión en otros protocolos de estudio.&lt;br&gt;16.	Hipertensión arterial de difícil control.&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes varones y mujeres de 18 a 70 años con trasplantes renales funcionantes de más de 1 año de evolución y una insuficiencia renal leve o moderada (creatinina sérica &gt; 1,3 mg/dl en mujeres y &gt; 1,5 mg/dl en varones y &lt; 3 mg/dl en ambos casos) y proteinuria (&gt;0,5 g/24 h y &lt; 3,5 g/24 h).</Condition>
    <Intervention>&lt;br&gt;Trade Name: DIOVAN&lt;br&gt;Product Name: Diovan&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: VALSARTÁN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 80-160&lt;br&gt;&lt;br&gt;Product Name: HIPOTENSORES&lt;br&gt;Product Code: C02&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: DIURETICOS&lt;br&gt;Product Code: C03&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: VASODILATADORES PERIFÉRICOS&lt;br&gt;Product Code: C04&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: BETABLOQUEANTES&lt;br&gt;Product Code: C07&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: CALCIO ANTAGONISTAS&lt;br&gt;Product Code: C08&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar la eficacia de Valsartán en comparación con el tratamiento estándar para el control de la progresión de la insuficiencia renal, definida como un incremento de la creatinina sérica igual o superior al 50% del valor basal, en pacientes con trasplantes renales funcionantes con proteinuria e insuficiencia renal leve o moderada.;Secondary Objective: 1.	La reducción de la proteinuria&lt;br&gt;2.	Tolerabilidad de valsartán, evaluada mediante la frecuencia, tipo y gravedad de los acontecimientos adversos observados durante el estudio.  Se valorará la seguridad mediante exploraciones físicas, parámetros de laboratorio hematológicos y bioquímicos (incluyendo la determinación de creatinina y potasio) y medición de las constantes vitales.&lt;br&gt;3.	La morbimortalidad cardiovascular, evaluada mediante la incidencia global y específica de cada uno de los siguientes parámetros:&lt;br&gt;-	infarto agudo de miocardio o angina de pecho&lt;br&gt;-	necesidad de revascularización coronaria&lt;br&gt;-	episodios de insuficiencia cardiaca&lt;br&gt;-	accidente vascular cerebral&lt;br&gt;-	amputación y/o revascularización de extremidades inferiores&lt;br&gt;-	muerte de causa cardiovascular&lt;br&gt;;Primary end point(s): Porcentaje de pacientes con progresión de la insuficiencia renal, definida como un incremento de la creatinina sérica igual o superior al 50% del valor basal.	&lt;br&gt;</Primary_outcome>
    <Secondary_ID>TRASVAL</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455462</Internal_Number>
    <TrialID>EUCTR2004-000655-41-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor</Public_title>
    <Scientific_title>A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica S.A</Primary_sponsor>
    <Date_registration3>20051201</Date_registration3>
    <Date_registration>01/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000655-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/02/2005</Date_enrollement>
    <Target_size>88</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;male and female adults between 6 and 60 months post renal transplantation, maintained for the last 6 months on the same triple immunussupressive regimen : CNI + MPA + corticosteroids or CNI + mTOR + corticosteroids&lt;br&gt;stable renal function and no history of rejection&lt;br&gt;PRA &lt;10% pre-transplantation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patient at high immunological risk of rejection&lt;br&gt;pulse rate &lt; 50bpm at screening&lt;br&gt;presence or history of second or third degree AV block&lt;br&gt;history of cardiac arrest&lt;br&gt;history of malignancy&lt;br&gt;systemic infection within 2 weeks prior to start study medication&lt;br&gt;HIV or hepatitis B surface Ag positive&lt;br&gt;</Exclusion_Criteria>
    <Condition>prevention of acute rejection in maintenance renal transplant recipients &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Product Name: FTY720&lt;br&gt;Product Code: FTY720&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Not applicable&lt;br&gt;Current Sponsor code: FTY720&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 2.5-5&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluate whether FTY720 can be safely introduced in a maintenance renal transplant population and can allow for CNI elimination resulting in an improvement of the renal function ;Secondary Objective: Validate discharge criteria following the first administration of FTY720;Primary end point(s): improvement of the renal function 12 months after FTY720 introduction, measured by the change in estimated glomerular filtration rate (Cockroft-Gault formula)</Primary_outcome>
    <Secondary_ID>CFTY720A2308</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455483</Internal_Number>
    <TrialID>EUCTR2005-004299-19-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation</Public_title>
    <Scientific_title>New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>University Hospital Ostrava</Primary_sponsor>
    <Date_registration3>20051007</Date_registration3>
    <Date_registration>07/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004299-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/10/2005</Date_enrollement>
    <Target_size>375</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;renal transplant patients on standart therapy with cyclosporine A&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;end of treatment with cyclosporine A, disagreement of patients&lt;br&gt;</Exclusion_Criteria>
    <Condition>patient on standart immunusupresive therapy with cyclosporine A after renal transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: not fixed in the protocol&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CICLOSPORINUM&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The target of this project is to clarify the importance of TDM of CsA and its principal metabolites by LC-MS in lymphocytes when compared with currently used methods C through, AUC, and C2. ;Secondary Objective: We further wish for detection the role of the lipofile metabolite AM4N in imunosupresion and toxicity, and alternatively other metabolites analyzed by LC-MS.;Primary end point(s): to clarify the importance of TDM of CsA and its principal metabolites by LC-MS in lymphocytes when compared with currently used methods C through, AUC, and C2. We further wish for detection the role of the lipofile metabolite AM4N in imunosupresion and toxicity, and alternatively other metabolites analyzed by LC-MS.&lt;br&gt;to find the therapeutic range for safety and effective therapy with CsA</Primary_outcome>
    <Secondary_ID>1A/8655-5</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455503</Internal_Number>
    <TrialID>EUCTR2005-003383-39-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.</Public_title>
    <Scientific_title>A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Roche Farma S.A.</Primary_sponsor>
    <Date_registration3>20051111</Date_registration3>
    <Date_registration>11/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003383-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/12/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;–	Patients who are males or non-pregnant females &gt; 18 years old.&lt;br&gt;–	Patients who are recipients of primary kidney allografts.&lt;br&gt;–	Patients who are single-organ recipients (kidney only).&lt;br&gt;–	Patients with PRA &lt;20%&lt;br&gt;–	If patients are women of childbearing potential, they must have a negative pregnancy test, and use a reliable form of contraception&lt;br&gt;–	Patients and their guardians must be capable of understanding the purpose and risks of the study.&lt;br&gt;–	Patients who are willing to give written informed consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;–	Patients previously treated with Daclizumab, MMF or SRL.&lt;br&gt;–	Patients who require in addition to the study immunosuppresive regimen anti-lymphocyte preparations for induction therapy.&lt;br&gt;–	Women lactating, pregnant or of childbearing potential not using a reliable contraceptive method during the study.&lt;br&gt;–		Patients with severe gastrointestinal disorders that interfere with  &lt;br&gt;Their ability to receive or absorb oral medication and patients with severe diarrhoea.&lt;br&gt;–	Patients who are expected than to require oral corticosteroids post-transplant (i.e. patients suffering autoinmune diseases).&lt;br&gt;–	Patients with active peptic ulcer disease.&lt;br&gt;–	Patients receiving bile-acid sequestrants.&lt;br&gt;–	Patients with severe anemia (Hb&lt;6 g/dl), leucopenia (WBC&lt;2500/mm3) or thrombocytopenia (Tc&lt;100’000/mm3)&lt;br&gt;–	Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.&lt;br&gt;–	HIV positive donor or patient&lt;br&gt;–	Patients with history of malignancy within the last 5 years, except localised and treated non melanoma skin cancer, treated and without recidive evidence.	&lt;br&gt;–	Patients for whom the investigator considers a treatment with the following medications necessary:&lt;br&gt;?	Azathioprine,&lt;br&gt;?	methotrexate&lt;br&gt;?	cyclophosphamide,&lt;br&gt;?	Cyclosporine&lt;br&gt;?	Tacrolimus&lt;br&gt;?	Everolimus&lt;br&gt;?	Mycophenolate sodium&lt;br&gt;?	polyclonal and monoclonal anti-lymphocyte antibodies other than daclizumab (e.g. OKT3, ATG, basiliximab) &lt;br&gt;–	Known hypersensitivity or absolute contraindications to any of the medications administered in the context of the study or any other substances present in the study medications&lt;br&gt;–		Patients who require concomitant treatment with other investigational or prohibited drugs.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: ZENAPAX&lt;br&gt;Product Name: Daclizumab&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Daclizumab&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the efficacy of a steroid free regimen against normal doses of corticosteroids for prevention of acute rejection, when given in conjunction with daclizumab, mycophenolate mofetil (MMF) and sirolimus as maintenance therapy in the management of renal allograft recipients.;Secondary Objective: To assess clinical efficacy and safety of  the two treatment regimens&lt;br&gt;;Primary end point(s): Proportion of patients experiencing a biopsy proven acute rejection episode 6 months post-randomization</Primary_outcome>
    <Secondary_ID>ML18690</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455613</Internal_Number>
    <TrialID>EUCTR2005-004431-21-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilización de suero anti-linfocitos T de conejo, tacrolimus y micofenolato, libre de corticoesteroides concomitantes desde el inicio. - IBERICA</Public_title>
    <Scientific_title>Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilización de suero anti-linfocitos T de conejo, tacrolimus y micofenolato, libre de corticoesteroides concomitantes desde el inicio. - IBERICA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Fresenius Biotech GmbH</Primary_sponsor>
    <Date_registration3>20051219</Date_registration3>
    <Date_registration>19/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004431-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/02/2006</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Triple terapia Tacro/MMF/Corticosteroides&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Varón o mujer adulto, candidato para un primer transplante cadavérico, hasta los 70 años.&lt;br&gt;Las mujeres que se encuentren en edad fértil deberán utilizar métodos anticonceptivos seguros a lo largo de todo el estudio.&lt;br&gt;Donante a corazón latiente hasta los 65 años de edad, con de isquemia fría &lt;36 horas.&lt;br&gt;El paciente que haya recibido la información relativa al estudio y prestado su consentimiento informado por escrito.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Embarazo actual o en período de lactancia. &lt;br&gt;Mujeres que hayan tenido más de 3 embarazos (incluidos abortos). &lt;br&gt;Paciente con riesgo inmunológico considerado alto, definido por la presencia de un porcentaje de anticuerpos anti-HLA (PRA) ³25 %.&lt;br&gt;Hipersensibilidad a las proteínas del conejo (¿test cutáneo?) o alergias conocidas a cualquier componente de la inmunosupresión prevista. &lt;br&gt;Paciente/Donante HCV+, HBV+, HIV+&lt;br&gt;Paciente en tratamiento inmunosupresor pretransplante.&lt;br&gt;Paciente con neoplasia maligna actual o con antecedentes de neoplasia maligna, a excepción de cánceres basocelulares o espinocelulares en remisión. &lt;br&gt;Paciente sometido algún tipo de trasplante previo o candidato a trasplante múltiple (p.ej SKP).&lt;br&gt;Leucocitos &lt;2000/mm3 y/o plaquetas &lt;50 000/mm3 antes de iniciar el trasplante&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal de donante cadavérico</Condition>
    <Intervention>&lt;br&gt;Trade Name: ATeGe Fresenius&lt;br&gt;Product Name: ATeGe-Fresenius&lt;br&gt;Product Code: ATG&lt;br&gt;Pharmaceutical Form: Concentrate for solution for injection&lt;br&gt;INN or Proposed INN: Inmunoglobulina de conejo anti-linfocitos T humanos&lt;br&gt;Other descriptive name: ATG Fresenius&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Incidencia de rechazo subclínico y rechazo agudo (demostrados por biopsia).&lt;br&gt;   incidencia y lapso de tiempo hasta su manifestación&lt;br&gt;   gravedad histológica (BANFF)&lt;br&gt;   incidencia de resistencia a los corticoesteroides;Secondary Objective: Incidencia y duración de retraso inicial función injerto.&lt;br&gt;Función renal a los 1, 3, 6, 12 meses.&lt;br&gt;Porcentaje de pacientes proteinúricos y cantidad de proteína secretada&lt;br&gt;Porcentaje de pacientes con hipertensión arterial y en tratamiento hipotensor.&lt;br&gt;Porcentaje de pacientes hiperlipidémicos y en tratamiento hipolipemiante&lt;br&gt;Porcentaje de diabetes mellitas post-trasplante&lt;br&gt;Fallo de tratamiento y porcentaje de pacientes libres de esteroides al año.&lt;br&gt;Incidencia de complicaciones infecciosas bacterianas, víricas, fúngicas o parasitarias al año.  &lt;br&gt;Incidencia de neoplasias y enfermedad linfoproliferativa post-trasplante al año&lt;br&gt;Incidencia de cataratas&lt;br&gt;Incidencia de fracturas y osteoporosis diagnosticada densitometría osea al año&lt;br&gt;Incidencia de complicaciones cardiovasculares al año&lt;br&gt;Supervivencia total de pacientes al año&lt;br&gt;Supervivencia del injerto al año&lt;br&gt;Histología renal al año ;Primary end point(s): Evaluación de eficacia: La eficacia será valorada por la observación de eventos de rechazo agudo y rechazo agudo subclínico.&lt;br&gt;Evaluación de seguridad/tolerancia:La seguridad y tolerancia será determinada por la observación de graves efectos adversos. La evaluación incluirá pruebas clínicas y de laboratorio (exploración física, constantes vitales, hematología, bioquímica  y análisis de orina).</Primary_outcome>
    <Secondary_ID>IBERICA</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455627</Internal_Number>
    <TrialID>EUCTR2005-005664-88-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis</Public_title>
    <Scientific_title>Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>University of Oxford</Primary_sponsor>
    <Date_registration3>20051215</Date_registration3>
    <Date_registration>15/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005664-88                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/12/2006</Date_enrollement>
    <Target_size>520</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: The RD1 based ex vivo enzyme linked immunospot assay&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients in chronic renal failure who are potential transplant recipients &lt;br&gt;OR &lt;br&gt;Patients with a rheumatological condition who are potential recipients of Tumour Necrosis Factor alpha blockade&lt;br&gt;&lt;br&gt;AND &lt;br&gt;adult (over 18)&lt;br&gt;AND&lt;br&gt;able to give written informed consent&lt;br&gt;AND &lt;br&gt;with risk factors for tuberculosis:&lt;br&gt;-[renal arm] from collaborating units in high prevalence areas of the UK&lt;br&gt;-[anti TNF alpha arm] patients who would be considered for tuberculin skin testing under current anti-TNFalpha treatment guidelines, including past history of exposure or disease, immigrant from high prevalence area, CXR changes suggestive of prior TB, grade 2 heaf test or above&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Children&lt;br&gt;Current active tuberculosis&lt;br&gt;Unable to give written informed consent&lt;br&gt;Hypersensitivity to tuberculin&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis
ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45</Condition>
    <Intervention>&lt;br&gt;Trade Name: Tuberculin PPD RT 23 SSI for mantoux testing&lt;br&gt;Product Name: Tuberculin PPD RT 23 SSI for mantoux testing&lt;br&gt;Product Code: 1&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To validate the use of the RD1 based Exvivo IFNy ELISpot in the immunodiagnosis of tuberculosis in iatrogenically immunosuppressed populations by calculation of positive and negative predictive values for the assay and for a comparator: the tuberculin based mantoux test;Secondary Objective: To investigate potential immune correlates of latency and active disease in tuberculosis and identify potential markers of prognosis and disease progression in tuberculosis.;Primary end point(s): Development of active tuberculosis</Primary_outcome>
    <Secondary_ID>HB996</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455632</Internal_Number>
    <TrialID>EUCTR2005-001714-41-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, abierto, randomizado,  de doce meses de duración,  sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novo

</Public_title>
    <Scientific_title>Estudio multicéntrico, abierto, randomizado,  de doce meses de duración,  sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novo

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica, S.A.</Primary_sponsor>
    <Date_registration3>20051205</Date_registration3>
    <Date_registration>05/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001714-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/05/2006</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;El investigador debe asegurarse de que cada paciente cumple todos los criterios de inclusión al momento de ingresar en el estudio (basal), inmediatamente antes de la aleatorización: &lt;br&gt;- Hombre o mujeres entre 18 y 65 años de edad.&lt;br&gt;- Paciente que haya recibido un primer trasplante de riñón de un donante cadavérico, de un donante vivo no emparentado o de un donante vivo emparentado con HLA no idéntico.&lt;br&gt;- Receptor de un riñón con un tiempo de isquemia fría (TIF) &lt; 30 horas.&lt;br&gt;- Receptor de un riñón procedente de un donante que tiene entre 10 y 65 años de edad.&lt;br&gt;- Paciente capaz de recibir la primera dosis de tacrolimus dentro de las 24 horas de efectuada la reperfusión del injerto.&lt;br&gt;- Mujeres con capacidad de procrear deben tener una prueba de embarazo negativa, y es necesario que utilicen un método anticonceptivo médicamente probado durante el estudio y por un periodo de tres meses tras la discontinuación del fármaco en investigación.&lt;br&gt;- Paciente dispuesto y capaz de dar consentimiento informado escrito para participar en el estudio y capaz de participar en el estudio durante 12 meses.&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;El paciente que cumpla con alguno de los siguientes criterios al momento de ingresar al estudio (basal) justo antes de la aleatorización no podrá participar en el estudio:&lt;br&gt;- Paciente que anteriormente haya recibido un trasplante de órgano.&lt;br&gt;- Receptor de trasplante múltiple de órganos.&lt;br&gt;- Receptor de un trasplante de riñón de un donante a corazón parado .&lt;br&gt;- Receptor con transfusiones específicas del  donante&lt;br&gt;- Receptor de un trasplante A-B-O incompatible o trasplante con cross-match para células T positivo.&lt;br&gt;- Paciente con un nivel actual con Panel de Anticuerpos Reactivos (PRA) = 50%.&lt;br&gt;- Receptor de un riñón de un donante con  antígeno de superficie positivo de la hepatitis B o anticuerpos contra hepatitis C .&lt;br&gt;- Paciente positivo para el virus de inmunodeficiencia humano (HIV).&lt;br&gt;- Paciente con serología positiva para hepatitis C, o que es positivo para el antígeno de superficie de la hepatitis B con evidencia de daño hepático indicado por niveles de AST/ALT = 2.5 veces el LSN. Se aceptan los resultados de serología viral obtenidos dentro de los 6 meses previos a la administración de la primera dosis de Certican®.&lt;br&gt;- Paciente con hipercolesterolemia severa ( = 350 mg/dl, 9.1 mmol/dl) o hipertrigliceridemia severa     ( = 500 mg/dl, 5.6 mmol/l).&lt;br&gt;- Paciente con recuento de glóbulos blancos (WBC) &lt; o = 3.000/mm3 o recuento plaquetario &lt; o =  75,000/mm3&lt;br&gt;- Paciente con alguna alergia severa que requiere tratamiento agudo (dentro de las 4 semanas anteriores al examen basal) o crónico, o que presenta hipersensibilidad a fármacos similares a Certican® (Ej. macrólidos).&lt;br&gt;- Paciente que ha recibido tratamiento con un fármaco inmunosupresor o un fármaco en investigación dentro de las 4 semanas previas a la administración de la primera dosis de Certican®.&lt;br&gt;- Paciente con infección no controlada.&lt;br&gt;- Paciente con alguna condición médica o quirúrgica, distinta del actual trasplante, que a criterio del investigador impida la participación en este ensayo.&lt;br&gt;- Paciente con una neoplasia conocida, o antecedentes de neoplasia en los últimos 5 años, excepto carcinoma cutáneo localizado de células basales o escamosas que haya sido tratado con éxito.&lt;br&gt;- Hallazgos anormales de importancia clínica, ya sea en las evaluaciones físicas o en las pruebas de laboratorio, efectuados en las 2 semanas previas a la administración de la primera dosis de Certican® y que, a juicio del investigador, podrían interferir con los objetivos del estudio.&lt;br&gt;- Mujeres en periodo de lactancia.&lt;br&gt;- Paciente con síntomas de enfermedad somática o mental significativa, o con historia no resuelta de abuso de drogas o alcohol.&lt;br&gt;- Paciente que no coopera ni se comunica con el investigador.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Transplante renal de novo

de novo kidney transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,1-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.50-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: El objetivo primario es determinar si la reducción de la dosis de tacrolimus puede preservar la función renal en pacientes receptores de trasplantes renales de novo que reciben tacrolimus además de Certican®, AR IL-2 y corticosteroides. Este objetivo se valorará comparando la función renal evaluada a los 12 meses de realizado el trasplante a través de una tasa de filtrado glomerular (GFR) calculada (fórmula MDRD) entre dos grupos de pacientes que reciben dos diferentes niveles de exposición al tacrolimus.&lt;br&gt;&lt;br&gt;;Secondary Objective: El objetivo secundario principal es evaluar la eficacia de los dos regímenes. Esto se evaluará con la comparación entre los dos grupos de la incidencia de rechazo agudo confirmado por biopsia (RACB), desde el Mes 4 hasta el Mes 12 después del trasplante. &lt;br&gt;Los otros objetivos secundarios son evaluar la eficacia y la seguridad de los dos regímenes. Esto se evaluará a los 12 meses, efectuando una comparación entre los dos grupos.&lt;br&gt;;Primary end point(s): La función renal se evaluará a los doce meses post-transplante por la creatinina sérica, el aclaramiento de creatinina calculado (fórmula de Cockcroft-Gault), la GFR calculada (fórmula de MDRD y fórmula de Nankivell). También se evaluará la proteinuria cuantitativa. </Primary_outcome>
    <Secondary_ID>CRAD001A2426</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456453</Internal_Number>
    <TrialID>EUCTR2005-005972-34-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten - Retrograde intrarenal Stone Surgery</Public_title>
    <Scientific_title>Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten - Retrograde intrarenal Stone Surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fredericia Hospital</Primary_sponsor>
    <Date_registration3>20060105</Date_registration3>
    <Date_registration>05/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005972-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/03/2006</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: saline irrigation fluid as usually used in this kind of procedures &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Stone surgery required&lt;br&gt;Age &gt; 18 years&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous coronary infarct&lt;br&gt;Use of alpha-blocking or beta-blocking drugs&lt;br&gt;Untreated hypertension&lt;br&gt;Ureteral stone&lt;br&gt;Malignant disase in the upper urinary tract&lt;br&gt;Pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney stone</Condition>
    <Intervention>&lt;br&gt;Trade Name: Isoprenalin&lt;br&gt;Product Name: isoprenalin&lt;br&gt;Product Code: 5115&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Current Sponsor code: HJ1&lt;br&gt;Other descriptive name: isoprenalin&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To lower the intrarenal pelvic pressure during retrograde intrarenal stone surgery by adding isoprenalin to the irrigation fluid during the operation.;Secondary Objective: To shorten surgical time in retrograde intrarenal stone surgery whilst optimizing security and quality of the procedure. To spare the kidney parenchyma  from high pressures.;Primary end point(s): Lowering of the renal pelvic pressure.&lt;br&gt;Making the procedure easier for the surgeon (=shorter duration of operation time, fewer complications)</Primary_outcome>
    <Secondary_ID>HJ1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456484</Internal_Number>
    <TrialID>EUCTR2006-000753-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.</Public_title>
    <Scientific_title>A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Oxford MioMedica UK Ltd.</Primary_sponsor>
    <Date_registration3>20060410</Date_registration3>
    <Date_registration>10/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000753-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/05/2006</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Locally advanced or metastatic, histologically proven clear cell or papillary cell renal&lt;br&gt;carcinoma.&lt;br&gt;&lt;br&gt;If previously treated at least four weeks from any previous therapy (except Interferon a) for renal cancer includi,ng surgery chemotherapy, immunotherapy, or radiotherapy. (Patients receiving interferon a whose renal cancer is stable may also be included in the study)&lt;br&gt;&lt;br&gt;Newly diagnosed or progressive of stable measurable disease as defined by the&lt;br&gt;RECIST criteria&lt;br&gt;&lt;br&gt;Patients receiving first or second line treatment for locally advanced or metastatic renal cancer.&lt;br&gt;&lt;br&gt;Patients on stable doses of bisphosphonates that show subsequent tumor progression may continue on this medication; however, patients are not allowed to initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.&lt;br&gt;&lt;br&gt;Patients must be well enough to tolerate first or second line immunotherapy with&lt;br&gt;interferon alpha.&lt;br&gt;&lt;br&gt;Measurable disease.&lt;br&gt;&lt;br&gt;Aged 18 years or more.&lt;br&gt;&lt;br&gt;Patients must comply with 2 out of 3 of the following:&lt;br&gt;a. Karnofsky score greater than or equal to  80%.&lt;br&gt;b. Haemoglobin concentration greater than or equal to  13g/dL (males) or 11.5 g/dL (females)&lt;br&gt;c. Corrected calcium less than or equal to 10 g/dL (2.5 mmols/L).&lt;br&gt;&lt;br&gt;Clinically immunocompetent.&lt;br&gt;&lt;br&gt;Free of clinically apparent autoimmune disease (including no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's disease, Hashimoto's thyroiditis, multiple sclerosis, insulin dependant diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease).&lt;br&gt;&lt;br&gt;Total white cell count greater than or equal to 3 x 10e9/L and lymphocyte count greater than or equal to 1 x 10e9/dL.&lt;br&gt;&lt;br&gt;Serum creatinine up to 1.5 times upper limit of normal.&lt;br&gt;&lt;br&gt;ALT, AST and bilirubin &lt; 2 times the upper limit of normal.&lt;br&gt;&lt;br&gt;Able to give written informed consent and to comply with the protocol.&lt;br&gt;&lt;br&gt;Women must be either post menopausal, or rendered surgically sterile or, if of child&lt;br&gt;bearing potential, must have been practising a reliable form of contraception (oral&lt;br&gt;contraception + a barrier method) for at least three months prior to the first dose of&lt;br&gt;TroVax and must continue while they are being treated with TroVax. Men must&lt;br&gt;practise a reliable form of contraception while they are being treated with TroVax.&lt;br&gt;&lt;br&gt;No acute changes on 12-lead ECG.&lt;br&gt;&lt;br&gt;No clinical suspicion that cardiac ejection fraction is less than 45% (If clinically&lt;br&gt;suspicion exists the ejection fraction should be measured according to local site&lt;br&gt;procedures)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Serious infections within the 28 days prior to entry to the trial.&lt;br&gt;&lt;br&gt;Prior TroVax&lt;br&gt;&lt;br&gt;Patients that initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.&lt;br&gt;&lt;br&gt;Already completed prior second line therapy for advanced or metastatic renal cancer.&lt;br&gt;(Note however that patients currently receiving interferon as second line therapy for&lt;br&gt;advanced or metastatic renal cancer who are stable (ie do not demonstrate response or progression by RECIST criteria) may enter the study)&lt;br&gt;&lt;br&gt;Major surgery or radiation therapy completed less than or equal to 4 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;Prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;Participation in any other clinical trial of a licensed or unlicensed drug within the&lt;br&gt;previous 30 days. (except sorafanib or sutnitinib who may enter the study after 7 days discontinuation)&lt;br&gt;&lt;br&gt;Cerebral metastesis on MRI scan&lt;br&gt;&lt;br&gt;"Currently active" second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse.&lt;br&gt;&lt;br&gt;Serious intercurrent infections or nonmalignant medical illnesses that are uncontrolled.&lt;br&gt;&lt;br&gt;Psychiatric illnesses/social situations that would limit compliance with protocol&lt;br&gt;requirements.&lt;br&gt;&lt;br&gt;Creatinine 21.5 x ULN.&lt;br&gt;&lt;br&gt;Chronic oral corticosteroid use unless prescribed as replacement therapy in the case&lt;br&gt;of adrenal insufficiency.&lt;br&gt;&lt;br&gt;Clinical indication of reduced cardiac function or an ejection fraction of r 40%.&lt;br&gt;&lt;br&gt;Requirement for radiotherapy (this is a sign of disease progression and is classed as a withdrawal criterion).&lt;br&gt;&lt;br&gt;Concurrent chemotherapy, immunotherapy and radiation therapy&lt;br&gt;&lt;br&gt;No investigational or commercial agents or therapies other than those included in protocol treatment may be administered with the intent to create regression of the&lt;br&gt;patient's malignancy.&lt;br&gt;&lt;br&gt;Life threatening illness unrelated to cancer.&lt;br&gt;&lt;br&gt;Cerebral metastases on MRI scan.&lt;br&gt;&lt;br&gt;History of allergic response to previous vaccinia vaccinations.&lt;br&gt;&lt;br&gt;Participation in any other clinical trial of a licensed or unlicensed drug within the&lt;br&gt;previous 30 days or during the course of this trial.&lt;br&gt;&lt;br&gt;Previous malignancies within the last 10 years other than successfully treated&lt;br&gt;squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone&lt;br&gt;biopsy.&lt;br&gt;&lt;br&gt;Previous history psychosis or of major a psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient's ability to provide&lt;br&gt;informed consent or to comply with the protocol.&lt;br&gt;&lt;br&gt;Known allergy to egg proteins.&lt;br&gt;&lt;br&gt;Known to test positive for HIV or hepatitis B or C.&lt;br&gt;&lt;br&gt;Pregnancy or lactation.&lt;br&gt;&lt;br&gt;Prior history of organ transplantation.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced or Metastatic Renal Cell Cancer</Condition>
    <Intervention>&lt;br&gt;Product Name: TroVax&lt;br&gt;Product Code: TV&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: TroVax&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.58 x 10e8-1.58 x 10e9&lt;br&gt;&lt;br&gt;Trade Name: Roferon-A&lt;br&gt;Product Name: Roferon-A&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Interferon A&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 18 x 10e6-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: Though this is a phase I/II feasibility study to assess the safety and immunological&lt;br&gt;activity of TroVax combined with IFN-a, tumour response in each patient will also&lt;br&gt;be evaluated using RECIST criteria.;Main Objective: To evaluate whether IFN-a markedly increases the cellular or humoral anti-5T4&lt;br&gt;response to TroVax compared to that observed in previous studies using TroVax&lt;br&gt;alone, in combination with IL-2 or with chemotherapy.;Primary end point(s): Immunology endpoints&lt;br&gt;Antibody response to 5T4 as measured by ELISA&lt;br&gt;Cellular response to 5T4 antigen as measured by lFN gamma Elispot&lt;br&gt;&lt;br&gt;Primary safety endpoints&lt;br&gt;Assessment of the number of adverse events and serious adverse events&lt;br&gt;Assessment of safety by analysis of clinical laboratory variables (complete blood&lt;br&gt;count and chemistry panel).&lt;br&gt;&lt;br&gt;Efficacy endpoint&lt;br&gt;Tumour outcomes will be reported according to RECIST criteria.</Primary_outcome>
    <Secondary_ID>TV2/003/06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456489</Internal_Number>
    <TrialID>EUCTR2005-005809-38-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography</Public_title>
    <Scientific_title>Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Research &amp; Development Department, Addenbrookes Hospital</Primary_sponsor>
    <Date_registration3>20060110</Date_registration3>
    <Date_registration>10/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005809-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/12/2006</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Any patient undergoing peripheral angiography in the Cambridge Vascular Unit, Addenbrooke’s Hospital, Cambridge who consents to participation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any patient undergoing peripheral angiography in Cambridge Vascular Unit, &lt;br&gt;Any patient that does not consent to participation in the study.&lt;br&gt;Any patient under the age of 18 years&lt;br&gt;Any patient with established renal failure on renal replacement therapy (dialysis).&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>We will use N acetylcystiene prophylactically in patient undergoing peripheral angiography at the Cambridge Vascular Unit at Addenbrooke's Hospital in order to prevent renal injury. Patients undergoing peripheral angiography have large quanities of contrast medium injected intravenously, contrast medium is a nephrotoxic substance. Thge drug will be administrated prophylactically to aviod acute renal failure.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fluimucil&lt;br&gt;Pharmaceutical Form: Effervescent tablet&lt;br&gt;INN or Proposed INN: N acetylcysteine&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the role of N acetylcysteine as a nephroprotective agent in patients undergoing peripheral angiography at Addenbrooke’s Hospital, Cambridge.&lt;br&gt;&lt;br&gt;Primarily we are looking for a reduction in the elevation of serum creatinine and also of other markers of renal damage in urine (retinol binding protein and albumin)&lt;br&gt;&lt;br&gt;A reduction in the mortality and morbidity related to renal failure that may result from a contrast medium induced nephropathy.&lt;br&gt;;Secondary Objective: ;Primary end point(s): To obtain eveidence that shows prophylactic use of N acetylcysteine is significantly nephroprotective for patients undergoing peripheral angiography</Primary_outcome>
    <Secondary_ID>NACP1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456539</Internal_Number>
    <TrialID>EUCTR2004-002852-33-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantation
Ensayo aleatorio, abierto para estudiar la eficacia de risedronato 35mg/semanal en la prevención de pérdida de masa ósea y calcificaciones vasculares post-trasplante renal - PREVENOS</Public_title>
    <Scientific_title>a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantation
Ensayo aleatorio, abierto para estudiar la eficacia de risedronato 35mg/semanal en la prevención de pérdida de masa ósea y calcificaciones vasculares post-trasplante renal - PREVENOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Dr. Jose Vicente Torregrosa Prats (fundacio clinic)</Primary_sponsor>
    <Date_registration3>20060124</Date_registration3>
    <Date_registration>24/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002852-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/04/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: same treatment (calcium carbonate and cholecalciferol) without risedronato&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male and female aged 18-75 years old; chronic renal failure's patients on dialysis that have had a kidney transplant; patients who have been fully informed and have given written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Hyperimmunized patients (PRA ›75%); multiorganic transplant; diabetes mellitus patients on insulin treatment at the transplant moment; parathyroidectomised patients with parathyroid hormone values ‹ 50 pg/ml; patients that have received fluorine, biphosphonates or hormone replacement therapy in the previous 6 months, antiepileptic or calcitonin treatment in the previous 3 months, patients with biphosphonate allergy history, dyspepsia or reflux history and pregnant patients or nursing mothers.&lt;br&gt;</Exclusion_Criteria>
    <Condition>bone metabolic pathology associated to kidney transplantation &lt;br&gt;MedDRA version: 7.1
Level: LLT
Classification code 10058972
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Actonel semanal&lt;br&gt;Product Name: Actonel semanal&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: risedronate&lt;br&gt;Other descriptive name: risedronic acid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 35-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: study the efficacy of risedronate 35 mg/week to reduce the bone mass loss in patients after kidney transplantation;Secondary Objective: study the efficacy of risedronate 35 mg/week in bone fractures prevention and in the vascular calcifications of kidney graft recipients. Safety evaluation;Primary end point(s): bone masses evolutions through bone densitometry tests: basal and after 6 and 12 months</Primary_outcome>
    <Secondary_ID>TOR-RIS-2004-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456630</Internal_Number>
    <TrialID>EUCTR2005-005155-18-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Study on the effectiveness of a treatment with statine in reducing the morbility and cardiovascular mortality in patients with moderate-strict renal insufficiency. - ND</Public_title>
    <Scientific_title>Study on the effectiveness of a treatment with statine in reducing the morbility and cardiovascular mortality in patients with moderate-strict renal insufficiency. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI</Primary_sponsor>
    <Date_registration3>20060125</Date_registration3>
    <Date_registration>25/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005155-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/02/2004</Date_enrollement>
    <Target_size>350</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients of age 18-80 years, with moderated light renal insufficiency, identified from a VFG calculated with formula of Cockcoft and Gault between the 60 and 20 ml/min.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients for which the cardiovascular risk is much elevated  40  .  Patients already in treatment with statine.&lt;br&gt;</Exclusion_Criteria>
    <Condition>patients with moderate-strict renal insufficiency &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10038474
</Condition>
    <Intervention>&lt;br&gt;Trade Name: TORVAST 10 10 CPR 10 MG&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Atorvastatin&lt;br&gt;CAS Number: 134523-03-8&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To verify in a population of patients with moderate-strict IR that an aggressive treatment of cholesterolemia  target   the levels of cholesterol LDL   100 mg/dL  meaningfully reduces the entity of a end point composite, constituted from mortality and cardiovascular morbility.;Secondary Objective: To verify in a population of patients with moderate-strict IR that an aggressive treatment of cholesterolemia  target   the levels of cholesterol LDL   100 mg/dL  meaningfully reduces the entity of a end point composite, constituted from mortality and cardiovascular morbility.;Primary end point(s): A composite of serious cardiovascular events  infarct, ictus, intestinal infarct, thrombosis renal arteries  and cardiovascular mortality.</Primary_outcome>
    <Secondary_ID>61/2003/O</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456830</Internal_Number>
    <TrialID>EUCTR2005-005770-72-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA  MRCC   A GOIRC PHASE II STUDY - RAPSODY</Public_title>
    <Scientific_title>RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA  MRCC   A GOIRC PHASE II STUDY - RAPSODY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>GRUPPO ONCOLOGICO ITALIANO DI RICERCA</Primary_sponsor>
    <Date_registration3>20060217</Date_registration3>
    <Date_registration>17/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005770-72                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/01/2006</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sorafenib 800 mg/die   interferone alfa 2a 9MU TIW&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Signed informed consent  2.Histologically or cytologically documented Clear Cell Renal Carcinoma  RCC . In the case of a mixed histology the presence of a documented component of clear cell histology   61619; 50  is mandatory . Other variants are excluded  3.Prior Nephrectomy for primary site  conservative approaches are allowed   4.In cases with initial diagnosis of RCC of more than 2 years  RFS   2 years  a histological/cytological confirmation of renal cell carcinoma origin of actual metastases is mandatory  5.Metastatic measurable disease  at least one uni-dimensional measurable lesion by CT-scan or MRI  according to RECIST criteria  reported in Appendix   6.ECOG performance status   8804;2  ECOG scale reported in Appendix   7.Age   8805; 18 years  8.Life expectancy   8805; 3 months  9.Prior Surgery and/or Radiation Therapy  to less or equal than 25  of the bone marrow  are allowed. However, at least 4 weeks must have been elapsed since surgery or completion of radiation therapy and the patient must has recovered from side effects  10.ANC   8805;1.5 x 109/L; PLT   8805;100 x 109/L; Hb   8805;10 g/dl  11.Adequate hepatic function  Total bilirubin  1.5 times the UNL ; ALT and AST  2.5 times the UNL   5 UNL in presence of liver metastases   12.Amylase and lipase  1.5 x the UNL  13.Serum creatinine  2.0 x the UNL  14.PT or INR and PTT  1.5 times the UNL  Note  patients who receive anti-coagulation treatment will be allowed to participate provided that no evidence of abnormality in these parameters exists   15.Patients must be accessible for treatment and follow up   UNL   upper normal limit of the institution.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.CNS metastases  2.Previous malignancy except for basal cell skin cancer and cervical carcinoma in situ adequately treated, or any other cancer from which the patient has been disease-free for   61619; 5 years  3.Any of the concomitant illness or medical condition indicated below     Serious respiratory or cardiovascular disease such as  congestive heart failure    NYHA Class II -refer to Appendix- ; previous history  within 6 months  of myocardial infarction, angina pectoris or cardiac arrhythmias requiring anti-arrythmics  excluding beta blockers or digoxin . Active coronary artery disease, uncontrolled hypertension  4.Unstable diabetes mellitus, significant neurological or psychiatric disorders or seizure disorder requiring medication  such as anti-epileptics   5.Active clinically serious bacterial or fungal infections    grade 2 NCI-CTC, Version 3  or active human immunodeficiency virus  HIV  infection or chronic hepatitis B or C  6.Previous treatment  chemotherapy, Immunotherapy or experimental drugs  for advanced disease  adjuvant immnunotherapy could be allowed in the case of a relapse free survival   6 months   7.Prior isotope treatment  e.g. strontium or samarium   8.Participation in clinical trials with other experimental agents within 30 days of study entry or concomitant treatment with other experimental drug  9.Concomitant treatment with bisphosphonates or any other anti-cancer therapy  10.Concomitant treatment with ketoconazole or itraconazole  11.Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial  12.History of organ allograft or autologous bone marrow transplant or stem cell rescue within four months of start of study drug   13.Prior use of Raf-kinase inhibitors  RKI , MEK or Farnesyl transferase inhibitors  14.Known or suspected allergy to the investigational agent or any agent given in association with this trial&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with histologically- or cytologically-confirmed, metastatic, clear cell renal cell cancer  RCC &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10050513
</Condition>
    <Intervention>&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Product Code: BAY 43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;CAS Number: 284461-73&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Product Code: BAY43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;CAS Number: 284461-73&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Aim of this study is to evaluate if the combination of Sorafenib 800 mg daily plus low-dose frequent interferon  total weekly dose 15 MU  has an increased antiangiogenic activity, and  a consequent possible increased activity, than Sorafenib 800 mg daily plus interferon in the classic schedule  total weekly dose 27 MU . Serum surrogate markers will be evaluated to eventually support clinical results of the study.;Secondary Objective: A pharmacoeconomic evaluation of the two treatment  schedules  Sorafenib same schedule and dosage, IFN total weekly dose 27 MU in Arm A vs  15 MU in ArmB  will be performed.;Primary end point(s): Primary end-point of the study is to determine the Progression Free Survival  PFS  rates in the two arms.</Primary_outcome>
    <Secondary_ID>0681</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456841</Internal_Number>
    <TrialID>EUCTR2005-005695-32-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Ensayo clínico aleatorizado, controlado y abierto, para evaluar la eficacia (biocompatibilidad peritoneal) de la adición de bemiparina a la solución de icodextrina, en pacientes en diálisis peritoneal con trastornos del trasporte peritoneal. - Bemidextrina</Public_title>
    <Scientific_title>Ensayo clínico aleatorizado, controlado y abierto, para evaluar la eficacia (biocompatibilidad peritoneal) de la adición de bemiparina a la solución de icodextrina, en pacientes en diálisis peritoneal con trastornos del trasporte peritoneal. - Bemidextrina                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fundación Renal Iñigo Álvarez de Toledo</Primary_sponsor>
    <Date_registration3>20060216</Date_registration3>
    <Date_registration>16/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005695-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/03/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sin tratamiento experimental&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Pacientes mayores de 18 años de ambos sexos, que hayan otorgado su consentimiento informado para participar en el estudio.&lt;br&gt;- Pacientes en tratamiento estable con diálisis peritoneal durante más de 6 semanas que presenten trastorno funcional peritoneal definido por capacidad de ultrafiltración estandarizada (glucosa 3.86% mantenida 4 horas en peritoneo) menor de 600 ml y/o transporte de creatinina elevado (definido por D/P de creatinina mayor de 0.65 a las 4h de permanencia). &lt;br&gt;- Pacientes con tratamiento con solución de icodextrina para diálisis peritoneal durante al menos un mes previo a su inclusión.&lt;br&gt;- Pacientes en los que el resto de líquidos dializantes que emplean en su DP contengan glucosa y PDG (productos de degradación de glucosa).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Peritonitis en los últimos 2 meses.&lt;br&gt;- Pacientes con hemorragia en el momento de la inclusión, o pacientes con antecedentes de episodios hemorrágicos clínicamente evidentes y/o con incremento del riesgo de sangrado debido a cualquier alteración de la hemostasia que contraindique la terapia anticoagulante, y/o que en los dos últimos meses hayan presentado, al menos, alguna de las siguientes situaciones: hemorragia activa o lesiones orgánicas susceptibles de sangrar (ej.: úlcera péptica activa, accidente cerebrovascular hemorrágico, aneurismas).&lt;br&gt;- Cirugía mayor en el último mes. &lt;br&gt;- Hipersensibilidad conocida a las HBPM, a la heparina o sustancias de origen porcino.&lt;br&gt;- Hipersensibilidad conocida a icodextrina.&lt;br&gt;- Pacientes tratados con anticoagulación sistémica.&lt;br&gt;- Pacientes con diátesis hemorrágica congénita o adquirida. &lt;br&gt;- Daños o intervenciones quirúrgicas en el sistema nervioso central, ojos y oídos dentro de los 6 meses previos. &lt;br&gt;- Endocarditis bacteriana aguda y endocarditis lenta. &lt;br&gt;- Pacientes con historia de trombocitopenia asociada a heparina. &lt;br&gt;- Pacientes con insuficiencia hepática (con valores de AST y/o ALT &gt; 5 veces el valor normal establecido en los rangos de referencia del laboratorio local del hospital).&lt;br&gt;&lt;br&gt;- Hipertensión arterial grave (presión arterial sistólica mayor de 200 mmHg y/o presión arterial diastólica mayor de 120 mmHg).&lt;br&gt;- Pacientes con sospecha o incapacidad para cumplir el tratamiento y/o seguimiento del estudio.&lt;br&gt;- Pacientes que estén participando en otro ensayo clínico o lo hayan hecho en los últimos 30 días. &lt;br&gt;- Pacientes que tengan una esperanza de vida inferior a 6 meses.&lt;br&gt;- Mujeres embarazadas o en edad fértil que no utilicen un método anticonceptivo eficaz o mujeres en periodo de lactancia. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes con insuficiencia renal en tratamiento con diálisis peritoneal y trastornos de la función peritoneal. &lt;br&gt;Classification code 10051055
</Condition>
    <Intervention>&lt;br&gt;Trade Name: HIBOR® 3.500 UI anti Xa&lt;br&gt;Product Name: HIBOR®&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Bemiparina sodica&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 17500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar si la adición de bemiparina (3500 Ul/día), una vez al día en la solución de icodextrina para la diálisis peritoneal durante 16 semanas, aumenta la capacidad peritoneal de ultrafiltración y/o disminuye la de transporte de creatinina de pacientes en diálisis peritoneal que presenten trastornos funcionales de tipo déficit de ultrafiltración y/o alto transporte.;Secondary Objective: Evaluar si la adición de bemiparina (3500 Ul/día), una vez al día en la solución de icodextrina para la diálisis peritoneal durante 16 semanas, modifica algunos biomarcadores del efluente peritoneal relacionados con los procesos de regeneración tisular.;Primary end point(s): La función peritoneal definida mediante la capacidad de ultrafiltración estandarizada (glucosa 3,86%, 4 horas de permanencia i.p.) y/o el transporte peritoneal de creatinina estimado por D/P y coeficiente de transferencia de masas o MTC durante el periodo de tratamiento aleatorizado (desde el día 1 al día 112).</Primary_outcome>
    <Secondary_ID>FRIAT-BEM-2005-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456879</Internal_Number>
    <TrialID>EUCTR2006-000607-42-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Treatment of borderline changesin protocol biopsy 3 months after renal transplantation</Public_title>
    <Scientific_title>Treatment of borderline changesin protocol biopsy 3 months after renal transplantation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Institute for clinical and experimental Medicine</Primary_sponsor>
    <Date_registration3>20060208</Date_registration3>
    <Date_registration>08/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000607-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/02/2006</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: no treatment&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a. 3 months after kidney transplantation&lt;br&gt;b. stabilised graft function with serum creatinine under 300 umol/l&lt;br&gt;c.  borderline changes according to Banff classification in protocol biopsy&lt;br&gt;d. signed  informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a. Graft dysfunction due to rejection or to other reasons less than 1 month before biopsy&lt;br&gt;b. reduced graft function with serum creatinine 300 umol/l or higher &lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with transplanted kidney and stabilised graft function</Condition>
    <Intervention>&lt;br&gt;Trade Name: SOLU-MEDROL inj.&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: methylprednisolon&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Impact of antirejection treatment with Solu-Medrol on graft function development&lt;br&gt;in patients with borderline changes in 3-months protocol graft biopsy.;Secondary Objective: Impact of antirejection treatment with Solu-Medrol on acute rejection prevalence and  graft survival in patients  with borderline changes in 3-months protocol graft biopsy ;Primary end point(s): Graft function assessed by serum creatinine and glomerular filtration rate calculated by Cockroft-Gault formula and MDRD at 1 and 2 years posttransplant</Primary_outcome>
    <Secondary_ID>KN-1/06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457059</Internal_Number>
    <TrialID>EUCTR2004-000678-30-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation. - Epomax (3 x week i.v.) A dose dependency evaluation</Public_title>
    <Scientific_title>An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation. - Epomax (3 x week i.v.) A dose dependency evaluation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Baxter Healthcare S.A.</Primary_sponsor>
    <Date_registration3>20040910</Date_registration3>
    <Date_registration>10/09/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000678-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/11/2004</Date_enrollement>
    <Target_size>105</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients who have provided written informed consent.&lt;br&gt;2. Patients with stable Hb &lt;10.5g/dL (stable = at least two Hb measurements &lt;10.5g/dL, a minimum of 7 days apart, in a 42 day period prior to formal screening for the study.  &lt;br&gt;3. Haemodialysis 3X/W for a minimum of 3 months and with delivered Kt/V =1.20/session (renal clearance to be added to K in case of residual renal function (RRF) [urine volume &gt;100mL] and renal urea clearance &gt;0.5mL/min). In the case that Kt/V determinations are not possible, a urea reduction rate (URR) of &gt; 65% will be accepted.&lt;br&gt;4. Patients 18-75 years of age (inclusive).&lt;br&gt;5. Patients with an adequate iron status defined as serum ferritin =100µg/L and transferrin saturation =20% at the screening visit.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Patients with uncontrolled hypertension (diastolic BP &gt;100 mm Hg determined during two separate pre-dialysis measurements, preferably the second session of the week).&lt;br&gt;2.	Patients with Vit B12 deficiency (&lt;200 ng/L) or folic acid deficiency (&lt;3.0µg/L).&lt;br&gt;3.	Patients receiving treatment for cancer.&lt;br&gt;4.	Patients with haemolytic anaemia or anaemia due to other diseases.&lt;br&gt;5.	Patients with clinically persistent blood loss (e.g. gastrointestinal).&lt;br&gt;6.	Patients with known epilepsy.&lt;br&gt;7.	Patients with severe hyperparathyroidism and/or indication for parathyroidectomy.&lt;br&gt;8.	Pregnant or lactating patients. &lt;br&gt;N.B. Female patients of childbearing potential must have a negative serum pregnancy test at the time of screening and will be required to use a medically acceptable means of contraception during their participation in this study.&lt;br&gt;9.	Patients who have received Interferon or Ribavirin within 30 days prior to the screening visit.&lt;br&gt;10.	Patients who have received Epoetin (Alpha, Beta) or darbepoetin alfa treatment, androgens or transfusions within the last 90 days prior to screening.&lt;br&gt;11.	Patients with acute infection(s).&lt;br&gt;12.	Patients with inflammatory status (CRP &gt;30mg/L).&lt;br&gt;13.	Patients with HIV.&lt;br&gt;14.	Patients with chronic hepatitis C or chronic hepatitis B (with transaminases &gt;2X upper limit).&lt;br&gt;15.	 Patients who have received cytotoxic agents, immunosuppressives or radiation therapy within 30 days prior to the screening visit.&lt;br&gt;16.	Patients participating in another interventional study.&lt;br&gt;17.	Patients who have received investigational drug within 30 days prior to the screening visit.&lt;br&gt;18.	Patients with known hypersensitivity to Epoetin, mammalian cell line products or human serum albumin.&lt;br&gt;19.	Patients with a history of pure red cell aplasia (any cause).&lt;br&gt;20.	Patients with a serum albumin &lt; 30 g/L.&lt;br&gt;21.	Patients with a life expectancy &lt; 6 months.&lt;br&gt;Patients who have had a renal transplant are allowed to participate in the study, as are those who are on the transplant waiting list.  Those who are scheduled to have a living related donor operation within the next 3 months must be excluded.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anaemia in End Stage Renal Disease  (ESRD) hemodialyzed Patients
 &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10009120
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NeoRecormon Multidose 50,000IU Powder and solvent for solution for injection&lt;br&gt;Product Name: NEORECORMON &lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50000-&lt;br&gt;&lt;br&gt;Product Name: EPOMAX 5000 IU, solution for injection&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: epoetin omega&lt;br&gt;Current Sponsor code: rHu-EPO&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to evaluate the dose dependency of the effects of Epoetin-Omega administered by thrice weekly intravenous (i.v.) injection on erythropoiesis in anaemic renal patients on haemodialysis.;Secondary Objective: The trial will also evaluate the dose dependency of possible untoward effects.;Primary end point(s): 1.       Response rate. The Response Rate is the proportion of “responders”, where response to the assigned dose is defined as Packed Red Cell (PRC)   transfusion-independent attainment of Hb levels during the trial that meet one of the  following criteria: a) two consecutive weekly Hb values &gt;1.5 g/dL higher than the baseline Hb (HbB); b) Hb level is &gt;13.0 g/dL at least once, c) reduction in Epoetin dose due to a too rapid increase in Hb (i.e. &gt; 2.5 g/dL/2 weeks).&lt;br&gt;The baseline Hb level is defined as the average value of three Hb concentrations determined at the Screening Visit, in between the  screening visit and visit 0, and at visit 0.&lt;br&gt;2.       The weekly change in Hb until the end of the study. This parameter is defined as the weekly consecutive differences in Hb for each patient  (Hbi - Hbi-1, where i is the visit number and may range from 1 to 12).  For Visit 1, the value Hbi-1 is the baseline Hb value. The duration of  the observed period is from enrolment until one of the following events (whichever occurs first).&lt;br&gt;a)	The Hb level &gt; 13 g/dL.&lt;br&gt;b)	Patient requires an Epoetin dose increase.&lt;br&gt;c)	Patient requires an Epoetin dose decrease.&lt;br&gt;d)	Patient receives a PRC transfusion.&lt;br&gt;e)	Patient drops out of the study and Hb values are no longer available.&lt;br&gt;f)	The planned end of the study (completed 12 weeks).</Primary_outcome>
    <Secondary_ID>PRO-RENAL-REG-056</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457194</Internal_Number>
    <TrialID>EUCTR2005-004052-12-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónica</Public_title>
    <Scientific_title>Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónica                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Asociación Científica para la investigación Nefrológica (ACINEF)</Primary_sponsor>
    <Date_registration3>20060330</Date_registration3>
    <Date_registration>30/03/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004052-12                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/06/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Sujetos de ambos sexos, con edad igual o superior a 18 años; Sujetos sometidos a hemodiálisis durante un período igual o superior a 3 meses;	Sujetos que otorguen su consentimiento informado por escrito.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Sujetos que padezcan algún tipo de enfermedad inflamatoria, infecciosa o tumoral; Sujetos que hayan presentado algún episodio de enfermedad cardiovascular en los 3 meses previos a su inclusión en el estudio; Sujetos con enfermedad gastrointestinal severa (disfagia, gastroparesia activa no tratada, problemas de motilidad gastrointestinal, cirugía intestinal...); Sujetos con antecedentes de alcoholismo o abuso de tóxicos; Sujetos con antecedentes de vasculitis; Sujetos con diabetes mellitus y/o hipertensión mal controlada;	Sujetos que estén tomando fármacos con propiedades antiinflamatorias o inmunosupresores (corticoides, AINEs, inmunosupresores o inmunomoduladores, cualquier principio activo en cuya ficha técnica aparezca reflejado efecto alguno sobre la síntesis y/o liberación de citoquinas)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Enfermedad renal terminal (ESRD)</Condition>
    <Intervention>&lt;br&gt;Trade Name: Renagel 800 mg&lt;br&gt;Product Name: Renagel&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sevelamer&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;Product Name: Acetato cálcico&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Acetato cálcico&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determinar la influencia del tratamiento con sevelamer en los niveles séricos de citoquinas pro-inflamatorias (TNF-alfa, IL-1beta, IL-6, IL-18), antiinflamatorias (IL-10) y de proteína C reactiva (PCR) en pacientes sometidos a hemodiálisis crónica.;Secondary Objective: Determinar la relación entre el metabolismo fosfocálcico y el estado inflamatorio.;Primary end point(s): Concentraciones séricas de citoquinas pro-inflamatorias (TNF-alfa, IL-1beta, IL-6, IL-18) y anti-inflamatorias (IL-10) en pacientes sometidos a hemodiálisis crónica.</Primary_outcome>
    <Secondary_ID>CAN-NEFRO-2005-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457243</Internal_Number>
    <TrialID>EUCTR2006-000830-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy - SALAMI</Public_title>
    <Scientific_title>A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy - SALAMI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Leeds Teaching Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20060403</Date_registration3>
    <Date_registration>03/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000830-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/07/2006</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Male and female patients who must be over age 18 years.&lt;br&gt;•	Patients must be recipients of heart-beating cadaveric, non-heart beating or living donors.&lt;br&gt;•	Patients receiving a 2nd or subsequent grafts must have maintained their primary graft for a minimum of 6 months, except if graft failure was due to technical reasons.&lt;br&gt;•	Written Informed consent&lt;br&gt;•	Women at risk of pregnancy must have a negative pregnancy test before commencing the trial and agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuing the trial.  The manufacturer of Alemtuzumab advises effective contraception for 6 months after administration to men or women.  Advice will be given to patients to discuss with the transplant medical staff if a pregnancy is planned. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Regional patients from Hull Royal Infirmary (due to the logistical difficulties in following these patients up from Leeds).&lt;br&gt;•	High Risk Recipients - defined as recipients who have one or more of the following; 2 HLA-DR mismatch, previous immunologically mediated graft loss in less than 6 months, Preoperative donor specific antibodies&lt;br&gt;•	Known hypersensitivity to the IMP including the standard drugs.&lt;br&gt;•	Prohibited prior or concomitant medications&lt;br&gt;•	Pregnant women or nursing mothers. &lt;br&gt;•	WBC count &lt; 3000/mm3 or platelets &lt; 75,000/mm3 at time of study entry&lt;br&gt;•	Any other concurrent cardiovascular, gastrointestinal, pulmonary or haematological conditions that would restrict the administration of study drugs in the opinion of the investigator.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>MabCampath / Alemtuzumab will be used as part of the immunosuppression regime following renal transplant.</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabCampath&lt;br&gt;Product Name: MabCampath&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;Product Name: Simulect&lt;br&gt;Pharmaceutical Form: Powder for injection*&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: CellCept&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The purpose of this study is to compare the efficacy of two tacrolimus-based steroid avoidance immunosuppressive regimens.&lt;br&gt;The primary objective of this study is to determine whether we can use a regime of immunosuppression that is both as effective as our standard regime and that offers advantages in terms of a lack of some of the specific side effects of our standard regime and one that is simpler and more cost effective.;Secondary Objective: Secondary endpoints can be categorised: 1- contains a number of standard clinical variables anticipated to be similar in both study groups, including rejection rates, patient and graft survival rates and rates of delayed graft function.  2- comprises a number of surrogate markers for cardiovascular outcome which are particularly important in this setting of studying steroid-free patients.  These include 24 hour blood pressure monitoring, pulse wave analysis and metabolic studies including glucose tolerance.  3- various socioeconomic endpoints with quality of life assessment, adherence monitoring and a cost analysis.  4- follows a number of scientific endpoints capitalising on the various expertise available both on and off site&lt;br&gt;;Primary end point(s): 1.	DTPA Isotopic Glomerular Filtration Rate (GFR) at 12 months </Primary_outcome>
    <Secondary_ID>RL05/7239</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457397</Internal_Number>
    <TrialID>EUCTR2004-002376-42-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER</Public_title>
    <Scientific_title>PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST</Primary_sponsor>
    <Date_registration3>20060421</Date_registration3>
    <Date_registration>21/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002376-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/01/2005</Date_enrollement>
    <Target_size>36</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>TREATMENT OF METASTATIC KIDNEY CANCER &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10050018
</Condition>
    <Intervention>&lt;br&gt;Trade Name: XELODA 120 CPR RIV. 500MG&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Capecitabine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>ASL603LIOM02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457519</Internal_Number>
    <TrialID>EUCTR2006-001265-41-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A comparison of Sirolimus versus Tacrolimus as a delayed treatment of recipients of non heart beating donor kidneys after anti-IL2 monoclonal antibody - Sirolimus vs Tacrolimus for NHBD Kidney Recipients after IL-2 mAb</Public_title>
    <Scientific_title>A comparison of Sirolimus versus Tacrolimus as a delayed treatment of recipients of non heart beating donor kidneys after anti-IL2 monoclonal antibody - Sirolimus vs Tacrolimus for NHBD Kidney Recipients after IL-2 mAb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Newcastle upon Tyne Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20060418</Date_registration3>
    <Date_registration>18/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001265-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/06/2006</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Recipients of kidneys from non heart beating donors&lt;br&gt;&lt;br&gt;Age 18-75&lt;br&gt;&lt;br&gt;Written informed consent obtained from the patient after receiving a comprehensive explanation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnant women&lt;br&gt;&lt;br&gt;Recipients of multiple transplants (e.g. Both kidneys from one donor transplanted into one recipient or a simultaneous kidney and liver or kidney and pancreas transplant)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney transplantation from non heart beating donors for end-stage renal disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sirolimus (Rapamune)&lt;br&gt;Product Name: Sirolimus&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the effects of sirolimus and tacrolimus on kidney function following non heart beating donor kidney transplantation into adult recipients.;Secondary Objective: To determine if the drugs have different effects on patient survival, survival of the transplanted kidney, acute rejection, chronic rejection and complications following surgery.;Primary end point(s): The primary end points are creatinine and calculated GFR (glomerular filtration rate) at monthly intervals from the date of transplant to 12 months.</Primary_outcome>
    <Secondary_ID>200621</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457646</Internal_Number>
    <TrialID>EUCTR2004-005241-36-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase II clinical trial of Cisplatin, Gemcitabine and Trastuzumab (Herceptin®) as first line treatment of advanced irresectable transitional-cell urothelial carcinoma with overexpression of C-erbB-2 - UROTELIALHER2</Public_title>
    <Scientific_title>Phase II clinical trial of Cisplatin, Gemcitabine and Trastuzumab (Herceptin®) as first line treatment of advanced irresectable transitional-cell urothelial carcinoma with overexpression of C-erbB-2 - UROTELIALHER2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>ACROSS Group</Primary_sponsor>
    <Date_registration3>20060508</Date_registration3>
    <Date_registration>08/05/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005241-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/06/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Histologically proven diagnosis of urothelial adenocarcinoma of bladder, ureter and renal pelvis with overexpression of C-erbB-2 determined by IHC (+++) or FISH/CISH (in IHC ++) &lt;br&gt;- Non-resectable metastasic or locally advanced disease at the time of inclusion. Any T, any N and M1; T4b, N0, M0 or any T , N1,2 or 3, M0 &lt;br&gt;- Presence of at least one dimensionally measurable target on a CT-scan available for external review, with at least one diameter &gt; or = 2 cm, in a non-irradiated area&lt;br&gt;- Adequate cardiac function (LVEF &gt; or = 50%)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Prior therapy for advanced disease. Adjuvant or Neoadjuvant therapy or chemo-radiotherapy for primary local disease are permitted if at least 6 months have elapsed&lt;br&gt;- Congestive heart failure (NYHA class II, III, IV) or history of  documented congestive heart failure, unstable angina pectoris, myocardial infarction in the last 6 months, poorly controlled hypertension (systolic &gt;180 mmHg or diastolic &gt;100 mmHg), clinically significant valvular heart disease, or high-risk uncontrolled arrhythmias&lt;br&gt;- Patients with dyspnoea at rest due to malignant or other disease or who require supportive oxygen therapy&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced irresectable transitional-cell urothelial carcinoma, that includes cancer of the bladder, ureter and renal pelvis</Condition>
    <Intervention>&lt;br&gt;Trade Name: Trastuzumab (Herceptin)&lt;br&gt;Product Name: Trastuzumab (Herceptin)&lt;br&gt;Product Code: 903674&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: TRASTUZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 21-&lt;br&gt;&lt;br&gt;Trade Name: Gemcitabine&lt;br&gt;Product Name: Gemcitabine&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: GEMZITABINE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 38-&lt;br&gt;&lt;br&gt;Trade Name: Cisplatin&lt;br&gt;Product Name: Cisplatin&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: CISPLATIN&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the efficacy to the combination of Cisplatin, Gemcitabine and Trastuzumab in terms of response rate in patients with advance urothelial carcinoma, that includes the cancer of bladder, of ureter and of renal pelvis with overexpression of C-erbB-2&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;;Secondary Objective: To determine the progression-free interval, the duration of the response, the toxicity profile and the overall survival in patients with advance urothelial carcinoma&lt;br&gt;;Primary end point(s): The principal variable of valoration will be the number of response rates in patientes treated with the combination </Primary_outcome>
  </Trial>
  <Trial>
    <Internal_Number>2457678</Internal_Number>
    <TrialID>EUCTR2005-000380-26-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients - CERTES02</Public_title>
    <Scientific_title>A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients - CERTES02                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica S.A.</Primary_sponsor>
    <Date_registration3>20060509</Date_registration3>
    <Date_registration>09/05/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000380-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/05/2005</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: The control arm is the no drug discont of one of the drugs,and the changes of the trial drug dosages&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Each patient must meet all of the following inclusion criteria:&lt;br&gt;1. Male or female patients between 18 and 65 years of age&lt;br&gt;2. Male or female patients who are recipients of a first renal transplant from a primary cadaveric or non-HLA identical living related donor .&lt;br&gt;3. The renal cold ischemic time (CIT) must be &lt; 36 hours&lt;br&gt;4. The age of the donor must be &lt; 65 years&lt;br&gt;5. Females of childbearing potential must have a negative pregnancy test at baseline and are required to practice an approved method of birth control for the duration of the study and for a period of three months following discontinuation of study medication. &lt;br&gt;6. Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients meeting any of the following criteria at baseline will be excluded from study participation.&lt;br&gt;1. Patients who are recipients of  multiple organ transplants including any organ other than kidney&lt;br&gt;2. Patients who have been previously transplanted with any organ other than a kidney&lt;br&gt;3. Recipients of non heart-beating donor organs&lt;br&gt;4. Patients with current or past panel reactive T-cell antibodies (PRA) titers of &gt;50%&lt;br&gt;5. Patients that had been treated with any investigational drug 4 weeks before the baseline period&lt;br&gt;6. Presence of any severe allergy requiring acute (within 4 weeks of baseline) or chronic treatment, or hypersensitivity to drugs similar to RAD001 (e.g. macrolides)&lt;br&gt;7. Existence of any surgical or medical condition, other than the current transplant, which in the opinion of the investigator, precludes enrollment in this trial&lt;br&gt;8. Evidence of liver dysfunction as indicated by an abnormal liver profile (AST, ALT, alkaline phosphatase or total bilirubin = 3 times ULN) before transplantation&lt;br&gt;9. Patients who are known to have a positive hepatitis C serology, who are human immunodeficiency virus (HIV) or hepatitis B surface antigen positive.  Laboratory  results obtained within 6 months prior to randomization are acceptable. Recipients of organs from donors who test positive for Hepatitis B surface antigen or Hepatitis C are excluded.&lt;br&gt;10. Patients with symptoms of significant somatic or mental illness. Unresolved history of drug or alcohol abuse&lt;br&gt;11. Presence of revascularized ischemic heart disease or AMI, (or any cardiac disease  considered to be unsafe for the study by the investigator)&lt;br&gt;12. Presence of severe hypercholesterolemia (= 350 mg/dL, 9.1 mmoL/dL) or hypertriglyceridemia (= 500mg/dL, 5.6 mmoL/L). Patients with controlled hyperlipidemia are acceptable&lt;br&gt;13. White blood cell (WBC) count= 3,500/mm3, or platelet count = 100,000/mm3 &lt;br&gt;14.  Patients with severe systemic infections&lt;br&gt;15. Patients with current or past malignancies (except for successfully treated localized basal cell carcinoma of the skin)&lt;br&gt;16. Patients who are recipients of A-B-O incompatible transplants or T-cell cross-match positive transplants &lt;br&gt;17. Patients with coagulopathy or any medical condition requiring long-term anticoagulation after transplantation (low  dose aspirin is allowed)&lt;br&gt;18. Abnormal physical or laboratory findings of clinical significance within 2 weeks prior to baseline visit, which at investigators discretion would interfere with the objectives of the study&lt;br&gt;19. Breast feeding women&lt;br&gt;20. Inability to cooperate or communicate with the investigator &lt;br&gt;21. Patients who have been treated with non-protocol immunosuppressive drug or treatment within 4 weeks prior to baseline visit&lt;br&gt;&lt;br&gt;Exclusion criteria for randomization at the end of month 3 (week 12):&lt;br&gt;&lt;br&gt;1. Any episode of acute rejection grade IIb/III (Banff classification) or a vascular acute rejection in the previous 4 weeks or any episode of acute rejection episode during the month prior to randomization.&lt;br&gt;2. Patients depending on dialysis&lt;br&gt;3. Serum creatinine &gt;3 mg/dL and/or more than 30% elevated during the previous month. &lt;br&gt;4. Patients who do not tolerate any increase in Certican ®  dose.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant &lt;br&gt;MedDRA version: M15
Classification code 10023438
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican®  &lt;br&gt;Product Name: Certican®&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.50-&lt;br&gt;&lt;br&gt;Trade Name: Certican®  &lt;br&gt;Product Name: Certican®&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to compare renal function in the two treatment groups at month 12 post-transplant, as measured by calculated GFR (Nankivell), serum creatinine and calculated creatinine clearance (Cockroft- Gault).&lt;br&gt;Intra-group change in GFR , as determined by Nankivell’s formula, and the GFR’s slope in the period between visits 6 and 12 months will also be determined.&lt;br&gt;;Secondary Objective: The secondary objectives of this study are:&lt;br&gt;•	To evaluate the incidence of biopsy-proven acute rejection (BPAR) episodes, graft loss, death or loss to follow-up after 12 months in both groups.&lt;br&gt;•	To evaluate the incidence of graft loss, death, BPAR episodes, antibody treated acute rejection episodes, clinically confirmed acute rejection episodes, clinically confirmed chronic rejection episodes and biopsy-proven chronic allograft nephropathy after 12 months in both groups.&lt;br&gt;•	To evaluate the safety of Certican® in combination with Simulect® and steroids, with either Neoral® discontinuation at 3 months post-transplant, or  Neoral® minimization.&lt;br&gt;;Primary end point(s): The GFR value is calculated using the Nankivell formula. This is the end point in witch sample size is based. </Primary_outcome>
    <Secondary_ID>CERTES02 (Ce-PoP-RAD001A2419)</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458046</Internal_Number>
    <TrialID>EUCTR2006-001504-37-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS  ACHN-IL2  MIXED TO AUTOLOGOUS TUMOR CELLS  CT-AUT  IN PATIENTS WITH METASTATIC RENAL CARCINOMA. - ND</Public_title>
    <Scientific_title>SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS  ACHN-IL2  MIXED TO AUTOLOGOUS TUMOR CELLS  CT-AUT  IN PATIENTS WITH METASTATIC RENAL CARCINOMA. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI</Primary_sponsor>
    <Date_registration3>20060623</Date_registration3>
    <Date_registration>23/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001504-37                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/05/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Terapie standard a base di Interleuchina2 e cellul&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1  documented Diagnosis of metastatic renal carcinoma; 2  Performance status  Karnofsky  80-100  and one prognosis quoad vitam advanced to 4 months;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1  Performance status  Karnofsky   80-100  and one prognosis quoad vitam inferior to 4 months;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic Kidney Cancer &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10050018
</Condition>
    <Intervention>&lt;br&gt;Product Name: ACHN-IL2&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: ACHN-IL2&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10000000-&lt;br&gt;&lt;br&gt;Product Name: CT-AUT&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: CT-AUT&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5000000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: appraisal of the survival and quality of the life;Secondary Objective: clinical regression of the lesions;Primary end point(s): appraisal of the survival</Primary_outcome>
    <Secondary_ID>30/2006/O/Sper</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458152</Internal_Number>
    <TrialID>EUCTR2006-000231-95-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A PHASE II STUDY OF BAY 43-9006 IN COMBINATION WITH WEEKLY GEMCITABINE FOR THE TREATMENT OF METASTATIC RCC EITHER UNSUITABLE FOR OR REFRACTORY TO PRIOR TREATMENT WITH CYTOKINES - TAGUSG6</Public_title>
    <Scientific_title>A PHASE II STUDY OF BAY 43-9006 IN COMBINATION WITH WEEKLY GEMCITABINE FOR THE TREATMENT OF METASTATIC RCC EITHER UNSUITABLE FOR OR REFRACTORY TO PRIOR TREATMENT WITH CYTOKINES - TAGUSG6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO</Primary_sponsor>
    <Date_registration3>20060622</Date_registration3>
    <Date_registration>22/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000231-95                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/02/2006</Date_enrollement>
    <Target_size>43</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Written informed consent  - Advanced, histologically confirmed, RCC  - ECOG PS 0-2  - Age 18 years  - UISS 3 cathegory  see appendix  or immunotherapy refractory disease  indipendently of UISS cathegory .  - Presence of measurable disease  - Adequate blood counts  WBC  3.000/ml; HB  10 gr/dl; Ptl  100.000/ml  liver  Transaminases  2N; bilirubin  2N  and kidney  creatinine  2 ng/ml  function tests.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Brain metastasis  - Comorbid conditions which could represent a contraindication to receive the drugs on study or to jeopardize patient compliance  - Unstable diabetes; active coronary disease; active serious infections  - Recent gastrointestinal bleeding&lt;br&gt;</Exclusion_Criteria>
    <Condition>METASTATIC RENAL CANCER CELL &lt;br&gt;MedDRA version: 8.1
Level: PT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Current Sponsor code: Bay 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Gemzar*1g Polv ev 1fl&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Gemcitabine&lt;br&gt;CAS Number: 122111-03-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: - To evaluate the response  expressed as  clinical benefit   to the combination of Gemcitabine and BAY 43-9006 in women and men with metastatic RCC either unsuitable for or refractory to prior treatment with cytokines.;Secondary Objective: - To evaluate progression-free survival, overall survival, response duration, time to response.  - To evaluate the combined regimen with respect to change in QoL status.  - To evaluate the possible predictive value of baseline phosho ERK  pERK , VEGFr 2 and 3 in tumour cells and of VEGF serum levels in determining tumor response.;Primary end point(s): To evaluate the response  expressed as  clinical benefit   to the combination of Gemcitabine and BAY 43-9006 in women and men with metastatic RCC either unsuitable for or refractory to prior treatment with cytokines.</Primary_outcome>
    <Secondary_ID>TAGUSG6</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458281</Internal_Number>
    <TrialID>EUCTR2006-001935-23-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy</Public_title>
    <Scientific_title>Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>University of Heidelberg</Primary_sponsor>
    <Date_registration3>20061024</Date_registration3>
    <Date_registration>24/10/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001935-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/10/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients who have had stable renal allograft function for at least three months. &lt;br&gt;Patients with a written informed consent.&lt;br&gt;Patients over 18 years.&lt;br&gt;Patients of the Department of Nephrology; University Heidelberg (D).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Allograft recipients with lymphocele (&gt;100ml),&lt;br&gt;Patients with significant renal transplant artery stenosis (&gt;70%) &lt;br&gt;Patients with hydronephrosis of grade 2 (dilatation of the renal pelvis and the calyces, with or without a dilatation of the proximal ureter) or more.&lt;br&gt;Patients with a familiar incompatibility against SonoVue TM &lt;br&gt;Patients with pregnancy.&lt;br&gt;Patients are allergic to proteins.&lt;br&gt;Patients with pulmonary hypertension.&lt;br&gt;Patients wirh a thrombotic diathesm&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Vascular allograft nephropathy represents the main cause of renal allograft loss after 1 yr of transplantation. The trial shall find a way for early diagnostics.
</Condition>
    <Intervention>&lt;br&gt;Trade Name: SonoVue 8 Mikroliter/ml Pulver und Lösungsmittel&lt;br&gt;zur Herstellung einer Dispersion&lt;br&gt;zur Injektion&lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: SonoVue 8 Mikroliter/ml Pulver und Lösungsmittel&lt;br&gt;CAS Number: 2551-62-4&lt;br&gt;Concentration unit: µl/ml microlitre(s)/millilitre&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Real-time contrast enhanced sonography can assess microvascular tissue perfusion using gas-filled microbubbles. The study shall evaluate the feasibility of RT-CES in detecting vascular allograft nephropathy  in comparison to colour Doppler ultrasonography.;Secondary Objective: ;Primary end point(s): to evaluate the feasibility of RT-CES in detecting vascular allograft nephropathy  in comparison to colour Doppler ultrasonography</Primary_outcome>
    <Secondary_ID>NZHD02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458376</Internal_Number>
    <TrialID>EUCTR2006-002851-33-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinoma</Public_title>
    <Scientific_title>Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Univ. Prof. Dr. Manuela Schmidinger</Primary_sponsor>
    <Date_registration3>20060816</Date_registration3>
    <Date_registration>16/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002851-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/08/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Age greater or equal to 18 years&lt;br&gt;•	Histologically confirmed renal cell carcinoma (primary tumour or biopsy/surgery of metastases)&lt;br&gt;•	Radiologically confirmed metastatic disease&lt;br&gt;•	Surgically removed primary tumour so feasible (nephrectomy or nephron-sparing surgery as indicated) &lt;br&gt;•	ECOG status of 0 or 1 &lt;br&gt;•	Life expectancy of at least 12 weeks&lt;br&gt;•	Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to treatment start:&lt;br&gt;o	Hemoglobin &gt; 9.0 g/L&lt;br&gt;o	Leucocytes greater than or equal to 3000/µL&lt;br&gt;o	Absolut neutrophil count &gt; or equal 1,500 µL&lt;br&gt;o	Platelet count above &gt; or equal 100,000 /µL&lt;br&gt;o	Total bilirubin &gt; or equal 1.5 x upper limit normal&lt;br&gt;o	Serum creatinine &lt; 2.5 x upper limit normal &lt;br&gt;o	ALT and AST &lt; 2.5 x upper limit normal (&lt; 5 x upper limit normal for patients with liver involvement of their cancer&lt;br&gt;o	PT or INR and PTT&lt; 1.5 x upper limit normal&lt;br&gt;•	Women of childbearing potential and men must agree to use adequate contraception &lt;br&gt;•	Signed informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Prior systemic treatment for advanced renal cell carcinoma&lt;br&gt;•	Previous or concurrent malignancy that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1) or any cancer curatively treated &gt; 5 years prior to study entry.&lt;br&gt;•	Complete renal shut down requiring hemo-or peritoneal dialysis&lt;br&gt;•	History of cardiac disease: congestive heart failure &gt; NYHA class 2, active cardiovascular disease (MI less than 6 months prior to study entry), cardiac arrhythmia requiring anti-arrhythmic therapy (beta-blockers and digoxins are permitted), uncontrolled hypertension or history of poor compliance with antihypertensive treatment&lt;br&gt;•	Active clinically serious bacterial or fungal infection (&gt; grade 2 NCI-CTCAE, Version 3)&lt;br&gt;•	Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B/C &lt;br&gt;•	Evidence of spinal cord compression or brain metastases. A CT or MRI of the brain must be performed within 4 weeks prior to enrolment if the presence of metastases at these sites is suspected.&lt;br&gt;•	History or evidence upon physical/neurological examination of CNS disease unrelated to cancer, unless adequately treated with standard medical therapy e.g. uncontrolled seizures.&lt;br&gt;•	Patients with evidence or history of bleeding diathesis, coagulopathy, or thromboembolic event&lt;br&gt;•	Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results&lt;br&gt;•	Known or suspected allergy to any agent given in association with this trial&lt;br&gt;•	Any condition that is unstable or which could jeopardize the safety of the patient and his compliance in the study (e.g. uncontrolled diabetes mellitus, pancreatitis, acute or chronic liver disease etc).&lt;br&gt;•	Investigational drug therapy outside this trial during or within 4 weeks of the study entry&lt;br&gt;•	Prior use of inhibitors of Ras/Raf-, MEK-, AKT kinase- and mTOR-signaling pathway or of Farnesyl transferase inhibitors&lt;br&gt;•	Prior use investigational or licensed angiogenesis inhibitors&lt;br&gt;•	Concomitant Rifampicin&lt;br&gt;•	Significant surgery within 4 weeks prior to study entry&lt;br&gt;•	Female patients who are pregnant or breast feeding&lt;br&gt;•	Proteinuria defined as a 24-hour urine protein excretion greater than 1000 mg. Urine dipstick proteinuria of 2+ or greater will require a 24 hour urine to determine eligibility for enrollment&lt;br&gt;•	Impairment of the gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Sorafenib&lt;br&gt;•	Therapeutic anticoagulation with coumadin, heparins or heparinoids&lt;br&gt;•	Current or recent (within 10 days of first dose of study treatment) daily use of aspirin (&gt;325 mg/day) or other NSAID &lt;br&gt;•	Thrombic or embolic events within the past 6 months&lt;br&gt;•	Hypertension defined as systolic blood pressure greater than 140 mm/Hg or diastolic pressure greater than 90 mm/Hg despite optimal management&lt;br&gt;•	Serious non-healing wounds, acute or non-healing ulcers, or bone fractures&lt;br&gt;•	Evidence of bleeding diathesis&lt;br&gt;•	History of hemoptysis or high grade varices&lt;br&gt;•	Primary tumor surgically removable&lt;br&gt;•	Solitary, surgically removable metastases&lt;br&gt;•	Patient unwilling or unable to give informed consent&lt;br&gt;•	Pregnancy or breast feeding&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with advanced renal cell carcinoma</Condition>
    <Intervention>&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Product Code: Bay 43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;CAS Number: 284461-73-0&lt;br&gt;Current Sponsor code: Bay 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Bevacizumab&lt;br&gt;Product Code: Ro4876646&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Bevacizumab&lt;br&gt;Current Sponsor code: Ro4876646&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: •	To assess the combination of Sorafenib and Bevacizumab with respect to progression free survival &lt;br&gt;;Secondary Objective: •	To assess the safety of Sorafenib and Bavacizumab when used in combination&lt;br&gt;•	To assess disease control rate (DCR)&lt;br&gt;•	To estimate response rate&lt;br&gt;•	To evaluate time to progression (TTP)&lt;br&gt;•	To evaluate overall survival (OS)&lt;br&gt;•	To evaluate Quality of Life&lt;br&gt;•	To compare VEGF plasma levels before and during the treatment&lt;br&gt;;Primary end point(s): Clinical response measured according to standard criteria&lt;br&gt;•	Progression free survival	&lt;br&gt;•	clinical adverse events&lt;br&gt;•	laboratory parameters</Primary_outcome>
    <Secondary_ID>12197</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458575</Internal_Number>
    <TrialID>EUCTR2006-003001-49-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease - Hercules</Public_title>
    <Scientific_title>Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease - Hercules                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Leiden University Medical Center</Primary_sponsor>
    <Date_registration3>20060601</Date_registration3>
    <Date_registration>01/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003001-49                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/08/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Willing and able to provide written consent;&lt;br&gt;- Patients must 18 years of age or older;&lt;br&gt;- Well-defined CKD&lt;br&gt;   for stage 4: GFR 15-30 ml/min/1.73m2 according to the abbreviated MDRD formula &lt;br&gt;   for stage 5: haemodialysis or peritoneal dialysis according to the K/DOQI guidelines&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- A diagnosis of diabetes mellitus for which the patient uses insulin;&lt;br&gt;- Significant co-morbidities which, according to the treating nephrologists, makes it unlikely that the patient will be able to complete the foreseen study period;&lt;br&gt;- Significant cardiovascular co-morbidities which are likely to interfere with the objectives of the study (morbid obesity, family history of dyslipidemia, etc.); at the discretion of the treating nephrologists or the principal investigator;&lt;br&gt;- Allergy for PPAR’s;&lt;br&gt;- Cardiac disease with marked limitation of functional capacity (New York Heart Association III or IV clinical status);&lt;br&gt;- Use of immunosuppressant agents;&lt;br&gt;- History of renal transplant;&lt;br&gt;- Hepatic insufficiency (defined as transaminase concentrations above &gt; 2.5 times the upper limit of normal for the laboratories);&lt;br&gt;- A history of alcohol abuse or excessive alcohol use defined as more than 21 consumptions per week;&lt;br&gt;- For female patients: pregnancy, the intention to become pregnant within the study period, or lactating patients.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Avandia&lt;br&gt;Product Name: Rosiglitazon&lt;br&gt;Product Code: 1360&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objectives of the study are to assess the effect of rosiglitazone in patients with severe renal impairment on the change of carotid artery intima media thickness (IMT) and carotid artery calcifications and to assess the tolerability of rosiglitazone in this patient population.;Secondary Objective: Secondary objectives are to study the effects on (a) inflammation determined by measurement of the serum levels of inflammatory markers, nutrition state, erythropoietin resistance, insulin resistance and peritoneal membrane function in peritoneal dialysis patients and (b) the change of arterial stiffness determined by pulse wave velocity measurements over 48 weeks and (c) the drug safety profile (liver function parameters, weight changes, adverse events, etc.).;Primary end point(s): Intima-media thickness carotid artery</Primary_outcome>
    <Secondary_ID>P05.020</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458668</Internal_Number>
    <TrialID>EUCTR2006-002913-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Randomised controlled, double blinded single centre trial to assess the effects of peri-operative dopexamine on morbidity after major abdominal surgery in patients with low anaerobic threshold. - Peri-operative effects of dopexamine in patients with low AT</Public_title>
    <Scientific_title>Randomised controlled, double blinded single centre trial to assess the effects of peri-operative dopexamine on morbidity after major abdominal surgery in patients with low anaerobic threshold. - Peri-operative effects of dopexamine in patients with low AT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>York Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20060930</Date_registration3>
    <Date_registration>30/09/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002913-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>31/07/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients undergoing scheduled resection for carcinoma of the colon, rectum, bladder, pancreas, stomach or kidney, who, after routine CPX testing at the Pre-assessment Clinic, have been found to have an Anaerobic Threshold (AT) less than or equal to 11.0 ml/min/m2 as measured by the V-slope method15, or with an AT of 11.0 -14.0 ml/min/m2 and ischaemic changes on ECG monitoring during testing or with a significant history of ischaemic heart disease (NYHA classification III and IV).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients less than 60 years of age unless they have significant co morbidities (ASA 3 or greater), patients having emergency or vascular procedures, those who are ASA grade 5, and patients who refuse or are unable to give informed consent&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients undergoing scheduled resection for carcinoma of the colon, rectum, bladder, pancreas, stomach or kidney, who, after routine CPX testing at the Pre-assessment Clinic, have been found to have an Anaerobic Threshold (AT) less than or equal to 11.0 ml/min/m2 as measured by the V-slope method15, or with an AT of 11.0 -14.0 ml/min/m2 and ischaemic changes on ECG monitoring during testing or with a significant history of ischaemic heart disease (NYHA classification III and IV).</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dopacard&lt;br&gt;Product Name: Dopexamine hydrochloride&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: DOPEXAMINE HYDROCHLORIDE&lt;br&gt;CAS Number: 86484915&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess morbidity at 1,3, 5, 8,10, 12 and 15 days using POMS score;Secondary Objective: To identify differences in&lt;br&gt;&lt;br&gt;1.	Length of stay in hospital after surgery&lt;br&gt;2.	Recovery parameters (drinking, eating, mobilising)&lt;br&gt;3.	Incidence of post-operative complications&lt;br&gt;4.	Peri-operative haemodynamic variables (heart rate, blood pressure, CVP)&lt;br&gt;5.	POSSUM score for surgical risk assessment.&lt;br&gt;6.	Oxygen delivery&lt;br&gt;;Primary end point(s): 1.	Morbidity at 1,3,5,8 10,12 and 15 days</Primary_outcome>
    <Secondary_ID>DOP 06;33549216</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458848</Internal_Number>
    <TrialID>EUCTR2006-003746-42-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma - ND</Public_title>
    <Scientific_title>Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>OSPEDALE ONCOLOGICO DI BARI</Primary_sponsor>
    <Date_registration3>20061003</Date_registration3>
    <Date_registration>03/10/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003746-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/02/2003</Date_enrollement>
    <Target_size>210</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: immunoterapia chemioterapia vs immunoterapia&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Histologic diagnosis of kidney carcinoma  2. Presence of metastases and/or  locally advanced primary tumour  3. Age   18 years old&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Severe infections  2. Previous treatment with IL-2  3. Brain metastasis  4. Pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic kidney carcinoma &lt;br&gt;MedDRA version: 6.1
Level: HLT
Classification code 10038408
</Condition>
    <Intervention>&lt;br&gt;Trade Name: PROLEUKIN*EV 1FL 18MUI 5ML &lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Aldesleukin&lt;br&gt;CAS Number: 110942-02-4&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 18000000-&lt;br&gt;&lt;br&gt;Trade Name: GEMZAR*INFUS 1FL 1G POLV &lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Gemcitabine&lt;br&gt;CAS Number: 122111-03-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: NAVELBINE 50*IV 50MG 5ML &lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Vinorelbine&lt;br&gt;CAS Number: 122111-03-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To estimate if the addition of Gemcitabine and Navelbine leads to  increase of activity and therapeutic efficacy with respect to immunotherapy alone;Secondary Objective: 1. To estimate the toxicity of the two treatments  2. To estimate the treatment impact on the patient s life quality  3. To find the meaning of some predictive factors  VES, PCR, LDH, total lymphocytes ;Primary end point(s): To estimate if immunotherapy with IL-2, Gemcitabina e Navelbine is more effective with respect to immunotherapy alone in patients with kidney carcinoma</Primary_outcome>
    <Secondary_ID>om 145</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2459275</Internal_Number>
    <TrialID>EUCTR2006-005294-22-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Performance de l’équation MDRD corrigée par la cimétidine chez le patient transplanté rénal</Public_title>
    <Scientific_title>Performance de l’équation MDRD corrigée par la cimétidine chez le patient transplanté rénal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>CHU Saint-Etienne</Primary_sponsor>
    <Date_registration3>20061207</Date_registration3>
    <Date_registration>07/12/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005294-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/12/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- &gt; 18 years&lt;br&gt;- Kidney transplantation &gt; 1 year &lt;br&gt;- Patient with immunosuppressant treatment of TACROLIMUS (PROGRAF?)&lt;br&gt;- Creatinine clearance &gt; 30 ml/min/1,73m2 within 3 months before inclusion&lt;br&gt;- Written informed consent&lt;br&gt;- Patient affiliated to social insurance&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Unstable renal fonction defined by serum creatinine (J0) &gt; 25% serum creatinine realised in 3 mois&lt;br&gt;- Treatment: Bactrim®, Fansidar®, Cimetidine arrow® withing the week before inclusion&lt;br&gt;- Contraindication listed in in the labeling of Cimetidine arrow® (absolue, relative et médicaments nécessitant des précautions d’emploi cf ficheVidal en annexe 3)&lt;br&gt;- Last residual rate of Tacrolimus &gt; 12 ng/ml.&lt;br&gt;- Treatment : carvedilol, phenytoïne (intercation with cimetidine)&lt;br&gt;- Serious hepatic insuffisancy&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Estimating glomerular filtration rate in kidney transplantation: a comparison between inulin clearance and MDRD equation with cimetidin (block of secretion renal tubule) &lt;br&gt;MedDRA version: 8.1
Level: PT
Classification code 10018355
Term: Glomerular filtration rate
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Cimetidine arrow&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: compare performance of inulin clearance and MDRD with or no block of secretion renal tubule with cimetidin,  in kidney transplantation;Secondary Objective: ? Performance of different prediction equations for estimating renal function in kidney transplantation with or no block of secretion renal tubule with cimetidin : &lt;br&gt;- Walser equation&lt;br&gt;- Nankivell equation &lt;br&gt;- Cockcroft and Gault equation&lt;br&gt;&lt;br&gt;? comparison between inulin clearance and cystatin C ;Primary end point(s): Performance of different prediction equation : accuracy -30%, ie defined by proportion of patients with a estimation of glomerular filtration glomerular is include in - 30 % et + 30 % of  inulin clearance value. &lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>060890</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2459410</Internal_Number>
    <TrialID>EUCTR2006-006491-38-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sunitinib  prior to nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ</Public_title>
    <Scientific_title>Sunitinib  prior to nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>NKI-AVL</Primary_sponsor>
    <Date_registration3>20061222</Date_registration3>
    <Date_registration>22/12/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006491-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/04/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Histologically confirmed metastatic renal cell cancer of clear-cell subtype with a resectable  asymptomatic primary in situ. Asymptomatic primary  is defined as the absence of symptoms which can be exclusively assigned to the primary tumor such as flank pain and/or gross hematuria necessitating blood transfusion. As paraneoplastic symptoms cannot be assigned to the primary tumor alone in metastatic disease, they are not included in this definition. Unless the diagnosis of a clear-cell subtype has been established after histological examination of a resected metastatic lesion, all patients need to undergo a transcutaneous tru-cut needle biopsy of the primary tumor.&lt;br&gt;2.	Extensive metastatic disease which is defined as 3 or more non-resectable metastases in case of 1 metastatic site, using the RECIST criteria,  or 2 or more metastatic sites.&lt;br&gt;3.	Age: 18 to 65 years&lt;br&gt;4.	Life expectancy &gt; 3 months&lt;br&gt;5.	WHO performance status 0 or 1&lt;br&gt;6.	Written informed consent obtained from the patient after having been informed about the objectives of the study and the medication used.&lt;br&gt;7.	Blood counts: Leucocytes &gt; 3.0 x 109/l, platelets &gt; 100 x 109/l, hemoglobin &gt; 6.0 mmol/l.&lt;br&gt;8.	Serum bilirubin, ASAT, ALAT and creatinin within 1.5 times of upper limit of reference values of laboratory.&lt;br&gt;9.	No prior systemic treatment with biological response modifiers, tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy. Patients who receive local radiotherapy for bone lesions can be included. &lt;br&gt;10.	An intermediate MSKCC risk profile&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Symptomatic primary necessitating nephrectomy. For definition see Inclusion criteria.&lt;br&gt;2.	Irresectable primary tumor&lt;br&gt;3.	Patients in whom complete surgical remission can be achieved by removing metastatic sites at nephrectomy or by delayed surgery.&lt;br&gt;4.	Previous nephrectomy&lt;br&gt;5.	Low metastatic burden (2 or less non-resectable metastases at 1 metastatic site) &lt;br&gt;6.	Metastatic RCC to the bone only. Bone metastases are considered truly non measurable.&lt;br&gt;7.	Current cardiovascular disease, hematopoetic, pulmonary, hepatic or renal dysfunction or WHO performance status &gt; 1.&lt;br&gt;8.	Previous immunotherapy, therapy with tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy.&lt;br&gt;9.	Presence of autoimmune disease, HIV and hepatitis.&lt;br&gt;10.	Corticosteroid and/ or other immunosuppressive therapies.&lt;br&gt;11.	Prior malignancies. In case of NED the period should be &gt; 5 years.&lt;br&gt;12.	Central nervous system metastases.&lt;br&gt;13.	non-clear cell subtype.&lt;br&gt;14.	Poor or good prognosis according to MSKCC risk assessment&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic renal cell carcinoma and the primary tumor in situ

</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: sunitinib&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the response rate of the primary tumor following pretreatment with sunitinib;Secondary Objective: Cancer specific survival and morbidity, overall response at metastatic sites and duration of metastatic response will be assessed. (Duration of overall survival; duration of hospital stay; percentage of withdrawal from nephrectomy due to sunitinib-related reduction of performance; response at metastatic sites; progression to irresectability of the primary tumor during initial treatment). &lt;br&gt;Immunomonitoring in the peripheral blood at different time intervals and the primary tumor after nephrectomy.&lt;br&gt;Imaging with CT and dynamic MRI scan prior to treatment with sunitinib and prior to nephrectomy to identify potential response criteria other than RECIST in association with histopathology.&lt;br&gt;;Primary end point(s): The main end point of this study is any objective response in the primary tumor according to RECIST criteria .</Primary_outcome>
    <Secondary_ID>N06SUN</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2459416</Internal_Number>
    <TrialID>EUCTR2005-004024-39-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Título completo del ensayo: Estudio multicéntrico, aleatorizado, abierto, de 12 semanas de duración, para determinar el efecto del  tratamiento con Myfortic® (micofenolato sódico) en términos de calidad de vida en pacientes con síntomas gastrointestinales (GI) en tratamiento con MMF (micofenolato mofetilo) después de un trasplante renal. - MYVIDA2</Public_title>
    <Scientific_title>Título completo del ensayo: Estudio multicéntrico, aleatorizado, abierto, de 12 semanas de duración, para determinar el efecto del  tratamiento con Myfortic® (micofenolato sódico) en términos de calidad de vida en pacientes con síntomas gastrointestinales (GI) en tratamiento con MMF (micofenolato mofetilo) después de un trasplante renal. - MYVIDA2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica, S.A.</Primary_sponsor>
    <Date_registration3>20060306</Date_registration3>
    <Date_registration>06/03/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004024-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/04/2006</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•Pacientes que hayan sido sometidos a un trasplante renal.&lt;br&gt;•Que estén recibiendo un régimen inmunosupresor que incluya MMF antes de la inclusión en el estudio. &lt;br&gt;•Que sufran efectos secundarios GI relacionados con la dosis estandar de MMF, o bien pacientes en tratamiento con una dosis reducida de MMF para controlar dichos efectos secundarios GI.&lt;br&gt;•Con edad = 18 años.&lt;br&gt;•Capaces de entender la información sobre el estudio y de otorgar su consentimiento informado por escrito.&lt;br&gt;•Que puedan cumplir todos los requisitos del estudio incluyendo la realización de los cuestionarios, y la asistencia a las 3 visitas del estudio.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•Que se conozca o se asuma que los síntomas GI no están causados por el tratamiento con ácido micofenólico (MPA, principio activo de Cellcept®) (por ejemplo, diarrea infecciosa inducida por bisfosfonatos orales).&lt;br&gt;•Rechazo agudo &lt; 1 semana antes de la inclusión en el estudio.&lt;br&gt;•Mujeres físicamente fértiles que tengan previsto quedarse embarazadas, estén embarazadas y/o en periodo de lactancia, o bien que no deseen utilizar un método anticonceptivo eficaz.&lt;br&gt;•Presencia de enfermedad psiquiátrica (como esquizofrenia, depresión mayor) que, a juicio del investigador, pudiese interferir con los requerimientos del estudio.&lt;br&gt;•Que estén siendo sometidos a intervención médica por patología aguda o que estén hospitalizados.&lt;br&gt;•Cualquier otra condición médica que, a juicio del investigador basándose en el recuerdo o en la revisión de historiales clínicos, pudiese afectar a la finalización del estudio, incluyendo, pero no limitado a problemas visuales o deterioro cognitivo.&lt;br&gt;•Que estén recibiendo cualquier fármaco en investigación o lo hayan recibido durante los 30 días previos a la inclusión en el estudio.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic ®&lt;br&gt;Product Name: Myfortic®&lt;br&gt;Product Code: ERL080&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: CellCept ®&lt;br&gt;Product Name: CellCept®&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determinar el efecto del uso de la formulación de comprimidos gastrorresistentes con película de MPA (Myfortic®) en la calidad de vida de los pacientes que requieran una disminución de la dosis de MMF debido a los síntomas gastrointestinales provocados por dicha medicación. ;Secondary Objective: El objetivo secundario será determinar si la formulación de comprimidos gastrorresistentes con película de MPA (Myfortic®) permite la administración con buena tolerancia de dosis más altas de MPA, comparado con el tratamiento estándar de MMF, en pacientes con susceptibilidad demostrada a efectos secundarios gastrointestinales.;Primary end point(s): La variable principal de valoración será la puntuación total de la escala GIQLI. Se hará una estadística descriptiva para la puntuación total de la escala GIQLI en las tres visitas del estudio. El análisis primario determinará los cambios en la puntuación total para dicha escala entre los dos grupos de tratamiento.</Primary_outcome>
    <Secondary_ID>CERL080AES06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460281</Internal_Number>
    <TrialID>EUCTR2006-002338-39-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmakokinetik von Linezolid bei Dialyse
(pharmacokinetics of linezolid under dialysis) - LINUS</Public_title>
    <Scientific_title>Pharmakokinetik von Linezolid bei Dialyse
(pharmacokinetics of linezolid under dialysis) - LINUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Heidelberg</Primary_sponsor>
    <Date_registration3>20060817</Date_registration3>
    <Date_registration>17/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002338-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/12/2006</Date_enrollement>
    <Target_size>15</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: dialysis and not dialysis&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- The receipt of linezolid in the normal treatment of care&lt;br&gt;- acute renale failure with a dialysis-therapy or sepsis without acute renale failure&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- hypersensivity against linezolid&lt;br&gt;- newborn, children, adolescent, pregnant women, nursing women, pre-menopausal women&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>acute renal failure and infection or sepsis without acute renal failure</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zyvoxid (R) 2mg/ml Infusionslösung&lt;br&gt;Product Name: Zyvoxid (R)2 mg/ml Infusionslösung&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: pharmacokinetic of Linezolid under dialysis;Secondary Objective: influence of sepsis alone without dialysis;Primary end point(s): no end points because it is only an accompanying pharmocokinetic-study</Primary_outcome>
  </Trial>
  <Trial>
    <Internal_Number>2460365</Internal_Number>
    <TrialID>EUCTR2007-005401-22-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease - Aliskiren and sympathetic activity</Public_title>
    <Scientific_title>Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease - Aliskiren and sympathetic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>University Medical Center Utrecht</Primary_sponsor>
    <Date_registration3>20071019</Date_registration3>
    <Date_registration>19/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005401-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/02/2009</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: no treatment&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with stable CKD and hypertension: i.e. using antihypertensive drugs and/or blood pressure &gt;145/90mmHg when off medication. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Patients on renal replacement therapy&lt;br&gt;-	Diabetes mellitus &lt;br&gt;-	Pregnancy&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hypertension and chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Product Name: Aliskiren (Rasilez)&lt;br&gt;Product Code: ATC-code: C09XA02&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to investigate the effect on MSNA by Aliskiren in hypertensive patients with CKD. We hypothesize that there will be a (substantial) decrease in MSNA as result of chronic treatment (6 weeks) of Aliskiren. ;Secondary Objective: Secondary objective is to assess whether MSNA normalizes after chronic treatment (6 weeks) of Aliskiren in hypertensive patients with CKD. &lt;br&gt;Furthermore, we will study the effect of Aliskiren on blood pressure, heart rate, kidney function and PRA in hypertensive patients with CKD.&lt;br&gt;;Primary end point(s): Primary endpoint: the effect of Aliskiren on MSNA&lt;br&gt;&lt;br&gt;Secondary parameters: Effect of aliskiren on blood pressure, heart rate, PRA and kidney function &lt;br&gt;- Comparison of the effect on MSNA after treatment with aliskiren with the effects on ACEi and ARB  as comared to the previous studies and assessment whether normalization of MSNA is obtained after treatment with aliskiren &lt;br&gt;</Primary_outcome>
    <Secondary_ID>24092007</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460545</Internal_Number>
    <TrialID>EUCTR2006-004857-86-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancer</Public_title>
    <Scientific_title>A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Caprion Pharmaceuticals Inc.</Primary_sponsor>
    <Date_registration3>20061128</Date_registration3>
    <Date_registration>28/11/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004857-86                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/01/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1) Patients must have histologically confirmed stage IV kidney clear cell carcinoma.  &lt;br&gt;&lt;br&gt;2) Patients must have progressive disease after receiving a previous systemic therapy. &lt;br&gt;&lt;br&gt;3) Patient must have progressive disease confirmed by 2 CT Scans or MRI performed within 6 months. &lt;br&gt;&lt;br&gt;4) Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as &gt;20 mm with conventional techniques or as &gt;10 mm with spiral CT scan.  &lt;br&gt;&lt;br&gt;5) Patients must have an age &gt;18 years.  &lt;br&gt;&lt;br&gt;6) Patients must have life expectancy of greater than 3 months.&lt;br&gt;&lt;br&gt;7) Patient must be at least 5 years free of any other cancer(s). Basal cell carcinoma, provided that is neither infiltrating nor sclerosing and carcinoma in situ of the cervix, is acceptable.&lt;br&gt;&lt;br&gt;8) Patients must have ECOG performance status ? ?2 (Karnofsky 60%).&lt;br&gt;&lt;br&gt;9) Patients must have normal organ and marrow function as defined below:&lt;br&gt;•	Leukocytes &gt;3,000/mm3&lt;br&gt;•	Absolute neutrophil count &gt;1,500/mm3&lt;br&gt;•	Platelets &gt;100,000/ mm3&lt;br&gt;•	Total bilirubin within normal institutional limits&lt;br&gt;•	AST(SGOT)/ALT(SGPT) ?2.5 X institutional upper limit of normal &lt;br&gt;•	Calculated creatinine clearance &gt;30 mL/min/1.73 m2 &lt;br&gt;&lt;br&gt;10) Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.  Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.&lt;br&gt;&lt;br&gt;11) Patients or the patient’s legal guardian must be able to understand and have the willingness to sign a written informed consent document.&lt;br&gt;&lt;br&gt;12) Patients must have the ability to receive central vein access catheter and manage an infusion pump.&lt;br&gt;&lt;br&gt;13) Women of child bearing potential must have a negative serum pregnancy test. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;11) Patients who have received any known medical treatment targeting cancer within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.&lt;br&gt;&lt;br&gt;2) Patients may not be receiving any other investigational agents at least 30 days prior to enrollment in the study or/and participate in another clinical trial.&lt;br&gt;&lt;br&gt;3) Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.&lt;br&gt;&lt;br&gt;4) Patients with a history of allergic reactions attributed to compounds of similar composition to CAP-232.  CAP-232 consists of a heptapeptide (active ingredient) in an acetate buffered saline solution with mannitol (0.2 M sodium acetate, 0.2 M acetic acid, 3% mannitol). &lt;br&gt; &lt;br&gt;5) Patient with past or current cancer other than kidney cancer, except for:&lt;br&gt;•	Curatively treated non-melanoma skin cancer&lt;br&gt;•	In situ carcinoma of the cervix&lt;br&gt;•	Other cancer curatively treated and with no evidence of disease for at least 10 years&lt;br&gt;&lt;br&gt;6) Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.&lt;br&gt;&lt;br&gt;7) Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAP-232, breastfeeding should be discontinued if the mother is treated with CAP-232.&lt;br&gt;&lt;br&gt;8) Patients that have previously been enrolled into this study and subsequently withdrawn must also be excluded.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic kidney cancer &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10023405
Term: Kidney cancer stage IV
</Condition>
    <Intervention>&lt;br&gt;Product Name: CAP 232&lt;br&gt;Product Code: CAP 232&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: synthetic peptide CAP-232 acetate&lt;br&gt;Other descriptive name: formerly known as TT-232&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to evaluate the efficacy of CAP-232 as a monotherapy (each 28-day cycle consists of 21 days continuous IV infusion of CAP-232 at 0.5 mg/kg/day followed by a 7-day rest period) in patients with metastatic kidney cancer.  The primary efficacy parameter will be the response rate based on RECIST criteria.;Secondary Objective: Secondary objectives include:&lt;br&gt;&lt;br&gt;•	Safety (through clinical and biological evaluations)&lt;br&gt;•	Other efficacy parameters (progression-free survival rate, time to progression and overall survival)&lt;br&gt;•	Pharmacokinetic (PK) characteristics of the first 15 recruited patients&lt;br&gt;•	Quality of life&lt;br&gt;•	Biological modulation (through potential blood and/or urine biomarkers including M2PK)&lt;br&gt;&lt;br&gt;;Primary end point(s): The primary safety endpoints will include the occurrence of AEs, clinical laboratory parameters, vital signs, ECGs and physical examination variables. &lt;br&gt;&lt;br&gt;The primary efficacy endpoints will: &lt;br&gt;- determine the M2PK plasma levels during the course of treatment&lt;br&gt;- determine disease state using RECIST criteria at the end of 2 cycles&lt;br&gt;- determine progression-free survival rate&lt;br&gt;- determine time to progression and overall survival&lt;br&gt;&lt;br&gt;Other endpoints will:&lt;br&gt;- evaluate the quality of life during each cycle&lt;br&gt;- determine the pharmacokinetic (PK) characteristics of CAP-232&lt;br&gt;- determine potential blood and/or urine biomarkers for predicting efficacy&lt;br&gt;&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CTP_CAP001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460676</Internal_Number>
    <TrialID>EUCTR2006-003364-64-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis</Public_title>
    <Scientific_title>A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Shire Development Inc</Primary_sponsor>
    <Date_registration3>20070105</Date_registration3>
    <Date_registration>05/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003364-64                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/05/2007</Date_enrollement>
    <Target_size>760</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Aged 18 or over and receiving stable regimen of haemodialysis (three times a week) for CKD (stage 5) for at least 2 months prior to screening.&lt;br&gt;&lt;br&gt;Females must be non-pregnant and non-lactating.&lt;br&gt;&lt;br&gt;On a stable phosphate binder dose (no change in medication or dose for one month) with screening serum phosphorus levels of between 5.6 and 7.5 mg/dL inclusive.  &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Subjects with a corrected serum calcium level &lt;2.2mmol/L (8.8mg/dL).&lt;br&gt;&lt;br&gt;Subjects with an intact parapthyroid hormone level &gt;500pg/ml or a history of parathyroidectomy within 12 months of screening.&lt;br&gt;&lt;br&gt;Any significant GI disorders (including bowel obstruction, active, inflammatory bowel disease, GI motility disorders, abnormal or irregular bowel motion, major GI surgery in last 6 months.&lt;br&gt;&lt;br&gt;Subjects receiving aluminium, magnesium, or combination therapy other than sevelamer HCl and calcium as a phosphate binder.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10020712
Term: Hyperphosphatemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fosrenol 750mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Trade Name: Fosrenol 1000mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Fosrenol 500mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the percentage of subjects who have serum phosphorus levels controlled to &lt;or= 1.78mmol/L (&lt;or=5.5mg/dl) following treatment with Fosrenol compared to their previous phosphate binder;Primary end point(s): The percentage of subjects acheiving serum phosphorus levels of less than or equal to 1.78mmol/L following treatment with Fosrenol at week 12 compared to treatment with their previous phosphate binder therapy.;Secondary Objective: To assess the following:&lt;br&gt;&lt;br&gt;If Fosrenol can maintain serum phosphorus levels in subjects converting to Fosrenol from their previous phosphate binder therapy.&lt;br&gt;&lt;br&gt;If Fosrenol can reduce serum phosphorus levels in subjects converting to Fosrenol from their previous phosphate binder therapy.&lt;br&gt;&lt;br&gt;To assess the control of serum calcium-phosphorus product.&lt;br&gt;&lt;br&gt;To assess the average dose of Fosrenol.&lt;br&gt;&lt;br&gt;To assess the safety and tolerability of Fosrenol</Primary_outcome>
    <Secondary_ID>SPD405-403</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460686</Internal_Number>
    <TrialID>EUCTR2006-005604-14-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomized, prospective, multicenter trial to compare the effect on chronic allograft nephropathy prevention of  mycophenolate mofetil versus azathioprine as the sole immunosuppressive therapy for kidney transplant recipients - MAMMOUTH</Public_title>
    <Scientific_title>A randomized, prospective, multicenter trial to compare the effect on chronic allograft nephropathy prevention of  mycophenolate mofetil versus azathioprine as the sole immunosuppressive therapy for kidney transplant recipients - MAMMOUTH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>IST. DI RICERCHE FARMACOLOG. M. NEGRI</Primary_sponsor>
    <Date_registration3>20070105</Date_registration3>
    <Date_registration>05/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005604-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/12/2006</Date_enrollement>
    <Target_size>224</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Males and females aged 18-60 years;  - First single kidney transplant from living or deceased donors;  - Written informed consent.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Specific contraindications to RATG therapy such as severe leucopenia  WBC 2000/mm3 ;  - High immunological risk   such as second transplant recipients or those who have a panel reactivity   10 ;  - history of malignancy  except non metastatic basal or squamous cell carcinoma of the skin that has been treated successfully;  - Evidence of active hepatitis C virus, hepatitis B virus or human acquired immunodeficiency virus infection;  - Any chronic clinical conditions that may affect completion of the trial or confound data interpretation;  - Pregnancy or lactating;  - Women of childbearing potential without following a scientifically accepted form of contraception;  - Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial;  - Evidence of an uncooperative attitude;  - Any evidence that patient will not be able to complete the trial follow-up.&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney transplant &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CELLCEPT*50CPR 500MG&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: AZATIOPRINA WELL*50CPR RIV50MG &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the incidence of CAN in kidney transplant patients receiving induction therapy with basiliximab and low-dose RATG and maintenance immunosuppression with low-dose MMF or AZA monotherapy.;Secondary Objective: - To evaluate whether MMF may exert an higher activity against acute allograft rejection as  compared to AZA when used as the sole immunosuppressive agent.   - To evaluate the relationships between acute rejection episodes and subsequent  occurrence of CAN, and long-term graft function/survival. Should the study demonstrate the superiority of any of the two drugs in preventing CAN, patients will be put on the more effective immunosuppressive treatment. This will allow assessing whether the lesions of CAN may recover in those patients who are shifted from the less to the more effective treatment. The extension phase of the study will be aimed at assessing the long-term patient and graft survival.;Primary end point(s): Incidence of biopsy-proven CAN at 3 years follow-up  end phase B .</Primary_outcome>
    <Secondary_ID>AIFA TX</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460833</Internal_Number>
    <TrialID>EUCTR2006-004959-38-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal disease</Public_title>
    <Scientific_title>A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Shire Development Inc</Primary_sponsor>
    <Date_registration3>20070101</Date_registration3>
    <Date_registration>01/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004959-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/05/2007</Date_enrollement>
    <Target_size>214</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Aged 18 or over&lt;br&gt;Females must be non-pregnant&lt;br&gt;Must have ESRD and have been receiving haemodialysis three times a week for at least 2 months&lt;br&gt;Being treated with a monotherapy calcium based phosphate binder or a combination therapy not containing Fosrenol or sevelamer hydrochloride and is sub-optimally controlled with screening serum phosphorus levels of greater or equal 5.6 to less than or equal 7.5 mg/dL.  Treatment naiive patients are permitted to enter study providing serum phosphorus levels are greater or equal 6.0 mg/dL (1.92 mmol/L)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients who require treatment with cinacalcet hydrochloride, or with compounds containing phosphorus, magnesium, aluminium or  calcium (except as indicated in section 6.4.1 of the protocol) that are used as a phosphate binder.&lt;br&gt;&lt;br&gt;Any significant GI surgery or GI disorders (including active, uncontrolled peptic ulcer, Crohns disease, GI bleed in last 6 months, past or present GI malignancy&lt;br&gt;&lt;br&gt;Cirrhosis or other clinically relevant liver disease&lt;br&gt;&lt;br&gt;Intact PTH &gt;500 pg/ml&lt;br&gt;&lt;br&gt;Serum calcium &lt;8.8 mg/dL&lt;br&gt;&lt;br&gt;Life threatening malignancy or current multiple myeloma&lt;br&gt;&lt;br&gt;HIV positive&lt;br&gt;&lt;br&gt;Hypersensitivity to investigational products&lt;br&gt;&lt;br&gt;Alcohol or substance abuse 1 year prior to screening&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10020712
Term: Hyperphosphatemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fosrenol 750mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Trade Name: Fosrenol 1000mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Renagel 800mg film-coated tablets&lt;br&gt;Product Name: sevelamer hydrochloride &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: SEVELAMER HYDROCHLORIDE&lt;br&gt;CAS Number: 182683007&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the efficacy of Fosrenol and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline;Secondary Objective: To assess the following:&lt;br&gt;&lt;br&gt;the percentage of patients acheiving KDOQI target for serum phosphorus (3.5-5.5mg/dL) following treatment with Fosrenol and sevelamer hydrochloride&lt;br&gt;&lt;br&gt;the percentage of responders, defined as &gt; or = 25% decrease in serum phosphorus from baseline following treatment with Fosrenol and sevelamer hydrochloride&lt;br&gt;&lt;br&gt;the effects of Fosrenol and sevelamer hydrochloride on calcium-phosphate product and parathyroid hormone (PTH)&lt;br&gt;&lt;br&gt;compliance&lt;br&gt;&lt;br&gt;safety and tolerability of Fosrenol and sevelamer hydrochloride;Primary end point(s): The change from baseline in serum phosphorus levels</Primary_outcome>
    <Secondary_ID>SPD405-319</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460943</Internal_Number>
    <TrialID>EUCTR2006-004606-97-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS - CONCERTO</Public_title>
    <Scientific_title>A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS - CONCERTO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Astellas Pharma GmbH</Primary_sponsor>
    <Date_registration3>20070125</Date_registration3>
    <Date_registration>25/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004606-97                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/02/2007</Date_enrollement>
    <Target_size>380</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: 1-way conversion&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Age = 18 years.&lt;br&gt;2. Kidney transplant at least 12 months prior to enrollment.&lt;br&gt;3. Received a CyA-based immunosuppressive regimen since last transplantation. The dose of CyA has remained unchanged during the last four weeks prior to enrollment.&lt;br&gt;4. Immunosuppressive regimen (combination of medications) remained unchanged for a minimum of four weeks prior to enrollment.&lt;br&gt;5. Experienced at least one of the following CyA-related adverse events at enrollment:&lt;br&gt;a) Gingival hyperplasia where, in the opinion of the investigator, therapeutical intervention is required.&lt;br&gt;b) Hypertrichosis/hirsutism where, in the opinion of the investigator, therapeutical intervention is required.&lt;br&gt;c) Arterial hypertension (with the exception of known pre-transplant malignant nephrosclerosis) stages I-III (systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90mmHg) despite treatment with at least one anti-hypertensive medication. The anti-hypertensive medication(s) has been prescribed at least 4 weeks prior to enrollment.&lt;br&gt;d) Hyperlipidemia defined as total cholesterol higher than 220 mg/dl despite treatment with lipid-lowering medication(s) requires therapeutical intervention. The lipid-lowering medication(s) has been prescribed at least four weeks prior to enrollment.&lt;br&gt;6. Serum creatinine &lt; 200 µmol/l (&lt; 2.3 mg/dl) at enrollment.&lt;br&gt;7. Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study.&lt;br&gt;8. Capable of understanding the purpose and risks of the study, has been fully informed and has given written informed consent (signed Informed Consent has been obtained).&lt;br&gt;9. Clinically stable in the opinion of the investigator.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Previously received an organ transplant other than a kidney.&lt;br&gt;2. Acute rejection episode within 12 weeks prior to enrollment, or an acute rejection episode within the 24 weeks prior to enrollment that required anti-lymphocyte antibody therapy.&lt;br&gt;3. Diagnosis of new-onset malignancy after transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully.&lt;br&gt;4. Known to have FSGS or MPGN Type II as an underlying disease.&lt;br&gt;5. Proteinuria &gt; 2 g / 24 hrs.&lt;br&gt;6. “Creeping creatinine” (defined as an increase of 20% within the 6 months prior to enrollment and at Baseline).&lt;br&gt;7. Elevated SGPT/ALT and/or SGOT/AST and/or Total Bilirubin levels = 2 times the upper value of the normal range of the investigational site.&lt;br&gt;8. Liver cirrhosis.&lt;br&gt;9. Pregnant woman or breast-feeding mother.&lt;br&gt;10. HIV positive.&lt;br&gt;11. Known allergy or intolerance to tacrolimus, macrolide antibiotics, steroids, additional concomitant immunosuppressive medication or to the excipients of the study medication.&lt;br&gt;12. Any unstable medical condition that could interfere with the study objectives in the opinion of the investigator.&lt;br&gt;13. Receiving prohibited concomitant therapy, or received prohibited concomitant therapy within 28 days prior to enrollment.&lt;br&gt;14. Currently participating in another clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment.&lt;br&gt;15. Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.&lt;br&gt;16. Unlikely to comply with the visits scheduled in the protocol.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Stable, adult kidney transplant recipients (at least 12 months post transplant) who are currently treated with cyclosporine and who meet the Inclusion and Exclusion Criteria will be enrolled. &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Product Name: FK506E (MR4)&lt;br&gt;Product Code: FK506E (MR4)&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Product Name: FK506E (MR4)&lt;br&gt;Product Code: FK506E (MR4)&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Product Name: FK506E (MR4)&lt;br&gt;Product Code: FK506E (MR4)&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Primary objective is to assess the changes in kidney function in kidney transplant subjects converted from a CyA-based immunosuppressive regimen to a tacrolimus modified release, FK506E (MR4), based immunosuppressive regimen.;Secondary Objective: The secondary objective is to assess the safety and the efficacy of a MR4-based immunosuppressive regimen in kidney transplant subjects converted from a CyA-based immunosuppressive regimen experiencing CyA-related side effects.;Primary end point(s): Change in creatinine clearance, calculated according to Cockcroft and Gault formula, between Baseline (Day 1) and week 24 (End of Study) for each specific CyA-related side-effect group (hypertrichosis/hirsutism, gingival hyperplasia, hyperlipidemia, arterial hypertension).</Primary_outcome>
    <Secondary_ID>PMR-EC-1209</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2461728</Internal_Number>
    <TrialID>EUCTR2007-001048-32-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prospective, multicentre, open-label study evaluating Fondaparinux (1,5 mg/day) in venous thromboembolic events prevention in patients with renal impairment defined by a creatinin clearance between 20 and 50 ml/min and undergoing a major orthopaedic surgery (hip fracture, total hip replacement and total knee replacement)</Public_title>
    <Scientific_title>Prospective, multicentre, open-label study evaluating Fondaparinux (1,5 mg/day) in venous thromboembolic events prevention in patients with renal impairment defined by a creatinin clearance between 20 and 50 ml/min and undergoing a major orthopaedic surgery (hip fracture, total hip replacement and total knee replacement)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>CHU SAINT-ETIENNE</Primary_sponsor>
    <Date_registration3>20070329</Date_registration3>
    <Date_registration>29/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001048-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/09/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patient affiliated with or a beneficiary of a social security category:&lt;br&gt;•	age &gt; 18 years old,&lt;br&gt;•	requiring a major orthopaedic surgery (THR, TKR, HF) whatever procedure techniques are used, 1st indication or resumption,&lt;br&gt;•	requiring an antithrombotic prophylaxis,&lt;br&gt;•	presenting a renal impairment defined by a creatinin clearance (CrCl) between 20 and 50 ml/min calculated by Cockcroft and Gault’s formula, &lt;br&gt;•	having signed the inform consent form.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	contra-indications to fondaparinux,&lt;br&gt;•	history of heparin inducted thrombopenia (HIT), &lt;br&gt;•	history of venous thromboembolic event,&lt;br&gt;•	Haemorrhagic diathesis, &lt;br&gt;•	PT &lt; 50 %, aPTT &gt; 1,5 of control value, platelets &lt; 100 G/l.&lt;br&gt;                incapacity to understand protocol&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with renal impairment defined by a creatinin clearance between 20 and 50 ml/min and undergoing a major orthopaedic surgery (hip fracture, total hip replacement and total knee replacement) &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038474
Term: Renal insufficiency
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020100
Term: Hip fracture
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023476
Term: Knee osteoarthritis
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10049909
Term: Venous thromboembolism prophylaxis
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020108
Term: Hips osteoarthritis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Arixtra 1,5 mg/0,3 ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Fondaparinux&lt;br&gt;CAS Number: 114870-03-0&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: to evaluate between D5 and D10, the incidence of major bleedings after a daily subcutaneous injection of fondaparinux 1,5 mg during at least 5 days for prevention of venous thromboembolic events after major orthopaedic surgery (TKR, THR and HF) in patients with a CrCl between 20 and 50 ml/min (estimated by Cockcroft and Gault formula). ;Secondary Objective: to evaluate: &lt;br&gt;•	The incidence of major bleedings at 1 month ± 5 days&lt;br&gt;•	The incidence of clinically significative bleedings between D5 and D10 and at 1 month ± 5 days&lt;br&gt;•	The incidence of symptomatic venous thromboembolic events (DVT and PE) between D5 and D10 and at 1 month ± 5 days&lt;br&gt;•	Pharmacodynamic parameters based on Xa activity (absorption half-life and elimination clearance of distribution volume and their variability) of fondaparinux based on a non-linear model at mixed effect and to compare the observed real clinical data with those simulated and described in MA file.&lt;br&gt;•	Estimation of haemorrhagic and thromboembolic risk factors.&lt;br&gt;•	Estimation of inter-laboratories variability in the measure of anti-Xa activity with fondaparinux;Primary end point(s): •	Major bleeding (occuring between D5 and D10) is defined by: &lt;br&gt;-	an exteriorised bleeding with a bleeding index &gt; 2 (g/dl of haemoglobin decrease + number of units transfused)&lt;br&gt;-	a bleeding needing a resumption surgery&lt;br&gt;-	a bleeding affecting a critical organ (ocular, retroperitoneal, pericardial, intra-cranial, intra-medullary, intramuscular with compression)&lt;br&gt;-	a fatal bleeding&lt;br&gt;</Primary_outcome>
    <Secondary_ID>0701017</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2461957</Internal_Number>
    <TrialID>EUCTR2006-007021-32-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose regimen - HERAKLES</Public_title>
    <Scientific_title>Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose regimen - HERAKLES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Novartis Pharma GmbH</Primary_sponsor>
    <Date_registration3>20070417</Date_registration3>
    <Date_registration>17/04/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-007021-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/05/2007</Date_enrollement>
    <Target_size>450</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: different treatment regimen&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Males or females, aged 18 – 70 years&lt;br&gt;2.	Recipients of de novo cadaveric, living unrelated or living related kidney transplants&lt;br&gt;3.	Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at Baseline visit 1, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility&lt;br&gt;4.	Patients who are willing and able to participate in the study and from whom written informed consent has been obtained&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	More than one previous renal transplantation&lt;br&gt;2.	Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney&lt;br&gt;3.	Patients receiving a kidney from a non-heart beating donor&lt;br&gt;4.	Donor age: &lt; 5 years or &gt; 70 years &lt;br&gt;5.	Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation) &lt;br&gt;6.	Patients who are recipients of A-B-O incompatible transplants&lt;br&gt;7.	Patients with a historical or current peak PRA of &gt; 25% (current = 3 months)&lt;br&gt;8.	Patients with already existing antibodies against the HLA-type of the receiving transplant&lt;br&gt;9.	Patients with any known hypersensitivity to Simulect®, Certican®, mycophenolic acid, cyclosporine A, other drugs similar to Certican® (e.g., macrolides), or other components of the formulations (e.g. lactose)&lt;br&gt;10.	Patients who have received an investigational immunosuppressive drug within four weeks prior to study entry (Baseline visit 1)&lt;br&gt;11.	Patients with thrombocytopenia (platelets &lt; 75,000/mm³), with an absolute neutrophil count of &lt; 1,500/mm³ or leucopenia (leucocytes &lt; 2,500/mm³), or hemoglobin &lt; 6 g/dL&lt;br&gt;12.	Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent&lt;br&gt;13.	Patients with a history of malignancy during the last five years, except squamous or basal cell carcinoma of the skin&lt;br&gt;14.	Patients who are HIV, HCV, or Hepatitis B surface antigen positive &lt;br&gt;15.	Evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. AST, ALT or total bilirubin &gt; 3 times UNL)&lt;br&gt;16.	Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception&lt;br&gt;17.	Presence of a clinically significant infection requiring continued therapy, severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus that in the opinion of the investigator would interfere with the appropriate conduct of the study&lt;br&gt;18.	Evidence of drug or alcohol abuse&lt;br&gt;19.	Patients receiving drugs known to strongly interact with CsA and/or everolimus according to the list provided in Appendix 3 to this protocol should be excluded, if in the opinion of the investigator this drug interaction interferes with the objectives of the study, namely a clinical meaningful potentiation of renal dysfunction and/or maintenance of adequate immunosuppressive drug levels&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>de novo kidney transplant patients &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023439
Term: Kidney transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Product Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Product Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;Trade Name: Simulect 20 mg&lt;br&gt;Product Name: Simulect 20 mg&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: Basiliximab&lt;br&gt;CAS Number: 179045-86-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic 180 mg/ -360 mg Filmtabletten&lt;br&gt;Product Name: Myfortic 180 mg/- 360 mg Filmtabletten&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolate sodium&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic 180 mg/ -360 mg Filmtabletten&lt;br&gt;Product Name: Myfortic 180 mg/- 360 mg Filmtabletten&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolate sodium&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 360-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral&lt;br&gt;10 mg, 25 mg, 50 mg, 100 mg Kapseln&lt;br&gt;Product Name: Sandimmun Optoral&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral&lt;br&gt;10 mg, 25 mg, 50 mg, 100 mg Kapseln&lt;br&gt;Product Name: Sandimmun Optoral&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral&lt;br&gt;10 mg, 25 mg, 50 mg, 100 mg Kapseln&lt;br&gt;Product Name: Sandimmun Optora</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this trial is to demonstrate superiority of a CNI-free regimen respect to the renal function at Month 12 post Tx assessed by glomerular filtration rate – Nankivell method – as compared to the standard regimen in de novo kidney transplant patients.;Secondary Objective: •	to assess renal function by glomerular filtration rate at Month 12 post Tx of the CNI-low dose regimen compared to the standard regimen&lt;br&gt;•	to assess renal function by glomerular filtration rate at Month 12 post Tx&lt;br&gt;•	to assess renal function by serum creatinine at month 12 post Tx&lt;br&gt;•	to assess efficacy at Month 6 and 12&lt;br&gt;•	to asses occurrence of treatment failures up to or at Month 12&lt;br&gt;•	to assess evolution of renal function between Month 3 and 12 &lt;br&gt;•	to assess safety and tolerability at Month 12:	&lt;br&gt;- AE/SAE	&lt;br&gt;- incidence of infections (with special emphasis on CMV) 	&lt;br&gt;- tumor incidence	&lt;br&gt;- cardiovascular risk (changes in Framingham score)	&lt;br&gt;- occurrence of proteinuria&lt;br&gt;•	to assess efficacy, safety and tolerability at Follow-up visits at month 18, 24, 36, 48, and 60&lt;br&gt;;Primary end point(s): The primary aim of this study is to demonstrate superior renal function under the CNI-free regimen as compared to the Standard regimen.&lt;br&gt;The primary variable for assessment of renal function is the glomerular filtration rate (GFR) at Month 12, as assessed by the Nankivell method.</Primary_outcome>
    <Secondary_ID>CRAD001ADE13</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2461961</Internal_Number>
    <TrialID>EUCTR2006-002455-33-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Carcinoma who have had no Previous Anti-VEGF Therapy.</Public_title>
    <Scientific_title>A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Carcinoma who have had no Previous Anti-VEGF Therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>AstraZeneca AB</Primary_sponsor>
    <Date_registration3>20060823</Date_registration3>
    <Date_registration>23/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002455-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/11/2006</Date_enrollement>
    <Target_size>65</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;Other trial design description: After double blind phase all patients are offered open label study drug&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Provision of informed consent	&lt;br&gt;2.	Males or females aged 18 years and older 	&lt;br&gt;3.	Histological/cytological confirmation of metastatic or recurrent renal cell clear cell/adenocarcinoma  &lt;br&gt;4.	One or more measurable lesions at least 10mm in the longest diameter by spiral computed tomography scan or 20mm with conventional techniques (RECIST criteria) 	&lt;br&gt;5.	WHO performance status 0-2 	&lt;br&gt;6.	Life expectancy = 12 weeks&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Previous anti-VEGF therapy  &lt;br&gt;2.	More than one previous type of immunotherapy &lt;br&gt;3.	Prior cytotoxic chemotherapy intended to treat RCC&lt;br&gt;4.	Surgery scheduled within 12 weeks after entry to the study.  &lt;br&gt;5.	Treatment with an investigational drug within 30 days prior to the first dose of  AZD2171.&lt;br&gt;6.	Other concomitant anti-cancer therapy (including LHRH agonists), except steroids&lt;br&gt;7.	Untreated unstable brain or meningeal metastases.  Patients with radiological evidence of stable brain metastases are eligible providing that they are asymptomatic and either do not require corticosteroids or have been treated with corticosteroids, with clinical and radiological evidence of stabilisation at least 10 days after discontinuation of steroids.&lt;br&gt;8.	History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease free for 2 years and there is a tissue diagnosis of renal cell carcinoma from a target lesion.  &lt;br&gt;9.	Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count =1.5 x 10(to power 9)/L or platelet count =100 x 10 (to power 9)/L or requiring regular blood transfusions to maintain haemoglobin &gt;9g/dL&lt;br&gt;10.	Serum bilirubin = 1.5 x ULRR&lt;br&gt;11.	ALT or AST = 2.5 x ULRR.  If liver metastases are present, ALT or AST &gt; 5 x ULRR&lt;br&gt;12.	Serum creatinine &gt; 1.5 x ULRR or a creatinine clearance of = 50mL/min calculated by Cockcroft-Gault&lt;br&gt;13.	Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein &lt; 1.5g in a 24 hr period.&lt;br&gt;14.	History of significant gastrointestinal impairment, as judged by the investigator, that would significantly affect the absorption of AZD2171, including the inability to swallow the tablet whole.&lt;br&gt;15.	Patients with a history of poorly controlled hypertension with resting blood pressure &gt;150/100 in the presence or absence of a stable regimen of anti-hypertensive therapy.&lt;br&gt;16.	Known hypersensitivity to AZD2171 or any of its excipients&lt;br&gt;17.	Any evidence of severe uncontrolled diseases e.g. unstable or uncompensated respiratory, cardiac (including arrhythmias), hepatic or renal disease.&lt;br&gt;18.	Unresolved toxicity &gt; CTCAE grade 2 from previous anti-cancer therapy except alopecia (if applicable)&lt;br&gt;19.	Mean QTc with Bazetts correction &gt;470msec in screening ECG or history of familial long QT syndrome.&lt;br&gt;20.	Significant haemorrhage (&gt;30mL bleeding/episode in previous 3 months) or haemoptysis (&gt;5mL fresh blood in previous 4 weeks)&lt;br&gt;21.	Recent (&lt;14 days) major surgery prior to entry into the study, or a surgical incision that is not fully healed&lt;br&gt;22.	Pregnant or breast-feeding women or women of childbearing potential with a positive pregnancy test prior to receiving study medication&lt;br&gt;23.	Known infection with hepatitis B or C or HIV&lt;br&gt;24.	Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)&lt;br&gt;25.	Previous enrolment or randomisation of treatment in the present study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal cell carcinoma &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10038410
Term: Renal cell carcinoma recurrent
</Condition>
    <Intervention>&lt;br&gt;Product Name: AZD2171&lt;br&gt;Product Code: AZD2171&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Current Sponsor code: AZD2171&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: AZD2171&lt;br&gt;Product Code: AZD2171&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Current Sponsor code: AZD2171&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: AZD2171&lt;br&gt;Product Code: AZD2171&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Current Sponsor code: AZD2171&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determine the efficacy of AZD2171 compared to the efficacy of placebo in patients with metastatic or recurrent renal cell carcinoma by comparing changes in tumour size after 12 weeks of therapy (or upon progression if this occurs before 12 weeks).  ;Secondary Objective: To determine the efficacy of AZD2171 compared to the efficacy of placebo by assessment of RECIST data in patients with metastatic or recurrent renal cell carcinoma.&lt;br&gt;To determine the steady-state pharmacokinetic (PK) parameters of AZD2171 in patients with metastatic or recurrent renal cell carcinoma.&lt;br&gt;To determine the safety and tolerability of AZD2171 in patients with metastatic or recurrent renal cell carcinoma.&lt;br&gt;To assess the effect of AZD2171 on angiogenesis biomarkers.&lt;br&gt;;Primary end point(s): Determine the efficacy of AZD2171 compared to the efficacy of placebo in patients&lt;br&gt;with metastatic or recurrent renal cell carcinoma by comparing changes in tumour&lt;br&gt;size after 12 weeks of therapy (or upon progression if this occurs before 12 weeks).</Primary_outcome>
    <Secondary_ID>D8480C00030</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462099</Internal_Number>
    <TrialID>EUCTR2007-002109-32-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>USE OF FENOLDOPAM TO IMPROVE  GLOMERULAR FILTRATION RATE  IN EARLY RENAL DYSFUNCTION AFTER LIVER TRANSPLANTATION - ND</Public_title>
    <Scientific_title>USE OF FENOLDOPAM TO IMPROVE  GLOMERULAR FILTRATION RATE  IN EARLY RENAL DYSFUNCTION AFTER LIVER TRANSPLANTATION - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>AZIENDA SANITARIA OSPEDALIERA  S. GIOVANNI BATTISTA DI TORINO</Primary_sponsor>
    <Date_registration3>20070424</Date_registration3>
    <Date_registration>24/04/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002109-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/05/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;adult liver transplanted patients  age &gt;  18 years , with  pre-transplantation  normal renal function  creatinine clearance &gt;  1ml/kg/min , characterized  in the first week after liver transplantation by   increase of serum creatinine more than 1,5 times compared to pre-operative value or  urine out-put reduction    0,5 ml/kg/h  for over 6 hours period without loop diuretics administration and after  cardiovascular  performance optimization  hemodynamic stability defined as stable values of systemic systolic blood pressure    100 mmHg over the 6-hr period  immediately preceding the enrollment  low doses  of vasopressor drugs are allowed .&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;life expectancy  &gt;  48 hrs  renal dysfunction requiring  renal  replacement therapies  hemodynamic instability  sepsis  urgent surgery need during the study  administration of loop diuretic drugs  furosemide    250 mg/24 hrs&lt;br&gt;</Exclusion_Criteria>
    <Condition>Adult liver transplanted patients  age   &gt; 18 years , with  pre-transplantation  normal renal function  creatinine clearance   1ml/kg/min &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038436
Term: Renal failure acute
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CORLOPAM 1F 2ML 20MG/2ML&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: to  evaluate, in patients with early renal dysfunction after liver transplantation, the efficacy of fenoldopam mesylate in preserving/improving renal function  glomerular filtration rate .;Secondary Objective: to evaluate  if cystatin-C can be a reliable marker of  glomerular filtration  GFR  changes  in critically  ill patient  to evaluate  if cystatin-C level  may detect  the changes in renal function due to vasoactive drugs as fenoldopam;Primary end point(s): to  evaluate, in patients with early renal dysfunction after liver transplantation, the efficacy of fenoldopam mesylate in preserving/improving renal function  glomerular filtration rate .</Primary_outcome>
    <Secondary_ID>CORL2007</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462123</Internal_Number>
    <TrialID>EUCTR2006-006815-62-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does N-Acetylcysteine (Parvolex) prophylaxis reduce the incidence of renal impairment after on pump Coronary artery bypass surgery?   A prospective randomised controlled trial.</Public_title>
    <Scientific_title>Does N-Acetylcysteine (Parvolex) prophylaxis reduce the incidence of renal impairment after on pump Coronary artery bypass surgery?   A prospective randomised controlled trial.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>University Hospitals of South Manchester NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20070417</Date_registration3>
    <Date_registration>17/04/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006815-62                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/05/2007</Date_enrollement>
    <Target_size>224</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt; Patients undergoing elective coronary artery bypasssurgery at Wythenshawe Hospital Manchester&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Urgent and emergency cases&lt;br&gt;Patients with history of hypersensitivity to N-Acetylcysteine&lt;br&gt;Patients already taking N-Acetylcysteine&lt;br&gt;Patients with existing renal failure (creatinine more than 120mmol/l –upper limit of normal range in our laboratory&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal impairment after coronary artery byapass surgery &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10006894
Term: CABG
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Parvolex&lt;br&gt;Product Name: Acetylcysteine&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous drip use (Noncurrent)&lt;br&gt;&lt;br&gt;Trade Name: Parvolex&lt;br&gt;Product Name: Acetylcysteine&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To find out whether prophylactic use of N-Acetylcysteine decreases the incidence of renal impairment after cardiac surgery;Secondary Objective: To find out whether prophylactic N-Acetylcysteine has effect on the length of ICU/HDU stay;Primary end point(s): serum creatinine levels first 48 hrs</Primary_outcome>
    <Secondary_ID>NAC/CT/2006.</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462381</Internal_Number>
    <TrialID>EUCTR2007-000229-23-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>RENAL SAFETY EVALUATION AFTER DOTAREM-ENHANCED  MRA COMPARED WITH NON-ENHANCED MRI IN PATIENTS AT HIGH RISK OF DEVELOPING CONTRAST MEDIUM INDUCED NEPHROPATHY.</Public_title>
    <Scientific_title>RENAL SAFETY EVALUATION AFTER DOTAREM-ENHANCED  MRA COMPARED WITH NON-ENHANCED MRI IN PATIENTS AT HIGH RISK OF DEVELOPING CONTRAST MEDIUM INDUCED NEPHROPATHY.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>GUERBET</Primary_sponsor>
    <Date_registration3>20070604</Date_registration3>
    <Date_registration>04/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000229-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/08/2007</Date_enrollement>
    <Target_size>134</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: comparative descriptive &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Comparator will be an examination without contrast media injection(unenhanced-MRI)&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;·Male or female, aged = 55 years;&lt;br&gt;·Patient presenting with a known stable stage III to stage IV renal insufficiency according to the K/DOQI definition, i.e., 15 &lt; estimated GFR &lt; 60 ml/min/1.73m² according to MDRD formula for 2 consecutive values (within 10% of each other) obtained over at least one week apart with the most recent value having been obtained within 24 hours prior to the study procedure;&lt;br&gt;·Patient scheduled to undergo a contrast enhanced MR Angiography or unenhanced MRI examination to specify a diagnosis;&lt;br&gt;·Patient able to understand and provide written informed consent to participate in the trial;Patient for whom blood samples can be obtained in the 24 hours preceding the procedure and 72 hours after the examination.   &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;·Patient with a contraindication to MRI (e.g., pacemaker, aneurysm clip, severe claustrophobia, metallic joint replacement or others according to the imaging laboratory's standard practice);&lt;br&gt;·Patient who has a diagnosis of a hemodynamic instability (cardiogenic shock – persistent systolic pressure &lt; 90 requiring inotropic support) or acute myocardial infraction within 15 days prior the inclusion;&lt;br&gt;·Patient who needs hemodialysis; &lt;br&gt;·Patient with known allergy to gadolinium chelates (only applicable for patient undergoing Dotarem-enhanced MRA);&lt;br&gt;·Patient receiving medications known to be nephrotoxic or to cause increases in serum creatinine level (i.e. selective inhibitors of cyclo-oxygenase 2, anti-Vascular Endothelium Growth Factors, Vancomycine, Aciclovir, aminoglycosides, amphotericin B, polymixin, platinium complexes and non-steroidal anti-inflammatory treatment except Acetyl Salicylic Acid) within 24 hours before first blood sample and during 72 hours after the procedure;&lt;br&gt;·Patients for whom the dosage of diuretic has been modified during the month prior the inclusion or should be modified during the 3 days after the imaging procedure&lt;br&gt;·Patients planned to either undergo surgery or receive chemotherapy within 72 hours post-procedure (i.e: before the blood test 72 hours post-procedure);&lt;br&gt;·Patient having an imaging procedure (with contrast media or not ) within 7 days of entering this protocol;&lt;br&gt;·Patient with a planned imaging procedure (with contrast media or not ) within 72 hours post-procedure;&lt;br&gt;·Patient with newly discovered unstable diabetes;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients suffering from renal insufficiency and scheduled for contrast enhanced-MR angiography or unenhanced-MRI &lt;br&gt;MedDRA version: 10.0
Level: LLT
Classification code 10038474
Term: &lt;Manually entered code. Term in E.1.1&gt;
</Condition>
    <Intervention>&lt;br&gt;Trade Name: DOTAREM 0.5 mmol/ml&lt;br&gt;Product Name: DOTAREM 0.5mmol/m, solution for injection&lt;br&gt;Product Code: Not applicable&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Gadoteric Acid (corresponding to DOTA+gadolinium oxide)&lt;br&gt;Other descriptive name: 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, Gadolinium complex&lt;br&gt;Concentration unit: mmol/ml millimole(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess in at risk patients (patients with at least moderate renal insufficiency) the frequency of contrast-induced nephropathy after Dotarem-enhanced MRA, in comparison with the frequency of nephropathy after unenhanced MRI and to observe an equivalence between both procedures regarding these frequencies.;Secondary Objective: -To confirm the clinical and biological safety of DOTAREM® by assessing vital signs, laboratory parameters and adverse events through a 72±12 hours post treatment (DOTAREM®) or post procedure follow-up period.&lt;br&gt;-To assess the serum creatinine level fluctuation in term of mean difference between baseline and 72 ±12 hours after examination.&lt;br&gt;-To evaluate the estimated Glomerular Filtration Rate fluctuation in term of percentage and mean difference between baseline and 72 ±12 hours after examination. Estimated GFR will be assessed using the MDRD study equation.&lt;br&gt;-If possible, to assess the potential influence of hydration protocol and/or prophylactic treatment on the renal function&lt;br&gt;In case of rise in Serum creatinine level at 72±12 hours of at least 25% or 0.5mg/dl (44.2µmol/l), to observe the percentage of patients returned at baseline level within 14 days after the last blood sample (at 72hours).&lt;br&gt;&lt;br&gt;;Primary end point(s): The evaluation of the renal tolerance after both procedures (MRI and DOTAREM®-MRA) will be done by assessing the serum creatinine levels from blood sampling taken within 24 hours before the imaging procedure and at 72 ±12 hours after the procedure. &lt;br&gt;&lt;br&gt;This study will calculate in the two groups the percentage of patients presenting with a significant creatinine level increase according to the approach described hereafter. &lt;br&gt;&lt;br&gt;Significant creatinine level increase (Nephrotoxicity) will be defined as a rise in serum creatinine level at 72±12 hours of at least 25% or 0.5mg/dl (=44.2µmol/l) compared to baseline.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DGD 44-044;not applicable</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462410</Internal_Number>
    <TrialID>EUCTR2007-001857-24-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection</Public_title>
    <Scientific_title>A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>NovImmune S.A.</Primary_sponsor>
    <Date_registration3>20070531</Date_registration3>
    <Date_registration>31/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001857-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/07/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Men and women = 18 and = 70 years of age.&lt;br&gt;2.	Recipient of a kidney graft (first or second) from a deceased or living donor (non-HLA-identical).&lt;br&gt;3.	Rise in SCr concentration by &gt; 20% compared to baseline, defined as the most recent creatinine level measured prior to rejection but after transplantation.&lt;br&gt;4.	Allograft biopsy showing evidence of acute cellular rejection, according to Banff 97 criteria.&lt;br&gt;5.	Men and women of childbearing potential must use adequate birth control measures until 6 months after receiving study drug. Therefore, women of childbearing potential and their partners are required to use two forms of contraception. Men with partners of childbearing potential are required to use barrier contraception, in addition to their partners using another method. Acceptable forms of contraception are as follows: &lt;br&gt;-	Barrier methods: condoms, diaphragms, cervical caps;&lt;br&gt;-	Hormonal contraceptives: combination or progesterone only;&lt;br&gt;	Includes depot contraceptives;&lt;br&gt;-	Intrauterine methods: intrauterine devices or systems.&lt;br&gt;6.	The screening laboratory tests must meet the following criteria:&lt;br&gt;a.	Hb ³ 8.5 g/dL (4.5 mmol/L)&lt;br&gt;b.	WBC ³ 2.5 x 109/L&lt;br&gt;c.	Neutrophils ³ 1.5 x 109/L&lt;br&gt;d.	Platelets ³ 100 x 109/L&lt;br&gt;e.	SGOT (AST) and alkaline phosphatase levels must be within 3 times the upper limit of normal range.&lt;br&gt;7.	Patients must be able to adhere to the study visits and protocol requirements.&lt;br&gt;8.	Patients must be able to give written informed consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Patients who have received therapy with anti-CD3 mAb (OKT3) or anti-lymphocytes polyclonal antibodies (ATG, Atgam) in the past.&lt;br&gt;2.	Patients with cardiac insufficiency or fluid overload (to be excluded by a chest X ray). &lt;br&gt;3.	Severe HLA sensitization (&gt;50% panel reactive antibodies prior to transplantation).&lt;br&gt;4.	Evidence of delayed renal graft function.&lt;br&gt;5.	Have received or are planned to receive immunization with a live vaccine within 6 weeks prior to receiving study drug and 12 weeks after treatment cessation.&lt;br&gt;6.	Concomitant disease:&lt;br&gt;a.	Current signs or symptoms of severe, progressive or uncontrolled disease. Patients with cardiac (e.g. recent myocardial infarction or symptomatic ischemic heart disease); pulmonary (e.g. chronic obstructive pulmonary disease); or neurologic disease (e.g. seizure disorder or head trauma).&lt;br&gt;b.	Previous diagnosis of, or known, malignancies, except for completely excised basal cell carcinoma.&lt;br&gt;c.	Ongoing severe infections, such as hepatitis or pneumonia, or any active infection (requiring therapy).&lt;br&gt;d.	History of opportunistic infections such as herpes zoster within 2 months prior to screening. History of active tuberculosis (TB) or currently undergoing treatment for TB.&lt;br&gt;e.	Evidence of acute CMV (or D+/R-) or EBV infection.&lt;br&gt;f.	Serum anti HCV positive, serum HBsAg positive, serum anti-HIV positive. &lt;br&gt;g.	Patients with BK Virus nephropathy.&lt;br&gt;7.	Patients with any history of coagulopathy or medical condition requiring long-term anticoagulation after transplantation (low-dose of aspirin treatment is allowed).&lt;br&gt;8.	Female patients who are pregnant or breast feeding.&lt;br&gt;9.	A psychiatric, addictive, or any other disorder that compromises the ability to give truly informed written consent for participation in this study.&lt;br&gt;10.	Suspected hypersensitivity to any component of the drug product.&lt;br&gt;11.	Has undergone or is undergoing treatment with another investigational drug or approved therapy for investigational use within 3 months prior to entry in this study. Has previously participated in this study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Acute cellular renal allograft rejection.</Condition>
    <Intervention>&lt;br&gt;Product Code: NI-0401&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess safety and tolerability of NI-0401&lt;br&gt;To determine whether NI-0401 can reverse BpACR;Secondary Objective: To assess changes in renal function overtime, as measured by serum creatinine.&lt;br&gt;To establish NI-0401 pharmacokinetics in patients with BpACR.&lt;br&gt;To assess pharmacodynamics of NI-0401.&lt;br&gt;To quantify the level of recurrent rejections, their severity and response to treatment.&lt;br&gt;To assess the incidence of anti-NI-0401 antibodies.&lt;br&gt;;Primary end point(s): Adverse events (nature, frequency, intensity, causality, seriousness, treatability and outcome).&lt;br&gt;The percentage of patients demonstrating a complete normalization of SCr at study day 14. Complete normalization is defined as a return of the SCr concentration to &lt; 120% of baseline value.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>NI-0401-02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462418</Internal_Number>
    <TrialID>EUCTR2006-005916-29-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>IFEROS – Influence of intravenous iron therapeutics on oxidative stress in hemodialysis patients - IFEROS</Public_title>
    <Scientific_title>IFEROS – Influence of intravenous iron therapeutics on oxidative stress in hemodialysis patients - IFEROS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Westpfalz-Klinikum GmbH</Primary_sponsor>
    <Date_registration3>20070605</Date_registration3>
    <Date_registration>05/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005916-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/10/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: yes&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;stable hemodialysis patients at least three months on HD&lt;br&gt;age &gt;  18 years&lt;br&gt;adequate hemodialysis with kt/v &gt; 1,3&lt;br&gt;adequate iron stores with Serum-Ferritin &gt;100 µg/dl and TSAT &gt;20% or hypochrome erythrocytes &lt; 10%&lt;br&gt;CRP &lt; 30 mg/l&lt;br&gt;Hemoglobin &gt;10 g/dl&lt;br&gt;stable on erythropoeitin: erythropoetin-dose  50 – 150 IU/kg/Woche and no change of erythropoeitin-dose &gt; 30% in the last 8 weeks&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;·clinical signs of relevant inflammation or CRP &gt; 30 mg/l &lt;br&gt;Hemoglobin &lt; 10 g/dl or Hemoglobin &gt;13g/dl&lt;br&gt;Serum-Ferritin &lt;100 µg/dl or Serum-Ferritin &gt; 800 µg/dl&lt;br&gt;TSAT  &gt; 50%&lt;br&gt;weekly iron substitition &gt; 100 mg &lt;br&gt;hematologic systemic disease&lt;br&gt;immunsuppressive or cytostatic therapy&lt;br&gt;therapy with vitamin C, vitamin E or Acetylcystein&lt;br&gt;pregnany&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>stable patients on hemodialysis with renal anemia &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10019480
Term: Hemodialysis
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10058132
Term: Renal anemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CosmoFer&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;CAS Number: 9004664&lt;br&gt;Other descriptive name: IRON DEXTRAN&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Ferrlecit&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;CAS Number: 8500011872&lt;br&gt;Other descriptive name: SODIUM-IRON-GLUCONATE COMPLEX&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 62,5/5-&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration number: 62,5/5-&lt;br&gt;&lt;br&gt;Trade Name: Venofer&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;CAS Number: 8047674&lt;br&gt;Other descriptive name: IRON SUCROSE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100/5-&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration number: 100/5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: investigate the influence of different iro preparations on oxidative stress and apoptotic changes of peripheral blood leukocytes in hemodialysis patients;Secondary Objective: none;Primary end point(s): measurement of oxidative stress and apoptotic changes in peripheral blood leukocytes:&lt;br&gt;- Malondialdehyd&lt;br&gt;- DNA-damage (Comet-test)&lt;br&gt;- Glutathion&lt;br&gt;- changes of mitochondrial membran potential&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>IFEROS V5-1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462439</Internal_Number>
    <TrialID>EUCTR2007-000416-91-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137
Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or
Locally Advanced Solid Malignancies.

Revised Protocol Number 07, incorporating Amendments 01, 02, 03, 04, 05, 06, 07 and Administrative Letter Dated 10-Mar-2006.
</Public_title>
    <Scientific_title>A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137
Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or
Locally Advanced Solid Malignancies.

Revised Protocol Number 07, incorporating Amendments 01, 02, 03, 04, 05, 06, 07 and Administrative Letter Dated 10-Mar-2006.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Bristol-Myers Squibb International Corporation</Primary_sponsor>
    <Date_registration3>20070611</Date_registration3>
    <Date_registration>11/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000416-91                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/07/2007</Date_enrollement>
    <Target_size>110</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: patients will be randomized to receive 1, 3 or 10 mg/kg of BMS-663513 in a 1:1:1 ratio&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Signed written informed consent&lt;br&gt;&lt;br&gt;- Target population&lt;br&gt;a) Able to comply with visits/procedures required by the protocol&lt;br&gt;b) Life expectancy of at least 3 months&lt;br&gt;c) ECOG performance status score 0 - 1 (Protocol Appendix 4).&lt;br&gt;d) Patients with histologic or cytologic diagnosis of an advanced solid malignancy&lt;br&gt;who have failed, refused or are unable to receive standard treatment.&lt;br&gt;NOTE: Patients enrolled after Amendment 7 is IRB approved are limited to:&lt;br&gt;• Melanoma (must be anti-CTLA-4 naive),&lt;br&gt;• Renal (clear cell) carcinoma, or&lt;br&gt;• Epithelial carcinoma arising from the ovary, fallopian tube or peritoneum.&lt;br&gt;e) At least 1 site of measurable disease (excluding epithelial carcinoma who must&lt;br&gt;have at least 1 site of “evaluable” disease)&lt;br&gt;f) A tumor paraffin embedded tissue block or 5 - 15 unstained slides from the tumor&lt;br&gt;tissue block (from the primary or a metastatic tumor) must be provided for&lt;br&gt;biomarker and predictive marker analyses. Note: If the tumor tissue block or unstained slides are not available or insufficient, additional fresh tumor tissue&lt;br&gt;could be collected during the optional pretreatment biopsy to satisfy this criteria&lt;br&gt;g) At least 4 weeks must have elapsed since the last chemotherapy, immunotherapy,&lt;br&gt;hormonal therapy, radiotherapy or major surgery, &amp; the 1st day of BMS-663513 therapy. At least 6 weeks for nitrosoureas, mitomycin C &amp; liposomal doxorubicin&lt;br&gt;h) Toxicities related to prior therapy must either have returned to = Grade 1, baseline or deemed irreversible&lt;br&gt;&lt;br&gt;-Age and Sex&lt;br&gt;a) Men and women, who are at least 18 years of age.&lt;br&gt;- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche &amp; who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea &gt;= 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level &gt; 35 IU/mL. Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an&lt;br&gt;intrauterine device or barrier methods (diaphragm, condoms, spermicides) to&lt;br&gt;prevent pregnancy or practicing abstinence or where partner is sterile (eg,&lt;br&gt;vasectomy), should be considered to be of child bearing potential.&lt;br&gt;- WOCBP must have a negative pregnancy test [minimum sensitivity 25 IU/L&lt;br&gt;or equivalent units of beta-human chorionic gonadatrophin (ßHCG)] within&lt;br&gt;72-hours prior to the start of study medication.&lt;br&gt;&lt;br&gt;- Physical and laboratory test findings:&lt;br&gt;a) Adequate bone marrow function defined as:&lt;br&gt;Absolute neutrophil count (ANC) &gt;= 1,500 cells/mm³&lt;br&gt;Platelet count &gt;= 100,000 cells/mm³&lt;br&gt;Hemoglobin &gt;= 9.0 g/dl&lt;br&gt;b) Adequate hepatic function defined as:&lt;br&gt;Total bilirubin =&lt; 1.5 times the institutional upper limit of normal (IULN)&lt;br&gt;ALT, AST and alkaline phosphatase =&lt; 2.5 times the IULN&lt;br&gt;c) Adequate renal function defined as:&lt;br&gt;Serum creatinine =&lt; 1.5 times the IULN or&lt;br&gt;Calculated creatinine clearance of &gt;= 60 mL/min/1.73m²&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Sex and Reproductive Status&lt;br&gt;a) WOCBP who are unwilling or unable to use an acceptable method to avoid&lt;br&gt;pregnancy for the entire study period and for up to 12 weeks after the study.&lt;br&gt;b) WOCBP using a prohibited contraceptive method.&lt;br&gt;c) Women who are pregnant or breastfeeding.&lt;br&gt;d) Women with a positive pregnancy test on enrollment or prior to study drug&lt;br&gt;administration.&lt;br&gt;e) Sexually active fertile men, whose partners are WOCBP, who are unwilling or&lt;br&gt;unable to use an acceptable method of birth control from the time of enrollment&lt;br&gt;and for 12 weeks after participation in the study.&lt;br&gt;&lt;br&gt;- Medical History and Concurrent Diseases&lt;br&gt;a) Active infection or uncontrolled significant acute or chronic medical illness other&lt;br&gt;than current cancer that would prohibit safe administration of BMS-663513.&lt;br&gt;b) Any concurrent malignancy other than adequately treated basal or squamous cell&lt;br&gt;skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix.&lt;br&gt;Patients with a previous malignancy but without evidence of disease for &gt;= 5 years&lt;br&gt;will be allowed to enter the trial.&lt;br&gt;c) History of autoimmune diseases including rheumatoid arthritis, lupus&lt;br&gt;erythermatosus, uveitis and autoimmune inflammatory eye disease, psoriasis,&lt;br&gt;multiple sclerosis, inflammatory bowel diseases, etc. Type I diabetes mellitus is&lt;br&gt;allowed.&lt;br&gt;d) Known or suspected human immunodeficiency virus (HIV) positive.&lt;br&gt;e) Any current condition requiring the continued use of systemic or topical steroids&lt;br&gt;or the use of immunosuppressive agents (eg, cyclosporine and its analog, or&lt;br&gt;chemotherapy agents). All corticosteroid use must have been discontinued&lt;br&gt;&gt;= 4 weeks prior to Day 1 of treatment.&lt;br&gt;f) Active/symptomatic brain metastasis. Patients with signs or symptoms suggestive&lt;br&gt;of brain metastasis are not eligible unless brain metastases are ruled out by&lt;br&gt;computerized axial tomography (CT) scan or magnetic resonance imaging (MRI).&lt;br&gt;Patients with stable brain metastasis and those who were previously treated with&lt;br&gt;radiotherapy or surgery must have no current evidence of active/symptomatic&lt;br&gt;brain metastasis and are off steroid therapy for at least 4 weeks prior to Day 1 of&lt;br&gt;treatment.&lt;br&gt;g) Uncontrolled or significant cardiovascular disease including myocardial infarction&lt;br&gt;within 6 months, uncontrolled angina, Class III-IV New York Heart Association&lt;br&gt;(NYHA) congestive heart failure (Appendix 5) and clinically significant&lt;br&gt;ventricular arrhythmias.&lt;br&gt;h) Any other sound medical, psychiatric and/or social reason, which in the opinion&lt;br&gt;of the principal investigator, would prohibit the understanding of the informed&lt;br&gt;consent and/or make the administration of study drug hazardous or obscure the&lt;br&gt;interpretation of adverse events.&lt;br&gt;i) History of hepatitis B or C, or alcohol induced liver disease.&lt;br&gt;&lt;br&gt;- Physical and Laboratory Test Findings&lt;br&gt;a) Evidence of organ dysfunction or any clinically significant deviation from normal&lt;br&gt;in physical examination, vital signs, ECG or clinical laboratory determinations.&lt;br&gt;b) Positive blood screen for hepatitis B surface antigen, or hepatitis C antibody.&lt;br&gt;&lt;br&gt;- Allergies and Adverse Drug Reactions&lt;br&gt;a) History of allergy to BMS-663513 or related compounds.&lt;br&gt;&lt;br&gt;- Prohibited Therapies and/or Medications&lt;br&gt;a) Exposure to any investigational products within 4 weeks prior to Day 1 of&lt;br&gt;treatment.&lt;br&gt;b) Use of any immunosuppressing treatments including corticosteroids,&lt;br&gt;cyclosporine, mycophenolate mofetil (CellCept®), chemotherapy, radiation, etc,&lt;br&gt;within 4 weeks prior to Day 1 of treatment.&lt;br&gt;&lt;br&gt;-Other Exclusion Criteria&lt;br&gt;a) Prisoners or patients w</Exclusion_Criteria>
    <Condition>Patients with Metastatic or Locally Advanced Solid Malignancies &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10025650
Term: Malignant melanoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038395
Term: Renal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10033131
Term: Ovarian carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: Anti-CD137&lt;br&gt;Product Code: BMS-663513&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Current Sponsor code: BMS-663513&lt;br&gt;Other descriptive name: Anti-CD137&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the safety and tolerability of BMS-663513 in the range of 0.3 mg/kg to&lt;br&gt;15 mg/kg administered once every 3 weeks to patients with metastatic or locally advanced solid malignancies in the dose escalation portion of the study. To estimate the reversible Grade 3-4 toxicity rate in the expanded dose cohorts of melanoma, ovarian and renal carcinoma patients at each of the 3 selected doses (1, 3 and 10 mg/kg).;Secondary Objective: •Assess the PK of BMS-663513&lt;br&gt;•Assess BMS-663513 dose &amp; biologic effect relationships using:&lt;br&gt; -Flow cytometry to quantitate subsets of immune cells (CD3, CD4, CD8, CD19, &amp; &lt;br&gt;   CD16/56)&lt;br&gt; -Flow cytometry to measure subsets of T cells (activated, memory)&lt;br&gt; -QRT-PCR to measure changes in RNA expression in peripheral blood&lt;br&gt; -ELISA to measure changes in levels of cytokines &amp;/or other biomolecules&lt;br&gt;•Screen for anti-tumor activity of single agent BMS-663513&lt;br&gt;•Assess the effect of BMS-663513 on immune response to non-cancer vaccines (influenza, tetanus, pneumoccocal)&lt;br&gt;•Assess the immunogenic potential of BMS-663513&lt;br&gt;•Assess the effect of BMS-663513 on intratumoral immune response pre and post treatment using immunohistochemistry&lt;br&gt;•Obtain fresh &amp; paraffin embedded tumor samples, &amp; blood, to identify potential predictive markers of biological response utilizing ribonucleic acid (RNA) profiling, protein profiling, single nucleotide polymorphism (SNP) analysis, &amp; other techniques;Primary end point(s): • Primary Safety Outcome Measures: &lt;br&gt;Safety assessments will be based on medical review of adverse event (AE) reports and the results of vital sign measurements, EKG/ECG, physical examinations, and clinical laboratory tests. AEs will be recorded using Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 and the incidence will be tabulated and reviewed for potential significance and clinical importance.&lt;br&gt;&lt;br&gt;• Pharmacokinetic Measures: &lt;br&gt;PK parameters (Cmax, Cmin, Tmax, AUC(INF), AUC(TAU), T1/2, CLT, Vss, and ?x) may be derived from serum concentration versus time for BMS-663513.&lt;br&gt;&lt;br&gt;• Efficacy Measures: &lt;br&gt;Tumor response will be determined for all patients using a modified form of the WHO criteria. These assessments will be made at week 12 and every 6 weeks thereafter or more frequently if indicated.&lt;br&gt;&lt;br&gt;• Pharmacodynamic Measures: &lt;br&gt;Exploratory research to assess dose and biologic effect relationships will be assessed by measurement of changes in peripheral T cell subsets using flow cytometry, changes in RNA expression in peripheral blood using QRT-PCR and changes in cytokines or other biomolecules using ELISA. Anti-influenza, anti-pneumoccocal and anti-tetanus antibody titers may be measured 3 to 4 weeks after immunization. Exploratory research to discover predictive markers of response will be performed using RNA profiling, SNP analysis and IHC of tumor tissue.</Primary_outcome>
    <Secondary_ID>CA186001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462502</Internal_Number>
    <TrialID>EUCTR2004-004947-23-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Eficacia de rapamicina en prevención secundaria de tumores cutáneos en trasplantados renales. Estudio abierto, aleatorizado, comparando rapamicina con inhibidores de calcineurina. - Tumorapa-1</Public_title>
    <Scientific_title>Eficacia de rapamicina en prevención secundaria de tumores cutáneos en trasplantados renales. Estudio abierto, aleatorizado, comparando rapamicina con inhibidores de calcineurina. - Tumorapa-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Hospices Civils de Lyon</Primary_sponsor>
    <Date_registration3>20070524</Date_registration3>
    <Date_registration>24/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004947-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/06/2007</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;patient aged 18 year old or more with kidney transplant with immunosuppressive treatment with calcineurines inhibitor recurrence of spinocellular carcinoma&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patient aged les tha 18 year old&lt;br&gt;metastatic carcinoma&lt;br&gt;previous treatment with rapamycine&lt;br&gt;pregnant woman&lt;br&gt;</Exclusion_Criteria>
    <Condition>Comparar el efecto de dos estrategias inmunosupresoras sobre la incidencia de nuevos carcinomas espinocelulares en pacientes con trasplante renal que hayan desarrollado un primer carcinoma espinocelular.


To evaluate the impact of two imnosupressive regimens on the incidence of skin cancers among patients who has a first spinocellular skin cancer after renal transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Cyclosporine&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;INN or Proposed INN: cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Micofenolato mofetilo&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Micofenolato mofetilo&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;INN or Proposed INN: Micofenolato mofetilo&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Imurel&lt;br&gt;Product Name: Azatioprina&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Azatioprina&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Rapapmycine replacement of calcineurines inhibitor could reduce the risk of a new kin cancer by 40% or more while preserving graft function;Secondary Objective: ;Primary end point(s): to analyse the annual incidence of spinocellular carcinoma</Primary_outcome>
    <Secondary_ID>Tumorapa-1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462629</Internal_Number>
    <TrialID>EUCTR2005-004509-27-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Utilidad de la Rapamicina para la prevención secundaria de tumores cutáneos en trasplantados renales con recidiva de carcinoma espinocelular - Tumorapa-N</Public_title>
    <Scientific_title>Utilidad de la Rapamicina para la prevención secundaria de tumores cutáneos en trasplantados renales con recidiva de carcinoma espinocelular - Tumorapa-N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Hospices Civils de Lyon</Primary_sponsor>
    <Date_registration3>20070622</Date_registration3>
    <Date_registration>22/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004509-27                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/07/2007</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;patient aged 18 year old or more with kidney transplant &lt;br&gt;with immunusuppressive treatment with calcineurines inhibitor&lt;br&gt;recurrence of spinocellular carcinoma&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patient aged less than 18year old&lt;br&gt;metastatic carcinoma&lt;br&gt;previous treatment with rapamycine&lt;br&gt;pregnant woman&lt;br&gt;</Exclusion_Criteria>
    <Condition>El objetivo principal consiste en comparar el efecto de dos estrategias inmunosupresoras, sobre la incidencia de carcinomas espinocelulares nuevos en pacientes receptores de trasplante renal que hayan desarrollado más de un carcinoma espinocelular.

To evaluate the impact of two immunosuppressive regimens on the incidence of skin cancers among patients who have had previously a first spinocellulaire skin cancer after transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Micofenolato Mofetilo&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Micofenolato mofetilo&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;INN or Proposed INN: Micofenolato mofetilo&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Imurel&lt;br&gt;Product Name: Azatioprina&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Azatioprina&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Cyclosporine&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: Cyclosporine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Rapamycine replacement of calcineurines inhibitor could reduce the risk of a new skin cancer by  40% or more while preserving graft function;Secondary Objective: ;Primary end point(s): to analyse the annual incidence of spinocellular carcinoma</Primary_outcome>
    <Secondary_ID>Tumorapa-N</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462737</Internal_Number>
    <TrialID>EUCTR2007-003045-33-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Fenoldopam and renal insufficiency - ND</Public_title>
    <Scientific_title>Fenoldopam and renal insufficiency - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>OSPEDALE S. RAFFAELE</Primary_sponsor>
    <Date_registration3>20070702</Date_registration3>
    <Date_registration>02/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003045-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/08/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;patients undergoing heart surgery developing, in any moment during post surgery hospitalization in Intensive Care Unit, renal problems named as "R" of RIFLE score&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;glaucoma,discharge from Intensive Care Unit within 24 hours,renal substitutive treatment,possible exitus,inclusion in other studies,age under 18,lack of informed consent,patients treated with fenoldopam in prevoius month,pre surgery dialisis&lt;br&gt;</Exclusion_Criteria>
    <Condition>patients undergoing heart surgery developing, in any moment during post surgery hospitalization in Intensive Care Unit, renal problems named as "R" of RIFLE score &lt;br&gt;MedDRA version: 9.1
Level: SOC
Classification code 10038359
Term: Renal and urinary disorders
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CORLOPAM&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Fenoldopam&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: to evaluate if Fenoldopam use versus placebo may improve the renal outcome in patients undergoing heart surgery;Secondary Objective: to evaluate if Fenoldopam use versus placebo may improve the renal outcome in patients undergoing heart surgery;Primary end point(s): prevention of placement of renal substitutive treatment</Primary_outcome>
    <Secondary_ID>FENO HSR</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462899</Internal_Number>
    <TrialID>EUCTR2007-000033-19-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open study to investigate the effect of 4 instead of 2 daily dosing mycophenolate mofetil (MMF) in renal transplant patients on diarrhea - 4xMMF</Public_title>
    <Scientific_title>An open study to investigate the effect of 4 instead of 2 daily dosing mycophenolate mofetil (MMF) in renal transplant patients on diarrhea - 4xMMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>UMC Utrecht</Primary_sponsor>
    <Date_registration3>20070302</Date_registration3>
    <Date_registration>02/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000033-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/06/2007</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: administartion of 4 daily dosing Cellcept is compared with 2 daily dosing&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female &gt; 18 years old&lt;br&gt;Renal transplantation &gt; 6 months with stable renal function (serum creatinine &lt; 250 mumol/L)&lt;br&gt;Use of MMF (Cellcept®) 2 times daily&lt;br&gt;History of diarrhea (&gt; 1 month = 3 times a day loose/ watery stool in at least 75% of the cases)&lt;br&gt;Willing and capable to give written informed consent&lt;br&gt;Able to communicate and cooperate with the investigators&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Usage of morfinomimetics, anti-diarretics, laxans or other drugs that are known to induce diarrhea.&lt;br&gt;Recent use of antibiotics (&lt; 4 weeks before study)&lt;br&gt;Gastro-intestinal infections (Yersinea, Campylobacter, Shigella, Salmonella, Clostridium difficile toxin, CMV)&lt;br&gt;Known gastro-intestinal diseases or recent major gastro-intestinal surgery&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diarrhea in renal transplanted patients which use Cellcept® &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10021176
Term: Iatrogenic diarrhea
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10054980
Term: Immunosuppressant drug therapy
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CellCept® (mycophenolate mofetil)&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: MYCOPHENOLATE MOFETIL&lt;br&gt;CAS Number: 115007346&lt;br&gt;Current Sponsor code: mmf4dd&lt;br&gt;Other descriptive name: 4xMMF&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1-3&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The main objective is to find out if dividing the daily oral dose prevents diarrhea without increasing risk of graft failure.;Secondary Objective: Increasing the quality of life and effect on intestinal permeability.;Primary end point(s): - Stool frequency and faeces weight&lt;br&gt;- Incidence of acute graft rejection (according to BANFF 1997 criteria)</Primary_outcome>
    <Secondary_ID>4xmmf</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2462980</Internal_Number>
    <TrialID>EUCTR2007-002562-35-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>ffet de l’Epoetin Beta sur la fonction rénale et l’anémie dans les trente jours suivant une transplantation rénale - Etude Neo-PDGF</Public_title>
    <Scientific_title>ffet de l’Epoetin Beta sur la fonction rénale et l’anémie dans les trente jours suivant une transplantation rénale - Etude Neo-PDGF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>CHU AMIENS</Primary_sponsor>
    <Date_registration3>20070723</Date_registration3>
    <Date_registration>23/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002562-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/09/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Comparaison à l'absence de traitement&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Patient d’âge compris entre 18 et 75 ans ayant délivré un consentement de participation libre et éclairé&lt;br&gt;- Patient devant être transplanté rénal bénéficiant d’une 1ère ou 2ème transplantation&lt;br&gt;- Patient anciennement traité par dialyse péritonéale ou par hémodialyse&lt;br&gt;- Patient recevant un greffon à risque de reprise retardée de fonction (score &gt; 7 combinant age du donneur, durée d’ischémie, ethnie du receveur et cause du décès)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Femme enceinte ou allaitante&lt;br&gt;- Déficience ne permettant pas une bonne compréhension des impératifs de l’essai&lt;br&gt;- Patient recevant des doses d’epoetin bêta ou alpha &gt; 30000 UI/semaine avant la transplantation&lt;br&gt;- Patient ayant participé à un essai clinique au cours du dernier mois &lt;br&gt;- Patient sous sauvegarde de justice, sous tutelle ou curatelle&lt;br&gt;- Patient bénéficiant d’une troisième greffe ou hyperimmunisé ou ayant un cross-match positif&lt;br&gt;- Greffon provenant d’un donneur vivant&lt;br&gt;- Greffon avec 3 artères ou plus&lt;br&gt;- Patient ayant une insuffisance cardiaque sévère, une cardiopathie ischémique instable ou ayant eu un événement coronarien majeur &lt; 6 mois, un AVC &lt; 6 mois ou une AOMI symptomatique&lt;br&gt;- Patient ayant une infection virale active : hépatites B, C ou HIV&lt;br&gt;- Patient ayant des antécédents d’anémie érythroblastopénique&lt;br&gt;- Patient recevant un traitement anticoagulant (AVK) avant la Tx rénale&lt;br&gt;- Patient ayant un taux d’Hb préopératoire &gt; 14 g/dL (avant ultrafiltration)&lt;br&gt;- Patient présentant une hypersensibilité connue au produit à l’essai&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients insuffisants rénaux chroniques, au stade terminal de leur affection, traités en dialyse. Patients, hommes ou femmes, agés de 18 à 75 ans, devant bénéficier d'une transplantation rénale à partir d'un donneur en coma dépassé et étant à risque de récupération lente de la fonction du greffon. Randomisés pour recevoir 4 injections de 30000 UI de NeoRecormon (Epoetin bêta) avant le déclampage, 12 heures après la greffe et à J7 et J14 (Groupe A), ou aucun traitement (Groupe B). &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10058116
Term: Nephrogenic anaemia
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10009120
Term: Chronic renal failure anaemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NeoRecormon® 30 000 UI&lt;br&gt;Product Name: NeoRecormon®&lt;br&gt;Product Code: RO 2053859&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluer l’effet de l’Epoetin bêta sur le débit de filtration glomérulaire (DFG) estimée 30 jours après transplantation rénale. Le DFG sera évaluer par la formule MDRD simplifiée;Secondary Objective: Comparer entre les 2 groupes à tous les temps de J0 à J90 :&lt;br&gt;- L’évolution de la fonction rénale&lt;br&gt;- La survie des patients et des greffons&lt;br&gt;- Le délai de survenue et l’incidence d’un rejet aigu prouvé par biopsie&lt;br&gt;- La correction de l’anémie&lt;br&gt;- Les besoins transfusionnels&lt;br&gt;- Les besoins en EPO&lt;br&gt;- La qualité de vie&lt;br&gt;- La tolérance du traitement;Primary end point(s): Evaluation de la fonction rénale à J30 mesurée par le débit de filtration glomérulaire estimé (formule MDRD simplifiée)</Primary_outcome>
    <Secondary_ID>P107 - Pr CHOUKROUN</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463028</Internal_Number>
    <TrialID>EUCTR2007-001904-18-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open label randomised controlled study to compare the efficacy, safety and tolerability of once every four weeks administration of subcutaneous C.E.R.A. versus darboepoetin alfa for the maintenance of haemoglobin levels in predialysis patients with chronic renal anaemia.

Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A. por vía subcutánea frente a darbepoetina alfa para el mantenimiento de las concentraciones de hemoglobina en pacientes con anemia renal crónica que no están en diálisis.</Public_title>
    <Scientific_title>An open label randomised controlled study to compare the efficacy, safety and tolerability of once every four weeks administration of subcutaneous C.E.R.A. versus darboepoetin alfa for the maintenance of haemoglobin levels in predialysis patients with chronic renal anaemia.

Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A. por vía subcutánea frente a darbepoetina alfa para el mantenimiento de las concentraciones de hemoglobina en pacientes con anemia renal crónica que no están en diálisis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>ROCHE FARMA S.A.</Primary_sponsor>
    <Date_registration3>20070730</Date_registration3>
    <Date_registration>30/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001904-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/08/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Darbepoetina alfa&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Consentimiento informado por escrito&lt;br&gt; &lt;br&gt;• Pacientes adultos (&gt;18 años) con enfermedad renal crónica en estadio 3 (VSGc 30-59 ml/min) o 4 (VSGc 15-29 ml/min) que no precisen diálisis&lt;br&gt; &lt;br&gt;• Concentración de hemoglobina basal entre 10,5 y 12,5 g/dl (media de los valores de hemoglobina semanales determinados en las semanas -4 a -1)&lt;br&gt;&lt;br&gt;• Estado de hierro adecuado (concentración de ferritina sérica &gt;100 ng/ml O TSAT &gt;20% O porcentaje de  hematíes hipocrómicos &lt;10%)&lt;br&gt; &lt;br&gt;• Tratamiento de mantenimiento continuo con darbepoetina alfa subcutánea utilizando la misma pauta de administración (una vez cada 2 semanas) durante los 2 meses previos.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) &lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) &lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Transfusiones de hematíes durante los 2 meses previos&lt;br&gt;• Hipertensión mal controlada, es decir, tensión arterial en posición sentada superior a 170/100 a pesar de la medicación, que haya requerido hospitalización o la interrupción del tratamiento con darbepoetina alfa en los 6 meses previos. &lt;br&gt;• Hemorragias agudas o crónicas significativas, tales como hemorragias gastrointestinales manifiestas&lt;br&gt;• Enfermedad maligna activa (excepto cáncer de piel no melanoma)&lt;br&gt;• Hemólisis &lt;br&gt;• Hemoglobinopatías (p. ej. anemia drepanocítica homocigótica, cualquier tipo de talasemia)&lt;br&gt;•	Deficiencia de ácido fólico &lt;br&gt;•	Deficiencia de vitamina B12 &lt;br&gt;•	Recuento de plaquetas &gt;500 x 109/l o &lt;100 x 109l&lt;br&gt;•	Aplasia eritrocítica pura&lt;br&gt;•	Ataques epilépticos durante los 6 meses previos &lt;br&gt;•	Insuficiencia cardíaca congestiva (Clase IV NYHA)&lt;br&gt;•	Infarto de miocardio o ictus, arteriopatía coronaria severa o inestable, enfermedad hepática severa de acuerdo con el criterio del investigador, durante los 3 meses previos&lt;br&gt;•	Hiperparatiroidismo secundario no controlado o sintomático (se podría definir como una concentración de PTH &gt; 1000 pg/ml en el ensayo de PTH intacta o de &gt;500 pg/ml en el ensayo de PTH completa).&lt;br&gt;•	Mujeres embarazadas o en período de lactancia&lt;br&gt;•	Mujeres potencialmente fértiles que no utilicen métodos anticonceptivos eficaces&lt;br&gt;•	Participación en un ensayo clínico o administración de un compuesto en investigación o un tratamiento experimental durante las 4 últimas semanas previas.&lt;br&gt;•	Cirugía programada (con fecha) durante el período de estudio, a excepción de &lt;br&gt;?	cirugía por cataratas&lt;br&gt;?	cirugía de acceso vascular&lt;br&gt;•	Hipersensibilidad confirmada a eritropoyetina recombinante humana, polietilenglicol o a cualquiera de los componentes de la medicación del estudio &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anemia en insuficiencia renal crónica &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10058124
Term: Nephrogenic anemia
</Condition>
    <Intervention>&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Trade Name: Aranesp®&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: darbepoetin alfa&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/µl microgram(s)/microlitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 677324-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: proposed: pegzerepoetin alfa&lt;br&gt;CAS Number: 67734-53-7&lt;br&gt;Current Sponsor code: RO0503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;&lt;br&gt;Product Name: C.E.R.A.&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or </Intervention>
    <Primary_outcome>Main Objective: • Comparar el mantenimiento a largo plazo de las concentraciones de hemoglobina con la administración subcutánea una vez cada cuatro semanas de C.E.R.A. frente a darbepoetina alfa subcutánea en pacientes con anemia renal crónica que no están en diálisis. ;Secondary Objective: • Comparar la seguridad y tolerancia de la administración de C.E.R.A una vez cada cuatro semanas para el tratamiento de la anemia en pacientes con enfermedad renal crónica ;Primary end point(s): Las variables principales se evaluarán durante las 8 semanas siguientes al período de corrección de dosis de 16 semanas, es decir, durante el período de evaluación de la eficacia (PEE).&lt;br&gt;La concentración de hemoglobina de referencia se define como la media de las cuatro determinaciones registradas durante el PVE (semanas -4,-3,-2,-1)&lt;br&gt;A los efectos de la evaluación de la eficacia, el rango diana de la concentración de hemoglobina se definirá como ± 1 g/dl de la concentración de hemoglobina de referencia O un valor que esté dentro del rango de 10,5 – 12,5 g/dl. &lt;br&gt;&lt;br&gt;Variable de eficacia principal &lt;br&gt;• Proporción de pacientes en los que se mantiene la concentración media de hemoglobina dentro del rango diana durante el período  PEE&lt;br&gt;</Primary_outcome>
    <Secondary_ID>ML21059</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463257</Internal_Number>
    <TrialID>EUCTR2006-001812-65-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomized, double-blind, placebo-controlled, parallel
group, multicenter study to evaluate the effect of valsartan
on proteinuria and glomerular filtration rate in children with
Chronic Kidney Disease who are receiving a standardized
dose of angiotensin converting enzyme inhibitor therapy</Public_title>
    <Scientific_title>A randomized, double-blind, placebo-controlled, parallel
group, multicenter study to evaluate the effect of valsartan
on proteinuria and glomerular filtration rate in children with
Chronic Kidney Disease who are receiving a standardized
dose of angiotensin converting enzyme inhibitor therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20070801</Date_registration3>
    <Date_registration>01/08/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001812-65                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/08/2006</Date_enrollement>
    <Target_size>314</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;(For Full list, see protocol)&lt;br&gt;• Pediatric outpatients, 5-17 years of age, with a history of chronic kidney disease.&lt;br&gt;• Male and female patients with body weight = 15 kg and = 100 kg are eligible.&lt;br&gt;• Must be able to swallow tablets.&lt;br&gt;• Must be receiving a standardized dose of an ACEI for at least for 2 months, for the treatment of proteinuria, without known ACEI-suspected adverse effects which could prevent the patient from continuing to receive the same dose of the ACEI for an additional 18 months.&lt;br&gt;• Urine dipstick for protein = trace at Visit 1.&lt;br&gt;• Proteinuria demonstrated in 2 of 3 early morning void urine specimen collections at Visit 2 (UPCR = 500 mg/g).&lt;br&gt;• GFR = 30 ml/min/1.73m2 and = 90 ml/min/1.73m2, as estimated by the Schwartz formula using the Visit 1 serum creatinine value.&lt;br&gt;• MSSBP/MSDBP must be &lt; 95th percentile, for age, gender and height, at Visit 2, by office blood pressure measurement.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;(For full list, see protocol):&lt;br&gt;Renal transplant patients&lt;br&gt;• Renal artery stenosis.&lt;br&gt;• Patients with active systemic disease(s) (e.g. diabetes, amyloidosis, vasculitis, lupus nephritis) defined as those with current, recent (in the past two months) or frequent (= 2 episodes in the past 12 months) exacerbations of disease activity, and those in whom immunosuppressive medication was increased within two months prior to screening &lt;br&gt;• Patients who are currently or within two months prior to screening on the following medications. [Note: Patients on maintenance immunosuppressive therapy (CsA, FK 506, MMF or azathioprine), administered at unchanged dose in the past 2 months pior to screening, and expected to remain unchanged throughout the study, are allowed.]:&lt;br&gt;               • Intraveous or oral cyclophosphamide&lt;br&gt;               • Intravenous or oral steroid pulse therapy&lt;br&gt;               • Oral steroid therapy &gt;0.5 mg/kg/d&lt;br&gt;• Serum potassium &lt; 3.5 or &gt; 5.3 mEq/L.&lt;br&gt;• Hemoglobin &lt; 8 gm/dL.&lt;br&gt;• WBC &lt; 3000/mm3.&lt;br&gt;• Patients currently on Angiotensin II type-1 Receptor Blocker (ARB) therapy&lt;br&gt;• Patients are not medically able or willing to discontinue aldosterone receptor antagonist and/or potassium sparing diuretic medications for the duration of the study.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease is characterized by a progressive decline of glomerular
filtration rate (GFR), which occurs irrespectively of the cause of the renal damage once a critical nephron mass has been lost.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Diovan 40 mg film-coated tablet&lt;br&gt;Product Name: Valsartan&lt;br&gt;Product Code: VAL489&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Valsartan&lt;br&gt;Current Sponsor code: VAL489&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Diovan 80 mg film-coated tablet&lt;br&gt;Product Name: Valsartan&lt;br&gt;Product Code: VAL489&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Valsartan&lt;br&gt;Current Sponsor code: VAL 489&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 80-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy, safety and tolerability of valsartan versus placebo in&lt;br&gt;children with Chronic Kidney Disease (CKD) manifested by persistent proteinuria (&gt; 500 mg/g) while receiving a standardized dose of ACEI therapy to provide important prescribing information to the pediatrician on the use of valsartan in children with CKD.;Primary end point(s): Period 1 : Change from baseline in log (UPCR) month 4&lt;br&gt;&lt;br&gt;Period 1 + Period 2 : Chronic slope of GFR over time, month 2 to 18   ;Secondary Objective: • Evaluate the proportion of patients who have their UPCR reduced by = 50% from baseline to end of Period 1.&lt;br&gt;• Evaluate the proportion of patients who have their urine albumin/creatinine ratio (UACR) reduced by = 50% from baseline to end of Period 1.&lt;br&gt;• Evaluate proteinuria reduction as measured by UACR from baseline to end of Period 1 &lt;br&gt;Entire study : To Evaluate: &lt;br&gt;• Proportion of patients who have their UPCR reduced by = 50% from baseline to end of Period 2.&lt;br&gt;• Proportion of patients who have their urine albumin/creatinine ratio (UACR) reduced&lt;br&gt;by = 50% from baseline to end of Period 2.&lt;br&gt;• Proteinuria reduction as measured by UPCR and UACR from baseline to end of&lt;br&gt;Period 2.&lt;br&gt;• Proportion of patients with = 25% GFR loss from baseline at end of Period 2.&lt;br&gt;• Change in GFR (difference in slope) from baseline to end of treatment Period 2.&lt;br&gt;• To evaluate the overall safety and tolerability of valsartan in this population.</Primary_outcome>
    <Secondary_ID>CVAL489K2301;Not applicable</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463276</Internal_Number>
    <TrialID>EUCTR2006-006652-35-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab,mycophenolate, ciclosporin and corticosteroids) in renal transplantation. - Bone Protection study</Public_title>
    <Scientific_title>A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab,mycophenolate, ciclosporin and corticosteroids) in renal transplantation. - Bone Protection study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Queen Mary University of London</Primary_sponsor>
    <Date_registration3>20070731</Date_registration3>
    <Date_registration>31/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006652-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/09/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;The enrolled patients must fulfil the following inclusion criteria:&lt;br&gt;1.	Male and female patients between 18 and 75 years of age&lt;br&gt;2.	Patients scheduled for a single-organ, renal transplantation from living or deceased donors. Patient receiving second renal transplants can be included, provided that the previous graft was not lost from acute rejection within the first year. &lt;br&gt;3.	Patients capable of understanding the purposes and risks of the study, who give written informed consent and who are willing to participate to and comply with the study.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;The following groups of patients will not be included in the study:&lt;br&gt;1.	Women lactating, pregnant or of childbearing potential not using a reliable contraceptive method before beginning study drug therapy, during therapy and for 4 months following their last dose of the drugs administered within this clinical study.&lt;br&gt;2.	Patients receiving the third or higher renal transplant.&lt;br&gt;3.	Patients with severe diarrhea or other gastrointestinal disorders that might interfere with their ability to absorb oral medication, including diabetic patients with previously diagnosed diabetic gastroenteropathy.&lt;br&gt;4.	Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.&lt;br&gt;5.	Patients with evidence of an active systemic infection requiring the continued use of antibiotics or evidence of an HIV infection, or the presence of a chronic active hepatitis B (HBs-Ag positive) or C.&lt;br&gt;6.	Patients with history of malignancy (except successfully treated localized non-melanistic skin cancer).&lt;br&gt;7.	Patients with active peptic ulcer disease.&lt;br&gt;8.	Patients with evidence of an active liver disease &lt;br&gt;9.	Patients with severe anemia (Hb&lt;6 g/dl) leucopenia (WBC&lt;2500/mm3), thrombocytopenia (Tc &lt;100’000/mm3)&lt;br&gt;10.	Patients for whom the investigator considers a treatment with the following medications necessary:&lt;br&gt;-	azathioprine,&lt;br&gt;-	methotrexate,&lt;br&gt;-	cyclophosphamide,&lt;br&gt;-	polyclonal and monoclonal anti-lymphocyte antibodies (e.g. OKT3, ATG), e.g. used for induction in immunological high-risk patients,&lt;br&gt;-	basiliximab,&lt;br&gt;-	mycophenolate - sodium&lt;br&gt;-	other investigational drugs.&lt;br&gt;11.	Known hypersensitivity or absolute contraindications to any of the medications administered in the context of the study or any other substances present in the study medications&lt;br&gt;12.	Panel Reactive Antibody (PRA) &gt; 30% within 6 months prior to enrollment; &lt;br&gt;13.	Cold ischemia time of the graft of more than 30 hours; &lt;br&gt;14.	Patients who had received an investigational new drug within the last three months.&lt;br&gt;15.	Patients previously treated with daclizumab or basiliximab.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplantation &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Product Code: Not available&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123889&lt;br&gt;Current Sponsor code: Not available&lt;br&gt;Other descriptive name: N/A&lt;br&gt;Concentration unit: IU/mg international unit(s)/milligram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;Trade Name: Zenapax&lt;br&gt;Product Name: Zenapax&lt;br&gt;Product Code: Ro 24-7375&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: DACLIZUMAB&lt;br&gt;CAS Number: 152923563&lt;br&gt;Current Sponsor code: Ro-24-7375&lt;br&gt;Other descriptive name: N/A&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Cellcept&lt;br&gt;Product Code: Ro 106-1443&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: MYCOPHENOLATE MOFETIL&lt;br&gt;CAS Number: 115007346&lt;br&gt;Current Sponsor code: Ro-106-1443&lt;br&gt;Other descriptive name: MMF&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Sandimune&lt;br&gt;Product Name: Sandimune&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Other descriptive name: CsA&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the present investigation is to evaluate the effect of sirolimus (converted from ciclosporin at 6 weeks) compared to cicolsporin, as part of a standard immunosuppressive regimen, on the severity of bone loss at 12 months post transplant.  .  Current standard immunosuppression (group A: mycophenolate mofetil, dacluzimab, ciclosporin and corticosteroids) will be compared to a CNI conversion regimen (group B: mycophenolate mofetil, dacluzimab, ciclosporin converted to sirolimus at 6 weeks, and corticosteroids).;Secondary Objective: Secondary objectives are:&lt;br&gt;•	To assess the tolerability of patients to the regimens, by recording the % of patients remaining CNI free at 12 months.&lt;br&gt;•	Evaluate the incidence of biopsy proven, type and severity of rejection &lt;br&gt;•	To characterize the safety (hypertension, hyperlipidemia, opportunistic infections, post transplant and diabetes mellitus) of the immunosuppressant combinations at 6 and 12 months.&lt;br&gt;•	To evaluate the renal function as expressed by the calculated creatinine clearance over the course of the study.&lt;br&gt;•	Assess the impact of CNI conversion to sirolimus on MPA AUC in 10 patients in group B.&lt;br&gt;;Primary end point(s): The primary efficacy parameter of the study is to compare the change in bone density between 6 weeks and 12 month post transplant between groups A &amp; B.</Primary_outcome>
    <Secondary_ID>ML 20958</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463301</Internal_Number>
    <TrialID>EUCTR2007-003369-42-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude de phase II randomisée, multicentrique, en ouvert, évaluant l'efficacité de l’association Avastin (bevacizumab) + Torisel (temsirolimus) versus Sutent (sunitinib) versus Avastin+ Roféron(interféron alpha-2a) en première ligne de traitement du cancer du rein métastatique

 - TORAVA</Public_title>
    <Scientific_title>Etude de phase II randomisée, multicentrique, en ouvert, évaluant l'efficacité de l’association Avastin (bevacizumab) + Torisel (temsirolimus) versus Sutent (sunitinib) versus Avastin+ Roféron(interféron alpha-2a) en première ligne de traitement du cancer du rein métastatique

 - TORAVA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>CENTRE LEON BERARD</Primary_sponsor>
    <Date_registration3>20070820</Date_registration3>
    <Date_registration>20/08/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003369-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/10/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1) Homme ou femme âgé de 18 ans ou plus&lt;br&gt;&lt;br&gt;2) Patient porteur d’un adénocarcinome du rein métastatique de toute forme histologique, sauf papillaire. Une preuve cytologique ou histologique, comprenant le grade de Fürhman, est obligatoire&lt;br&gt;&lt;br&gt;3) Patient n’ayant pas subi de traitement systémique antérieur (chimiothérapie, immunothérapie, traitement anti-angiogénique, traitement en cours d’investigation) pour cancer du rein métastatique&lt;br&gt;&lt;br&gt;4) Patient ne présentant pas de métastase cérébrale attestée par une imagerie par résonance magnétique (IRM) ou un scanner dans les 28 jours précédant la randomisation. (Les patients avec des antécédents de métastases cérébrales traitées par chirurgie +/- irradiation cérébrale et présentant une IRM cérébrale normale peuvent être inclus)&lt;br&gt;&lt;br&gt;5) Performance Status Eastern Cooperative Oncology Group (ECOG) &lt; 2&lt;br&gt;&lt;br&gt;6) Maladie mesurable ou non mesurable selon les critères Response Evaluation Criteria in Solid Tumours (RECIST)&lt;br&gt;&lt;br&gt;7) Patient présentant, dans les 7 jours précédant la randomisation, des constantes hématologiques, paramètres fonctionnels rénaux et hépatiques tels que les numérations sanguines ou taux sériques, conformes aux valeurs suivantes :&lt;br&gt;• Hémoglobine &gt; 8 g/dL,&lt;br&gt;• Polynucléaires neutrophiles (PN) &gt; 1,5 G/L,&lt;br&gt;• Plaquettes &gt; 100 G/L,&lt;br&gt;• Créatinine sérique &lt; 200 µmol/L,&lt;br&gt;• Bilirubine totale &lt; 1,5 fois la limite supérieure de la normale (LSN),&lt;br&gt;• Alanine Amino Transférase (ALAT) et Spartate Amino Transférase (ASAT) &lt; 2,5 fois la LSN ou &lt; 5 fois la LSN pour les patients avec métastases hépatiques,&lt;br&gt;• Taux de prothrombine (TP) ou International Normalized Ratio (INR) &lt; 1,5 fois la limite supérieure à la normale en l’absence de traitement anticoagulant. (Les patients sous traitement anticoagulant à titre préventif peuvent être inclus)&lt;br&gt;&lt;br&gt;8) Patient ne présentant pas de protéinurie attestée par bandelette urinaire. Si le test par bandelette est positif au moins 2 fois, la protéinurie sera mesurée sur recueil des urines de 24 heures (le taux de protéines doit être &lt; 1 g/L)&lt;br&gt;&lt;br&gt;9) Pour les femmes en âge de procréer, une méthode contraceptive fiable (contraception hormonale, dispositif intra-utérin, double barrière) est nécessaire&lt;br&gt;&lt;br&gt;10) Patient affilié à un régime de sécurité sociale&lt;br&gt;&lt;br&gt;11) Patient ayant daté et signé le consentement éclairé de participation&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1) Patient porteur d’un carcinome du rein à forme papillaire pure&lt;br&gt;&lt;br&gt;2) Patient ayant subi un traitement systémique antérieur pour cancer du rein métastatique&lt;br&gt;&lt;br&gt;3) Patient présentant des antécédents d’autre cancer hormis un cancer in situ du col utérin, ou un carcinome cutané basocellulaire traité de manière curative, ou tout autre cancer traité de manière curative et sans signe de récidive pendant au moins 5 ans&lt;br&gt;&lt;br&gt;4) Patient porteur de métastase cérébrale après contrôle tomodensitométrique ou par IRM réalisé dans les 28 jours précédant la randomisation. (Les patients avec antécédents de métastases cérébrales traitées par irradiation cérébrale exclusive ne peuvent être inclus, même avec une IRM cérébrale normale)&lt;br&gt;&lt;br&gt;5) Patient souffrant d’affection cardiovasculaire significative de type insuffisance cardiaque congestive &gt; classe 2 de la New York Heart Association (NYHA), infarctus du myocarde dans les 6 mois précédant la randomisation, angor instable, troubles du rythme graves, accident vasculaire cérébral dans les 6 mois précédant la randomisation, antécédents thromboemboliques sévères dans les 6 mois précédant la randomisation, allongement de l'intervalle QT, bradycardie, troubles électrolytiques, hypertension artérielle non contrôlée par un traitement adapté (PAsystolique = 160 mm Hg et/ou PAdiastolique = 90 mm Hg), (La méthode recommandée pour la mesure de la pression artérielle est la mesure par la méthode auscultatoire, au moyen d'un sphygmomanomètre à mercure, le patient étant depuis plusieurs minutes en position assise ou couchée. La mesure devra être systématiquement répétée au minimum 2 fois)&lt;br&gt;&lt;br&gt;6) Patient souffrant d’affection hépatique de type hépatite chronique évoluée et décompensée, cirrhose hépatique ou hépatite chronique récemment traitée ou en cours de traitement par des agents immunosuppresseurs, hépatite auto-immune ou antécédent de maladie auto-immune&lt;br&gt;&lt;br&gt;7) Patient ayant subi une intervention chirurgicale lourde, une biopsie ouverte, ou porteur d’une plaie non complètement cicatrisée dans les 28 jours précédant la randomisation&lt;br&gt;&lt;br&gt;8) Patient présentant une hypercalcémie non contrôlée par un traitement adapté&lt;br&gt;&lt;br&gt;9) Patient présentant une hypercholestérolémie ou hypertriglycéridémie non contrôlée&lt;br&gt;&lt;br&gt;10) Patient traité par anti-vitamine K au long cours&lt;br&gt;&lt;br&gt;11) Patient traité par inhibiteurs puissants du CYP3A4&lt;br&gt;&lt;br&gt;12) Patient porteur d'une maladie neuropsychiatrique grave ou souffrant de comitialité&lt;br&gt;&lt;br&gt;13) Patient participant à un autre essai thérapeutique, à l’exception des essais de soins de support&lt;br&gt;&lt;br&gt;14) Femme enceinte ou allaitante (un test de grossesse sérique ou urinaire doit être négatif au moment de l’entrée dans l’étude pour toutes les femmes en âge de procréer)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient en 1ère ligne de traitement d'un cancer du rein métastique. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050076
Term: Metastatic renal carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Avastin&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;&lt;br&gt;Trade Name: TORISEL&lt;br&gt;Product Name: TEMSIROLIMUS&lt;br&gt;Product Code: CCI-779&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;&lt;br&gt;Trade Name: SUTENT&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;Trade Name: ROFERON&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Estimer, chez des patients traités en première ligne d’un cancer du rein métastatique par l’association bevacizumab et temsirolimus, le taux de non progression 48 semaines après le début du traitement;Secondary Objective: Pour les 3 stratégies thérapeutiques :	&lt;br&gt;- estimer les taux de réponse objective et de régression tumorale,&lt;br&gt;- estimer la durée de réponse,&lt;br&gt;- Estimer précocement la réponse tumorale par échographie de contraste avec quantification de la perfusion tumorale (uniquement dans certains centres sélectionnés),&lt;br&gt;- estimer la survie sans progression et la survie globale,&lt;br&gt;- évaluer leur profil de tolérance,&lt;br&gt;- étudier la qualité de vie des patients.&lt;br&gt;&lt;br&gt;;Primary end point(s): 48 SEMAINES APRES LE DEBUT DU TRAITEMENT</Primary_outcome>
    <Secondary_ID>ET2007-035</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463355</Internal_Number>
    <TrialID>EUCTR2007-004069-16-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Hepatic and intestinal CYP3A4/5 activity in renal transplantation.

A study assessing in vivo hepatic and intestinal CYP3A4/5 activity at different time-points and in different clinical settings after renal transplantation and its relationship with genotype, pharmacokinetics and metabolism of Tacrolimus and outcome.</Public_title>
    <Scientific_title>Hepatic and intestinal CYP3A4/5 activity in renal transplantation.

A study assessing in vivo hepatic and intestinal CYP3A4/5 activity at different time-points and in different clinical settings after renal transplantation and its relationship with genotype, pharmacokinetics and metabolism of Tacrolimus and outcome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Department of Nephrology and Renal Transplantation, KU Leuven</Primary_sponsor>
    <Date_registration3>20071003</Date_registration3>
    <Date_registration>03/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004069-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/10/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- De novo primary renal allograft recipients.&lt;br&gt;- Chronic stable renal allograft recipients.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Age &lt; 18 years. &lt;br&gt;- Females with child bearing potential, not using an acceptable method of birth control. &lt;br&gt;- Nursing and pregnant women. Pregnancy tests will be performed before drug administration.&lt;br&gt;- Known allergy or intolerance to either Erythromycin or Midazolam.&lt;br&gt;- Concomitant treatment with opioid- or antipsychotic drugs. &lt;br&gt;- Severe chronic lung disease and chronic respiratory insufficiency. &lt;br&gt;- Chronic heart failure. &lt;br&gt;- Severe liver disease. &lt;br&gt;- Anaemia (haemoglobin &lt; 11 g/dL).&lt;br&gt;- Hypoalbuminemia (&lt; 25 g/L).&lt;br&gt;- Combined organ transplants.&lt;br&gt;- Known non-compliance.&lt;br&gt;- Alcohol intake &gt; 7 units/week.&lt;br&gt;- Smoking.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Effect of genetic (single nucleotide polymorphisms of genes encoding  drug metabolising enzymes and drug transporters) and non-genetic factors (e.g. age, time after transplantation, concommitant medication, renal function, liver dysfunction) on in vivo hepatic and intestinal CYP3A4 and 5 activity in renal allograft recipients. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dormicum 5mg/5ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: MIDAZOLAM HYDROCHLORIDE&lt;br&gt;CAS Number: 59467968&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): The effect of genetic and non-genetic factors on the disposition of Midazolam, as a marker of in vivo CYP3A4 and 5 activity, in renal allograft recipients.;Main Objective: To asses in vivo hepatic and intestinal CYP3A4 and 5 activity in renal allograft recipients at different time-points and in different clinical settings after renal transplantation.  ;Secondary Objective: To asses the relationship of in vivo hepatic and intestinal CYP3A4 and 5 activity in renal allograft recipients with:&lt;br&gt;- the recipients genotype.&lt;br&gt;- pharmacokinetics and metabolism of immunosuppressive drugs.&lt;br&gt;- outcome. </Primary_outcome>
    <Secondary_ID>CYP3A4/5RenalTx</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463391</Internal_Number>
    <TrialID>EUCTR2007-002208-17-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase IIa, Multi-Center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DNB-001 in Patients with Angina Pectoris and Moderate Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention</Public_title>
    <Scientific_title>A Phase IIa, Multi-Center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DNB-001 in Patients with Angina Pectoris and Moderate Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Danube Pharmaceuticals</Primary_sponsor>
    <Date_registration3>20070809</Date_registration3>
    <Date_registration>09/08/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002208-17                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/08/2007</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•Males and sterile/post-menopausal = 1 year females aged 18 to 80 years inclusive.&lt;br&gt;&lt;br&gt;•Scheduled for elective percutaneous coronary intervention for angina pectoris (angioplasty with or without stents).&lt;br&gt;&lt;br&gt;•Planned administration of an iodine based contrast agent.&lt;br&gt;&lt;br&gt;•Angina pectoris as classified by the CCS grading system.&lt;br&gt;&lt;br&gt;•Stage III chronic kidney failure as defined by the National Kidney Foundation (NKF).&lt;br&gt;             *	eGFR calculated by the MDRD equation of 30 to 59 mL/min/1.73 m2.&lt;br&gt;&lt;br&gt;•Provide written informed consent.&lt;br&gt;&lt;br&gt;•Ability to return for all trial visits.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•Emergency cardiac catheterization.&lt;br&gt;&lt;br&gt;•Hemodynamic instability (Systolic Blood Pressure &lt; 80 mm Hg, or &gt; 200 mm Hg; Heart Rate &lt; 50 bpm, or &gt; 120 bpm).&lt;br&gt;&lt;br&gt;•Hemodynamic instability (SBP &lt; 80, or &gt; 200; HR &lt; 50, or &gt; 120).&lt;br&gt;&lt;br&gt;•Cardiac biomarkers (cTnI, cTnT) out of reference ranges at the time of screening.&lt;br&gt;&lt;br&gt;•Severe/unstable diabetes requiring emergency room or inpatient therapy for control of diabetes within previous 30 days.&lt;br&gt;&lt;br&gt;•Patients with liver function enzymes (AST, ALT, GGT) out of the normal range at the time of screening.&lt;br&gt;&lt;br&gt;•Serum creatinine greater than 5 mg/dL for males or greater than 4 mg/dL for females.&lt;br&gt;&lt;br&gt;•End-stage renal disease requiring dialysis.&lt;br&gt;&lt;br&gt;•Known acute renal failure at the time of screening.&lt;br&gt;&lt;br&gt;•Acute pulmonary edema.&lt;br&gt;&lt;br&gt;•Administration of contrast agent within previous 48 hours.&lt;br&gt;&lt;br&gt;•Planned re-administration of contrast agent for 28 days post-PCI.&lt;br&gt;&lt;br&gt;•Known allergy to the planned contrast agent.&lt;br&gt;&lt;br&gt;•Planned administration of dopamine, mannitol, or fenoldopam during study.&lt;br&gt;&lt;br&gt;•New therapy or change in dose of a diuretic, ACE inhibitor, or ARB within previous 14 days or during the study.&lt;br&gt;&lt;br&gt;•Planned new therapy or titration of dose of a diuretic, ACE inhibitor, or ARB within previous 14 days, or during the study, EXCEPT as indicated for the periprocedural period.&lt;br&gt;&lt;br&gt;•Any treatment with an investigational agent in the past 60 days for any condition.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Angina pectoris and renal insufficiency whilst undergoing percutaneous coronary intervention (PCI). &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10063886
Term: Renal insufficiency aggravated
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10002384
Term: Angina pectoris aggravated
</Condition>
    <Intervention>&lt;br&gt;Product Name: DNB-001&lt;br&gt;Product Code: DNB-001&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Current Sponsor code: DNB-001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 750-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study will be to evaluate the potential efficacy and safety of BID dosing of DNB-001 (750 mg) given over 72 hours in patients with angina pectoris and chronic kidney disease undergoing elective PCI. The primary objectives include:&lt;br&gt;&lt;br&gt;•	To evaluate the cardio-protective efficacy of DNB-001 versus placebo, as measured by the change in cardiac biomarkers of myonecrosis (cTnI) from baseline to peak levels post-PCI.&lt;br&gt;&lt;br&gt;•	To evaluate the safety of DNB-001 when used in a patient population with angina pectoris and moderate chronic kidney disease undergoing elective percutaneous coronary intervention (angioplasty +/- stent deployment).&lt;br&gt;&lt;br&gt;;Secondary Objective: •To evaluate the renal-protective efficacy of DNB-001 versus placebo, as measured by the change in SCr (renal function) from baseline to peak level post-PCI. &lt;br&gt;&lt;br&gt;•Composite endpoint of death, MI, or re-hospitalization for acute coronary syndrome within 28 days of treatment.&lt;br&gt;&lt;br&gt;•To evaluate the difference in additional potential biomarkers (CKMB).;Primary end point(s): •The change in cardiac cTnI between the active and placebo arms of the trial from baseline to peak levels post-PCI &lt;br&gt;&lt;br&gt;•The change in renal function (SCr) between the active and placebo arms of the trial from baseline to peak levels post-PCI&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DNB-001-CT002</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463518</Internal_Number>
    <TrialID>EUCTR2007-002763-27-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A multi-center, randomized, controlled trial with programmed introduction of Sirolimus-based, Calcineurin inhibitor free immunosuppression in recipients of non-heart-beating donor kidney grafts. - PRINS study</Public_title>
    <Scientific_title>A multi-center, randomized, controlled trial with programmed introduction of Sirolimus-based, Calcineurin inhibitor free immunosuppression in recipients of non-heart-beating donor kidney grafts. - PRINS study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Erasmus MC</Primary_sponsor>
    <Date_registration3>20070809</Date_registration3>
    <Date_registration>09/08/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002763-27                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/09/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Age = 18 years.&lt;br&gt;2.	Acceptable renal function (eGFR Nankivell &gt; 30ml, Proteinuria &lt; 1.0 g/day)&lt;br&gt;3.	3-4 months post renal transplantation with a NHBD graft&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Banff grade &gt; 2 acute or vascular rejection at any time during this transplant pre-randomization&lt;br&gt;2.	Multiple organ transplants (i.e., prior or concurrent transplantation of any organs other than renal transplant)..&lt;br&gt;3.	Evidence of active systemic or localized major infection.&lt;br&gt;4.	Use of any investigational drug or treatment up to 4 weeks prior to transplantation.&lt;br&gt;5.	Planned use of agents with a known interaction with any of the following: sirolimus or its derivatives, macrolide antibiotics, corticosteroids,  tacrolimus, or IMPDH inhibitor. &lt;br&gt;6.	Immunosuppressive therapies other than those described above&lt;br&gt;7.	Planned treatment with voriconazole, cisapride, or ketoconazole, that will not be discontinued prior to randomization.&lt;br&gt;8.	Treatment with aminoglycosides, amphotericin B, cisplatin, or other drugs associated with renal dysfunction that is not discontinued prior to enrolment.&lt;br&gt;9.	Subjects with a screening/baseline total white blood cell count  &lt; 2,000/mm3 or ANC &lt; 1000, platelet count &lt; 100,000/mm3.&lt;br&gt;10.	 Fasting triglycerides &gt; 400 mg/dL (&gt; 4.5 mmol/L) or fasting total cholesterol &gt; 300 mg/dL (&gt; 7.8 mmol/L) despite optimal lipid-lowering therapy.&lt;br&gt;11.	Subjects who are known to be HIV positive and/or subjects with active Hepatitis B or   active Hepatitis C.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Recipients of a renal allograft from a non-heart-beating donor, three months after transplantation. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Sirolimus&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123889&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-2&lt;br&gt;&lt;br&gt;Trade Name: Prograft&lt;br&gt;Product Name: Tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.5-5&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the safety and efficacy of a programmed introduction of a Sirolimus-based, Calcineurin inhibitor free, maintenance immunosuppressive regime, three months after renal transplantation in recipients of a non-heart-beating donor kidney graft on: graft function as determined by eGFR and biopsy proven acute rejection rates at twelve months post randomization to programmed Sirolimus introduction&lt;br&gt;;Secondary Objective: Graft and patient survival. Infection rate. Malignancy rate. Dyslipidaemia. Proteinuria rate. Change in selectivity index of proteinuria. Blood pressure. Number of antihypertensive drugs. Cardiovascular event rate.;Primary end point(s): eGFR as determined by Nankivell at month 12 post randomization </Primary_outcome>
    <Secondary_ID>PRINS study</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463554</Internal_Number>
    <TrialID>EUCTR2007-003092-39-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmacokinetics of colistimethate and colistine after a 60 minutes intravenous infusion of colistimethate 1 million UI (80 mg) in 12 healthy volunteers</Public_title>
    <Scientific_title>Pharmacokinetics of colistimethate and colistine after a 60 minutes intravenous infusion of colistimethate 1 million UI (80 mg) in 12 healthy volunteers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>CHU DE POITIERS</Primary_sponsor>
    <Date_registration3>20070918</Date_registration3>
    <Date_registration>18/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003092-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/11/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-	Subjects aged from 18 to 65, male&lt;br&gt;-	Without major known disease,&lt;br&gt;-	Non smokers or moderate smokers (&lt; 15 cigarettes p. day), &lt;br&gt;-	During the study, subjects accepted to drink 250 ml p. hour during the 4th first hours, then 100 ml p. hour next hours,&lt;br&gt;-	Subjects accepted to feed only with the collations which are proposed to them,&lt;br&gt;-	Non pathologic blood pressure and heart rate,&lt;br&gt;-	A written assent must be signed.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Hypersensitivity to colistine or polymyxines,&lt;br&gt;-	Familial or personal known myasthenia,&lt;br&gt;-	Renal, hepatic, cardiac, hematologic, neurologic, psychiatric or digestive known disease &lt;br&gt;-	Asthma or severe allergy ,&lt;br&gt;-	Surgical operation during the previous month,&lt;br&gt;-	Drug or alcohol addiction,&lt;br&gt;-	Previous administration of colistine or other medication. Other planned administration of any medication during the study.&lt;br&gt;-	Blood gift during the previous month&lt;br&gt; -	Positive HIV, HBV et HCV serological status.&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney infection
genital infection &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023424
Term: Kidney infection
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10018152
Term: Genital infection bacterial NOS
</Condition>
    <Intervention>&lt;br&gt;Trade Name: COLIMYCINE&lt;br&gt;Product Name: COLIMYCINE&lt;br&gt;Product Code: J01XB01&lt;br&gt;Pharmaceutical Form: Powder for injection*&lt;br&gt;INN or Proposed INN: COLISTIMETHATE SODIQUE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1,6 -&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Plasmatic and urinary concentrations, pharmacokinetics parameters of colistine and colistimethate. ;Secondary Objective: Evaluation of safety. ;Primary end point(s): Plasmatic and urinary concentrations, pharmacokinetics parameters of colistine and colistimethate. </Primary_outcome>
    <Secondary_ID>PHARMACOLIS</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463756</Internal_Number>
    <TrialID>EUCTR2007-002102-22-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, prospective, randomized, open-label study of the safety and efficacy of a Certican® -based regimen versus a calcineurin inhibitor (CNI)-based regimen in maintenance heart transplant recipients with CNI-related renal insufficiency - CeCaRi</Public_title>
    <Scientific_title>Multicenter, prospective, randomized, open-label study of the safety and efficacy of a Certican® -based regimen versus a calcineurin inhibitor (CNI)-based regimen in maintenance heart transplant recipients with CNI-related renal insufficiency - CeCaRi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Gasthuisberg Leuven</Primary_sponsor>
    <Date_registration3>20070921</Date_registration3>
    <Date_registration>21/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002102-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/10/2007</Date_enrollement>
    <Target_size>150</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Male or female over 18 years old&lt;br&gt;•	Patients who have undergone a heart transplantation at least 12 months ago&lt;br&gt;•	Patients with a calculated GFR (MDRD formula) = 60 ml/min and = 30 ml/min/1.73m2 (CKD stage 3) &lt;br&gt;•	Patients who are willing and capable to participate in the study for 12 months and who have given written informed consent.&lt;br&gt;•	Females capable of becoming pregnant must have a negative pregnancy test within 7 days prior to randomization and are required to practice a medically approved method of birth control for the duration of the study.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Dialysed patients&lt;br&gt;•	Patients with any treated acute rejection within 6 months prior to randomization&lt;br&gt;•	Patients with an identifiable cause of renal dysfunction other than CNI toxicity&lt;br&gt;•	Patients with platelet count = 75.000/mm3 or white blood cell count = 2.500/mm3 or  hemoglobin value = 8 g/dL&lt;br&gt;•	Patients with proteinuria = 0.8 g/24h&lt;br&gt;•	Presence of a severe hypercholesterolemia (total cholesterol ? 9 mmol/l; ? 350mg/dl) or hypertriglyceridemia (? 8.5 mmol/l, ? 750 mg/dl) despite lipid lowering therapy&lt;br&gt;•	Patients with a current severe systemic infection&lt;br&gt;•	Patients with any history(within the past 5 years) or currently suffering from a malignancy, with an expected life-span of less than 2 years&lt;br&gt;•	Patients currently being treated with a mTOR inhibitor&lt;br&gt;•	Patients with a known intolerance or hypersensitivity to Certican®  (everolimus) or similar drugs.&lt;br&gt;•	Severe hepatic disorders&lt;br&gt;•	Patients suffering from chronic hepatitis C  (PCR positive) or who are HIV- or HBsAg-positive. The result of a laboratory test performed within the 6 months preceding the inclusion must be available.&lt;br&gt;•	Patients with a significant mental illness, which in the opinion of the investigator may interfere with patients’ ability to comply with the protocol.&lt;br&gt;•	Women who are pregnant or breastfeeding&lt;br&gt;•	Patients who have received an investigational drug within 4 weeks prior to study enrolment&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>This study is designed to evaluate whether Certican® initiation, together with discontinuation of calcineurin inhibitors (CNIs) will have a beneficial effect on the renal function in maintenance heart transplant recipients with CNI-related renal impairment, while maintaining efficacy.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: •	Change in renal function assessed by mGFR  from baseline to month 12 after randomization between the group of patients receiving Certican® and the control group with unchanged CNI-based immunosuppressive treatment.  ;Secondary Objective: •	Incidence of treated acute rejection episodes  &lt;br&gt;•	Proteinuria (protein/creatinine ratio, measured in first morning urine sample)&lt;br&gt;•	Incidence of graft loss/retransplantation&lt;br&gt;•	Patient survival&lt;br&gt;•	Ultrasound left ventricular ejection fraction&lt;br&gt;•	Incidence of MACEs. MACEs include:  acute myocardial infarction, congestive heart failure, percutaneous coronary intervention (PCI), automatic implanted cardiac defibrillator (AICD), coronary artery bypass graft surgery (CABG), cerebral vascular accident, and peripheral vascular disease.  &lt;br&gt;•	Calculated GFR (cGFR n-MDRD formula) change from baseline.&lt;br&gt;•	Ambulatory 24h blood pressure monitoring&lt;br&gt;•	Safety parameters including: hypertension, diabetes mellitus, hyperlipidemia, anemia, infections and malignancies&lt;br&gt;•	Incidence of discontinuations, AEs and SAEs&lt;br&gt;;Primary end point(s): •	Change in renal function assessed by mGFR  from baseline to month 12 after randomization between the group of patients receiving Certican® and the control group with unchanged CNI-based immunosuppressive treatment.  </Primary_outcome>
    <Secondary_ID>CeCaRi </Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463927</Internal_Number>
    <TrialID>EUCTR2007-005079-32-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Treatment of secondary renal amyloidosis A with the Intereleukin – 1 antagonist anakinra</Public_title>
    <Scientific_title>Treatment of secondary renal amyloidosis A with the Intereleukin – 1 antagonist anakinra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Medical University of Vienna</Primary_sponsor>
    <Date_registration3>20071031</Date_registration3>
    <Date_registration>31/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005079-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/12/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Biopsy proven renal amyoidosis&lt;br&gt;2.	Serum Amyloid A concentration greater than 25mg/l&lt;br&gt;3.	Estimated GFR between 30 to 90ml/min&lt;br&gt;4.	Men or women aged &gt;18years&lt;br&gt;5.	Provision of informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Estimated GFR &lt; 30ml/min&lt;br&gt;2.	Kidney disease other than renal amyloidosis&lt;br&gt;3.	Child bearing potential with lack of a reliable method of contraception.&lt;br&gt;4.	Poor compliance&lt;br&gt;5.	Medical history that might limit the individual’s ability to take the trial treatment for the duration of the study. &lt;br&gt;6.	Simultanous administration of TNF-blocking agents (etanercept, adalimumab, and infliximab)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Amyloidosis</Condition>
    <Intervention>&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Kineret&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: ;Main Objective: Outcome assessment at the end of the study &lt;br&gt;The primary end point  is measurement of kidney function by the estimated glomerular filtration rate and extent of proteinuria as 24h urinary excretion and fractional protein excretion. The results will be compared with the change of eGFR during the preceeding six months, and the mean of two protein excretion measurements at study entry. Progresssion of disease is defined as a significant more rapid decline of eGFR compared to pretreatment values, or a significant higher protein excretion. Improvement of both markers is defined as improvement of the disease, and no change as disease beeing stable. &lt;br&gt;;Primary end point(s): The primary end point  is measurement of kidney function by the estimated glomerular filtration rate and extent of proteinuria as 24h urinary excretion and fractional protein excretion. The results will be compared with the change of eGFR during the preceeding six months, and the mean of two protein excretion measurements at study entry. Progresssion of disease is defined as a significant more rapid decline of eGFR compared to pretreatment values, or a significant higher protein excretion. Improvement of both markers is defined as improvement of the disease, and no change as disease beeing stable. </Primary_outcome>
    <Secondary_ID>00001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2463941</Internal_Number>
    <TrialID>EUCTR2007-005627-15-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Evaluation de l'échographie de contraste pour l'appréciation précoce de l'effet d'un traitement anti-angiogénique sur le carcinome rénal avancé</Public_title>
    <Scientific_title>Evaluation de l'échographie de contraste pour l'appréciation précoce de l'effet d'un traitement anti-angiogénique sur le carcinome rénal avancé                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>CHRU de TOURS</Primary_sponsor>
    <Date_registration3>20071031</Date_registration3>
    <Date_registration>31/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005627-15                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/12/2007</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Adénocarcinome rénal métastatique devant recevoir un traitement anti-angiogénique&lt;br&gt;•	Présence d’une lésion cible visible, localisable et mesurable en échographie conventionnelle et scanner / IRM &lt;br&gt;•	Signature du consentement éclairé&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	contre-indication aux traitements anti-angiogéniques&lt;br&gt;•	contre-indication au produit de contraste &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>adenocarcinome rénal métastatique à cellule claire &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Trade Name: SONOVUE&lt;br&gt;Product Name: hexafluorure de soufre&lt;br&gt;Pharmaceutical Form: Powder and solvent for suspension for injection&lt;br&gt;&lt;br&gt;Trade Name: SUTENT&lt;br&gt;Product Name: Sunitinib&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;Trade Name: NEXAVAR&lt;br&gt;Product Name: Sorafénib&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: AVASTIN&lt;br&gt;Product Name: Bevacizumab&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Montrer que l’étude fonctionnelle par échographie de contraste de la microvascularisation d’une lésion primitive ou secondaire de patients atteints d’un adénocarcinome rénal, permet d’évaluer précocement l’effet pharmacodynamique d’un traitement antiangiogénique afin de prédire l’efficacité anti-tumorale définie par les critères RECIST;Secondary Objective: - Etudier l'association entre la réponse précoce objectivée au niveau de la lésion cible à partir des paramètres de l’échographie de contraste et la survie sans progression&lt;br&gt;- Etudier l'association entre la réponse précoce objectivée au niveau de la lésion cible à partir des paramètres de l’échographie de contraste et la survie globale&lt;br&gt;- Décrire la tolérance au traitement anti-angiogénique par le suivi des effets indésirables survenant au cours de l’étude.&lt;br&gt;&lt;br&gt;En cas de lésions mesurables multiples : &lt;br&gt;- Etudier l’association  entre les paramètres échographiques mesurés au niveau de la lésion cible  et la réponse au niveau des autres lésions, définie par les critères RECIST.&lt;br&gt;;Primary end point(s): Paramètres mesurés à l’échographie de contraste (à chacun des temps) :&lt;br&gt;•	Seront ainsi déterminés à chaque examen :&lt;br&gt;o	Taille de la lésion : plus grand diamètre, volume global&lt;br&gt;o	Temps d’arrivée de l’agent de contraste dans la lésion&lt;br&gt;o	Temps jusqu’au pic de rehaussement&lt;br&gt;o	Paramètre ß de l’exponentielle de rehaussement&lt;br&gt;o	Densité de microvaisseaux au pic du rehaussement&lt;br&gt;o	Rapport de rehaussement entre la lésion et le parenchyme voisin au pic&lt;br&gt;o	Volumes nécrotique et viable&lt;br&gt;&lt;br&gt;Paramètre de réponse :&lt;br&gt;La réponse tumorale sera évaluée par les critères RECIST&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CIT07-FB/CREIN;CREIN </Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464016</Internal_Number>
    <TrialID>EUCTR2007-002378-68-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio piloto de Selección de la Inmunosupresión basado en un régimen basado en inhibidores de CNI o libre de CNI dependiendo de la aloreactividad donante-especifica mediante el ensayo ELISPOT en receptores de un injerto renal e bajo riesgo - SIRES</Public_title>
    <Scientific_title>Estudio piloto de Selección de la Inmunosupresión basado en un régimen basado en inhibidores de CNI o libre de CNI dependiendo de la aloreactividad donante-especifica mediante el ensayo ELISPOT en receptores de un injerto renal e bajo riesgo - SIRES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>SERVICIO NEFROLOGIA HOSPITAL BELLVITGE</Primary_sponsor>
    <Date_registration3>20071024</Date_registration3>
    <Date_registration>24/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002378-68                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>30/10/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Age of donor and recipient  between 18 and 65 years.&lt;br&gt;2.End-stage renal disease and scheduled to receive a primary or secondary renal allograft from a cadaveric, a living-unrelated, or a living-related donor. Patients scheduled for a second transplant must have maintained their primary graft for at least 6 months after transplantation, with the exception of graft failure due to technical reasons.&lt;br&gt;3.PRA = 20%&lt;br&gt;4.Negative cytotoxic T-cell cross-match.&lt;br&gt;5.Women of childbearing potential must have a negative serum pregnancy test before randomization.&lt;br&gt;6.Women of childbearing potential must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of assigned treatment.  &lt;br&gt;7.Signed and dated informed consent prior to transplantation.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Multiple organ transplants &lt;br&gt;2.Recipients of adult or pediatric en bloc kidney transplants or dual transplantation or non-heart beating donors.&lt;br&gt;3.Evidence of active systemic or localized major infection.&lt;br&gt;4.Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during the screening/baseline evaluation.&lt;br&gt;5.Use of any investigational drug or treatment up to 4 weeks prior to transplantation.&lt;br&gt;6.Treatment with voriconazole, ketoconazole, itraconazole, fluconazole, clotrimazole, astemizole, pimozide, terfenadine, erythromycin, clarithromycin, telithromycin, troleandomycin, rifampin, rifabutin, or St. John’s Wort that is not discontinued prior to randomization.&lt;br&gt;7.Treatment with aminoglycosides, amphotericin B, cisplatin, cisapride, metoclopramide, cimetidine, bromocriptine, danazol, or other drugs associated with renal dysfunction that are not discontinued prior to randomization.&lt;br&gt;8.Subjects with a screening/baseline total white blood cell count &lt; 2,000/mm3 or ANC &lt; 500, platelet count &lt; 100,000/mm3.&lt;br&gt;9.Fasting triglycerides &gt; 400 mg/dL (&gt; 4.6 mmol/L) or fasting total cholesterol &gt; 300 mg/dL (&gt; 7.8 mmol/L) despite optimal lipid-lowering therapy.&lt;br&gt;10.History of malignancy within 2 years of enrollment (except for adequately treated basal cell or squamous cell carcinoma of the skin).&lt;br&gt;11.Auto-inmune diseases in active inmunosupressive treatment ( 3 months prior to inclusion).&lt;br&gt;12.Patients with psiquiatric disorders that could be non-compliance for the treatment.&lt;br&gt;13. Active peptic ulcers that could produce intestinal absortion disorders.&lt;br&gt;14. Subjects who are known to be HIV or HBV positive ( surface antigen, HBV DNA, or e antigen positive).  Patients with HCV positive should be excluded if PCR positive or transaminates values are =2UNV.&lt;br&gt;15. Diabetic patients.&lt;br&gt;16. Body mass index (BMI) higher than 30 Kg/m2. (See Attachment 5: Nomogram for Determining Body Mass Index).&lt;br&gt;17. Recipients of kidneys from deceased donor after a cardiac arrest.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>PATIENTS THAT RECEIVE A FIRST RENAL ALLOGRAFT TRANSPLANTATION.
 It has been shown that the assessment of the donor specific T-cell alloimmune response can be successfully performed by using new tools, such as the Elispot assay. The aim of this protocol is to make use of the pre-transplant donor specific cellular alloreactivity assessment by the Elispot assay, in order to evaluate if low aloresponders patients can be safely managed with a CNI-free immunosuppression regimen &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123889&lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,5-&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: MICOFENOLATO MOFETIL&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;INN or Proposed INN: MICOFENOLATO MOFETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;INN or Proposed INN: MICOFENOLATO MOFETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;INN or Proposed INN: MICOFENOLATO MOFETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;INN or Proposed INN: MYCOPHENOLATE MOFETIL&lt;br&gt;CAS Number: 115007346&lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: TIMOGLOBULINA&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To describe cumulative biopsy-confirmed acute rejection at month 6th and month 12th  in both groups by intention to treat analysis.;Secondary Objective: 1.To describe the percentage of steroid-sensitive and resistent acute rejections episodes at month 6 and 12 in both groups by intention to treat analysis.&lt;br&gt;2.To describe renal function measured by MDRD at month 12 and 24 in both groups.&lt;br&gt;4.To describe proteinuria in g/day at month 6and 12 in both groups.&lt;br&gt;5.To describe histology at month 6 in both groups .&lt;br&gt;6.To describe percentage of patients with negative ELISPOT at 6 and 12 months in both groups-&lt;br&gt;7.To describe the percentage of patients in group A requiring CNI introduction. &lt;br&gt;8.To describe adverse events in the whole group.&lt;br&gt;9. To assess if low pre-transplantation donor specific T-cell reactive patients measured by ELISPOT can be safely managed with CNI-free SRL-based immunossuppression.&lt;br&gt;10.To assess if post-transplant donor specific T-cell alloresponse monitoring together with graft histology assessment could be useful for minimization or strengthen the immunosuppressive therapy in month 6.;Primary end point(s): To describe cumulative biopsy-confirmed acute rejection at month 6th after transplantation and month 12th  in both groups by intention to treat analysis.</Primary_outcome>
    <Secondary_ID>SIRES</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464056</Internal_Number>
    <TrialID>EUCTR2007-001394-29-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multi-center, prospective trial to demonstrate Improved Metabolic control of PPEN vs DDDD in DIAbetic CAPD patients -The IMPENDIA Trial - IMPENDIA</Public_title>
    <Scientific_title>Multi-center, prospective trial to demonstrate Improved Metabolic control of PPEN vs DDDD in DIAbetic CAPD patients -The IMPENDIA Trial - IMPENDIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Baxter Healthcare Corporation</Primary_sponsor>
    <Date_registration3>20071120</Date_registration3>
    <Date_registration>20/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001394-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/12/2007</Date_enrollement>
    <Target_size>236</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Dianeal&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients who meet ALL of the following criteria at both Screening and randomization are eligible for the study:&lt;br&gt;1.	Male or female patients who are at least 18 years of age&lt;br&gt;2.	Patients who have read, understood and given written Informed Consent after the nature of the study has been explained&lt;br&gt;3.	Patients who have a diagnosis of ESRD (GFR = 15 mL/min)&lt;br&gt;4.	Patients performing CAPD using only Dianeal, a daily prescription including at least 1 exchange of Dianeal 2.5% or 4.25% dextrose (2.27% or 3.86% glucose, respectively), for at least 30 days prior to Screening and who have no prescribed dry time&lt;br&gt;5.	Patients who are in a stable clinical condition in the judgment of the treating physician and as demonstrated by medical history, physical examination, and laboratory testing&lt;br&gt;6.	Incident and prevalent patients with diagnosed diabetes (Type 1 and Type 2), as verified by the treating physician, and who have received glycemic-control medication, i.e., insulin and/or oral hypoglycemic agents, for at least 90 days prior to Screening&lt;br&gt;7.	Patients with an HbA1c &gt; 6.0% but = 10.0% (to be determined at the Screening visit using regional central laboratories and reported according to the Diabetes Control and Complications Trial (DCCT)/National Glycohemoglobin Standardization Program (NGSP) standard)&lt;br&gt;8.	Patients who have a blood hemoglobin concentration = 9.0 g/dL, but = 13.0 g/dL (to be determined at screening visit using local lab)&lt;br&gt;9.	Patients with a total Kt/V = 1.7 at Screening&lt;br&gt;10.	Patients who are expected to remain on CAPD for at least 6 months&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients who have any of the following at the time of either Screening or randomization are not eligible for enrollment in this study.&lt;br&gt;1.	Patients performing Automated Peritoneal Dialysis (APD)&lt;br&gt;2.	Female patients who are pregnant, lactating or planning to become pregnant during the study period.  Note:  Female patients of childbearing potential must not be pregnant and not lactating.  They must also have a negative serum human chorionic gonadotropin (hCG) pregnancy test result prior to receiving any dose of study medication (14 day window).  Women of childbearing potential are defined as women less than 55 years old who have not had a partial or full hysterectomy or oophorectomy.  Patients are required to use medically acceptable means of contraception during their participation in this study.&lt;br&gt;3.	Patients with concomitant participation in any other interventional study &lt;br&gt;4.	Patients who have used any investigational device or received any investigational drug, biologic within five half-lives of the physiological action (if drug or biologic) or 30 days prior to Screening, whichever is longer&lt;br&gt;5.	Patients who have previously participated in this study&lt;br&gt;6.	Patients who have previously participated in the PRePEND study&lt;br&gt;7.	Patients who have had an acute myocardial infarction (MI) with hospitalization, coronary bypass surgery, or acute coronary ischemia with percutaneous transluminal coronary angioplasty (PTCA)/stent within the last 90 days&lt;br&gt;8.	Patients who have had a failed kidney transplant without nephrectomy of the graft&lt;br&gt;9.	Patients who have a history of abdominal fistulae, tumors, open wounds, herniae, or other conditions, which compromised the integrity of the abdominal wall, abdominal surface, or intra-abdominal cavity, within the last 30 days&lt;br&gt;10.	Patients who have undergone abdominal surgery within the last 30 days except for PD catheter insertion&lt;br&gt;11.	Patients who are receiving or have received Calcineurin inhibitors (e.g., cyclosporin) or corticosteroids within the last 90 days&lt;br&gt;12.	Patients who have any other serious acute or active conditions that in the investigator’s opinion would preclude their participation in the study&lt;br&gt;13.	Patients who have a history of drug, or alcohol abuse in the last six months&lt;br&gt;14.	Patients who have active liver disease such as cirrhosis of the liver, active hepatitis or other active liver disease as evidenced by biopsy, laboratory (unstable liver enzymes over the last 90 days) or clinical examination&lt;br&gt;15.	Patients who have active infectious conditions, including but not limited to septicemia and pneumonia, within the last 90 days&lt;br&gt;16.	Patients who have ongoing clinically significant congestive heart failure (New York Heart Association [NYHA] class III or IV)&lt;br&gt;17.	Patients who have malignancy or other severe co-morbidity associated with a life expectancy of less than 1 year&lt;br&gt;18.	Patients who have had an episode of life threatening systemic infection, or other serious disease, such as active, or previously treated, residual malignancy (exceptions - malignant free for two years or life threatening systemic infection free for 90 days)&lt;br&gt;19.	Patients who have any medical condition that, in the judgment of the Investigator, would jeopardize the patient’s safety following exposure to the study drugs, or in the judgment of the Investigator, will not be able to tolerate one of the solution regimens (i.e., DDDD or PPEN)&lt;br&gt;20.	Patients who are allergic to starch-based polymers&lt;br&gt;21.	Patients who have glycogen storage disease&lt;br&gt;22.	</Exclusion_Criteria>
    <Condition>End stage renal disease patients with Diabetes Type I and II on Continuous Ambulatory Peritoneal Dialysis &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10012660
Term: Diabetic end stage renal disease
</Condition>
    <Intervention>&lt;br&gt;Trade Name: EXTRANEAL, solution pour dialyse péritonéale&lt;br&gt;Product Name: EXTRANEAL&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: Icodextrin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75.0-&lt;br&gt;INN or Proposed INN: Sodium chloride&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5.40-&lt;br&gt;INN or Proposed INN: Calcium chloride dihydrate&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.257-&lt;br&gt;INN or Proposed INN: Magnesium chloride hexahydrate&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.051-&lt;br&gt;INN or Proposed INN: Sodium lactate solution&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4.50-&lt;br&gt;&lt;br&gt;Trade Name: NUTRINEAL PD4 à 1.1% d'acides aminés, solution pour dialyse péritonéale&lt;br&gt;Product Name: NUTRINEAL&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: L-alanin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.951-&lt;br&gt;INN or Proposed INN: L-arginin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.071-&lt;br&gt;INN or Proposed INN: L-glycin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.51-&lt;br&gt;INN or Proposed INN: L-histidin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.714-&lt;br&gt;INN or Proposed INN: L-isoleucin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.850-&lt;br&gt;INN or Proposed INN: L-leucin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.020-&lt;br&gt;INN or Proposed INN: L-lysin chlorydrate&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.955-&lt;br&gt;INN or Proposed INN: L-methionin&lt;br&gt;Concentration unit: g/l gram(s)/litre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.850-&lt;br&gt;INN or Proposed INN: </Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to demonstrate that use of glucose-sparing prescriptions (PPEN vs DDDD) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients leads to improved metabolic control as measured by the magnitude of change from the baseline value for HbA1c levels.;Secondary Objective: The secondary objectives of the study are to demonstrate that use of glucose-sparing (i.e., 2nd generation) PD solutions prescriptions (PPEN vs DDDD) in diabetic (Type 1 and Type 2) CAPD patients leads to lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic events requiring medical intervention, improved metabolic control, improved nutritional status, and improvement in Quality of Life.  In a subgroup of patients, the impact of glucose-sparing PD solutions (PPEN vs DDDD) on abdominal fat and left ventricular (LV) structure and function will be assessed.&lt;br&gt;The exploratory objectives of the study are to assess the impact of glucose-sparing PD solutions prescriptions (PPEN vs DDDD) in the study population on advanced glycation end-products (AGEs) and fructosamine, on insulin action, on markers of systemic inflammation, and on markers of membrane status.;Primary end point(s): The primary efficacy assessment is change from the baseline value of HbA1c at Months 2, 4, and 6, which will be measured using a Tina-quant® immunological assay for HbA1c (Roche Diagnostic) suitable for samples from ESRD patients and with icodextrin metabolites or equivalent.  HbA1c analysis for primary efficacy assessment will be performed at Baxter’s Clinical Laboratory Services, Technology Resources, Round Lake, IL.</Primary_outcome>
    <Secondary_ID>31998</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464120</Internal_Number>
    <TrialID>EUCTR2007-005757-28-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude française multi-centrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insuffisants rénaux chroniques non dialysés - PRADO</Public_title>
    <Scientific_title>Etude française multi-centrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insuffisants rénaux chroniques non dialysés - PRADO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Roche</Primary_sponsor>
    <Date_registration3>20071126</Date_registration3>
    <Date_registration>26/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005757-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/01/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Relatifs à la population :&lt;br&gt;•Patient ayant délivré un consentement de participation écrit&lt;br&gt;•Patient apte selon l'investigateur à se plier aux impératifs de l'étude&lt;br&gt;•Patient affilié à un régime de sécurité sociale ou bénéficiaire d'un tel régime&lt;br&gt;•Patient adulte âgé de plus de 18 ans&lt;br&gt;&lt;br&gt;Relatifs à la pathologie :&lt;br&gt;•Patient atteint d’une insuffisance rénale chronique stade 3 = clairance créatinine (CrCl)/Taux de filtration glomérulaire (GFR) &lt; 60 mL/min et = 30 mL/min (calculée et corrigée selon Cockcroft-Gault) ou stade 4 = CrCl/GFR &lt; 30 mL/min et = 15 mL/min (calculée et corrigée selon Cockcroft-Gault) confirmée à la valeur de baseline soit à la semaine -4 associée à une anémie, et non dialysé &lt;br&gt;•Patient ayant un taux moyen d’hémoglobine (Hb) compris entre [10;12] g/dL sur les 3 valeurs de la période de baseline (semaines -4, -2 et J0)&lt;br&gt;•Patient ayant un traitement de maintenance continu en sous-cutané par epoetin beta ou darbepoetin alfa avec la même fréquence d’administration et sans modification de la dose totale hebdomadaire (calculée) dans les 4 semaines avant et pendant la période de baseline &lt;br&gt;•Patient ayant un statut martial adéquat: ferritine sérique &gt; 100 ng/mL et TSAT &gt; 20% (ou pourcentage de globules rouges hypochromes &lt; 10%) &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Relatifs à la population :&lt;br&gt;•Femme enceinte ou allaitant&lt;br&gt;•Femme en période d’activité génitale sans contraception efficace&lt;br&gt;•Patient atteint d’une déficience ne lui permettant pas une bonne compréhension des impératifs de l’essai&lt;br&gt;•Patient ayant déjà été inclus dans le présent essai&lt;br&gt;•Patient participant ou ayant participé à un essai clinique dans les 3 derniers mois&lt;br&gt;&lt;br&gt;Relatifs au traitement à l’essai :&lt;br&gt;•Patient présentant un saignement aigu ou chronique significatif, comme un saignement d’origine gastro-intestinale &lt;br&gt;•Patient recevant une ou plusieurs transfusion de culots globulaires dans les 8 semaines précédant la période de baseline&lt;br&gt;•Patient ayant une dose hebdomadaire d’epoetin beta &gt; 16000UI ou une dose hebdomadaire de darbepoetin alfa &gt; 80µg dans les 4 semaines avant et pendant la période de baseline (soit 8 semaines avant l’inclusion)&lt;br&gt;•Patient présentant un greffon allogénique en place&lt;br&gt;•Patient présentant une hémoglobinopathie (anémie falciforme homozygote, thalassémie de tous types)&lt;br&gt;•Patient présentant une hémolyse (haptoglobine &lt; 30mg/dL ou autre test d’hémolyse)&lt;br&gt;•Patient présentant une maladie maligne active dans les 5 dernières années (excepté les cancers cutanés hors mélanome) &lt;br&gt;•Patient ayant un déficit connu en Vitamine B12 &lt;br&gt;•Patient ayant un déficit connu en acide folique &lt;br&gt;•Patient ayant une hyperparathyroïdie secondaire non contrôlée ou symptomatique &lt;br&gt;•Patient présentant une hypertension artérielle mal contrôlée, c’est-à-dire une pression artérielle assise &gt; 170/100 mmHg et nécessitant une interruption de traitement par ASE  dans les 6 mois précédant la période de baseline&lt;br&gt;•Patient présentant une crise d’épilepsie dans les 6 mois précédant la période de baseline&lt;br&gt;•Patient présentant un infarctus du myocarde, un accident vasculaire cérébral, une coronaropathie sévère ou instable, une maladie hépatique sévère dans les 12 semaines précédant la période de baseline&lt;br&gt;•Patient présentant une insuffisance cardiaque congestive (stade III-IV de la New York Heart Association)&lt;br&gt;•Patient présentant un nombre de plaquettes &gt; 500 x 10 9/L ou &lt; 100 x   10 9/L&lt;br&gt;•Patient présentant une érythroblastopénie&lt;br&gt;•Patient ayant une chirurgie planifiée pendant la durée de l’étude excepté pour la cataracte et pour la voie d’abord vasculaire&lt;br&gt;•Patient présentant une hypersensibilité connue à une érythropoïétine recombinante, au polyéthylène glycol ou tout autre constituant du traitement à l’étude&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anémie symptomatique de l'insuffisance rénale chronique &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10054353
Term: Chronic renal failure anemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F03&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F04&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F05&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Code: RO 503821/F21&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F06&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F07&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: MIRCERA&lt;br&gt;Product Code: RO 503821/F08&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyéthylène glycol-epoetin bêta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-</Intervention>
    <Primary_outcome>Main Objective: Evaluer le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. chez des patients insuffisants rénaux chroniques non dialysés.;Secondary Objective: Evaluer la variabilité de l’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. dans cette population de patients.&lt;br&gt;&lt;br&gt;Evaluer la tolérance avec une administration sous-cutanée mensuelle de C.E.R.A. dans cette population de patients.&lt;br&gt;;Primary end point(s): Proportion de patients maintenant un taux d’hémoglobine moyen dans l’intervalle [10;12] g/dL pendant la période d’évaluation (S16 à S24)</Primary_outcome>
    <Secondary_ID>ML21146</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464121</Internal_Number>
    <TrialID>EUCTR2007-003114-34-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The impact of oral curcumin (Curcuma longa) on mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients: exploratory investigation of the role of intestinal uridine-diphosphate-glucuronosyltransferases (UGTs) in in vivo mycophenolic acid disposition.</Public_title>
    <Scientific_title>The impact of oral curcumin (Curcuma longa) on mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients: exploratory investigation of the role of intestinal uridine-diphosphate-glucuronosyltransferases (UGTs) in in vivo mycophenolic acid disposition.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Department of Nephrology and Renal Transplantation, University Hospitals Leuven</Primary_sponsor>
    <Date_registration3>20071126</Date_registration3>
    <Date_registration>26/11/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003114-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/11/2007</Date_enrollement>
    <Target_size>12</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Primary and secondary renal allograft recipients.&lt;br&gt;Stable (clinically and biochemically) renal transplant patients.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Age &lt; 18 yrs of age.&lt;br&gt;Combined solid organ transplantations.&lt;br&gt;History of medical or surgical diseases of the gastrointestinal and hepato-biliary tract.&lt;br&gt;Recipients with active infectious or inflammatory disease as well as anti-infectious or anti-inflammatory treatment for at least 2 weeks prior to enrolment.&lt;br&gt;Severe hypoalbuminemia (&lt; 25 g/L).&lt;br&gt;Severe anemia (&lt; 8 g/dL).&lt;br&gt;Patients with documented non-compliance.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Stable renal allograft recipients</Condition>
    <Intervention>&lt;br&gt;Trade Name: C3 Complex&lt;br&gt;Product Name: Curcumin&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Other descriptive name: Curcumin longa&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: not less then&lt;br&gt;Concentration number: 95%-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Assessing the impact of oral curcumin (Curcuma longa) on mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients. ;Secondary Objective: Investigate the role of intestinal uridine-diphosphate-glucuronosyltransferases (UGTs) in in vivo mycophenolic acid disposition. ;Primary end point(s): Differences in mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients before and after 7 days administration of Curcumin longa.</Primary_outcome>
    <Secondary_ID>CUR001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464203</Internal_Number>
    <TrialID>EUCTR2007-004875-21-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma</Public_title>
    <Scientific_title>A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Bayer Healthcare AG, D-51368 Leverkusen, Germany</Primary_sponsor>
    <Date_registration3>20071207</Date_registration3>
    <Date_registration>07/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004875-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/01/2008</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Age &gt; 18 years. &lt;br&gt;•	Histological or cytological documentation of metastatic and/or unresectable clear cell RCC is required&lt;br&gt;•	Subjects with at least one uni-dimensional measurable lesion. Lesions must be measured by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumours (RECIST).&lt;br&gt;•	ECOG Performance Status of 0 or 1&lt;br&gt;•	MSKCC good or intermediate category&lt;br&gt;•	Life expectancy of at least 12 weeks.&lt;br&gt;•	Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:&lt;br&gt;•	Hemoglobin &gt; 9.0 g/dl &lt;br&gt;•	Absolute neutrophil count (ANC) &gt;1,500/mm3  &lt;br&gt;•	Platelet count ? 100,000/?l &lt;br&gt;•	Total bilirubin &lt; 1.5 times the upper limit of normal &lt;br&gt;•	ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for subjects with liver involvement of their cancer)&lt;br&gt;•	Alkaline phosphatase &lt;  2.5 x ULN &lt;br&gt;	PT-INR/PTT &lt; 1.5 x upper limit of normal.  Subjects who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. For subjects on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care (exluding subjects being anticaogulated for deep vein thrombosis and/or pulmonary embolus occurring  within 12 months of the start of treatment).&lt;br&gt;•	Serum creatinine &lt; 1.5 x upper limit of normal &lt;br&gt;•	Signed informed consent must be obtained prior to any study specific procedures.&lt;br&gt;•	Subjects must have received no prior systemic anticancer therapy for the treatment of their renal cell carcinoma&lt;br&gt;•	Prior nephrectomy&lt;br&gt;•	Prior palliative radiotherapy to metastatic lesion(s) is permitted&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) &lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) &lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	History of cardiac disease;&lt;br&gt;•	congestive heart failure &gt;NYHA class 2&lt;br&gt;•	active CAD (MI more than 6 mo prior to study entry is allowed)&lt;br&gt;•	 cardiac arrhythmias requiring  anti-arrhythmic therapy( beta blockers or digoxin are permitted) &lt;br&gt;•	uncontrolled hypertension (defined as blood pressure &gt;160mmHg systolic and/or &gt; 90mmHg diastolic on medication) &lt;br&gt;•	History of HIV infection or chronic hepatitis B or C &lt;br&gt;•	Active clinically serious infections (&gt; grade 2 NCI-CTCAE version 3.0) &lt;br&gt;•	Symptomatic metastatic brain or meningeal tumors unless the subject is &gt; 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry.  Also the subject must not be undergoing acute steroid therapy or taper therapy (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies) &lt;br&gt;•	Subjects with seizure disorder requiring medication (such as steroids or anti-epileptics)&lt;br&gt;•	History of organ allograft &lt;br&gt;•	Subjects with evidence or history of bleeding diathesis&lt;br&gt;•	Deep vein thrombosis and/or pulmonary embolus within 12 months of the start of treatment.&lt;br&gt;•	Delayed healing of wounds, ulcers or bone fractures&lt;br&gt;•	Subjects with pre-existing thyroid abnormality whose thyroid function cannot be maintained within the normal range by medication &lt;br&gt;•	Subjects undergoing renal dialysis&lt;br&gt;•	Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively treated &gt; 3 years prior to study entry.&lt;br&gt;•	Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study&lt;br&gt;•	Pregnant or breast-feeding subjects.  Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and three months after the completion of trial. The investigator is requested to advise the subject how to achieve an adequate contraception.    &lt;br&gt;&lt;br&gt;•	Subjects unable to swallow oral medications. This applies to subjects with severe obstruction of upper GI that require gavage.&lt;br&gt;Excluded therapies and medications, previous and concomitant:&lt;br&gt;•	Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents, experimental therapy (adjuvant or neo-adjuvant therapy including IFN-IL2-5FU is permitted).&lt;br&gt;•	Prior adjuvant sorafenib is excluded.&lt;br&gt;•	Radiotherapy during study or within 3 weeks of start of study drug&lt;br&gt;•	 Major surgery within 4 weeks of start of study &lt;br&gt;•	Autologous bone marrow transplant or stem cell rescue within 4 months of study &lt;br&gt;•	Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however they may not be substituted for a required dose reduction.]  Subjects taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study.&lt;br&gt;•	Investigational drug therapy outside of this trial during or within 4 weeks of study entry&lt;br&gt;•	Subst</Exclusion_Criteria>
    <Condition>renal cell carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NEXAVAR&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: sorafenib&lt;br&gt;CAS Number: 28844-1-73-1&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of intrapatient dose escalation in previously untreated subjects with mRCC.  The initial dose of sorafenib will be 400mg bid administered orally, on a continuous basis.  Intrapatient dose escalation will occur as defined in the table below, providing no grade 3 or 4 toxicities (except for alopecia, nausea and vomiting) are observed. &lt;br&gt;&lt;br&gt;The primary objective is to assess the response rates (by independent assessment)  observed in subjects treated with a continuous, daily dose of 400 mg bid sorafenib dose escalated up to 800mg bid. ;Secondary Objective: The secondary objectives are to assess the following:&lt;br&gt;•	Safety and tolerability&lt;br&gt;•	Pharmacokinetics &lt;br&gt;•	Progression free survival (PFS)&lt;br&gt;•	Time to progression (TTP)&lt;br&gt;	;Primary end point(s): Primary end point is to assess the response rates observed for patients treated with continuous daily dose of sorafenib escalated from 400mg to 600mg to a maximum of 800mg bid.</Primary_outcome>
    <Secondary_ID>BAY 43-9006 / 12913</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464205</Internal_Number>
    <TrialID>EUCTR2007-001755-19-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A double-blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy - Benfotiamine in Diabetic Nephropathy</Public_title>
    <Scientific_title>A double-blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy - Benfotiamine in Diabetic Nephropathy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>UMCG</Primary_sponsor>
    <Date_registration3>20071026</Date_registration3>
    <Date_registration>26/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001755-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/11/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Diabetes mellitus, with onset of disease after the age of 40 years&lt;br&gt;• Age: 50-70 years&lt;br&gt;• Patients are on treatment with angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin II antagonists (AIIA) in an unchanged dose for at least 3 months&lt;br&gt;• Active diabetic nephropathy as indicated by presence of microalbuminuria (30-300 mg/24 h urine) in at least two samples within 2-6 weeks in advance of inclusion in the trial&lt;br&gt;• HbA1c &lt; 8.5%, a higher HbA1c ? 9.5% is acceptable if the treating physician and the patient have accepted that striving for lower values is an unreachable goal (patients with high HbA1c values are the ones that one would expect to be benefit most from treatment with benfotiamine)&lt;br&gt;• eGFR (estimated by MDRD formula) &gt; 30 ml/min&lt;br&gt;• Males and postmenopausal females&lt;br&gt;• Written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Renal impairment by other causes than diabetes&lt;br&gt;• Stage of the disease more severe than indicated in "Inclusion criteria"&lt;br&gt;(macroalbuminuria or renal insufficiency)&lt;br&gt;• Severe hypoglycemia during the last 3 months, needing help from another person&lt;br&gt;• Severe hepatopathy (liver function enzymes about three times higher than normal)&lt;br&gt;• Endocrine disorders, e.g. hyper-/hypothyroidism&lt;br&gt;• Blood pressure &gt; 160/90 mmHg&lt;br&gt;• Severe cardiac function disturbances and severe heart rhythm disturbances&lt;br&gt;• Neoplasm&lt;br&gt;• Severe general diseases or mental disorders making the participation in the study&lt;br&gt;impossible&lt;br&gt;• Drug abuse&lt;br&gt;• Female patients during pregnancy and lactation period and female patients with active menses during the past year&lt;br&gt;• Hypersensitivity to benfotiamine or other constituents of the study medication&lt;br&gt;• HbA1c &gt;9.5%&lt;br&gt;• Use of vitamin B containing supplements during the last 3 months&lt;br&gt;• Use of NSAIDs more than 3x per week (including self-medication)&lt;br&gt;• Participation in another study within one month before joining the benfotiamine&lt;br&gt;study&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diabetic nephropathy is a serious complication of diabetes mellitus, which is the leading cause of end-stage renal disease (ESRD).
Benfotiamine has been shown to reduce diabetic nephropathy and retinopathy in animal experimental models. 
We investigate the effect of benfotiamine supplementation in patients with diabetic nephropathy, and hypothesize that it will slow down the progression to ESRD.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Milgamma mono 300&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate whether short-term treatment (3 months) with benfotiamine leads to a reduction in urinary excretion of ß2-microglobulin and albumin.;Secondary Objective: To investigate whether short-term treatment (3 months) with benfotiamine leads to reduction in urinary excretion of markers of renal tubulointerstitial damage and inflammation (Kidney Injury Molecule-1, Monocyte Chemo-attractant Protein-1, Macrophage Inhibiting Factor, Complement factor C3d);Primary end point(s): Change in urinary excretion of (measured in 24-hour urine):&lt;br&gt;• ß2-microglobulin&lt;br&gt;• Albumin</Primary_outcome>
    <Secondary_ID>BENFO-1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464331</Internal_Number>
    <TrialID>EUCTR2007-005083-28-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda línea tras el fracaso a sunitinib en pacientes con carcinoma metastásico de células renales (CCR) 
(A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib Failure in Patients with Metastatic Renal Cell Carcinoma (RCC))
 - CONCERT</Public_title>
    <Scientific_title>Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda línea tras el fracaso a sunitinib en pacientes con carcinoma metastásico de células renales (CCR) 
(A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib Failure in Patients with Metastatic Renal Cell Carcinoma (RCC))
 - CONCERT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Bayer Healthcare AG, Leverkusen</Primary_sponsor>
    <Date_registration3>20071228</Date_registration3>
    <Date_registration>28/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005083-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/02/2008</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sorafenib with or without low dose interferon alpha-2a&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Disease progression as defined by RECIST criteria following documented stable disease or better after at least 8 weeks of sunitinib as first-line treatment (or two cycles of 4 weeks on and 2 weeks off treatment)&lt;br&gt;•	And/or patients who have discontinued sunitinib treatment at any point due to toxicity&lt;br&gt;•	Study entry at least 2 weeks after treatment with sunitinib but up to a maximum of 8 weeks&lt;br&gt;•	MSKCC prognostic score low or intermediate&lt;br&gt;•	ECOG Performance Status of 0 or1&lt;br&gt;•	Patient must have histologically confirmed metastatic renal cell carcinoma with predominant clear cell histology (clear cell component more than 50%)&lt;br&gt;•	Age &gt; 18 years&lt;br&gt;•	Life expectancy of at least 12 weeks&lt;br&gt;•	Patients with at least one measurable lesion.  Lesions must be measured by CT-scan or MRI (Magnetic Resonance Imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST, see Appendix 10.5 )&lt;br&gt;•	Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:&lt;br&gt;•	Hemoglobin &gt; 9.0 g/dl&lt;br&gt;•	Absolute neutrophil count (ANC) &gt;1,500/mm3 &lt;br&gt;•	Platelet count ? 100,000/µl &lt;br&gt;•	Total bilirubin &lt; 1.5 times the upper limit of normal &lt;br&gt;•	ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for patients with liver involvement of their cancer)&lt;br&gt;•	Alkaline phosphatase &lt; 4 x ULN&lt;br&gt;•	PT or INR and PTT &lt; 1.5 x upper limit of normal (patients who receive anti-coagulation treatment with an agent such as coumarin derivates or heparin will be allowed to participate.  For patients on coumarin derivates , close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care).&lt;br&gt;•	Serum creatinine &lt; 2.0 x upper limit of normal.&lt;br&gt;•	Ability to understand and the willingness to sign a written informed consent.  A signed informed consent must be obtained prior to performing any study specific procedures.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Patient should be excluded if they have unresolved chronic toxicity grade &gt; 1 and related to prior therapy with sunitinib.&lt;br&gt;•	History of cardiac disease: &lt;br&gt;o	Congestive heart failure NYHA (New York Heart Association) class &gt; 2&lt;br&gt;o	Active CAD (Coronary artery disease) or MI (Myocardial Infarction) more than 6 months prior to study entry is allowed)&lt;br&gt;o	Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) &lt;br&gt;o	Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic pressure &gt; 90 mmHg, despite optimal medical management.&lt;br&gt;•	Known history of HIV (Human immunodeficiency virus) infection or chronic Hepatitis B or C &lt;br&gt;•	Active clinically serious infections (grade &gt; 2 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE Version 3.0))&lt;br&gt;•	Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)&lt;br&gt;•	Symptomatic metastatic brain or meningeal tumors unless the patient is &gt; 6 months from definitive therapy, has a negative brain imaging study within &lt;br&gt;4 weeks of study entry and is clinically stable , with respect to CNS metastases, at the time of study entry.  Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies)&lt;br&gt;•	History of organ allograft &lt;br&gt;•	Patients with evidence or history of bleeding diathesis or coagulopathy&lt;br&gt;•	Patients undergoing renal dialysis&lt;br&gt;•	Previous or concurrent cancer that is distinct in primary site or histology form the renal cell carcinoma EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors [Ta (Noninvasive tumor), Tis (Carcinoma in situ) &amp; T1 (Tumor invades lamina propria)] or any cancer curatively treated &gt; 3 years prior to study entry&lt;br&gt;•	Any hemorrhage/bleeding event grade &gt; 3 within 4 weeks of first dose of study drug&lt;br&gt;•	Serious, non-healing wound, ulcer, or bone fracture &lt;br&gt;•	Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.  The investigator is requested to advise the patient how to achieve an adequate contraception.    &lt;br&gt;•	Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results&lt;br&gt;•	Known or suspected allergy to the investigational agent or any agent given in association with this trial &lt;br&gt;•	Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study&lt;br&gt;•	Patients unable to swallow oral medications &lt;br&gt;•	Any malabsorption condition &lt;br&gt;Excluded therapies and medications, previous and concomitant:&lt;br&gt;•	Any anticancer therapy during the study &lt;br&gt;•	Radiotherapy during study or within 3 weeks of start of study drug.  (Palliative radiotherapy will be allowed as described in the Prior and concomitant Therapy section)&lt;br&gt;•	Major surgery, or significant traumatic injury within 4 weeks of the first dose of study drug &lt;br&gt;•	Autologous bone marrow transplant or stem cell rescue&lt;br&gt;•	Investigational drug therapy outside of this trial during or within 4 weeks of study entry&lt;br&gt;•	Use of biologic response modifiers, such as</Exclusion_Criteria>
    <Condition>Carcinoma metastásico de células renales (Advanced renal cell cancer.) &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038407
Term: Renal cell cancer
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NEXAVAR&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: sorafenib&lt;br&gt;CAS Number: 28844-1-73-1&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Roferon-A &lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: interferon alpha-2a&lt;br&gt;CAS Number: 76543-88-9&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The aim of the study is to evaluate if the addition of low doses of IFN alpha-2a to sorafenib would be beneficial, by estimating the median PFS, in patients who have previously either progressed or are intolerant to sunitinib.  &lt;br&gt;&lt;br&gt;The primary end-point is the PFS before dose escalation.&lt;br&gt;;Secondary Objective: Secondary variables include response rate, time to progression, duration of response and overall survival.;Primary end point(s): After progression the dose of sorafenib can be increased in both arms.&lt;br&gt;&lt;br&gt;The primary end-point is the first PFS time which will be described using Kaplan-Meier curves for each treatment group.  The median PFS time and the percentage of patients progression-free at 3, 6, and 12 months will be displayed with their 95% confidence intervals for each treatment group.  In addition, the Hazard Ratio will be presented with its 95% confidence interval.  &lt;br&gt;&lt;br&gt;For the PFS time after dose escalation to 600 mg BID, the medians will be estimated with their 95% confidence interval.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>BAY 43-9006 / 12782</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464371</Internal_Number>
    <TrialID>EUCTR2007-005546-20-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Systemic effects of mild renal insufficiency: the relation between forearm blood flow and ADMA.</Public_title>
    <Scientific_title>Systemic effects of mild renal insufficiency: the relation between forearm blood flow and ADMA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>academisch ziekenhuis Maastricht</Primary_sponsor>
    <Date_registration3>20071010</Date_registration3>
    <Date_registration>10/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005546-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/02/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;hypertension (without medication BP &gt;140/90 mmHg and &lt;180/110 mmHg)&lt;br&gt;creatinine clearance 60-90 ml/min&lt;br&gt;microalbuminuria (30-300 mg albumin/24 hour)&lt;br&gt;age 18-75&lt;br&gt;total cholesterol &gt;4,5 mmol/l&lt;br&gt;BMI between 18 and 30 kg/m2&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;diabetes mellitus&lt;br&gt;contra-indication for use of an angiotensin-II-receptorblocker or statin&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>hypertension
mild renal insufficiency</Condition>
    <Intervention>&lt;br&gt;Trade Name: Crestor&lt;br&gt;Product Name: Rosuvastatine&lt;br&gt;Product Code: ZD4522&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 287714414&lt;br&gt;Current Sponsor code: ZD4522&lt;br&gt;Other descriptive name: ROSUVASTATIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: Olmetec&lt;br&gt;Product Name: Olmetec&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 144689-24-7&lt;br&gt;Other descriptive name: OLMESARTAN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the relation between systemic effects of ADMA and mild renal dysfunction. ;Secondary Objective: -;Primary end point(s): forearm blood flow</Primary_outcome>
    <Secondary_ID>2605</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464443</Internal_Number>
    <TrialID>EUCTR2007-001604-20-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A PROSPECTIVE RANDOMIZED STUDY ON THE EFFICACY AND SAFETY OF THE PROPHYLACTIC USE OF RITUXIMAB, ADDED TO STANDARD IMMUNOSUPPRESSIVE TREATMENT IN COMPARISON WITH STANDARD IMMUNOSUPPRESSIVE TREATMENT ALONE IN RENAL TRANSPLANTATION - Rituximab in renal transplantation</Public_title>
    <Scientific_title>A PROSPECTIVE RANDOMIZED STUDY ON THE EFFICACY AND SAFETY OF THE PROPHYLACTIC USE OF RITUXIMAB, ADDED TO STANDARD IMMUNOSUPPRESSIVE TREATMENT IN COMPARISON WITH STANDARD IMMUNOSUPPRESSIVE TREATMENT ALONE IN RENAL TRANSPLANTATION - Rituximab in renal transplantation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Radboud University Nijmegen Medical Center</Primary_sponsor>
    <Date_registration3>20070627</Date_registration3>
    <Date_registration>27/06/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001604-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/09/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: yes&lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. All renal transplant recipients older than 18 years&lt;br&gt;2. All female patients at risk for pregnancy must have a negative serum pregnancy test before randomization. Female patients at risk for pregnancy must agree to use a medically acceptable method of contraception throughout the treatment period and for 12 weeks after discontinuation of study medication.&lt;br&gt;3. Signed, dated, and witnessed institutional review board (IRB) approved informed consent before screening and before any tests are performed that are specific to the protocol.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Recipients of a kidney from a living donor, who is HLA identical.&lt;br&gt;2. Patients with hemolytic uremic syndrome as original kidney disease.&lt;br&gt;3. Patients with focal segmental glomerulosclerosis that had recurred in a previous graft&lt;br&gt;4. Recipients with more than two previously failed grafts and/or PRA &gt; 85%&lt;br&gt;5. Previous treatment with anti-CD20 antibodies.&lt;br&gt;6. Diabetes mellitus that is currently not treated with insulin&lt;br&gt;7. Total white blood cell count &lt;3,000/mm3 or platelet count &lt;75,000/mm3.&lt;br&gt;8. Active infection with hepatitis B, hepatitis C, or HIV.&lt;br&gt;9. History of tuberculosis.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>prophylaxis of acute rejection after renal transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the incidence and severity of biopsy-confirmed acute rejection within the first six months after transplantation.;Secondary Objective: To analyze:&lt;br&gt;-Renal function as estimated by the endogenous creatinine clearance at 6 months&lt;br&gt;-Occurrence of chronic allograft nephropathy at 6 months&lt;br&gt;-Cumulative incidence of  infections and malignancies at 6 months&lt;br&gt;-Medical costs during the first 6 months after transplantation&lt;br&gt;-Patient and graft survival&lt;br&gt;;Primary end point(s): The incidence and severity of biopsy-confirmed acute rejections within the first six months after transplantation.</Primary_outcome>
    <Secondary_ID>RRT6</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464744</Internal_Number>
    <TrialID>EUCTR2007-005985-10-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Análisis del Efecto Renoprotector de la Pentoxifilina en Pacientes con Enfermedad Renal Crónica Secundaria a Nefropatía Diabética - Pentoxifilina y renoprotección</Public_title>
    <Scientific_title>Análisis del Efecto Renoprotector de la Pentoxifilina en Pacientes con Enfermedad Renal Crónica Secundaria a Nefropatía Diabética - Pentoxifilina y renoprotección                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Juan Francisco Navarro González</Primary_sponsor>
    <Date_registration3>20080121</Date_registration3>
    <Date_registration>21/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005985-10                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/03/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: No tratamiento activo ni placebo en el grupo control.&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Edad superior a 35 años.&lt;br&gt;2. Diabetes mellitus tipo 2 con un tiempo de diagnóstico superior a 10 años.&lt;br&gt;3. Diagnóstico clínico compatible con nefropatía diabética establecida tras exclusión de acuerdo con la práctica clínica habitual de otras posibles etiologías de la ERC y sin precisar confirmación histológica.&lt;br&gt;4. ERC estadio 3 ó 4 (filtrado glomerular estimado entre 15 y 60 ml/min).&lt;br&gt;5. Tratamiento con fármacos bloqueadores del sistema renina-angiotensina durante al menos los 6 meses previos a la inclusión en el estudio.&lt;br&gt;6. Ausencia de terapéutica inmunosupresora en los 6 meses previos a la inclusión en el estudio.&lt;br&gt;7. Obtención del consentimiento por parte del paciente.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. HTA severa (definida con una PAS mayor o igual a 180 mmHg y/o una PAD mayor o igual a 110 mmHg) y/o HbA1c &gt; 10%.&lt;br&gt;2. Padecer enfermedades sistémicas (LES, vasculitis, amiloidosis, etc) o tumorales activas.&lt;br&gt;3. Presencia de enfermedad renal no diabética.&lt;br&gt;4. Agudización de la insuficiencia renal crónica por proceso intercurrente en los últimos 6 meses.&lt;br&gt;5. Necesidad de tratamiento concomitante con glucocorticoides o antiinflamatorios no esteroideos en los 3 meses previos a la inclusión en el estudio.&lt;br&gt;6. Tratamiento con antagonistas de la aldosterona y bloqueo doble del sistema renina-angiotensina.&lt;br&gt;7. Mujeres en edad fértil que no utilizan medidas anticonceptivas.&lt;br&gt;8. Mujeres en período de lactancia.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Enfermedad renal crónica secundaria a nefropatía diabética. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10061835
Term: Diabetic nephropathy
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Hemovas 600 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: PENTOXIFYLLINE&lt;br&gt;CAS Number: 6493056&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar el efecto renoprotector aditivo de la terapéutica con pentoxifilina en pacientes diabéticos tipo 2 con nefropatía diabética tratados con bloquedores del sistema renina-angiotensina. Se analizará la progresión de la insuficiencia renal crónica mediante la valoración de la tasa media de progresión de la creatinina sérica (Crs) expresada en mg/dl/mes y/o  1/Crs con el tiempo, así como mediante el análisis del filtrado glomerular estimado a través de la ecuación abreviada del estudio MDRD (Modification of Diet in Renal Disease), la ecuación que hoy en día es recomendada por la gran mayoría de las sociedades científicas para la estimación del filtrado glomerular.;Secondary Objective: •	Porcentaje de pacientes que duplican su Crs, llegan a diálisis o trasplante renal.&lt;br&gt;•	Evolución de la albuminuria.&lt;br&gt;•	Influencia de presión arterial, albuminuria, anemia, dislipemia y alteraciones del metabolismo  calcio-fósforo, e influencia del tratamiento con PTF. &lt;br&gt;•	Análisis de la sensibilidad a la insulina, su relación con la progresión de la enfermedad renal y la influencia del tratamiento con PTF.&lt;br&gt;•	Evolución de los niveles de TNFa, interleukina 18 e interelukina 10. &lt;br&gt;•	Morbi-mortalidad cardiovascular (muerte de causa cardiovascular, hospitalización por insuficiencia cardiaca, coronariografía y/o revascularización coronaria, accidente cerebrovascular, amputación y/o revascularización de miembros inferiores).&lt;br&gt;•	Seguridad y tolerancia del tratamiento combinado con PTF y bloqueadores del sistema renina-angiotensina.&lt;br&gt;;Primary end point(s): - Tasa media de progresión de la creatinina sérica.&lt;br&gt;- Evolución del filtrado glomerular estimado.&lt;br&gt;- Porcentaje de pacientes que duplican su Crs durante el estudio, llegan a diálisis o trasplante renal.&lt;br&gt;- Evolución de la excreción urinaria de albúmina.&lt;br&gt;- Morbi-mortalidad cardiovascular (muerte de causa cardiovascular, hospitalización por insuficiencia cardiaca, coronariografía y/o revascularización coronaria, accidente cerebrovascular, amputación y/o revascularización de miembros inferiores).</Primary_outcome>
    <Secondary_ID>PTF-REN-001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2464760</Internal_Number>
    <TrialID>EUCTR2007-005648-25-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatique et intratumorale des molécules impliquées dans la voie VHL/HIF/VEGF. - S-TRAC</Public_title>
    <Scientific_title>Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatique et intratumorale des molécules impliquées dans la voie VHL/HIF/VEGF. - S-TRAC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>C.H.U. de RENNES</Primary_sponsor>
    <Date_registration3>20071217</Date_registration3>
    <Date_registration>17/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005648-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>31/01/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Les sujets devront répondre à tous les critères d'inclusion suivants pour pouvoir être inclus dans l'étude :&lt;br&gt;1.	les sujets doivent signer et dater le consentement éclairé approuvé par le comité d'éthique ; &lt;br&gt;2.	Âge = 18 ans ; &lt;br&gt;3.	indice de performance ECOG 0 – 2 avant la néphrectomie ;&lt;br&gt;4.	un des diagnostics suivants doit être posé selon le système de stadification UISS :&lt;br&gt;a.	T3 N0 ou Nx, M0, grade de Fuhrman ³ 2 et indice de performance ECOG ³ 1, ou &lt;br&gt;b.	T4 N0 ou Nx, M0, grade de Fuhrman quelconque et indice de performance ECOG quelconque, ou&lt;br&gt;c.	Tout T, N1-2, M0, grade de Fuhrman quelconque et indice de performance ECOG quelconque ;&lt;br&gt;5.	le diagnostic de carcinome rénal (cancer du rein à cellules claires) doit être confirmé par histologie ;&lt;br&gt;6.	aucune preuve de maladie macroscopique résiduelle ou de maladie métastatique ne doit être mise en évidence. Les sujets présentant des preuves de maladie microscopique (R1) sont acceptés ;&lt;br&gt;7.	les sujets ne doivent avoir reçu aucun traitement médical systémique spécifique antérieur pour le cancer du rein ; &lt;br&gt;8.	les sujets ne doivent pas avoir reçu un traitement anti-angiogénique antérieur ; &lt;br&gt;9.	les sujets doivent avoir reçu la première dose orale de sunitinib pas plus de 10 semaines après la date de la néphrectomie ; &lt;br&gt;10.	les sujets doivent présenter des fonctions organiques adéquates définies de la manière suivante : &lt;br&gt;a.	plaquettes ³ 100 x 109/l, hémoglobine ? 8 g/dl, numération absolue des neutrophiles ? 1,5 x 109/l ;&lt;br&gt;b.	bilirubine ? 3 mg/dl,  aspartate transaminase (ASAT) et alanine transaminase (ALAT) £ 2,5 fois la limite supérieure de la normale ;&lt;br&gt;c.	International Normalized Ratio (INR) £ 1,7 ou temps de Quick £ 6 s de plus que le témoin ; &lt;br&gt;d.	clairance de la créatinine calculée = 30 ml/mn.&lt;br&gt;11.	Fonction d’éjection ventriculaire gauche suffisante définie par une valeur = 50 %, 3 à 10 semaines après la date de la néphrectomie sur la base d'un échocardiogramme bidimensionnel (ECHO) ou d’une ventriculographie isotopique (MUGA) ; &lt;br&gt;12.	les femmes et les hommes doivent utiliser des méthodes de contraception adéquates au cours de l'étude. Les méthodes de contraception adéquates comprennent les implants, les produits injectables, les contraceptifs oraux associés, les dispositifs intra-utérins efficaces, l'abstinence sexuelle ou un partenaire vasectomisé ou une vasectomie ;&lt;br&gt;13.	la volonté et la capacité de se rendre aux visites programmées, et de se conformer aux programmes thérapeutiques, aux analyses biologiques et aux autres procédures de l'étude.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Les sujets répondant à l'un des critères suivants ne seront pas inclus dans l'étude : &lt;br&gt;1.	carcinome non différencié sur le plan histologique ou carcinome des tubes collecteurs, lymphome, sarcome ou sujets présentant des sites métastatiques rénaux ; &lt;br&gt;2.	hémorragie de grade 3 (NCI CTCAE) moins de 4 semaines après la date de la randomisation ; &lt;br&gt;3.	diagnostic d'une affection maligne secondaire quelconque dans les 5 ans suivant la date de randomisation, à l'exception d'un épithélioma basocellulaire, d'un épithélioma spinocellulaire ou d'un cancer in situ du col de l'utérus traité de manière adéquate et sans signe de récidive pendant 12 mois ;&lt;br&gt;4.	angor sévère/instable, infarctus du myocarde, pontage coronaire, insuffisance cardiaque congestive symptomatique, accident vasculaire cérébral, y compris accidents ischémiques transitoires ou embolie pulmonaire, survenus dans les 12 mois précédents l’administration du traitement à l’étude ;&lt;br&gt;5.	traitement concomitant avec des inhibiteurs et des inducteurs puissants connus de l'isoenzyme CYP3A4 et/ou administration de ces médicaments 7 et 12 jours avant la date de la randomisation (par exemple respectivement kétoconazole, rifampicine, etc.) ;&lt;br&gt;6.	arythmie cardiaque en cours de grade NCI CTCAE ³ 2, fibrillation auriculaire de tout grade, ou allongement de l'intervalle QTc &gt; 500 ms ;  &lt;br&gt;7.	hypertension non contrôlée par des médicaments ; &lt;br&gt;8.	traitement par des anticoagulants et traitement à doses thérapeutiques par la warfarine en cours ou au cours des deux semaines précédant le premier jour de l'administration du sunitinib. L'administration de warfarine à faible dose pour une prophylaxie de la thrombose veineuse profonde est autorisée (jusqu'à 2 mg/jour). L'administration d'héparine de bas poids moléculaire ou d'aspirine est autorisée ; &lt;br&gt;9.	incapacité à avaler des médicaments oraux, ou présence d'une maladie inflammatoire chronique de l'intestin, d’une occlusion intestinale partielle ou complète ou d'une diarrhée chronique ; &lt;br&gt;10.	infection connue par le virus de l'immunodéficience humaine (VIH) ou d'une pathologie liée au syndrome d'immunodéficience acquise (SIDA) ; &lt;br&gt;11.	hépatite active connue ;&lt;br&gt;12.	grossesse ou allaitement. Toutes les femmes en âge de procréer doivent présenter un test de grossesse négatif (sur sérum ou urine) dans les 7 jours précédant la date de la randomisation ; &lt;br&gt;13.	tout autre affection médicale ou psychiatrique ou anomalie biologique sévère aiguë ou chronique susceptible d'augmenter le risque associé à la participation à l'étude ou à l'administration du médicament à l'étude, ou pouvant interférer avec l'interprétation des résultats de l'étude, et susceptible de rendre l'inclusion du sujet dans l'étude inappropriée selon l'avis de l'investigateur ; &lt;br&gt;14.	administration de toute substance oncologique expérimentale ou anti-angiogénique autorisée ou expérimentale avant l'entrée dans l'étude ; &lt;br&gt;15.	traitement en cours dans un autre essai clinique thérapeutique. Les essais portant sur les traitements de soutien ou les essais non thérapeutiques, par exemple les études portant sur les méthodes d'évaluation des résultats notifiés par les patients, sont autorisés.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10001326
Term: Adrenal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10001327
Term: Adrenal carcinoma NOS
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038395
Term: Renal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038396
Term: Renal carcinoma recurrent
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038397
Term: Renal carcinoma stage I
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038398
Term: Renal carcinoma stage II
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038399
Term: Renal carcinoma stage III
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038400
Term: Renal carcinoma stage IV
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050076
Term: Metastatic renal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10001326
Term: Adrenal carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Product Name: Sunitinib&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: L’objectif principal de ce projet est de déterminer dans les CRCC,  si les facteurs suivants sont prédictifs de la réponse (définie par la survie sans cancer) ou de la non réponse aux thérapies antiangiogéniques de type inhibiteur de l’activité tyrosine kinase (Sunitinib) :&lt;br&gt;- statut VHL (présence de mutations, délétions, d’hyperméthylation du promoteur) &lt;br&gt;- taux circulants ou expression intratumorale de molécules impliquées dans la voie VHL/HIF/VEGF.&lt;br&gt;;Secondary Objective: Les objectifs secondaires sont de :&lt;br&gt;- déterminer si les facteurs listés ci-dessus sont pronostiques de la survie sans cancer et de la survie globale,&lt;br&gt;- Explorer l’association entre le statut VHL et les biomarqueurs de la voie VHL/HIF/VEGF.&lt;br&gt;;Primary end point(s): Critère de jugement principal :&lt;br&gt;Relation entre les marqueurs biologiques et moléculaires explorés dans cette étude ancillaire et la réponse au Sunitinib&lt;br&gt;•	anomalies du gène VHL (mutations, délétions ou hyperméthylation du promoteur)&lt;br&gt;•	taux plasmatiques de VEGF-A et C, de VEGFR1 et R2, bFGF, SDF-1, PDGF AA, PDGF AB, PDGF BB, des précurseurs endothéliaux circulants, des cellules endothéliales circulantes, des microparticules endothéliales et des microparticules plaquettaires.&lt;br&gt;•	expression intratumorale de VEGF-A, B, C, D, de VEFG-R1, R2, R3, PDGFR,  HIF1?, HIF2, CAIX, p53, PTEN, et pVHL.&lt;br&gt;&lt;br&gt;Critères de jugement secondaires :&lt;br&gt;•	Relation entre les marqueurs biologiques et moléculaires explorés dans cette étude ancillaire, la survie sans cancer et la survie globale&lt;br&gt;•	Relations entre le statut VHL, les marqueurs biologiques et tissulaires explorés et les caractéristiques histo-pronostiques des tumeurs.&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>PHRC/07-03/RENNES</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465162</Internal_Number>
    <TrialID>EUCTR2005-004360-23-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Randomised controlled study of “physiological” peritoneal dialysis solutions. - Physiological PD</Public_title>
    <Scientific_title>Randomised controlled study of “physiological” peritoneal dialysis solutions. - Physiological PD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Barts and The London NHS Trust</Primary_sponsor>
    <Date_registration3>20060611</Date_registration3>
    <Date_registration>11/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004360-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/07/2006</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;All incident patients selected to use a PD system that has physiological and standard solutions available.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Patients unable to provide informed consent &lt;br&gt;-	Patients where the use of a certain solution is indicated or contra-indicated for medical reasons (e.g. known allergy).&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>End stage renal failure</Condition>
    <Intervention>&lt;br&gt;Product Name: Physioneal PD solutions&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: glucose&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.36-3.86&lt;br&gt;Pharmaceutical form of the placebo: Solution for peritoneal dialysis&lt;br&gt;Route of administration of the placebo: Intraperitoneal use&lt;br&gt;&lt;br&gt;Product Name: Dineal&lt;br&gt;Product Code: Dianeal&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: glucose&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.36-3.86&lt;br&gt;Pharmaceutical form of the placebo: Solution for peritoneal dialysis&lt;br&gt;Route of administration of the placebo: Intraperitoneal use&lt;br&gt;&lt;br&gt;Product Name: Balance&lt;br&gt;Product Code: Balance&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: glucose&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.5-3.5&lt;br&gt;Pharmaceutical form of the placebo: Solution for peritoneal dialysis&lt;br&gt;Route of administration of the placebo: Intraperitoneal use&lt;br&gt;&lt;br&gt;Product Name: CAPD/DPCA staysafe&lt;br&gt;Product Code: CAPD/DPCA staysafe&lt;br&gt;Pharmaceutical Form: Solution for peritoneal dialysis&lt;br&gt;INN or Proposed INN: glucose&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.5-3.5&lt;br&gt;Pharmaceutical form of the placebo: Solution for peritoneal dialysis&lt;br&gt;Route of administration of the placebo: Intraperitoneal use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the outcome of peritoneal dialysis when "standard" or "biocompatible" solutions are used. Primary end-point is: peritonitis rate. ;Secondary Objective: Secondary Endpoints:&lt;br&gt;·	Patients using physiological solutions will have better preservation of residual kidney function.&lt;br&gt;·	Patients using physiological solutions will have smaller changes in peritoneal membrane function assessed by PET than control&lt;br&gt;·	Patients using physiological solutions will have reduced composite end-point of mortality and PD failure defined by transfer to HD&lt;br&gt;·	Patients using physiological solutions will have better quality of life assessed by SF-36&lt;br&gt;;Primary end point(s): Primary aim is to compare peritonitis. However, some patients may have more than 1 episode</Primary_outcome>
    <Secondary_ID>P-03-235</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465175</Internal_Number>
    <TrialID>EUCTR2006-000674-73-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM,
PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND
EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WITH A HISTORY OF
RENAL DISEASE</Public_title>
    <Scientific_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM,
PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND
EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WITH A HISTORY OF
RENAL DISEASE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>La Jolla Pharmaceutical Company</Primary_sponsor>
    <Date_registration3>20060615</Date_registration3>
    <Date_registration>15/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000674-73                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/08/2006</Date_enrollement>
    <Target_size>730</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Each patient must meet all the following criteria in order to participate in&lt;br&gt;this trial:&lt;br&gt;&lt;br&gt;2.1.1 Males or females between 12 and 70 years old, inclusive.&lt;br&gt;2.1.2 Female patients must be non-pregnant and non-lactating and have a negative serum pregnancy test result prior to enrollment in the study. Female patients of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate of less than 1% per year, when used consistently and correctly, for example oral contraceptives, contraceptive patch, implants,&lt;br&gt;injectables, some intrauterine contraceptive devices [IUDs], or sexual abstinence) during the entire duration of the study. Males enrolled in the trial must have no plans to father a child during the course of the trial and agree to use adequate birth control methods.&lt;br&gt;2.1.3. Diagnosis of SLE for purposes of this trial utilize the 1996 Revised Criteria for the Classification of SLE as defined by the American College of Rheumatology (ACR) where a diagnosis of SLE is established when = 4 of the 11 criteria are met (refer to Section 8.2 of protocol).&lt;br&gt;2.1.4 At least one documented episode of active SLE renal disease within 4 years prior to randomization at study Visit 3 as defined by at least one of the following:&lt;br&gt;- A renal biopsy showing active lesions of SLE, Morphologic Classification of Lupus Nephritis defined by the World Health Organization (WHO) Class III, IV or V (refer to Section 8.3 of protocol)&lt;br&gt;- Increase in serum creatinine:&lt;br&gt;• by greater than 0.3 mg/dL if previous value was less than 2.0 mg/dL&lt;br&gt;• by greater than 0.4 mg/dL if previous value was 2.0 mg/dL to 5.0 mg/dL&lt;br&gt;• AND either hematuria OR a C3, C4 or CH50 below lower limits of normal or at least 25% lower than a previous value.&lt;br&gt;Patients with hereditary C4 deficiency cannot qualify on the C4 or CH50 criterion alone.&lt;br&gt;-Increase in proteinuria:&lt;br&gt;• to greater than 1000 mg/24 hr if the previous value was &lt; 200 mg/24 hr&lt;br&gt;• to greater than 2000 mg/24 hr if the previous value was = 200 mg/24 hr and = 1000 mg/24 hr&lt;br&gt;• to greater than 2 times the previous value if that value was &gt; 1000 mg/24 hr&lt;br&gt;- Use of cyclophosphamide to treat lupus nephritis that is documented in clinical or hospital records.&lt;br&gt;2.1.5 Elevated anti-dsDNA antibody concentration at pre-screening Visit 0 (= 10 IU/mL) as measured by the Farr assay at the regional central laboratory.&lt;br&gt;2.1.6. Ability to communicate meaningfully with the investigational staff, competence to give written informed consent, and ability to comply with the entire study procedure.&lt;br&gt;2.1.7 Duly executed, written, informed consent obtained from the patient, next of kin, or other legal representative.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any of the following will exclude a patient from this trial:&lt;br&gt;&lt;br&gt;2.2.1 Active SLE renal disease in the 3 months prior to Visit 3 as evidenced by:&lt;br&gt;- Increase in serum creatinine:&lt;br&gt;• by greater than 0.3 mg/dL if previous value was less than 2.0 mg/dL&lt;br&gt;• by greater than 0.4 mg/dL if previous value was 2.0 mg/dL to 5.0 mg/dL&lt;br&gt;• AND either hematuria OR a C3, C4 or CH50 below lower limits of normal or at least 25% lower than a previous value.&lt;br&gt;- Reproducible increase in proteinuria:&lt;br&gt;• to greater than 1000 mg/24 hr if the previous value was &lt; 200 mg/24 hr&lt;br&gt;• to greater than 2000 mg/24 hr if the previous value was = 200 mg/24 hr and = 1000 mg/24 hr&lt;br&gt;• to greater than 2 times the previous value if that value was &gt; 1000 mg/24 hr&lt;br&gt;2.2.2 An increase in the anti-dsDNA antibody concentration of more than 50% with an incremental increase of at least 50 units in anti-dsDNA antibody concentration by Farr assay between the samples taken at Visit 0 and Visit 1 during the screening period. &lt;br&gt;2.2.3 Use of the following therapeutics:&lt;br&gt;- Prednisone &gt; 20 mg/day within 1 month prior to Visit 1&lt;br&gt;- Any use of the following therapies or therapeutics within 2 months prior to randomization or 1 month prior to Visit 1:&lt;br&gt;• alkylating agents (e.g., cyclophosphamide)&lt;br&gt;• TNF inhibitors (e.g., etanercept, infliximab)&lt;br&gt;• cyclosporine&lt;br&gt;• plasmapheresis&lt;br&gt;• intravenous immunoglobulin&lt;br&gt;• prosorba column&lt;br&gt;- Any use of mycophenolate mofetil that exceeds 1000 mg/day 1 month prior to Visit 1&lt;br&gt;- Any use of azathioprine that exceeds 100 mg/day within 1 month prior to Visit 1&lt;br&gt;- Any use of methotrexate that exceeds 10 mg/week within 1 month prior to Visit 1&lt;br&gt;- Any use of leflunomide that exceeds 10 mg/day within 1 month prior to Visit 1&lt;br&gt;- Any use of rituximab within 5 months prior to Visit 1&lt;br&gt;- Previous or concurrent medications and other therapies or devices that in the judgment of the Investigator are likely to confound the evaluation of the safety or efficacy of abetimus sodium. Examples include:&lt;br&gt;- immunosuppressants or immunomodulatory drugs other than those therapies specifically noted above to include new immunomodulatory agents that may become commercially available during the course of the study&lt;br&gt;- drugs that have the potential to induce SLE (e.g., isoniazid, phenytoin, hydralazine, procainamide, etc.)&lt;br&gt;- radiation therapy within 1 year.&lt;br&gt;- If the Investigator has any question concerning a particular medication, he/she should discuss this with the Medical Monitor prior to enrollment.&lt;br&gt;- Patient has received any investigational new drug or device within 30 days prior to screening or 5 half-lives of the agent (whichever is longer), or any investigational new drug with a long-term effect.&lt;br&gt;- Prior participation in study LJP 394-90-14&lt;br&gt;2.2.4 Exclusionary laboratory values:&lt;br&gt;• leukocyte count &lt; 2,000 cells/mm3&lt;br&gt;• platelet count &lt; 50,000 cells/mm3&lt;br&gt;• hemoglobin &lt; 8.5 gm/dL&lt;br&gt;• serum hepatic transaminases = 3X the upper limit of normal&lt;br&gt;• serum creatinine &gt; 3.5 mg/dL within the 2 months prior to randomization&lt;br&gt;2.2.5 Malignant disease or immunodeficiency syndrome within 5 years, excepting patients with basal cell or squamous cell carcinoma of the skin with complete excision and clean borders.&lt;br&gt;2.2.6 Evidence of current abuse of drugs or alcohol.&lt;br&gt;2.2.7 History of poor procedural compliance in previous investigational studies.&lt;br&gt;2.2.8 History of serious cardiac disease or functional classification New York Heart Association Class III or IV.&lt;br&gt;2.2.9 Patient has previously undergone organ transplantation.&lt;br&gt;2.2.10 Other medical c</Exclusion_Criteria>
    <Condition>Systemic lupus erythematosus patients with a history of renal disease &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10042945
Term: Systemic lupus erythematosus
</Condition>
    <Intervention>&lt;br&gt;Product Name: Abetimus sodium&lt;br&gt;Product Code: LJP 394&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Abetimus Sodium&lt;br&gt;CAS Number: 167362-48-3&lt;br&gt;Current Sponsor code: LJP 394&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this trial is to determine whether abetimus&lt;br&gt;sodium is more effective than placebo in delaying the time to renal flare in SLE&lt;br&gt;patients with a history of SLE renal disease. The safety and efficacy of abetimus&lt;br&gt;sodium in SLE patients will be evaluated at weekly doses of 300 and 900 mg&lt;br&gt;over the intended 52-week exposure period.&lt;br&gt;;Secondary Objective: The secondary objectives of the trial are to determine whether treatment with&lt;br&gt;abetimus sodium is more effective than placebo&lt;br&gt;--in reducing proteinuria&lt;br&gt;--in delaying time to all major SLE flares;Primary end point(s): 4.13.1. The primary efficacy endpoint, time to first renal flare, will be based on laboratory data from the central laboratory and confirmed by supporting data as stipulated in section 4.13.2. and other relevant sections. &lt;br&gt;For renal flare, laboratory data leading to the primary endpoint will be considered valid for defining the endpoint only after causes other than increased activity of SLE renal disease have been excluded and the Principal Investigator, with concurrence of the Medical Monitor, has attributed the changes in laboratory values to an SLE-related renal flare. An independent Renal Events Committee will review renal flare data to adjudicate the attribution of renal flares to SLE prior to the data from the trial being unblinded. &lt;br&gt;Patients reaching a renal flare endpoint are encouraged to stay in the study and receive weekly administration of study drug until they complete the one-year evaluation period. Patients experiencing a renal flare may be treated with prednisone, cyclophosphamide, and//or other immunosuppressive agents as needed.&lt;br&gt;&lt;br&gt;4.13.2. .... A renal flare endpoint will have been reached if one or the other of the following criteria, or both, are met following a renal flare signal as outlined in the protocol.&lt;br&gt;Either:&lt;br&gt;A reproducible increase in serum creatinine of &gt; 20% OR at least 0.3&lt;br&gt;mg/dL, whichever is greater. This endpoint cannot be met using this&lt;br&gt;criterion unless this increase is documented by two consecutive tests&lt;br&gt;from two different days and each consecutive test continues to meet the&lt;br&gt;endpoint increase in serum creatinine and each of the consecutive tests&lt;br&gt;is accompanied by the presence of clinically significant proteinuria&lt;br&gt;(&gt; 1000 mg/24 h) and/or red cell casts.&lt;br&gt;Or:&lt;br&gt;A reproducible increase in 24-hr urine protein:&lt;br&gt;• to greater than 1000 mg/24 hr if the screening value was&lt;br&gt;&lt; 200 mg/24 hr&lt;br&gt;• to greater than 2000 mg/24 hr if the screening value was&lt;br&gt;= 200 mg/24 hr and = 1000 mg/24 hr &lt;br&gt;• to greater than 2 times the screening value if that value was&lt;br&gt;&gt; 1000 mg/24 hr&lt;br&gt;AND the documentation of increased urinary protein is reproducible and&lt;br&gt;is based on specimens from 2 different days. This will require at least two&lt;br&gt;24-hr urine collections. &lt;br&gt;&lt;br&gt;4.13.3 Subsequent Flares&lt;br&gt;A subsequent flare (second flare, third flare, etc.) will be considered to have occured if the first flare has resolved, i.e., the parameters responsible for the first flare have returned to baseline and remain at baseline for at least 3 months. The primary endpoint, time to renal flare, will be based exclusively on the occurence of the first on-study renal flare.&lt;br&gt;&lt;br&gt;Safety and tolerability Endpoints:&lt;br&gt;Adverse experiences, laboratory parameters, reasons for premature&lt;br&gt;study termination, and cause(s) of death will be collected and assessed&lt;br&gt;as measures of safety and tolerability.&lt;br&gt;All patients who receive at least one dose of study drug will be included in&lt;br&gt;analyses of safety and tolerability.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>LJP 394-90-14</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465537</Internal_Number>
    <TrialID>EUCTR2006-005774-50-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Protocol for taking pharmacogenetic testing of tacrolimus into the clinical arena: patient tailored anti-rejection therapy</Public_title>
    <Scientific_title>Protocol for taking pharmacogenetic testing of tacrolimus into the clinical arena: patient tailored anti-rejection therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Central Manchester &amp; Manchester Children's University Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20061221</Date_registration3>
    <Date_registration>21/12/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005774-50                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/05/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: &lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Subjects who have undergone a kidney transplant and are receiving oral tacrolimus as part of their clinical management&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any form of substance abuse (including drug or alcohol abuse) psychiatric disorder or condition which, in the opinion of the investigator, may invalidate the patient's ability to give informed consent.&lt;br&gt;</Exclusion_Criteria>
    <Condition>The study is to determine whether MDR-1 genotyping correlates with tacrolimus dose in individual patients and could therefore be used in future to predict tacrolimus dose.  All patients will have undergone or be about to undergo a kidney transplant and require treatment with tacrolimus immunosuppression. &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10021510
Term: Immunosuppression NOS
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine in a well-powered study whether MDR-1 genotyping correlates with tacrolimus dose in individual patients and could therefore be used in future to predict tacrolimus starting dose.;Secondary Objective: ;Primary end point(s): The MDR-1 genotype of 400 patients taking tacrolimus.  This information will be used to predict whether the patients are on standard, intermediate or reduced therapy dose.</Primary_outcome>
    <Secondary_ID>9834p</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465755</Internal_Number>
    <TrialID>EUCTR2006-006137-41-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prospective, randomized, open, 2-arm national multi-center study to 
evaluate the value of Rituximab in humoral chronic rejection 
after renal transplantation
 - Rituximab 2006</Public_title>
    <Scientific_title>Prospective, randomized, open, 2-arm national multi-center study to 
evaluate the value of Rituximab in humoral chronic rejection 
after renal transplantation
 - Rituximab 2006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Medizinische Fakultät der Technischen Universität München, vertreten durch den Dekan</Primary_sponsor>
    <Date_registration3>20070326</Date_registration3>
    <Date_registration>26/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006137-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/08/2007</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;GFR &gt; 25 ml/min x 1,73m2 (MDRD)Time after transplantation &gt;3 months &lt;br&gt;Age &gt;18 yearsInformed consent&lt;br&gt;Biopsy proven CAN with C4d+ and/or plasma-cell and/or B-Lymphocyte (CD20+ cells) within the last 4 weeks before inclusion&lt;br&gt;ACE/AT1 blocker started more than 1 week before inclusion&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Hepatitis B, HIV &lt;br&gt;Signs of acute cellular rejection&lt;br&gt;Proteinuria &gt;4g/24h&lt;br&gt;History of malignancy within the last 5 years (except non-metastatic basal or squamous cell carcinoma of the skin)&lt;br&gt;Systemic infection&lt;br&gt;Leukopenia&lt;br&gt;Pregnancy &lt;br&gt;Participation in another investigational drug study&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal transplant patients beyond 1 year post Tx, suffering from CAN and histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera 100mg&lt;br&gt;Product Name: MabThera®&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: Rituximab&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 375-&lt;br&gt;&lt;br&gt;Trade Name: Prograf Hartkapseln&lt;br&gt;Product Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Prograf&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: see D.3.5, D.3.6-&lt;br&gt;&lt;br&gt;Trade Name: CellCept®&lt;br&gt;Product Name: CellCept®&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: CellCept&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 2,0 g -&lt;br&gt;&lt;br&gt;Trade Name: Urbason® solubile&lt;br&gt;Product Name: Urbason® solubile&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Urbason solubile&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100 mg-&lt;br&gt;&lt;br&gt;Trade Name: Decortin H &lt;br&gt;Product Name: Decortin H &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Decortin H&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 40 mg-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the benefit of Rituximab in patients with CAN with histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.;Secondary Objective: Renal function at 1 year&lt;br&gt;Tolerability/ safety &lt;br&gt;Graft survival at 1 and 2 years;Primary end point(s): Serum creatinine level 12 month </Primary_outcome>
    <Secondary_ID>VAL-518-HEE-0200-S</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2465811</Internal_Number>
    <TrialID>EUCTR2008-000088-40-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmacocinétique de l’association pipéracilline-tazobactam chez les patients septiques, en insuffisance rénale oligo-anurique, traités par hémodiafiltration veino-veineuse continue</Public_title>
    <Scientific_title>Pharmacocinétique de l’association pipéracilline-tazobactam chez les patients septiques, en insuffisance rénale oligo-anurique, traités par hémodiafiltration veino-veineuse continue                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>CHU de TOULOUSE</Primary_sponsor>
    <Date_registration3>20080527</Date_registration3>
    <Date_registration>27/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000088-40                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>09/04/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Patient (homme ou femme) âgé de plus de 18 ans&lt;br&gt;- Durée attendue de survie &gt; à 7 jours&lt;br&gt;- Patient oligo-anurique (diurèse &lt; 20cc/heure) devant bénéficier d’une CVVHDF (présentant une insuffisance rénale aiguë ou une poussée d’insuffisance rénale aiguë sur une insuffisance rénale chronique sous jacente ou habituellement traité par  hémodialyse intermittente chronique)&lt;br&gt;- Patient présentant une infection*, déjà colonisé ou non, de localisation variable,  à germe non identifié supposé sensible à l’association pipéracilline-tazobactam&lt;br&gt;- Au stade de sepsis sévère* ou de choc septique*&lt;br&gt;- Consentement éclairé du patient ou, s’il est sédaté du fait de la gravité de son état clinique et ainsi hors d’état d’exprimer son consentement, d’un membre de sa famille ou de la personne de confiance désignée dans son dossier médical.&lt;br&gt;- Patient affilié à un régime de sécurité sociale&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Antécédents d’allergie aux Bêta-lactamines&lt;br&gt;- Isolement d’un germe résistant à l’association pipéracilline-tazobactam&lt;br&gt;- Insuffisance hépatocellulaire sévère aiguë ou chronique avec un score de Child &gt; 9&lt;br&gt;- Contre-indication à une héparinothérapie curative&lt;br&gt;- Présence d’une fonction rénale résiduelle&lt;br&gt;- Femme enceinte (test de grossesse au moment de l’inclusion positif) ou allaitant&lt;br&gt;- Personne sous sauvegarde de justice, sous tutelle ou sous curatelle&lt;br&gt;- Refus de signer le consentement par le patient ou la personne de confiance désignée dans son dossier médical si le patient est hors d’état d’exprimer lui-même son consentement.&lt;br&gt;- Interruption du traitement par pipéracilline-tazobactam et / ou hémodiafiltration au cours de l’étude.&lt;br&gt;- Participation du patient à un autre protocole de recherche clinique.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>patient septique hospitalisé en réanimation présentant  une infection, déjà colonisé ou non, de localisation variable,  à germe non identifié supposé sensible à l’association pipéracilline-tazobactam. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10022519
Term: Intensive care
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10040580
Term: Shock septic
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038435
Term: Renal failure
</Condition>
    <Intervention>&lt;br&gt;Trade Name: TAZOCILLINE&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: piperacilline&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;INN or Proposed INN: tazobactam&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: L’objectif principal est d’évaluer chez les patients de réanimation septiques en insuffisance rénale oligo-anurique, l’impact d’une épuration rénale extra corporelle continue par CVVHDF sur la pharmacocinétique de l’association pipéracilline-tazobactam.&lt;br&gt;Pour cet antibiotique, l’activité bactéricide est temps-dépendante. L’efficacité est donc conditionnée par la valeur de sa concentration résiduelle plasmatique qui doit être un multiple de la CMI (à peu près 5 fois la CMI).&lt;br&gt;;Secondary Objective: L’objectif secondaire est purement observationnel et consiste à évaluer l’épuration de la pipéracilline-tazobactam par la mesure des clairances combinées diffusive et convective que l’on rapportera à la clairance totale des 2 molécules étudiées.;Primary end point(s): Le critère principal de jugement sera donc la comparaison, au cours de la séance de CVVHDF, des concentrations plasmatiques de pipéracilline et tazobactam à la CMI documentée à partir du germe identifié.</Primary_outcome>
    <Secondary_ID>07 300 02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2466128</Internal_Number>
    <TrialID>EUCTR2005-005745-18-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial. - Levamisol Trial</Public_title>
    <Scientific_title>Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial. - Levamisol Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Emma Children's Hospital-AMC</Primary_sponsor>
    <Date_registration3>20070910</Date_registration3>
    <Date_registration>10/09/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005745-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/10/2007</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Frequently relapsing idiopathic SSNS with or without steroid dependency&lt;br&gt;- Age between 2 and 18 years&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Patient previously treated with Levamisole&lt;br&gt;- Patients unresponsive to Cyclosporine or MMF&lt;br&gt;- Nephrotic Syndrome due to specific kidney disease&lt;br&gt;- Patients presenting with leucopenia, convulsions or with hepatic diseases&lt;br&gt;</Exclusion_Criteria>
    <Condition>Steroid Sensitive Nephrotic Syndrome (SSNS) &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10029172
Term: Nephrotic syndrome with unspecified pathological lesion in kidney
</Condition>
    <Intervention>&lt;br&gt;Product Name: Levamisole Hydrochloride&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Levamisole Hydrochloride&lt;br&gt;CAS Number: 14769734&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the efficacy of one year of alternate days Levamisole treatment in a dose of 2.5mg/kg in the prevention of relpases and prolonging the time to relapse after cessation of corticosteroids treatment in children with SNSS;Secondary Objective: - Evaluation whether the effect of Levamisole varies with disease status&lt;br&gt;- Evaluation whether the effect of Levamisole varies with prior treatment with Cyclosphosphamide.&lt;br&gt;- Assessment of steroid sparing effect of Levamisole treatment as well as the sparing effect of other immunosuppressive drugs&lt;br&gt;- Determination whether the effectiveness of Levamisole remains constant or wanes over time&lt;br&gt;- Assessment of pharmacokinetics of Levamisole in the target population&lt;br&gt;- Assessment of the safety of treatment with Levamisole;Primary end point(s): Time to relapse</Primary_outcome>
    <Secondary_ID>EUDRACT 2005-005745-18</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2466449</Internal_Number>
    <TrialID>EUCTR2007-004403-34-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Eficacia y seguridad del telmisartan en pacientes hipertensos con insuficiencia renal crónica en hemodiálisis</Public_title>
    <Scientific_title>Eficacia y seguridad del telmisartan en pacientes hipertensos con insuficiencia renal crónica en hemodiálisis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Fundació Puigvert</Primary_sponsor>
    <Date_registration3>20071204</Date_registration3>
    <Date_registration>04/12/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004403-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/04/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Pacientes de ambos sexos con edad &gt; de 18 años con insuficiencia renal en programa de hemodiálisis crónica (más de 6 meses) en nuestro centro.&lt;br&gt;- Pacientes diagnosticados de HTA no controlada entendida como cifras de PA sistólica = 130 mmHg y/o PA diastólica = 80 mmHg medida con aparato automático de PA homologado y calibrado a las 24 horas de la sesión de hemodiálisis según las recomendaciones de la Sociedad Española de HTA (21) y habiendo previamente asegurado que se encuentra en su peso seco. Se realizaran tres medidas de PA a intervalos de 1 minuto y se calculará la media.&lt;br&gt;- Presencia de una MAPA de 48 horas patológica en la visita basal. Definido MAPA patológica según los criterios de la Sociedad Europea de HTA: media diurna (actividad) de la PA sistólica/PA diastólica &gt; de 135/85 mmHg o la media nocturna (ciclo de descanso) &gt; de 120/70 mmHg.&lt;br&gt;- El sujeto comprende y acepta los procedimientos del ensayo y otorga por escrito su consentimiento informado.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Hipervolemia definida como presencia de edemas maleolares o insuficiencia cardiaca.&lt;br&gt;- Pacientes con patología terminal y pronóstico de vida inferior a un año.&lt;br&gt;- Historia clínica con alergia o intolerancia confirmada o probable a alguno de los principios activos usados en el estudio.&lt;br&gt;- Embarazo o periodo de lactancia&lt;br&gt;- Trastornos obstructivos biliares o insuficiencia hepática grave&lt;br&gt;- Historia de incumplimiento de tratamiento médico o no disposición a cumplir con el protocolo del estudio.&lt;br&gt;- Consumidores de alcohol o drogas.&lt;br&gt;- HTA severa (grado 3 según criterios de la Sociedad Europea de HTA, PA sistólica = 180 mmHg y/o PA diastólica = 110 mmHg)&lt;br&gt;- Tratamiento con un ARA-II en los 15 días previos del inicio del estudio.&lt;br&gt;-Cualquier enfermedad o alteración analítica que a criterio del investigador contraindique la participación del paciente en el estudio.&lt;br&gt;-Pacientes que hayan participado en otro ensayo clínico, o donado sangre durante los 3 meses anteriores al inicio del presente estudio. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes con insuficiencia renal crónica en programa de hemodiálisis</Condition>
    <Intervention>&lt;br&gt;Trade Name: Micardis&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Telmisartan&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40 o 80-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar la eficacia del telmisartan en el control de la PA en pacientes con insuficiencia renal en programa crónico de hemodiálisis a través de la reducción de la PA sistólica y diastólica medida por MAPA a las 16 semanas comparando respecto al basal.;Secondary Objective: Evaluar la eficacia del telmisartan en la reducción de la PA medida mediante esfingomanometría&lt;br&gt;&lt;br&gt;Evaluar el % de pacientes que responden y/o normalizan la PA&lt;br&gt;&lt;br&gt;Evaluar la eficacia del telmisartan en el control de la PA media durante el periodo de día-actividad y la PA media durante el periodo de noche-descanso.&lt;br&gt;&lt;br&gt;Evaluar la seguridad del telmisartan en esta población de pacientes.&lt;br&gt;;Primary end point(s): El criterio de valoración principal de este estudio es la reducción de la PA sistólica y diastólica medida por MAPA a las 16 semanas comparando respecto a visita basal.</Primary_outcome>
    <Secondary_ID>FP 2007/01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2466454</Internal_Number>
    <TrialID>EUCTR2007-004284-21-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A prospective randomized study of antibiotic prophylaxis for renal transplantation: short term vs standard treatment - ND</Public_title>
    <Scientific_title>A prospective randomized study of antibiotic prophylaxis for renal transplantation: short term vs standard treatment - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI</Primary_sponsor>
    <Date_registration3>20080104</Date_registration3>
    <Date_registration>04/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004284-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>06/07/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;renal transplantation - age 18-65 years&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;increased risk for infections for diabetes, BMI &gt;30Kg/m2,WBC &lt; 3500, age&gt;65 years and &lt;18years&lt;br&gt;</Exclusion_Criteria>
    <Condition>antibiotic prophylaxis for renal tranplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CEFAZOLINA TEVA&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Cefazolin&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Superiority of single dose - same incidence of infectious complications;Secondary Objective: Incidence of infections - use of antibiotics (dose and days of treatment) - mean hospitalization;Primary end point(s): low incidence of infections - low toxicity - low costs</Primary_outcome>
    <Secondary_ID>987</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2466840</Internal_Number>
    <TrialID>EUCTR2008-000102-36-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Immunosoppressive protocol based on everolimus and calcineurin inhibitor low doses in lung transplant recipients with moderate-severe kidney disease after standard immnuotherapy. - ND</Public_title>
    <Scientific_title>Immunosoppressive protocol based on everolimus and calcineurin inhibitor low doses in lung transplant recipients with moderate-severe kidney disease after standard immnuotherapy. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>OSPEDALE POLICLINICO S. MATTEO</Primary_sponsor>
    <Date_registration3>20080220</Date_registration3>
    <Date_registration>20/02/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000102-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/02/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;eta' &gt; 18 anni Maschi o femmine seguiti in follow-up presso il nostro centro in regime ambulatoriale, trapianto, di polmone singolo o doppio o cuore polmone, da almeno 6 mesi alla data di inclusione nello studio, valori di creatinina persistentemente (per la durata del periodo di screening) &gt;/= a 1.50 mg/dl, quadro istologico di nefrotossicita' cronica da ciclosporina &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Saranno esclusi pazienti con, ad esame istologico, presenza di nefropatia primitiva o secondaria (ad es. nefrite interstiziale, glomerulosclerosi diabetica, glomerulosclerosi ipertensiva con ialinosi arteriolare intimale), riscontro di proteinuria significativa &gt; di 0.6 gr/24 ore, riceventi di trapianto renale, riceventi di trapianto polmonare (polmone singolo o doppio, o cuore polmone) da meno di 6 mesi all’atto del reclutamento, portatori nel post-trapianto di una patologia neoplastica sia cutanea che viscerale o ematologica, con significativo grado di compromissione tossica midollare (&gt;/= a 2: secondo i criteri del NCI corrispondenti ad una conta nel sangue periferico di neutrofili &lt;/= 1500/mcl e/o di piastrine &lt;/= 75.000 /mcl), con evidenza di infezione o colonizzazione cronica delle vie aeree o dei seni paranasali da parte di batteri multireristenti o funghi, con infezione cronica da Virus epatite B o C, con persistente incremento di EBVDNA-emia &gt; 5000 gEq/100.000 cellule mononucleate controllate a tempo -3 e 0, con un declino funzionale del graft tale da configurare una diagnosi di rigetto cronico (sindrome da bronchiolite obliterante) di grado &gt;2 (sulla base delle recenti linee guida ISHLT), con stenosi significative a livello delle anastomosi bronchiali complicate da evidenza di cronica colonizzazione batterica o fungina, gia' inclusi in altri protocolli di trattamento sperimentali, con nota ipersensibilita' o che abbiano presentato reazioni avverse con tacrolimus o everolimus. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney disease after pulmonary transplant &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038474
Term: Renal insufficiency
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CERTICAN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: to obtain a significative reduction of slope of curve after one year of treatment;Secondary Objective: to evaluate graft immunological and infective complications;Primary end point(s): significative reduction of slope of curve after one year of treatment.</Primary_outcome>
    <Secondary_ID>Everopolm</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467207</Internal_Number>
    <TrialID>EUCTR2007-004014-13-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude française, randomisée, controlée, parallèle, en ouvert, multicentrique, comparant le maintien du taux d’hémoglobine avec une administration mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) versus epoetin beta ou darbepoetin alfa chez des patients insuffisants rénaux chroniques hémodialysés. - HELYS</Public_title>
    <Scientific_title>Etude française, randomisée, controlée, parallèle, en ouvert, multicentrique, comparant le maintien du taux d’hémoglobine avec une administration mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) versus epoetin beta ou darbepoetin alfa chez des patients insuffisants rénaux chroniques hémodialysés. - HELYS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>ROCHE</Primary_sponsor>
    <Date_registration3>20080401</Date_registration3>
    <Date_registration>01/04/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004014-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/05/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Patient ayant délivré un consentement de participation écrit&lt;br&gt;• Patient adulte âgé de plus de 18 ans&lt;br&gt;• Patient atteint d’une insuffisance rénale chronique associée à une anémie, hémodialysé régulièrement avec la même technique de dialyse et à la même fréquence (3 fois par semaine) depuis au moins 12 semaines&lt;br&gt;• Patient ayant un Kt/V = 1.2 (ou URR = 70%)&lt;br&gt;• Patient ayant un taux moyen d’hémoglobine (Hb) compris entre [10 ; 12] g/dL sur les 3 valeurs de la période de baseline (semaines -4, -2 et J0)&lt;br&gt;• Patient ayant un traitement de maintenance continu en sous-cutané ou en intraveineux par epoetin beta, une, deux ou trois fois, par semaine, ou par darbepoetin alfa, une fois par semaine ou une fois toutes les deux semaines, avec la même fréquence d’administration et sans modification de la dose totale hebdomadaire dans les 4 semaines avant et pendant la période de baseline.&lt;br&gt;• Patient ayant un statut martial adéquat : ferritine sérique &gt; 100 ng/mL et TSAT &gt; 20% (ou pourcentage de globules rouges hypochromes &lt; 10%)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Patient présentant un saignement aigu ou chronique significatif, comme un saignement d’origine gastro-intestinale&lt;br&gt;• Patient recevant une ou plusieures transfusion de culots globulaires dans les 8 semaines précédant la période de baseline&lt;br&gt;• Patient ayant une dose hebdomadaire d’epoetin beta &gt; 16000 UI ou une dose hebdomadaire de darbepoetin alfa &gt; 80 µg dans les 4 semaines avant et pendant la période de baseline (soit 8 semaines avant l’inclusion)&lt;br&gt;• Patient présentant un greffon allogénique en place&lt;br&gt;• Patient présentant une hémoglobinopathie (anémie falciforme homozygote, thalassémie de tous types)&lt;br&gt;• Patient présentant une hémolyse&lt;br&gt;• Patient présentant une maladie maligne active dans les 5 dernières années (excepté les cancers cutanés hors mélanomes) &lt;br&gt;• Patient ayant un déficit connu en Vitamine B12&lt;br&gt;• Patient ayant un déficit connu en acide folique&lt;br&gt;• Patient ayant une hyperparathyroïdie secondaire on controlée ou symptomatique&lt;br&gt;• Patient présentant une hypertension artérielle mal contrôlée, c’est-à-dire une pression artérielle assise &gt; 170/100 mmHg et nécessitant une interruption de traitement par epoetin beta/darbepoetin alfa dans les 6 mois précédant la période de baseline&lt;br&gt;• Patient présentant une crise d’épilepsie dans les 6 mois précédant la période de baseline&lt;br&gt;• Patient présentant un infarctus du myocarde, un accident vasculaire cérébral, une coronaropathie sévère ou instable, une maladie hépatique sévère dans les 12 semaines précédant la période de baseline&lt;br&gt;• Patient présentant une insuffisance cardiaque congestive (stade III-IV de la New York Heart Association)&lt;br&gt;• Patient présentant un nombre de plaquettes &gt; 500 x 10.9/L ou &lt; 100 x 10.9/L&lt;br&gt;• Patient présentant une érythroblastopénie&lt;br&gt;• Patient ayant une chirurgie planifiée pendant la durée de l’étude excepté pour la cataracte et pour la voie d’abord vasculaire&lt;br&gt;• Femme enceinte ou allaitant&lt;br&gt;• Femme en période d’activité génitale sans contraception efficace&lt;br&gt;• Patient participant ou ayant participé à un essai clinique dans les 3 derniers mois&lt;br&gt;• Patient présentant une hypersensibilité connue à une érythropoïétine recombinante, au polyethylène glycol ou tout autre constituant du traitement à l’étude&lt;br&gt;•Patient ayant un catheter de dialyse temporaire non tunnélisé&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients insuffisants rénaux chroniques hémodialysés &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10054353
Term: Chronic renal failure anemia
</Condition>
    <Intervention>&lt;br&gt;Product Code: RO503821/F03&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F04&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F05&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F21&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F06&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F07&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F08&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: NeoRecormon&lt;br&gt;Product Code: RO2053859&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Epoet</Intervention>
    <Primary_outcome>Main Objective: Comparer le maintien du taux d'hémoglobine avec une administration mensuelle sous-cutanée ou intraveineuse de C.E.R.A. versus l'administration sous-cutanée ou intra-veineuse d'epoetin beta ou de darbepoetin alfa chez des patients insuffisants rénaux chroniques hémodialysés;Secondary Objective: * Evaluer la variabilité de l’hémoglobine avec une administration mensuelle sous cutanée ou intraveineuse de C.E.R.A. dans cette population de patients.&lt;br&gt;* Evaluer la tolérance avec une administration mensuelle sous-cutanée ou intraveineuse de C.E.R.A. dans cette population de patients.&lt;br&gt;;Primary end point(s): Proportion de patients maintenant un taux d’hémoglobine moyen dans l’intervalle [10 ; 12] g/dL pendant la période d’évaluation (S16 à S24)&lt;br&gt;</Primary_outcome>
    <Secondary_ID>ML21145</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467343</Internal_Number>
    <TrialID>EUCTR2008-000948-13-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude de phase II, multicentrique, en ouvert, évaluant l'efficacité d'un traitement par Sutent (sunitinib) chez des patients porteurs de métastases cérébrales d'origine rénale non traitées antérieurement ou en reprise évolutive après radiothérapie ou chirurgie
 - Sutent Métastases cérébrales</Public_title>
    <Scientific_title>Etude de phase II, multicentrique, en ouvert, évaluant l'efficacité d'un traitement par Sutent (sunitinib) chez des patients porteurs de métastases cérébrales d'origine rénale non traitées antérieurement ou en reprise évolutive après radiothérapie ou chirurgie
 - Sutent Métastases cérébrales                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Institut Claudius Regaud</Primary_sponsor>
    <Date_registration3>20080414</Date_registration3>
    <Date_registration>14/04/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000948-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/07/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-               Homme ou femme âgé(e) de 18 ans ou plus.&lt;br&gt;&lt;br&gt;-	Patient porteur d’un adénocarcinome du rein métastatique de toute forme histologique. Preuve cytologique ou histologique, avec grade de Fürhman, obligatoire.&lt;br&gt;	Strate 1 : présence de métastases cérébrales non traitées, non symptomatiques ou avec symptomatologie contrôlée (non évolutive depuis au moins 2 semaines sous traitement) ;&lt;br&gt;                Strate 2 : présence de métastases cérébrales en reprise évolutive après radiothérapie ou chirurgie (récidive sur le site du traitement).&lt;br&gt;&lt;br&gt;-	Patient non traité par sunitinib. Les patients antérieurement traités par sunitinib peuvent être inclus si un intervalle libre d’au moins 6 mois entre la fin du traitement et l’inclusion est respecté.&lt;br&gt;&lt;br&gt;-	PS ECOG. £ 2 (échelle OMS), sauf si parésie liée à métastase cérébrale.&lt;br&gt;&lt;br&gt;-	Maladie mesurable selon les critères RECIST (au moins une lésion mesurable).&lt;br&gt;&lt;br&gt;-	Patient présentant, dans les 7 jours précédant l’inclusion, des constantes hématologiques, paramètres fonctionnels rénaux et hépatiques tels que les numérations sanguines ou taux sériques, conformes aux valeurs suivantes :&lt;br&gt;•	Hémoglobine &gt; 8 g/dL,&lt;br&gt;•	Polynucléaires neutrophiles &gt; 1,5 G/L,&lt;br&gt;•	Plaquettes &gt; 100 G/L,&lt;br&gt;•	Créatinine sérique &lt; 200 µmol/L,&lt;br&gt;•	Bilirubine totale &lt; 1,5 fois la LSN,&lt;br&gt;•	ALAT et ASAT &lt; 2,5 fois la LSN ou &lt; 5 fois la LSN pour les patients avec métastases hépatiques,&lt;br&gt;•	TP ou INR &lt; 1,5 fois la limite supérieure à la normale en l’absence de traitement anticoagulant.(Les patients sous traitement anticoagulant à titre préventif peuvent être inclus)&lt;br&gt;&lt;br&gt;-	Homme et femme en âge de procréer utilisant une méthode de contraception efficace avant d’entrer dans l’étude et ce jusqu’à 30 jours après l’administration du dernier traitement à l’essai.&lt;br&gt;&lt;br&gt;-	Patient affilié à un régime de sécurité sociale.&lt;br&gt;&lt;br&gt;-	Patient capable de comprendre, de lire et d’écrire le français.&lt;br&gt;&lt;br&gt;-	Patient ayant daté et signé un consentement éclairé.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-               Métastase cérébrale révélée par une hémorragie.&lt;br&gt;&lt;br&gt;-	Présence d’une métastase cérébrale unique &lt; 2 cm, accessible à une prise en charge chirurgicale ou par radio-chirurgie.&lt;br&gt;&lt;br&gt;-	Patient présentant des antécédents d’autre cancer hormis un cancer in situ du col utérin, ou un carcinome cutané basocellulaire traité de manière curative, ou tout autre cancer traité de manière curative et sans signe de récidive pendant au moins 5 ans.&lt;br&gt;&lt;br&gt;-	Traitement antinéoplasique antérieur dont l’intervalle libre entre la fin du traitement et l’inclusion est inférieur à 6 mois pour le sunitinib et 4 semaines pour les autres traitements.&lt;br&gt;&lt;br&gt;-	Administration de facteurs de croissance hématopoïétiques (G-CSF, GM-CSF) dans les 3 semaines précédant l’inclusion.&lt;br&gt;&lt;br&gt;-	HTA non contrôlée par un traitement adapté (PAsystolique = 160 mm Hg et/ou PAdiastolique = 90 mm Hg).[La méthode recommandée pour la mesure de la pression artérielle est la mesure par la méthode auscultatoire, au moyen d'un sphygmomanomètre à mercure, le patient étant depuis plusieurs minutes en position assise ou couchée. La mesure devra être systématiquement répétée au minimum 2 fois]&lt;br&gt;&lt;br&gt;-	Affection cardiovasculaire significative (insuffisance cardiaque congestive &gt; classe 2 de la NYHA, IDM dans les 6 mois précédant l’inclusion, angor instable, troubles du rythme graves, AVC dans les 6 mois précédant l’inclusion, antécédents thromboemboliques sévères dans les 6 mois précédant l’inclusion).&lt;br&gt;&lt;br&gt;-	Patient traité par anti-vitamine K à doses curatives ou par anti-aggrégant.&lt;br&gt;&lt;br&gt;-	Patient porteur d'une maladie neuropsychiatrique grave.&lt;br&gt;&lt;br&gt;-	Femme enceinte ou allaitante (test de grossesse sérique ou urinaire &lt;br&gt;négatif au moment de l'entrée dans l'étude pour toutes les femmes en âge de procréer).&lt;br&gt;&lt;br&gt;-	Patient privé de liberté par décision de justice ou administrative.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients porteurs de métastases cérébrales d'origine rénale non traitées antérieurement ou en reprise évolutive après radiothérapie ou chirurgie &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10028979
Term: Neoplasia renal
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent 12.5mg gélules&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 25-50&lt;br&gt;&lt;br&gt;Trade Name: Sutent 25mg gélules&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 25-50&lt;br&gt;&lt;br&gt;Trade Name: Sutent 50mg gélules&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib malate&lt;br&gt;CAS Number: 341031-54-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Déterminer dans chacune des strates de l’étude l’efficacité du sunitinib dans le traitement des métastases cérébrales du cancer du rein en estimant le taux de réponses objectives sur l’encéphale après 2 cycles de traitement, réponse évaluée par IRM et définie selon les critères RECIST.;Secondary Objective: Evaluer dans les 2 strates : &lt;br&gt;§	la durée de la réponse&lt;br&gt;§	la réponse objective sur les cibles hors SNC&lt;br&gt;§	le temps jusqu’à progression de la maladie&lt;br&gt;§	la survie sans progression &lt;br&gt;§	la survie globale &lt;br&gt;§	l’évolution des symptômes neurologiques liés à la tumeur&lt;br&gt;§	la faisabilité et la tolérance globale du traitement ;Primary end point(s): Déterminer dans chacune des strates de l’étude l’efficacité du sunitinib dans le traitement des métastases cérébrales du cancer du rein en estimant le taux de réponses objectives sur l’encéphale après 2 cycles de traitement, réponse évaluée par IRM et définie selon les critères RECIST (comité centralisé de relecture des IRM).</Primary_outcome>
    <Secondary_ID>07URO02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467479</Internal_Number>
    <TrialID>EUCTR2007-005844-26-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function, patient and graft survival, and cardiovascular surrogate markers during the first five years after transplantation. - Cistcert</Public_title>
    <Scientific_title>Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function, patient and graft survival, and cardiovascular surrogate markers during the first five years after transplantation. - Cistcert                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Antwerp University Hospital</Primary_sponsor>
    <Date_registration3>20080425</Date_registration3>
    <Date_registration>25/04/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005844-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/06/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;?	Male or female recipients of a de novo kidney transplant, aged above 18 yrs.&lt;br&gt;?	Women of childbearing potential must have a negative serum or urine pregnancy test with sensitivity equal to at least 50 mIU/ml.&lt;br&gt;?	Patients must be capable of understanding the purpose and risks of the study, and must sign an informed consent form&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;?	Multiple organ transplantation (e.g. Kidney-pancreas, kidney-heart, kidney-liver,…)&lt;br&gt;?	Transplantation of a patient who got another organ transplant previously&lt;br&gt;?	Recipients of a HLA-identical living-related renal transplant&lt;br&gt;?	Patients with PRA &gt; 30%, patients who have lost a first graft from rejection within two years after transplantation, and African European patients.&lt;br&gt;?	Patients with primary renal disease at risk for recurrence: FSGS, MPGN, HUS&lt;br&gt;?	Pregnant or lactating women&lt;br&gt;?	WBC &lt; 2.5 x 109/l (IU), platelet count &lt; 100 x 109/l (IU), or Hb &lt; 6 g/dl at the time of entry into the study&lt;br&gt;?	Active peptic ulcer&lt;br&gt;?	Severe diarrhea or other gastrointestinal disorder, which might interfere with their ability to absorb oral medication, including diabetic patients with previously diagnosed diabetic gastroenteropathy&lt;br&gt;?	Known HIV-1 or HTLV-1 positive tests&lt;br&gt;?	The use of investigational drugs or other immunosuppressive drugs, as those specified in this protocol&lt;br&gt;?	Patients receiving bile acid sequestrants&lt;br&gt;?	Psychological illness or condition, interfering with the patient’s compliance or ability to understand the requirements of the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Preservation of renal function after kidney transplantation in a 5-year, multicentre, prospective, randomized, open-label, controlled study

Patients will be randomized within 24 hours prior to transplantation.

?	Group 1: Simulect + Neoral + Myfortic + steroid stop at 3 months

?	Group 2: Simulect + Neoral (decrease dose in one week at mo 3 and replace by Certican) + Myfortic + steroid maintenance.  



</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican 0.25 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;CAS Number: 159351696&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0.50 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;CAS Number: 159351696&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.50-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0.75 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;CAS Number: 159351696&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess if superior graft function (GFR difference of 10 ml/min) will be achieved at 1 year after transplantation in cohorts of de novo kidney transplant patients treated with Myfortic-Certican plus steroids compared to Myfortic-Neoral.   ;Secondary Objective: 1.	Efficacy variables:&lt;br&gt;To compare the evolution of graft function during the first 5 years post transplantation.&lt;br&gt;To compare the evolution of intragraft lesions (subclinical rejections, fibrosis, vasculopathy, and glomerular lesions) in protocol biopsies at baseline, and at one year.&lt;br&gt;To compare the number and severity of BPAR.&lt;br&gt;To compare patient and graft survival. &lt;br&gt;&lt;br&gt;2.	Safety variables:&lt;br&gt;To compare the incidence of malignancy.&lt;br&gt;To compare the incidence of MACES.&lt;br&gt;To compare the progression of atherosclerosis by means of exploration of carotid artery with doppler echography (thickness of intima/media, IMT).&lt;br&gt;To compare the evolution of left ventricular mass by echocardiography.&lt;br&gt;To compare the development of proteinuria.&lt;br&gt;To compare the safety profile by assessing the incidence of hypertension, hyperlipidemia, diabetes mellitus, infections and bone marrow toxicity. &lt;br&gt;;Primary end point(s): graft function (GFR measured by 51 CrEDTA clearance) at 1 year </Primary_outcome>
    <Secondary_ID>Cistcert</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467736</Internal_Number>
    <TrialID>EUCTR2007-001503-38-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>effect of everolimus on adult polycystic nephropaty; a study pilot - PolEver</Public_title>
    <Scientific_title>effect of everolimus on adult polycystic nephropaty; a study pilot - PolEver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA PROVINCIALE DI LECCO</Primary_sponsor>
    <Date_registration3>20080603</Date_registration3>
    <Date_registration>03/06/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001503-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/06/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;male and female ADPKD mayor 18 , estimated GFR between 30 and 60 mil/min/1.73 mq, almost 1 creatinine value/year in the previous 2 years, progressive renal insufficiency&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;female of childbearing potential who is planning to become pregnant. granulocytopenia or thrombocytopenia,hyperlipidemia&lt;br&gt;</Exclusion_Criteria>
    <Condition>Autosomal Dominant Plycystic Kidney Disease &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10010607
Term: Congenital renal cyst
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CERTICAN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .75-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: the aim of the study is to investigate wheter everolimus ratards cyst growth and slow renal funcional deterioration in patients with ADPKD;Secondary Objective: a positiv influence of everolimus on ADPKD in adults;Primary end point(s): glomerular filtration rate at any visit</Primary_outcome>
    <Secondary_ID>PolEver</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2467754</Internal_Number>
    <TrialID>EUCTR2006-001787-23-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 12-week, open label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis</Public_title>
    <Scientific_title>A 12-week, open label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20080606</Date_registration3>
    <Date_registration>06/06/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001787-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/08/2008</Date_enrollement>
    <Target_size>378</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Stratified per serum phosphorus levels (&lt;or&gt;= to 75.mg/dL)&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients must give written informed consent before any assessment is performed.&lt;br&gt;2. Men or women of at least 18 years old.&lt;br&gt;3. Patient must be treated with a stable maintenance hemodialysis (i.e. no change in dialysis material and parameters) 3 times per week for &gt; 3 months before screening and planned to be maintained the same throughout the study duration.&lt;br&gt;4. Patient must be on restricted phosphate diet at screening and throughout the study.&lt;br&gt;5. Patient has a controlled serum phosphate &gt; 3.0 mg/dL (&gt; 0.97 mmol/L) and &lt; 6.0 mg/dL (&lt; 1.9 mmol/L), as indicated by the average of the 2 latest pre-dialysis laboratory values reported prior to screening, if currently under phosphate binder therapy.&lt;br&gt;6. Patient has a serum phosphate level &gt; 6.0 mg/dL (&gt; 1.9 mmol/L), obtained from central laboratory, prior to study treatment initiation.&lt;br&gt;7. Patient must have a Urea Reduction Ratio of &gt; 65% (obtained within 2 weeks prior to screening).&lt;br&gt;8. If patient has a history of parathyroidectomy, iPTH and calcium-phosphate product levels should be stable within 30 days prior to screening.&lt;br&gt;9. Patient must be on a stable phosphate binder dose (i.e. No change in prescribed dose) for at least 30 days prior to screening, or is newly diagnosed with hyperphosphatemia and has not initiated treatment with phosphate binder yet.&lt;br&gt;10. Patient must, in the investigator’s opinion, be compliant with prescribed phosphate binders.&lt;br&gt;11. If patient is currently being treated with calcimimetics, the prescribed dose must be constant for at least 30 days prior to screening and should remain constant during the total core study duration.&lt;br&gt;12. If patient is currently being treated with vitamin D, the prescribed dose must be constant for at least 30 days prior to screening and should remain constant during the total core study duration.&lt;br&gt;13. If patient is currently being treated with IV iron, the prescribed dose must be constant for at least 30 days prior to screening and should remain constant during the total core study duration.&lt;br&gt;14. If patient is currently being treated for osteoporosis, the prescribed dose must be constant for at least 30 days prior to screening and during the total core study duration.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patient is on peritoneal dialysis or a non-conventional hemodialysis technique (e.g.&lt;br&gt;hemofiltration, hemodiafiltration)&lt;br&gt;2. Patient has a parathyroidectomy or transplant scheduled during the study.&lt;br&gt;3. Patient has an uncontrolled hyperparathyroidism (i.e. intact PTH &gt; 800 pg/mL within 30 days prior to study screening)&lt;br&gt;4. Patient has a history of hemochromatosis or ferritin &gt; 800 µg/L.&lt;br&gt;5. Patient has a clinically significant GI disorder (i.e. swallowing disorder, active dysphagia, bowel obstruction, severe GI motility disorder)&lt;br&gt;6. Patient has a chronic unstable GI disorder (e.g. Irritable Bowel Syndrome, Inflammatory Bowel Disease, chronic abdominal pain, chronic diarrhea)&lt;br&gt;7. Patient has an history of major gastrointestinal tract surgery such as gastrectomy,&lt;br&gt;gastroenterostomy, or bowel resection.&lt;br&gt;8. Patient has a clinically significant unstable medical condition (e.g. uncontrolled diabetes, etc.), other than Chronic Kidney Disease.&lt;br&gt;9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.&lt;br&gt;10. Patient is known to currently have a drug or alcohol abuse problem.&lt;br&gt;11. Patient has a known history of immunodeficiency disease, e.g. existing positive HIV (ELISA or Western blot) test result.&lt;br&gt;12. Patient is / has been treated with sevelamer HCl monotherapy or SBR759 within 3 months prior to screening.&lt;br&gt;13. History of intolerance to sevelamer HCl.&lt;br&gt;14. Patient is currently being treated with oral iron.&lt;br&gt;15. Patient currently has an active infection or is being treated with antibiotics (within 14 days prior to screening).&lt;br&gt;16. Patient currently has an active antiviral treatment for Hepatitis B and/or C (within 30 days prior to screening).&lt;br&gt;17. Patient is currently being treated with anti-seizure medications for the control of a seizure disorder (i.e. phenobarbital, valproate, carbamazepine)&lt;br&gt;18. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of enrollment, whichever is longer&lt;br&gt;19. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes&lt;br&gt;20. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation&lt;br&gt;21. Women of child-bearing potential, defined as all women physiologically capable of&lt;br&gt;becoming pregnant. UNLESS they are using a highly effective method of birth control&lt;br&gt;(i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some&lt;br&gt;intrauterine devices (IUDs). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) are not acceptable.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in patients with Chronic Kidney Disease (CKD) on hemodialysis &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020712
Term: Hyperphosphatemia
</Condition>
    <Intervention>&lt;br&gt;Product Name: SBR759 &lt;br&gt;Product Code: SBR759&lt;br&gt;Pharmaceutical Form: Powder for oral suspension&lt;br&gt;INN or Proposed INN: not yet established&lt;br&gt;Current Sponsor code: SBR759-NXA 001&lt;br&gt;Other descriptive name: Fe(OH)+ Starch + saccharose complex&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000 mg -&lt;br&gt;&lt;br&gt;Product Name: SBR759 &lt;br&gt;Product Code: SBR759&lt;br&gt;Pharmaceutical Form: Powder for oral suspension&lt;br&gt;INN or Proposed INN: not yet established&lt;br&gt;Current Sponsor code: SBR759-NXA 001&lt;br&gt;Other descriptive name: Fe(OH)+ Starch + saccharose complex&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1500 mg-&lt;br&gt;&lt;br&gt;Trade Name: Renagel &lt;br&gt;Product Name: RENAGEL&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: sevelamer hydrochloride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800mg-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: This study is designed to demonstrate superior or at least non-inferior&lt;br&gt;efficacy of SBR759 in phoshate binding,  versus sevelamer HCl and evaluate safety over a long term exposure. Efficacy will be measured by the number of patients with a serum phosphate level below or equal to 5.5 mg/dl (i.e. 1.78 mmol/L) at 12 weeks;Primary end point(s): To demonstrate superior efficacy or at least non-inferiority of SBR759 compared to sevelamer HCl, as measured by the number of patients with a serum phosphate level below or equal to 5.5 mg/dl (i.e. 1.78 mmol/L) at 12 weeks.;Secondary Objective: To evaluate safety and tolerability of SBR759 compared to sevelamer HCl over a 12-week period.&lt;br&gt;To evaluate whether SBR759 has superior efficacy at week 12 compared to sevelamer HCl, as measured by the number of patients with a serum calcium-phosphate product levels below or equal to 55 mg2/dL2.&lt;br&gt;to evaluate whether SBR759 is associated with less increase in serum iPTH levels compared to sevelamer HCl at 12 weeks&lt;br&gt;to evaluate whether SBR759 has an equivalent rate of hypercalcemia events at 12 weeks compared to sevelamer HCl as measured by serum calcium levels&lt;br&gt;to evaluate changes in patient-reported gasrointestinal symptom burden, using gastrointestinal symptom rating scale (GSRS) total and subscales scores, in patients treated with SBR759 compared to patients treated with sevelamer HCl</Primary_outcome>
    <Secondary_ID>CSBR759A2201</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468037</Internal_Number>
    <TrialID>EUCTR2008-001204-23-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio comparativo de mupirocina versus acido fusidico tópico en la erradicación de portadores nasales de Staphylococcus aureus en pacientes con insuficiencia renal crónica en hemodiálisis por cateter permanente</Public_title>
    <Scientific_title>Estudio comparativo de mupirocina versus acido fusidico tópico en la erradicación de portadores nasales de Staphylococcus aureus en pacientes con insuficiencia renal crónica en hemodiálisis por cateter permanente                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Dra. Beatriz Sanchez Sobrino</Primary_sponsor>
    <Date_registration3>20080702</Date_registration3>
    <Date_registration>02/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001204-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/09/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-El rango de edad estará comprendido entre los 18 y los 80 años. &lt;br&gt;-Insuficiencia renal crónica estadio 5 en programa de hemodiálisis cuyo acceso vascular sea catéter permanente.&lt;br&gt;-Consentimiento informado escrito, conforme a ICH/GCP y a la legislación local, obtenido antes de cualquier procedimiento de estudio.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Rechazo o incapacitación para otorgar el consentimiento informado por escrito.&lt;br&gt;-Embarazo o lactancia en curso.&lt;br&gt;-Alergia conocida a medicamentos del estudio (mupirocina y/ó ácido fusídico).&lt;br&gt;-Pacientes con cualquier valor analítico anormal clínicamente significativo según la opinión del investigador médico en la selección. &lt;br&gt;-Participación en otros ensayos clínicos con fármacos en los 3 meses previos.&lt;br&gt;-Donación de sangre en los tres meses previos al comienzo del estudio.&lt;br&gt;-Incapacidad para cumplir los procedimientos del protocolo.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes con insuficiencia renal crónica estadio 5 en Hemodialisis que se encuentren realizando la técnica mediante un acceso vascular tipo catéter central permanente tunelizado portadores nasales de Pacientes con insuficiencia renal crónica estadio 5 en Hemodialisis que se encuentren realizando la técnica mediante un acceso vascular tipo catéter central permanente tunelizado portadores nasales de Staphylococcus aureus.</Condition>
    <Intervention>&lt;br&gt;Trade Name: FUCIDINE POMADA&lt;br&gt;Product Name: FUCIDINE POMADA&lt;br&gt;Pharmaceutical Form: Ointment&lt;br&gt;INN or Proposed INN: FUSIDICO ACIDO&lt;br&gt;CAS Number: 6990-06-3&lt;br&gt;Other descriptive name: FUSIDIC ACID&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;&lt;br&gt;Trade Name: BACTROBAN NASAL, pomada&lt;br&gt;Product Name: BACTROBAN NASAL, POMADA&lt;br&gt;Pharmaceutical Form: Nasal ointment&lt;br&gt;INN or Proposed INN: MUPIROCINA CALCICA&lt;br&gt;Other descriptive name: MUPIROCIN CALCIUM&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar la eficacia del tratamiento tópico con mupirocina versus acido fusidico en pacientes portadores de S aureus con insuficiencia renal crónica estadio 5 en programa de hemodiálisis cuyo acceso vascular sea catéter permanente;Secondary Objective: -Evaluar la seguridad y tolerabilidad de la administración tópica de los fármacos a estudio.&lt;br&gt;-Conocer la prevalencia de portador nasal de Staphylococcus aureus en el Área a estudio. &lt;br&gt;-Establecer un protocolo de profilaxis de infecciones en los sujetos portadores nasales de Staphylococcus aureus;Primary end point(s): La variable principal de eficacia será la tasa de erradicación a las 48 horas desde la finalización del tratamiento</Primary_outcome>
    <Secondary_ID>MUFU001-SA-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468173</Internal_Number>
    <TrialID>EUCTR2007-003649-34-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>RENAL RESCUE IMMUNOSUPPRESSION FOLLOWING HEART TRANSPLANTATION - RRescue Trial</Public_title>
    <Scientific_title>RENAL RESCUE IMMUNOSUPPRESSION FOLLOWING HEART TRANSPLANTATION - RRescue Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>University Hospital of South Manchester NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20080627</Date_registration3>
    <Date_registration>27/06/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003649-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/08/2008</Date_enrollement>
    <Target_size>56</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Stable patients more than 6 months after heart transplantation, receiving immunosuppression based on cyclosporine or tacrolimus.&lt;br&gt;2.	Moderate renal impairment - serum creatinine 150-220 micro mol/l or GFR (glomerular filtration rate) 30-59, in the 3 months period prior to enrolment in the study.&lt;br&gt;3.	Patients who have given written informed consent to take part in the study.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Acute rejection (grade 3a or above from the ISHLT criteria) requiring treatment in the last 3 months.&lt;br&gt;2.	Alternative causes for renal dysfunction (e.g. renal obstruction, small kidneys or other gross abnormalities).&lt;br&gt;3.	Females of childbearing potential who are planning to become pregnant, who are pregnant who are unwilling to use effective means of contraception. Patients should use a reliable medically approved method of contraception during the trial period. If unwilling or unable to use a medically approved reliable form of contraception then patients should abstain from penetrative sex. &lt;br&gt;It is recommended that MMF or Myfortic therapy should not be initiated until a negative pregnancy test has been obtained. Effective contraception must be used before beginning MMF / Myfortic therapy, during therapy, and for six weeks following discontinuation of therapy. Patients should be instructed to consult their physician immediately should pregnancy occur. &lt;br&gt;The use of MMF / Myfortic is not recommended during pregnancy and should be reserved for cases where no more suitable alternative treatment is available. MMF / Myfortic should be used in pregnant women only if the potential benefit outweighs the potential risk to the foetus. There are no adequate data from the use of MMF / Myfortic in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown. &lt;br&gt;Mycophenolate mofetil has been shown to be excreted in the milk of lactating rats. It is not known whether this substance is excreted in human milk. Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, MMF / Myfortic are contraindicated in nursing mothers.&lt;br&gt;4.	Pre-existing severe cardiac allograft dysfunction (LVEF &lt; 40%).&lt;br&gt;5.	Hb persistently (on 3 consecutive occasions) &lt; 10 g/dl, white cell count persistently (on 3 consecutive occasions) &lt; 4.0 x 109/l.&lt;br&gt;6.	Platelets persistently (on 3 consecutive occasions) &lt; 100 x 109/l&lt;br&gt;7.	Heavy proteinuria without any evidence of urinary infection (&gt;1g/24hrs)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal impairment following heart transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10010184
Term: Complications of transplanted heart
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Mycophenolic acid&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 180-360&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Ciclosporin&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-100&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Ciclosporin&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.5-5&lt;br&gt;&lt;br&gt;Product Name: Azathioprine&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 25-50&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Mycophenolate mofetil&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Cellcept&lt;br&gt;Product Name: Mycophenolate mofetil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Improvement of kidney function 6 months following the introduction of trial medication.&lt;br&gt;;Secondary Objective: •	Efficacy: improvement of renal function at 12 months, treated acute rejection episodes.&lt;br&gt;•	Safety of the trial medications by reduction in adverse events (including infection, haematological and gastrointestinal effects, bleeding, skin rash, pneumonitis, any cause of hospitalization for treatment, death), cardiovascular risk factors, and standard laboratory assessments&lt;br&gt;;Primary end point(s): To show an improvment in renal function at 6 months following the introduction of trial medication ( in the low dose ciclosporin group).</Primary_outcome>
    <Secondary_ID>RRT001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468205</Internal_Number>
    <TrialID>EUCTR2008-000738-39-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>EFFECTS ON INCIDENCE OF CARDIOVASCULAR EVENTS OF THE ADDITION OF PIOGLITAZONE AS COMPARED WITH A SULFONYLUREA IN TYPE 2 DIABETIC PATIENTS INADEQUATELY
CONTROLLED WITH METFORMIN
Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents (TOSCA) - TOSCA Study</Public_title>
    <Scientific_title>EFFECTS ON INCIDENCE OF CARDIOVASCULAR EVENTS OF THE ADDITION OF PIOGLITAZONE AS COMPARED WITH A SULFONYLUREA IN TYPE 2 DIABETIC PATIENTS INADEQUATELY
CONTROLLED WITH METFORMIN
Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents (TOSCA) - TOSCA Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Societa' Italiana di Diabetologia</Primary_sponsor>
    <Date_registration3>20080716</Date_registration3>
    <Date_registration>16/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000738-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>02/03/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-Patients with type 2 diabetes (WHO criteria) of at least 2 years duration&lt;br&gt;-Males and females&lt;br&gt;-Age 50-75 years&lt;br&gt;-BMI 20-40 Kg/m2&lt;br&gt;-Stable treatment for the last three months with metformin in monotherapy&lt;br&gt;-Glycated haemoglobin (HbA1c) &gt;7.0% and &lt;9.0%&lt;br&gt;-Potentially childbearing women must use a reliable contraceptive method&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Type 1 diabetes&lt;br&gt;-Previous or current use of insulin (if not on pregnancy or for surgery or for intercurrent acute illness).&lt;br&gt;-Current use of glucose lowering therapies other than metformin&lt;br&gt;-Contraindication/intolerance to metformin or sulphonylureas or thiazolidinediones&lt;br&gt;-Chronic use of glucocorticoids&lt;br&gt;-Documented coronary or cerebrovascular events in the previous 6 months&lt;br&gt;-Serum creatinine &gt;1.5 mg/dl&lt;br&gt;-Proliferative retinopathy&lt;br&gt;-Ischemic ulcer or gangrene&lt;br&gt;-History of congestive heart failure, NYHA (New York Heart Association ) class I or higher&lt;br&gt;-Liver cirrhosis or severe hepatic dysfunction (2.5 times the upper limit of normal concentration of alanine aminotransferase)&lt;br&gt;-Pregnancy or breast feeding&lt;br&gt;-Cancer, substance abuse, any health problem that may interfere with the compliance to study protocol or limit life expectancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>diabetes mellitus &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10012654
Term: Diabetic complications cardiovascular
 &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10012658
Term: Diabetic complications renal
</Condition>
    <Intervention>&lt;br&gt;Product Name: Pioglitazone&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Pioglitazone&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;&lt;br&gt;Product Name: Glibenclamide&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Glibenclamide&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Product Name: Gliclazide&lt;br&gt;Pharmaceutical Form: Modified-release capsule, hard&lt;br&gt;INN or Proposed INN: Gliclazide&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Product Name: Glimepiride&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Glimepiride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Our aim is to ascertain whether in patients with type 2 diabetes poorly controlled with the maximal tolerated dose of metformin, the addition of pioglitazone reduces the rate of cardiovascular events as compared with the addition of a SU. Glucose control, major CV risk factors, safety, tolerability and economic costs with the two therapeutic regimens will also be compared. Sample size and study power are calculated on the primary efficacy outcome.;Secondary Objective: PRINCIPAL secondary outcome:&lt;br&gt;-	A composite ischemic end point of: sudden death, fatal and non fatal MI (including silent MI), fatal and non fatal stroke, major leg amputation (above the ankle), endovascular or surgical interventions on the coronary, leg or carotid arteries&lt;br&gt;&lt;br&gt;OTHER secondary outcomes:&lt;br&gt;-	a composite cardiovascular endpoint including the primary endpoint plus  heart failure - by the full version of the Boston criteria - endovascular or surgical intervention on the coronary, leg or carotid arteries, angina - by WHO criteria and confirmed by a new electrocardiogram abnormalities - intermittent claudication with an ankle/brachial index &lt; 0.85;&lt;br&gt;-	glycemic control (changes from baseline in HbA1c, time to failure of oral hypoglycaemic therapy, i.e., HBA1c &gt;8.0% on two consecutive occasions three months apart); &lt;br&gt;-	major cardiovascular risk factors (lipids, blood pressure, microalbuminuria, inflammation markers, waist circumference);&lt;br&gt;-	a microvascular composite e;Primary end point(s): A composite endpoint including: all-causes mortality, non fatal myocardial infarction (MI) - including silent MI- , non fatal stroke, unplanned coronary revascularization</Primary_outcome>
    <Secondary_ID>FARM6T9CET</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468332</Internal_Number>
    <TrialID>EUCTR2008-000928-71-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>?TWIST?. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008 - TWIST</Public_title>
    <Scientific_title>?TWIST?. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008 - TWIST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>GRUPPO ONCOLOGICO ITALIANO DI RICERCA</Primary_sponsor>
    <Date_registration3>20080710</Date_registration3>
    <Date_registration>10/07/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000928-71                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>14/11/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Stesso farmaco piu' altro farmaco&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Signed informed consent  Histologically or cytologically documented non-clear Cell Renal Carcinoma (with centralized review of histological specimens). In the case of a mixed histology the presence of a documented component of clear cell histology &lt;50% is mandatory. Urothelial upper urinary tract tumors are excluded.  In cases with initial diagnosis of non-clear RCC of more than 2 years (RFS &gt;2 years) a histological/cytological confirmation of renal cell carcinoma origin of actual metastases is mandatory.  Metastatic measurable disease (at least one uni-dimensional measurable lesion by CT-scan or MRI) according to RECIST criteria (reported in Appendix  Karnofsky performance status (KPS) &amp;#8805; 70 (KPS scale reported in Appendix)  Age &amp;#8805; 18 years§  Life expectancy &amp;#8805; 3 months  Prior Surgery and/or Radiation Therapy (to less or equal than 25% of the bone marrow) are allowed. However, at least 4 weeks must have been elapsed since surgery or completion of radiation therapy and the patient must has recovered from side effects  ANC &amp;#8805;1.5 x 109/L; PLT &amp;#8805;100 x 109/L; Hb &amp;#8805; 9 g/dl  Adequate hepatic function: Total bilirubin &amp;#8804;1.5 times UNL*; ALT and AST &amp;#8804;2.5 times UNL (&amp;#8804;5 UNL in presence of liver metastases)  Serum creatinine &amp;#8804;2.0 x the UNL. Serum cholesterol &amp;#8804;350 mg/dL; serum triglycerides &amp;#8804; 300 mg/dL  Patients must be accessible for treatment and follow up&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;CNS metastases  Previous malignancy except for basal cell skin cancer and cervical carcinoma in situ adequately treated, or any other cancer from which the patient has been disease-free for &gt;=5 years  Any of the concomitant illness or medical condition indicated below: Serious respiratory or cardiovascular disease such as: congestive heart failure (³ NYHA Class II -refer to Appendix-); previous history (within 6 months) of myocardial infarction, angina pectoris or cardiac arrhythmias requiring anti-arrythmics (excluding beta blockers or digoxin). Active coronary artery disease, uncontrolled hypertension  Unstable diabetes mellitus, significant neurological or psychiatric disorders or seizure disorder requiring medication (such as anti-epileptics). Uncontrolled hypertension (systolic pressure ³ 160 mm Hg and/or diastolic ³ 90mm Hg) while receiving chronic medication.  Active clinically serious bacterial or fungal infections (&gt; grade 2 NCI-CTC, Version 3) or active human immunodeficiency virus (HIV) infection or chronic hepatitis B or C  Previous or concomitant treatment with antiangiogenic agents (e.g.: bevacizumab, sorafenib, sunitinib) or m-TOR inhibitors. Previous treatment with chemotherapy, immunotherapy (IFN and/or Interleukin-2) for advanced disease is allowed  Prior isotope treatment (e.g. strontium or samarium)  Participation in clinical trials with other experimental agents within 30 days of study entry or concomitant treatment with other experimental drug  Use of immunosuppressive agents including systemic steroids). History of organ allograft or autologous bone marrow transplant or stem cell rescue within four months of start of study drug  Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial  Known or suspected allergy to the investigational agent or any agent given in association with this trial&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with advanced non-clear Cell Renal Carcinoma. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10038458
Term: Renal granular cell carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10038414
Term: Renal cell carcinoma stage IV
</Condition>
    <Intervention>&lt;br&gt;Trade Name: ROFERON A&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Interferon alfa-2a&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;&lt;br&gt;Product Name: Temsirolimus&lt;br&gt;Product Code: CCI-779&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: temsirolimus&lt;br&gt;CAS Number: 162635-04-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Progression Free Survival (PFS);Secondary Objective: Overall Response Rate (RECIST Criteria); Time to Progression (TTP); Safety; Overall Survival (OS).;Primary end point(s): Progression Free Survival (PFS) rates in the two arms.</Primary_outcome>
    <Secondary_ID>GOIRC02/2008-TWIST</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468370</Internal_Number>
    <TrialID>EUCTR2008-002177-13-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Intérêt de la mesure de l’activité calcineurine dans le suivi thérapeutique du tacrolimus chez des patients transplantés rénaux</Public_title>
    <Scientific_title>Intérêt de la mesure de l’activité calcineurine dans le suivi thérapeutique du tacrolimus chez des patients transplantés rénaux                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)</Primary_sponsor>
    <Date_registration3>20080805</Date_registration3>
    <Date_registration>05/08/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002177-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/10/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Adultes (&gt;= 18 ans) ayant bénéficié d'une transplantation rénale de novo;&lt;br&gt;Patients bénéficiant d'une couverture immunosuppressive principale par tacrolimus associé aux coritcoïdes et au Cellcept avec ou sans induction;&lt;br&gt;Patients affiliés au régime de la sécurité sociale.(bénéficiaire ou ayant droit)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients présentant un risque avéré de non observance (principalement antécédent de toxicomanie, troubles psychiatriques intercurrents, etc.) ;&lt;br&gt;Greffes multiorganes ;&lt;br&gt;Patients bénéficiant d'une couverture immunosuppressive complémentaire par sirolimus -RAPAMUNE  ou everolimus ;&lt;br&gt;Patients infectés par le VIH.&lt;br&gt;Femmes enceintes&lt;br&gt;Femmes  allaitantes&lt;br&gt;Majeurs sous tutelle&lt;br&gt;Refus de consentement&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant &lt;br&gt;MedDRA version: 8.1
Level: PT
Classification code 10038533
Term: Transplantation rénale
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Product Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Advagraf&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Product Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Advagraf&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Product Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Advagraf&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Etudier la relation entre l'activité calcineurine résiduelle et la survenue d'un rejet aigu, chez les transplantés rénaux traités par tacrolimus au cours des 3 premiers mois suivant la transplantation. &lt;br&gt;;Secondary Objective: Déterminer à l'aide d'une courbe ROC, le seuil d'activité le plus performant pour prédire la survenue du rejet;&lt;br&gt;Etudier les variations entre la mesure de l'activité calcineurine dans les PBMC et les concentrations sanguines de tacrolimus; &lt;br&gt;Comparer l'activité calcineurine chez les sujets en rejet aigu et ceux présentant un rejet borderline diagnostiqué sur la PBR systématique à M3. ;Primary end point(s): Evaluation du rejet du greffon rénal se fait grace à la pharmacocinétique, par la mesure d'une part de l'activité calcineurine et d'autre part par le dosage du Tacrolimus dans le sang.</Primary_outcome>
    <Secondary_ID>P071004</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468589</Internal_Number>
    <TrialID>EUCTR2008-002807-21-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>VITA-D: Cholecalciferol substitution in vitamin D deficient kidney transplant recipients: A randomized, placebo-controlled study to evaluate the posttransplant outcome - VITA-D</Public_title>
    <Scientific_title>VITA-D: Cholecalciferol substitution in vitamin D deficient kidney transplant recipients: A randomized, placebo-controlled study to evaluate the posttransplant outcome - VITA-D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>MUW, Universitätsklinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse</Primary_sponsor>
    <Date_registration3>20080904</Date_registration3>
    <Date_registration>04/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002807-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/10/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Age &gt;18&lt;br&gt;Deceased donor kidney transplant recipients &lt;br&gt;Only kidney transplant recipients &lt;br&gt;Vitamin D deficiency defined as 25OHD &lt;50nmol/l &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Re-transplantation for the second time if the patient is highly immunized and therefore included in the apheresis program&lt;br&gt;Re-transplantation for the third time or more often&lt;br&gt;Significant impaired intestinal resorption: malabsorption due to celiac sprue, systemic scleroderma; maldigestion due to chronic pancreatitis, pancreatic insufficiency, pancreas resection, mukoviscidosis,  Zollinger-Ellison-syndrom&lt;br&gt;History of inflammatory bowel disease: Crohn’s disease, Ulcerative Colitis&lt;br&gt;Previouse gastrectomy, small bowel or large bowel resection, intestinal bypass surgery &lt;br&gt;Severe liver disease: cirrhosis &lt;br&gt;HIV positive  (HAART enhances Vitamin D catabolism) &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Vitamin D deficiency in kidney transplant recipients &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10047626
Term: Vitamin D deficiency
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Oleovit D3 Tropfen&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;Pharmaceutical form of the placebo: Oral solution&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1. Does vitamin D3 substitution in vitamin D deficient kidney transplant recipients influence the posttransplant outcome compared to placebo?&lt;br&gt;&lt;br&gt;Hypothesis 1a&lt;br&gt;Vitamin D3 substitution improves graft function compared to placebo analysed by means of serum creatinine within the first year after transplantation. Another surrogate marker used to evaluate the immunomodulatory properties of vitamin D3 is the incidence of acute rejection episodes within the first year after kidney transplantation.&lt;br&gt;&lt;br&gt;Hypothesis 1b&lt;br&gt;Vitamin D3 substitution reduces the frequency and severity (analysed by means of CRP) of posttransplant infections compared to placebo within the first year after kidney transplantation.&lt;br&gt;;Secondary Objective: 2. Does vitamin D3 substitution influence renal osteopathy analysed using absolute bone mineral density?&lt;br&gt;&lt;br&gt;Hypothesis 2&lt;br&gt;Vitamin D3 substitution prevents the usual decline in bone mineral density within the first year after transplantation;Primary end point(s): The immunologic effects of vitamin D3 substitution in vitamin D deficient kidney transplant recipients will be evaluated by means of &lt;br&gt;- serum creatinine levels within the first year after transplantation, &lt;br&gt;- number of acute rejection episodes within the first year after transplantation,&lt;br&gt;- number of infections within the first year after transplantation,&lt;br&gt;- and CRP levels within the first year after transplantation.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>VitaD-1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468591</Internal_Number>
    <TrialID>EUCTR2008-004158-33-BE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>CYP3A4/5 and PGP activity in renal transplantation.

A study assessing in vivo hepatic and intestinal CYP3A4/5 and PGP activity in kidney transplant recipients and its relationship with genetic and non-genetic variables and the pharmacokinetics and metabolism of Tacrolimus.</Public_title>
    <Scientific_title>CYP3A4/5 and PGP activity in renal transplantation.

A study assessing in vivo hepatic and intestinal CYP3A4/5 and PGP activity in kidney transplant recipients and its relationship with genetic and non-genetic variables and the pharmacokinetics and metabolism of Tacrolimus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Department of Nephrology and Renal Transplantation, KU Leuven</Primary_sponsor>
    <Date_registration3>20080909</Date_registration3>
    <Date_registration>09/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004158-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/09/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Chronic stable renal allograft recipients (&gt; 1 year after transplantation) treated with Tacrolimus (Prograft® or Advagraf®).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Age &lt; 18 years. &lt;br&gt;- Females with child bearing potential, not using an acceptable method of birth control. &lt;br&gt;- Nursing and pregnant women. Pregnancy tests will be performed before drug administration.&lt;br&gt;- Known allergy or intolerance to either Erythromycin, Midazolam or Fexofenadine.&lt;br&gt;- Concomitant treatment with opioid- or antipsychotic drugs. &lt;br&gt;- Severe chronic lung disease and chronic respiratory insufficiency. &lt;br&gt;- Chronic heart failure. &lt;br&gt;- Severe liver disease. &lt;br&gt;- Anaemia (haemoglobin &lt; 11 g/dL).&lt;br&gt;- Hypoalbuminemia (&lt; 25 g/L).&lt;br&gt;- Combined organ transplants.&lt;br&gt;- Known non-compliance.&lt;br&gt;- Alcohol intake &gt; 7 units/week.&lt;br&gt;- Smoking.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Effect of genetic (single nucleotide polymorphisms of genes encoding drug metabolising enzymes and drug transporters) and non-genetic factors (e.g. age, time after transplantation, concommitant medication, renal function, liver dysfunction) on in vivo hepatic and intestinal CYP3A4 and 5 and PGP activity in renal allograft recipients. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dormicum 5 mg/5ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: MIDAZOLAM HYDROCHLORIDE&lt;br&gt;CAS Number: 59467968&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Telfast 180 mg&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: FEXOFENADINE HYDROCHLORIDE&lt;br&gt;CAS Number: 8000051492&lt;br&gt;Other descriptive name: FEXOFENADINE HYDROCHLORIDE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To asses in vivo hepatic and intestinal CYP3A4 and 5 and PGP activity in renal allograft recipients.;Secondary Objective: To asses the relationship of in vivo hepatic and intestinal CYP3A4 and 5 and PGP activity in renal allograft recipients with:&lt;br&gt;- the recipients genotype.&lt;br&gt;- potential non-genetic determinants of in vivo CYP3A4 and 5 and PGP activity (e.g. concomittant medication, renal function, liver function, age, gender, .....)&lt;br&gt;- pharmacokinetics and metabolism of immunosuppressive drugs.;Primary end point(s): The effect of genetic and non-genetic factors on the disposition of Midazolam and Fexofenadine, as markers of, respectively,  in vivo CYP3A4/5 and PGP activity in renal allograft recipients.</Primary_outcome>
    <Secondary_ID>CYP3A4/5+PGPinRenalTx</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468776</Internal_Number>
    <TrialID>EUCTR2008-005657-38-IE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Transversus Abdominis Plane Block for Analgesia in Renal Transplantation: A Randomised Controlled Trial</Public_title>
    <Scientific_title>Transversus Abdominis Plane Block for Analgesia in Renal Transplantation: A Randomised Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Royal College of Surgeons Ireland</Primary_sponsor>
    <Date_registration3>20080909</Date_registration3>
    <Date_registration>09/09/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005657-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/11/2008</Date_enrollement>
    <Target_size>62</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: TAP Block with saline&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Renal transplantation surgery&lt;br&gt;Age 18 years or over&lt;br&gt;ASA I-III&lt;br&gt;No allergy to bupivacaine&lt;br&gt;No allergy to morphine&lt;br&gt;Able to use a PCA device&lt;br&gt;Informed consent obtained&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Aged under 18 years&lt;br&gt;ASA IV-V&lt;br&gt;Allergy to bupivavcaine&lt;br&gt;Allergy to morphine&lt;br&gt;Unable to use a PCA device&lt;br&gt;No consent obtained&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Condition to be investigated - Analgesia requirements in patients having renal transplant surgery. 
The study proposes to reduce current requirements for morphine post-operatively by the use of a Tranversus Abdominis Plane (TAP) Block. This is a technique of depositing local anaesthetic (bupivacaine) into the plane between the transversus abdominis and internal oblique muscles of the abdominal wall, thus providing analgesia to the area in which the surgery takes place. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10036276
Term: Postoperative analgesia
</Condition>
    <Intervention>&lt;br&gt;Product Name: bupivacaine&lt;br&gt;Product Code: bupivacaine&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;INN or Proposed INN: BUPIVACAINE HYDROCHLORIDE&lt;br&gt;CAS Number: 18010407&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.25-0.5&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Not mentioned (Noncurrent)&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate, in a renal transplantation population, a reduction in morphine use postoperatively in patients who have received a Transversus Abdominis Plane (TAP) block compared with those who received a placebo block.;Secondary Objective: To measure pain scores at rest and on movement, incidence of post-operative nausea and vomiting, incidence of sedation and incidence of respiratory depression for 24 hrs post-operatively and compare them between the TAP group versus the placebo group.;Primary end point(s): The primary endpoint is total morphine consumption in 24hrs.  We expect the group who receive a TAP block to have a reduction in morphine requirements compared with those who receive a placebo block.</Primary_outcome>
    <Secondary_ID>TAPprotocol12008</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2468831</Internal_Number>
    <TrialID>EUCTR2008-000889-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomised controlled comparison of standard release Tacrolimus vs extended-release Tacrolimus as baseline maintenance monotherapy for kidney transplantation after induction with Campath 1-H. - TAESR</Public_title>
    <Scientific_title>A randomised controlled comparison of standard release Tacrolimus vs extended-release Tacrolimus as baseline maintenance monotherapy for kidney transplantation after induction with Campath 1-H. - TAESR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Imperial College Healthcare NHS Trust</Primary_sponsor>
    <Date_registration3>20081003</Date_registration3>
    <Date_registration>03/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000889-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/11/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Adults undergoing live donor or deceased donor kidney transplantation who are able to give written informed consent to the study.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patients who would not be treated with Campath 1-H under current renal unit protocols:&lt;br&gt;a. Patents with prior exposure to potent anti-proliferative or myelosuppressive agents.&lt;br&gt;b. Patients with previous malignancy.&lt;br&gt;c. Patients with chronic hepatitis B hepatitis C or HIV infection.&lt;br&gt;2. Patients receiving non-heart-beating deceased donor kidney transplants.&lt;br&gt;3. Patients receiving simultaneous kidney/pancreas transplants.&lt;br&gt;4. Patients undergoing desensitization for ABO incompatible or positive cross-match transplantation&lt;br&gt;5. Women of child-bearing age who would not be treated with Alemtuzumab because they are unable or unwilling to use effective contraception during therapy and continue its use for 6 months following the last dose of Alemtuzumab.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prevention of allograft rejection after renal transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023439
Term: Kidney transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;&lt;br&gt;Trade Name: Advagraf&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare outcomes of kidney transplantation after induction with Alemtuzumab/short course steroids, followed by maintenance with either standard release Tacrolimus (Prograf) monotherapy, or extended-release tacrolimus (Advagraf) monotherapy.&lt;br&gt;&lt;br&gt;Primary outcome measures: Survival with a functioning graft at 1 year and 3 years.;Secondary Objective: Secondary outcomes: Rejection rate / Time to achievement of target Tacrolimus levels / Inter-visit variance in Tacrolimus trough level / Lymphocyte subset recovery rates after Campath / Donor-specific ?-IFN producing lymphocyte frequency and phenotype / Functional Calcineurin inhibition levels.;Primary end point(s): Survival with a functioning graft at 1 and 3 years.</Primary_outcome>
    <Secondary_ID>ICKTI08TX01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469007</Internal_Number>
    <TrialID>EUCTR2008-005727-28-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>BK viremi efter njurtransplantation: Screening, tidig diagnostik, tidig reduktion av immunhämning samt behandling med leflunomid (Arava®) - BK Viremia</Public_title>
    <Scientific_title>BK viremi efter njurtransplantation: Screening, tidig diagnostik, tidig reduktion av immunhämning samt behandling med leflunomid (Arava®) - BK Viremia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Karolinska Universitetssjukhuset</Primary_sponsor>
    <Date_registration3>20081021</Date_registration3>
    <Date_registration>21/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005727-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/12/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Recipienter&lt;br&gt;-	Skriftligt informerat samtycke&lt;br&gt;-	Vuxna mottagare av njurtransplantat&lt;br&gt;-	Man eller kvinna =18 år&lt;br&gt;&lt;br&gt;&lt;br&gt;Donatorer (levande eller avlidna donatorer)&lt;br&gt;-	Skriftligt informerat samtycke (från levande donator eller anhörig till avliden donator)&lt;br&gt;-	Njurdonator&lt;br&gt;-	Man eller kvinna =18 år&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Recipienter&lt;br&gt;För screeningfasen: Inga studiespecifika.&lt;br&gt;För behandling med reducerad immunosuppression: Inga studiespecifika. &lt;br&gt;För behandling med leflunomid&lt;br&gt;- Kontraindikationer för leflunomid (Arava?) (enligt produktresumén)&lt;br&gt;- Gravida eller ammande kvinnor&lt;br&gt;Donatorer&lt;br&gt;Inga exklusionskriterier&lt;br&gt;&lt;br&gt;För de recipienter som under studien blir aktuella för Arava-behandling tillkommer följande kriterier för Arava-behandling:&lt;br&gt;-	Kvinnor i fertil ålder måste använda tillförlitlig kontraception under Arava-behandling och under upp till 2 år efter avslutad behandling.&lt;br&gt;-	Män i fertil ålder måste använda tillförlitlig kontraception under behandling med Arava och en viss tid efter behandlingen enligt riktlinjer i produktresumén för Arava.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>BK Virusinfektion vid Njurtransplantation &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10055181
Term: BK virus infection
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Arava 20 mg filmdragerade tabletter&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Leflunomid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Kan leflunomid användas säkert i behandlingen av BK viremi och förstärka/förbättra den antivirala effekten hos patienter där reducerad immunosuppression är otillräckligt?;Secondary Objective: 1) Kan screening, tidig diagnostik samt tidig minskning av immunhämningen vara av värde vid behandlingen BK virus infektion?&lt;br&gt;&lt;br&gt;2) Påverkar graden av immunhämning förekomsten av BK virus infektion och resultatet av behandlingen samt det kliniska förloppet?&lt;br&gt;&lt;br&gt;3) Föreligger en korsneutralisation hos antikroppar riktade mot olika subtyper av BK virus och kan BKV subtypsspecifika neutraliserande antikroppar hos donator och recipient före njurtransplantation utgöra ett diagnostiskt verktyg för att förebygga BKVAN hos recipienten?&lt;br&gt;&lt;br&gt;4) Vilken är förekomsten av BK viremi samt BK virus nefropati efter njurtransplantation?&lt;br&gt;;Primary end point(s): Primär endpoint&lt;br&gt;Transplantatöverlevnad eller transplantatförlust ett år efter diagnos (transplantatförlust = åter i dialys)&lt;br&gt;&lt;br&gt;&lt;br&gt;Sekundära endpoints&lt;br&gt;•	Patientöverlevnad ett år efter diagnos &lt;br&gt;•	Akut avstötning under studieperioden&lt;br&gt;•	Kronisk allograft neuropati ett år efter diagnos&lt;br&gt;•	Banff klassifikation vid histopatologisk undersökning av biopsi från den transplanterade njuren&lt;br&gt;•	Transplantatfunktion 1 år efter diagnos (P-Kreatinin, GFR – beräknat enligt Cockroft Gault)&lt;br&gt;•	Kvoten: P-Kreatinin efter 1 månad/P-Kreatinin efter 12 månader&lt;br&gt;•	Biverkningar vid leflunomid (Arava®) -behandling&lt;br&gt;•	Hematologi (Hb, LPK, TPK)&lt;br&gt;•	Infektioner&lt;br&gt;•	Malignitet&lt;br&gt;</Primary_outcome>
    <Secondary_ID>2008-005727-28</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469112</Internal_Number>
    <TrialID>EUCTR2008-002191-98-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>"Efecto del ARA-II Olmesartan sobre el metabolismo del potasio en pacientes con insuficiencia renal crónica"</Public_title>
    <Scientific_title>"Efecto del ARA-II Olmesartan sobre el metabolismo del potasio en pacientes con insuficiencia renal crónica"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Servicio de Nefrologia-Hospital Universitario Vall d'Hebron</Primary_sponsor>
    <Date_registration3>20081023</Date_registration3>
    <Date_registration>23/10/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002191-98                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/11/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: enalapril&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Insuficiencia renal crónica con aclaramientos entre 30 y 60 ml/minuto por MDRD.&lt;br&gt;Hipertensión arterial leve - moderada.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Niveles de potasio superiores a 5 mEq/l&lt;br&gt;Hipertensión arterial secundaria&lt;br&gt;Alergia a cualquiera de los dos fármacos&lt;br&gt;</Exclusion_Criteria>
    <Condition>Microalbuminúria, hipertensión arterial y renoprotección en la insuficiencia renal crónica.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Openvas&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: olmesartan&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-20&lt;br&gt;&lt;br&gt;Trade Name: Enalapril&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: enalapril&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-20&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar el efecto de la administración de un inhibidor del enzima de conversión del angiotensina con un antagonista de los receptores AT1 de la angiotensina, sobre los niveles de potasio plasmáticos.;Secondary Objective: Valorar los efectos de ambos fármacos sobre la función renal y sobre los niveles de renina, angiotensina y aldosterona.;Primary end point(s): Niveles de potasio en sangre, creatinina en sangre y microalbuminúria.</Primary_outcome>
    <Secondary_ID>PREVARENAL-08</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469116</Internal_Number>
    <TrialID>EUCTR2008-000627-26-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Conversion from cyclosporine to tacrolimus followed by randomized C0 or Bayesian monitoring using the C4 timepoint The effect on kidney function - FK04-study</Public_title>
    <Scientific_title>Conversion from cyclosporine to tacrolimus followed by randomized C0 or Bayesian monitoring using the C4 timepoint The effect on kidney function - FK04-study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Leiden University Medical Center</Primary_sponsor>
    <Date_registration3>20080529</Date_registration3>
    <Date_registration>29/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000627-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/09/2008</Date_enrollement>
    <Target_size>50</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: First pase uncontrolled, second phase parrallel group &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard TDM vs Baysian monitoring&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Livertransplant recipients at least 18 years of age at least 6 months past last transplantation on a stable calcineurin inhibitor based immunosuppressive regimen capable of understanding the purpose and risk of the study. &lt;br&gt;&lt;br&gt; &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Multi-organ transplant recipients&lt;br&gt;Allergy/intollerance to the study drugs&lt;br&gt;Patients with a serum creatinine &gt;200 umol/l&lt;br&gt;Pregnant or breastfeading mother&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Effect of immunosuppressive medication on renal function following livertransplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10024716
Term: Liver transplantation
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf(t)&lt;br&gt;Product Name: Prograft&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987113&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Other descriptive name: Prograf(t)&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 4-8&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Change in cratinine clearance measured by creatinine clearence in 24 hours urine collection and serum creatinine between baseline and week 12, week 12 and 14, and baseline and week 24   ;Secondary Objective: - Changes in mean arterial blood pressure and number and dose of antihypertensive medications used between baseline and week 12 and baseline and week 24&lt;br&gt;&lt;br&gt;- Tacrolimus pharmacokinetics&lt;br&gt;&lt;br&gt;- Changes in mean lipid levels (total cholesterol, TG, LDL, HDL), and the number and &lt;br&gt;dose of lipid-lowering medications between baseline and week 12 and week 24&lt;br&gt;&lt;br&gt;- Subject and graft survival&lt;br&gt;&lt;br&gt;- Creatinine clearance calculated by BSA corrected Cockcroft and GAult and MDRD&lt;br&gt;&lt;br&gt;- Biopsy proven treated graft rejection&lt;br&gt;&lt;br&gt;- Side effects;Primary end point(s): Change in renal function, as measured by:&lt;br&gt;Creatinine clearance, measured by creatinine clearance in a 24 hour urine collection and serum creatinine between: 1) baseline and week 12, 2) week 12 and week 24 and 3) baseline and week 24 &lt;br&gt;Creatinine clearance calculated by BSA adjusted Cockcroft and Gault and MDRD</Primary_outcome>
    <Secondary_ID>FK04</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469124</Internal_Number>
    <TrialID>EUCTR2008-000628-25-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The effectiveness of intensive treatment on sympathetic hyperactivity. A randomized, cross-over trial in patients with chronic kidney disease and hypertension</Public_title>
    <Scientific_title>The effectiveness of intensive treatment on sympathetic hyperactivity. A randomized, cross-over trial in patients with chronic kidney disease and hypertension                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>UMC Utrecht</Primary_sponsor>
    <Date_registration3>20080529</Date_registration3>
    <Date_registration>29/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000628-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/05/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with stable chronic kidney disease and hypertension: i.e. using antihypertensive drugs and/or blood pressure &gt;145/90mmHg when off medication. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients with diabetes mellitus and patients on renal replacement therapy are excluded. In addition, patients with severe liver insufficiency, biliary cirrhosis and cholestasis, pregnant patients and patients in lactation are excluded as Valsartan is contra-indicated for these patients.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Sympathetic nerve system in hypertensive patients with chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Diovan&lt;br&gt;Product Name: Valsartan&lt;br&gt;Product Code: RVG34472&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to investigate if there is an incremental inhibiting effect on MSNA by increasing dosage valsartan above the presently advised dosage. We hypothesize that there will be a further decrease in MSNA as compared to the MSNA during standard dosage valsartan.;Secondary Objective: econdary objective is to assess whether MSNA normalizes after application of higher than usual dosage of valsartan. The second secondary objective is to study the effect of higher than usual dosage of valsartan on blood pressure.;Primary end point(s): Primary endpoint: Change in MSNA during higher than usual dosage valsartan as compared to MSNA during standard dosage &lt;br&gt;Primary expected outcome: further decrease in MSNA as compared to the MSNA during standard dosage &lt;br&gt;&lt;br&gt;Secondary endpoint: Assess whether normalization of MSNA occurs during higher than usual dosage of valsartan&lt;br&gt;Secondary expected outcome: normalization of MSNA after application of higher than usual dosage of valsartan&lt;br&gt;Secondary endpoint: assessment of effect of higher than usual dosage valsartan on blood pressure&lt;br&gt;Secondary expected outcome: higher than usual dosage of valsartan will cause no changes in blood pressure&lt;br&gt;</Primary_outcome>
    <Secondary_ID>23012008</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469320</Internal_Number>
    <TrialID>EUCTR2008-006014-20-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effects of the dose of erythropoiesis stimulating agents on cardiac-cerebrovascular outcomes and quality of life in hemodialysis patients. The DOSe of Erythropoietins (DOSE) trial. - C.E. DOSE</Public_title>
    <Scientific_title>Effects of the dose of erythropoiesis stimulating agents on cardiac-cerebrovascular outcomes and quality of life in hemodialysis patients. The DOSe of Erythropoietins (DOSE) trial. - C.E. DOSE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>CONSORZIO MARIO NEGRI SUD</Primary_sponsor>
    <Date_registration3>20081121</Date_registration3>
    <Date_registration>21/11/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006014-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/01/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator:  - same IMP used at different dosage&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female, age&gt;=18, with end stage kidney disease and anemia, treated with hemodialysis for renal replacement therapy, with no contraindications to erythropoietin stimulating agents (ESA) or already treated with ESA&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients with Hb levels &gt;10 g/dl without ESA&lt;br&gt;</Exclusion_Criteria>
    <Condition>End stage kidney disease and anemia, treated with hemodialysis for renal replacement therapy &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10014647
Term: End stage renal failure
</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2000-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate the benefits and harms of high versus low EPOS doses for major patient-level outcomes (mortality, cardiac and cerebrovascular events, safety),quality of life and costs in a population of prevalent outpatient hemodialysis patients;Secondary Objective: xxx;Primary end point(s): composite of all-cause mortality, fatal and non fatal myocardial infarction, fatal and non fatal stroke, hospitalizations due to acute coronaric syndrome, transitory ischemich attacs, not planned coronaric revascularization, periferic revascularization.</Primary_outcome>
    <Secondary_ID>FARM6X822T</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469342</Internal_Number>
    <TrialID>EUCTR2008-002696-27-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open label, single-arm, baseline-controlled, multicenter study to evaluate the efficacy, safety and immunogenicity of subcutaneous HX575 administered once a week (qw) and once every two weeks (q2w) in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis subjects
 - SWEEP Study</Public_title>
    <Scientific_title>An open label, single-arm, baseline-controlled, multicenter study to evaluate the efficacy, safety and immunogenicity of subcutaneous HX575 administered once a week (qw) and once every two weeks (q2w) in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis subjects
 - SWEEP Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Hexal AG</Primary_sponsor>
    <Date_registration3>20081125</Date_registration3>
    <Date_registration>25/11/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002696-27                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/11/2008</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Male and female CKD subjects with or without dialysis treatment&lt;br&gt;• Age &gt; 18 years&lt;br&gt;• Subjects under documented stable maintenance therapy with rHuEPO, once, twice or thrice weekly, s.c., for at least 3 months with a total weekly dose of = 300 IU/kg/week&lt;br&gt;• Subjects with controlled symptomatic anemia, defined as Hb level between 10.0 g/dL and 12.0 g/dL, based on four Hb measurements during the four-week baseline period&lt;br&gt;• Adequate iron status, serum ferritin = 100 µg/L or transferrin saturation = 20%&lt;br&gt;• Confirmed negative anti-EPO antibody assay from sample taken at screening visit -4&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Systemic cyclosporine or any other drugs known to adversely affect the Hb level&lt;br&gt;• History of PRCA or aplastic anemia&lt;br&gt;• History of anti-EPO antibodies&lt;br&gt;• Uncontrolled hypertension&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anemia associated with chronic kidney disease in pre-dialysis and dialysis subjects &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10009120
Term: Chronic renal failure anaemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Binocrit (referred in the protocol to as HX575)&lt;br&gt;Product Name: HX575 epoetin alfa (registered as Binocrit®)&lt;br&gt;Product Code: HX575&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000 IU/0.5ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2000 IU/1 ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4000 IU/0.4 ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6000 IU/0.6 ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 8000 IU/0.8 ml-&lt;br&gt;INN or Proposed INN: Epoetin alfa&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10000 IU/1 ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate that HX575 administered s.c. qw and q2w maintains the correction of anemia associated with CKD.;Secondary Objective: To document the safety and immunogenicity of HX575.&lt;br&gt;To determine the optimal dosing regimen of HX575 s.c. administration.;Primary end point(s): Successful 1:1 conversion from rHuEPO to weekly HX575, and from weekly HX575 to fortnightly HX575, as assessed by the mean absolute change in Hb levels.</Primary_outcome>
    <Secondary_ID>HX575-304;not applicable</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469357</Internal_Number>
    <TrialID>EUCTR2008-007017-76-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio prospectivo, randomizado para comparar paratiroidectomía subtotal versus cinacalcet en el tratamiento del hiperparatiroidismo secundario persistente post trasplante renal. 


 - 01PTHi</Public_title>
    <Scientific_title>Estudio prospectivo, randomizado para comparar paratiroidectomía subtotal versus cinacalcet en el tratamiento del hiperparatiroidismo secundario persistente post trasplante renal. 


 - 01PTHi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Josep M Cruzado</Primary_sponsor>
    <Date_registration3>20081126</Date_registration3>
    <Date_registration>26/11/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007017-76                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/03/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: subtotal parathyroidectomy&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Inclusion criteria: &lt;br&gt;1.Functionning renal allograft, estimated GFR = 30 ml/min&lt;br&gt;2.More than 6 m after transplantation&lt;br&gt;3.PTHi =15 pmol/L&lt;br&gt;4.Calcemia =2.7 mmol/L with phosphatemia =1.2 mmol/L&lt;br&gt;5.MIBI &lt;br&gt;6.Written informed consent &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Exclusion criteria: &lt;br&gt;1.Surgical contraindication&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hiperparatiroidismo secundario post trasplante renal




 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020708
Term: Hyperparathyroidism secondary
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Mimpara&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: CINACALCET&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To study the percentage of patients with normocalcemia at 1 year after treatment with cinacalcet versus subtotal parathyreidectomy;Secondary Objective: Percentage of patients with PTHi according guidelines, renal function, economic cost study, incidence of cardiovascular events and graft and patient survival at year 1;Primary end point(s): percentage of patients with normocalcemia at year 1</Primary_outcome>
    <Secondary_ID>01PTHi</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469383</Internal_Number>
    <TrialID>EUCTR2008-005110-41-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Circadian Influence on Renal Clearance of Aminoglycosides in cystic fibrosis patients 
 - CIRCA</Public_title>
    <Scientific_title>Circadian Influence on Renal Clearance of Aminoglycosides in cystic fibrosis patients 
 - CIRCA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>not applicable</Primary_sponsor>
    <Date_registration3>20081210</Date_registration3>
    <Date_registration>10/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005110-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>09/12/2008</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: dosing tobramycin in the morning vs. evening&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: controlled by comparing morning arm to evening arm&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Inclusion criteria :&lt;br&gt;-	Age: = 18 years&lt;br&gt;-	a diagnosis of cystic fibrosis (ie, sweat chloride _60 mmol/L or a genotype associated with cystic fibrosis) &lt;br&gt;-	chronic infection with Pseudomonas aeruginosa with the most recently isolated organism showing sensitivity to tobramycin.&lt;br&gt;-	Pulmonary exacerbation as defined by Fuchs and colleagues&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	use of nephrotoxic drugs (NSAID´s, furosemide, vancomycin)&lt;br&gt;-	allergy for aminoglycosides&lt;br&gt;-	granulocytopenia (&lt;1,0 x 109/L)&lt;br&gt;-	pregnancy&lt;br&gt;-	calculated GFR &lt; 40 ml/min &lt;br&gt;-	pre-existing hearing impairment (_20 dB hearing level at any two frequencies between 2kHz and 8 kHz on the standard audiogram)&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Repeated or extended dosing of aminoglycosides may cause damage to the proximal tubuli, resulting in renal impairment. Renal impairment affects up to 40 % of adult CF patients, measured after estimation using an appropriate formula. The true number is probably even greater.</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form:</Intervention>
    <Primary_outcome>Main Objective: To compare renal elimination constant in CF patients receiving a daily intravenous dose of tobramycin in the morning compared to patients receiving a daily intravenous dose of tobramycin in the evening.;Secondary Objective: To compare biochemical signs of nephrotoxicity in patients who receive their dose of aminoglycoside in the morning against patients who receive their dose of aminoglycoside in the evening.;Primary end point(s): The primary end point will be a significant or non-significant difference in the rate elimination constant (Kelm) between CF patients receiving a daily intravenous dose of tobramycin in the morning and CF patients receiving a daily intravenous dose of tobramycin in the evening.</Primary_outcome>
    <Secondary_ID>9999999999999999999;not available</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469465</Internal_Number>
    <TrialID>EUCTR2008-006798-33-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENESIS INHIBITORS - MOTOR</Public_title>
    <Scientific_title>Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENESIS INHIBITORS - MOTOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>CONSORZIO ONCOTECH</Primary_sponsor>
    <Date_registration3>20081215</Date_registration3>
    <Date_registration>15/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006798-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/11/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Study subjects must have a histologically/cytologically confirmed diagnosis of metastatic RCC (regardless of nephrectomy status) with well-documented progressive disease (PD) after any of the following: cytokines (± chemotherapy), sunitinib, sorafenib, or bevacizumab (± IFN).&lt;br&gt;&lt;br&gt;2.	No more than one prior systemic treatment for advanced disease is allowed.&lt;br&gt;&lt;br&gt;3.	At least 2 weeks since prior systemic treatment, palliative radiation therapy, and/or surgery must have elapsed and resolution of all toxic effects of prior therapy to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE, version 3.0) Grade &amp;amp;#61603;1 must be observed prior to inclusion. &lt;br&gt;&lt;br&gt;4.	At least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter &amp;amp;#61619; 10 mm when measured by spiral computerized tomography (CT, 5-mm slice thickness contiguous) or &amp;amp;#61619; 20 mm when measured by conventional CT (10-mm slice thickness contiguous).  Lesion must be &amp;amp;#61619; 2 times the size of the slice thickness per Response Evaluation Criteria in Solid Tumors (RECIST).&lt;br&gt;&lt;br&gt;5.	Age &gt; 18 years.&lt;br&gt;&lt;br&gt;&lt;br&gt;6.	Screening laboratory values within the following limits:&lt;br&gt;&amp;amp;#61607;	ANC  &gt;=1500/mL &lt;br&gt;&amp;amp;#61607;	Platelet count  &gt;=100,000/mL&lt;br&gt;&amp;amp;#61607;	Leukocyte count &gt;=2000/uL&lt;br&gt;&amp;amp;#61607;	Hemoglobin  &gt;= 8.0 g/dL (80g/L) without transfusion within 2 weeks of first dose of test article&lt;br&gt;&amp;amp;#61607;	Serum creatinine  &lt;= 2.0 X ULN&lt;br&gt;&amp;amp;#61607;	Total bilirubin  &lt;= 1.5 X ULN&lt;br&gt;&amp;amp;#61607;	AST and ALT &lt;=3 X ULN [&amp;amp;#61603;5 X ULN if liver metastases are present]&lt;br&gt;&amp;amp;#61607;	Fasting serum cholesterol &lt;=350 mg/dL (9.0 mmol/L)&lt;br&gt;&amp;amp;#61607;	Fasting serum triglycerides &lt;=400 mg/dL (4.56 mmol/L)&lt;br&gt;&amp;amp;#61607;	Fasting hemoglobin A1c (HbA1c) &lt; 10% (therapy permitted)&lt;br&gt;&amp;amp;#61607;	PTT/INR or PT &lt; 1.3 x ULN&lt;br&gt;&amp;amp;#61607;	Urinalysis within normal limits&lt;br&gt;&lt;br&gt;6.	Metabolic, thyroid, and pancreatic function within laboratory limits of normal&lt;br&gt;&lt;br&gt;7.	Adequate cardiac (left ventricular ejection fraction &gt;=40%) as assessed by electrocardiogram (ECG), echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan&lt;br&gt;&lt;br&gt;8.	Eastern Cooperative Oncology Group (ECOG) performance status 0-2&lt;br&gt;&lt;br&gt;9.	Life expectancy of at least 3 months&lt;br&gt;&lt;br&gt;10.	Written, signed, dated, and witnessed IRB or IEC approved informed consent form (ICF)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	History of a central nervous system (CNS) malignancy or metastatic disease to the CNS or known, active CNS malignancy (primary or metastatic).&lt;br&gt;2.	More than one prior systemic therapy for mRCC other than sunitinib.  &lt;br&gt;3.	Subjects receiving known strong CYP3A4 isoenzyme inhibitors and/or inducers.  Subjects taking CYP3A4 isoenzyme inhibitors and/or inducers not listed in Appendix are eligible, provided they have been on a stable regimen for at least 4 weeks prior to enrollment.&lt;br&gt;4.	Subjects with a non-healing wound or ulcer.&lt;br&gt;5.	Grade &gt;=3 hemorrhage within the past month.&lt;br&gt;6.	Systolic blood pressure of  &gt; 160 mm Hg and/or diastolic pressure &gt; 100 mg Hg (anti-hypertensive medications permitted).&lt;br&gt;7.	AHA Class 3/4 heart disease.&lt;br&gt;8.	QTc interval &gt; 450 msec for males and &gt; 470 msec for females and/or any ventricular arrhythmia and/or any uncontrolled atrial arrhythmia.  &lt;br&gt;9.	Subjects receiving anticoagulation with warfarin (therapeutic doses of warfarin for catheter patency are permitted).  Low molecular weight (LMW) heparin is permitted.&lt;br&gt;10.	Glycosylated hemoglobin A1c (HbA1c) &gt; 10% despite therapy.  &lt;br&gt;11.	History of pulmonary hypertension or interstitial lung disease.&lt;br&gt;12.	Subjects receiving immunosuppressive agents within 4 weeks of the screening visit.  Replacement doses of corticosteroids and topical/inhaled steroids are permitted.   &lt;br&gt;13.	Chronic viral/bacterial/fungal illnesses such as human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. &lt;br&gt;14.	Active infection(s), active antimicrobial therapy or serious intercurrent illness.&lt;br&gt;15.	Subjects with a ?currently active? second malignancy other than non-melanoma skin cancers.  Subjects are not considered to have a ?currently active? malignancy if they have completed anti-cancer therapy and are considered by their physician to be at less than 30% risk of relapse.  &lt;br&gt;16.	Pregnant or nursing women, women who are of childbearing potential  (biologically capable of becoming pregnant) who are not using a medically acceptable contraceptive method, or men who are not using a medically acceptable contraceptive method with partners of childbearing potential.&lt;br&gt;17.	Subjects who do not agree to use medically acceptable contraceptive methods for 3 months after their last dose of Torisel therapy.&lt;br&gt;18.	Any other major illness that, in the investigator?s judgment, will substantially increase the risk associated with the subject?s participation in this study.&lt;br&gt;19.	Known hypersensitivity to any of the components in the Torisel infusion products or other medical reasons for not being able to receive adequate premedication (for example, antihistamines).&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with metastatic RCC &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TEMSIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: PFS rate at 6 months;Secondary Objective: ORR (RECIST criteria)&lt;br&gt;Duration of response&lt;br&gt;Duration of stable disease&lt;br&gt;Toxicity&lt;br&gt;PFS&lt;br&gt;OS&lt;br&gt;Quality of life (EORTC QLQ C-30)&lt;br&gt;Biological/molecular correlates (TBD);Primary end point(s): 	Medical history&lt;br&gt;	Physical Examination&lt;br&gt;	CBC (including WBC with differential)&lt;br&gt;	Serum electrolytes&lt;br&gt;	Serum chemistry&lt;br&gt;	Coagulation tests&lt;br&gt;	HbA1c&lt;br&gt;	Routine urinalysis&lt;br&gt;	CT of chest, abdomen and pelvis&lt;br&gt;	ECG/ECHO or MUGA&lt;br&gt;	Chest x-ray&lt;br&gt;	Vital signs&lt;br&gt;	Adverse events&lt;br&gt;	Concomitant medications</Primary_outcome>
    <Secondary_ID>MOTOR</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469553</Internal_Number>
    <TrialID>EUCTR2008-008235-28-FI</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Parasetamolin käyttö oheiskipulääkkeenä oksikodonin kanssa ohitusleikkauksen jälkeisen kivun hoidossa 

Paracetamol as Adjuctive Treatment for Postoperative Pain after Off-Pump Bypass Surgery
 - PARA-CABG-01</Public_title>
    <Scientific_title>Parasetamolin käyttö oheiskipulääkkeenä oksikodonin kanssa ohitusleikkauksen jälkeisen kivun hoidossa 

Paracetamol as Adjuctive Treatment for Postoperative Pain after Off-Pump Bypass Surgery
 - PARA-CABG-01                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Vesa Pakanen</Primary_sponsor>
    <Date_registration3>20081210</Date_registration3>
    <Date_registration>10/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008235-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/01/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient with chronic ischemic heart disease ongoing elective coronary artery bypass grafting. Any major organ failures like  heart, kidney, liver  failures are excluded.
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10008937
Term: Chronic ischemic heart disease, unspecified
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Perfalgan&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: PARACETAMOL&lt;br&gt;CAS Number: 103902&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>82772673</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2469669</Internal_Number>
    <TrialID>EUCTR2008-007881-45-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction - ARIANA-CHF-RD</Public_title>
    <Scientific_title>A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction - ARIANA-CHF-RD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>University Medical Center Groningen</Primary_sponsor>
    <Date_registration3>20081209</Date_registration3>
    <Date_registration>09/12/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007881-45                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/03/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Out patients = 18  years of age, male or female.&lt;br&gt;•	Patients with a diagnosis of chronic heart failure (NYHA Class II – IV)&lt;br&gt;•	LVEF = 45% at visit 1 (local measurement, measured within the past 6 months assessed by  echocardiogram, MUGA or ventricular angiography)&lt;br&gt;•	Estimated GFR between 30 and 60 ml/min/1.73m2 as measured by the MDRD formula&lt;br&gt;•	Patients must be treated with an ACE inhibitor at a stable dose (enalapril 10 mg daily at least or any other ACE inhibitor, e.g. ramipril, quinapril, lisinopril, fosinopril, perindopril, trandolapril; on equivalent doses, or maximum tolerated dose) or if intolerant to ACE inhibitors with ARB therapy (Candesartan 32 mg daily or any other ARB in equivalent dose, or maximum tolerated dose) for at least 4 weeks prior to visit 1.&lt;br&gt;•	Patients must be treated with a beta blocker unless contraindicated or not tolerated at a stable dose for at least 4 weeks prior to visit 1 (for patients not on target dose or in absence of that medication, the reason should be documented). &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	History of hypersensitivity to any of the study drugs including history or allergy to ACEi’s as well as known or suspected contraindications to the study drugs or previous history of intolerance to high doses of ACEi’s during up titration process.&lt;br&gt;•	Patients treated concomitantly with both ARB and aldosterone antagonist.&lt;br&gt;•	Current acute decompensated heart failure (HF). &lt;br&gt;•	Symptomatic hypotension and/ or less than 90 mmHg SBP at randomisation&lt;br&gt;•	Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or major vascular surgery, percutaneous coronary intervention (PCI) or carotid angioplasty, within the past 3 months.&lt;br&gt;•	Coronary or carotid artery disease likely to require surgical or PCI.&lt;br&gt;•	Right heart failure due to severe pulmonary disease.&lt;br&gt;•	Diagnosis of peripartum or chemotherapy induced cardiomyopathy within the last year. &lt;br&gt;•	Patients with a history of heart transplant or who are on a transplant list or with LVAD device (left ventricular assistance device). &lt;br&gt;•	Documented ventricular arrhythmia with syncopal episodes within past 3 months that is untreated.&lt;br&gt;•	Documented history of ventricular tachycardia or ventricular fibrillation without ICD.&lt;br&gt;•	Symptomatic bradycardia, or second or third degree heart block without a pacemaker.&lt;br&gt;•	Implantation of a CRT (cardiac resynchronization therapy) device within prior 3 months. &lt;br&gt;•	Presence of hemodynamically significant mitral and /or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation. &lt;br&gt;•	Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic stenosis.&lt;br&gt;•	Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs including, but not limited to, any of the following:&lt;br&gt;•	Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase.&lt;br&gt;•	Primary liver disease considered to be life threatening.&lt;br&gt;•	Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1.&lt;br&gt;•	Serum potassium =  5.2 mEq/L at randomisation visit.&lt;br&gt;•	History or presence of any other diseases (i.e. including malignancies) with a life expectancy of &lt; 5 years.&lt;br&gt;•	Current double-blind treatment in HF trials.&lt;br&gt;•	Participation in an investigational drug study at the time of enrollment or within the past 30 days or 5 half lives of enrollment whichever is longer.&lt;br&gt;•	Any surgical or medical condition that in the opinion of the investigator or medical monitor would jeopardize the evaluation of efficacy or safety.&lt;br&gt;•	History of noncompliance to medical regimens and patients who are considered potentially unreliable.&lt;br&gt;•	Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human Chorionic Gonadotropin (hCG) laboratory test (&gt; 5 mIU/ml).&lt;br&gt;•	Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (</Exclusion_Criteria>
    <Condition>Patients with chronic heart failure and reduced glomerular filtration rate. &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10038443
Term: Renal failure and impairment
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10008908
Term: Chronic heart failure
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rasilez&lt;br&gt;Product Name: Aliskiren&lt;br&gt;Product Code: SPP100&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 173334571&lt;br&gt;Other descriptive name: ALISKIREN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-300&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to test if add-on therapy with aliskiren improves RBF in patients with CHF (NYHA Class II - IV) and RD treated with renin-angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II type 1 receptor blockers (ARB).;Secondary Objective: Secondary objectives are to examine the effect of addition of aliskiren on RD expressed as glomerular filtration rate(GFR) as measured by clearance of 125I-Iothalamate, filtration fraction(FF) as measured by GFR/Effective Renal Plasma Flow, circulating plasma values of markers of renin-angiotensin (RAS) system activity, including plasma renin activity, angiotensin II, angiotensin converting enzyme activity and chymase activity, levels of N Terminal-proBrain Natriuretic Peptides, left ventricular ejection fraction as measured by radionucleotide ventriculography, urinary levels of markers of glomerular and tubular damage, including urinary albumin ecretion (UAE), N-acetyl-beta-D-glucosaminidase (NAG), neutrophil gelatinase associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1), NYHA Association class, Patient’s and Physician’s global assessment score’s and on heart rate, systolic and diastolic blood pressure.;Primary end point(s): Change in Renal Blood Flow from baseline to 26 weeks with additive renin-inhibition with aliskiren</Primary_outcome>
    <Secondary_ID>SPP100ANL02T</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470033</Internal_Number>
    <TrialID>EUCTR2005-005124-14-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The unlicensed and off-label use of diclofenac in paediatric patients: Pharmacokinetic, pharmacodynamic and pharmacogenomic evlauations - Diclofenac in Paediatrics</Public_title>
    <Scientific_title>The unlicensed and off-label use of diclofenac in paediatric patients: Pharmacokinetic, pharmacodynamic and pharmacogenomic evlauations - Diclofenac in Paediatrics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Joint Sponsor: University of Glasgow with NHS greater Glasgow and Clyde</Primary_sponsor>
    <Date_registration3>20070516</Date_registration3>
    <Date_registration>16/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005124-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/07/2007</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Age 6m-12y&lt;br&gt;Weight 5-50kg&lt;br&gt;Undergoing elective surgery where diclofenac would routinely be used&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;&lt;6m&lt;br&gt;&lt;5kg&lt;br&gt;&gt;50kg&lt;br&gt;Dehydration&lt;br&gt;Renal impairment&lt;br&gt;High risk of bleeding&lt;br&gt;Receiving anticoagluants&lt;br&gt;Allergy to NSAIDs&lt;br&gt;Poorly controlled asthma&lt;br&gt;Emergency surgery&lt;br&gt;Receiving diazepam, barbiturates, rifampicin, azole antifungals and any other drugs which may induce or block the metabolic pathway related to diclofenac&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Children undergoing surgery for orthapaedic, ENT, renal or abdominal conditions &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10042609
Term: Surgery
</Condition>
    <Intervention>&lt;br&gt;Product Name: Diclofenac Sodium 50mg/5ml Oral Suspension&lt;br&gt;Pharmaceutical Form: Oral suspension&lt;br&gt;INN or Proposed INN: Diclofenac&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine population pharmacokinetics of diclofenac in children aged 6m-12y;Secondary Objective: To determine proportion of children with each of the three genotypes relevant to metabolism of diclofenac (CYP2C8, CYP2C9 and UGT2B7) .&lt;br&gt;To correlate pharmacokinetics with pharmacogenetic profile and pharmacodynamic effects.;Primary end point(s): Population pharmacokinetics of diclofenac&lt;br&gt;Pharmacogenetic subtypes for diclofenac metabolism</Primary_outcome>
    <Secondary_ID>2005DICPAED</Secondary_ID>
    <Secondary_Sponsor>Joint Sponsor: University of Glasgow with NHS Greater Glasgow and Clyde</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2470035</Internal_Number>
    <TrialID>EUCTR2006-002328-40-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant. - Stem cell and diabetes study</Public_title>
    <Scientific_title>A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant. - Stem cell and diabetes study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Imperial College London</Primary_sponsor>
    <Date_registration3>20060723</Date_registration3>
    <Date_registration>23/07/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002328-40                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/05/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female patients aged from 16 to 65 years of age&lt;br&gt;Patient with Type I diabetes mellitus plus:&lt;br&gt;Successful previous kidney transplant. &lt;br&gt;Good kidney allograft function /no episodes of rejection &lt;br&gt;for at least one year post-transplant&lt;br&gt;Not taking steroids as part of standard  immuno-suppression&lt;br&gt;Has a WHO performance score of less than 2&lt;br&gt;Has a life expectancy of at least 3 months&lt;br&gt;Ability to give written consent&lt;br&gt;Women of childbearing potential may be included, but must use a reliable and appropriate contraceptive method&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients below the age of 16 or above the age of 65 years&lt;br&gt;Patients with chronic pancreatitis and poor exocrine pancreatic function&lt;br&gt;Pregnant or lactating women&lt;br&gt;Patients with recent recurrent GI bleeding or spontaneous bacterial peritonitis&lt;br&gt;Patients with evidence of HIV or other life threatening infection&lt;br&gt;Patients unable to give written consent&lt;br&gt;Patients with a history of hypersensitivity to G-CSF &lt;br&gt;Patients who have been included in any other clinical trial within the previous month&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diabetes mellitus type 1 and succesful renal transplant &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10012638
Term: Diabetes with renal manifestations
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Product Name: Autologous CD34+ stem cell subset&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the safety and tolerance of a high dose of autologous expanded progeny of adult CD34+ stem cell subset (InsulinCytes) when introduced into either the body or tail of the pancreas.  ;Secondary Objective: To assess improvement in endocrine pancreatic function as measured by serological and biochemical analysis and determine any symptomatic improvements as they are reported by the patients.;Primary end point(s): To assess the safety and tolerance of a high dose of autologous expanded progeny of adult CD34+ stem cell subset (InsulinCytes) when introduced into either the body or tail of the pancreas.  </Primary_outcome>
    <Secondary_ID>HHSC/005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470136</Internal_Number>
    <TrialID>EUCTR2006-002770-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The effects of oral sodium bicarbonate on extracellular water in patients with chronic renal failure - Sodium bicarbonate use in renal patients</Public_title>
    <Scientific_title>The effects of oral sodium bicarbonate on extracellular water in patients with chronic renal failure - Sodium bicarbonate use in renal patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>York Hospital NHS Trust</Primary_sponsor>
    <Date_registration3>20060918</Date_registration3>
    <Date_registration>18/09/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002770-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/09/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with chronic renal failure defined as stage 3-5 CKD (an estimated glomerular filtration rate (MDRD GFR) of &lt;60 ml/min). Using a serum creatinine &gt;180 µmol/l will mean that nearly all subjects will actually have stage 4/5 CKD (MDRD GFR &lt;30 ml/min). &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients on dialysis; already on sodium bicarbonate; poorly controlled hypertension (systolic BP &gt; 160 mmHg; diastolic BP &gt; 90 mmHg); peripheral oedema on clinical assessment; active nephrotic syndrome; history of congestive cardiac failure and/or pulmonary oedema.&lt;br&gt;</Exclusion_Criteria>
    <Condition>We will investiagte the use of sodium bicarbonate on extracellular water in patients with CHRONIC RENAL FAILURE</Condition>
    <Intervention>&lt;br&gt;Product Name: sodium bicarbonate&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 144-55-8&lt;br&gt;Current Sponsor code: SOB06&lt;br&gt;Other descriptive name: Sodium Bicarbonate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: This is a double blind placebo controlled trial of oral sodium bicarbonate against placebo in patients with chronic renal failure.  The aim of the trial is to determine the effects of oral sodium bicarbonate on extracellular fluid volumes and blood pressure in patients with renal failure.;Secondary Objective: To determine whether or not biometric impedence monitoring will detect changes demonstrated by gold standard techniques of body water measurements.;Primary end point(s): Change in the ratio Vecf/Vtbw&lt;br&gt;Change in body weight/blood pressure. Agreement between gold standard and bioimpedance measurements of Vecf/Vtbw.</Primary_outcome>
    <Secondary_ID>SOB06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470366</Internal_Number>
    <TrialID>EUCTR2006-006948-65-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The effect of acidosis correction and exercise on tissue wasting and immune function in renal patients</Public_title>
    <Scientific_title>The effect of acidosis correction and exercise on tissue wasting and immune function in renal patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>University Hospitals of Leicester NHS Trust</Primary_sponsor>
    <Date_registration3>20070126</Date_registration3>
    <Date_registration>26/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006948-65                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/11/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Lower dose of sodium bicarbonate&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Chronic kidney disease patients at CKD  stages 4 to 5 &lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Physical disability sufficient to preclude participating in an exercise programme&lt;br&gt;Age less than 18 years&lt;br&gt;Pregnancy&lt;br&gt;Congestive heart failure&lt;br&gt;Live cirrhosis&lt;br&gt;&lt;br&gt;The Summary of Product Characteristics also recommends caution in the use of sodium bicarbonate in those with impaired renal function , hypertension, and dietary sodium restriction. These features characterise all subjects recruited to this study. Due caution will be exercised based on the expert clinical knowledge and experience of the investigators.&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sodium bicarbonate 500mg capsules&lt;br&gt;Product Name: Sodium bicarbonate&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The interaction between exercise and metabolic acidosis in chronic kidney disease has never been investigated. Important questions to be answered are:&lt;br&gt;•	What influence does correcting acidosis have on exercise tolerance? &lt;br&gt;•	Are the expected beneficial effects of exercise and acidosis correction additive?&lt;br&gt;           OR&lt;br&gt;•	Does exercise (which generates lactic acid in muscle) worsen the acidosis problem? This may be important in kidney patients because the level of exercise needed to generate lactic acid  (the lactate threshold) is low. &lt;br&gt;•	Does correcting acidosis allow an improved response to exercise in those kidney patients who currently respond poorly to exercise therapy alone? &lt;br&gt;;Secondary Objective: ;Primary end point(s): Muscle mass and ability to perform exercise&lt;br&gt;Signals in muscle which control protein synthesis&lt;br&gt;Blood pressure, pulse wave velocity, finometry&lt;br&gt;Quality of life using Leicester uraemic symptoms score&lt;br&gt;</Primary_outcome>
    <Secondary_ID>Version 4</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470481</Internal_Number>
    <TrialID>EUCTR2006-004511-21-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] - SuMR</Public_title>
    <Scientific_title>Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] - SuMR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Queen Mary University London</Primary_sponsor>
    <Date_registration3>20070309</Date_registration3>
    <Date_registration>09/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004511-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/08/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Histopathologically confirmed renal cell carcinoma (clear cell) with measurable metastases on CT/ imaging.Patients with suspicion of renal cancer on radiology must have a biopsy to confirm diagnosis of clear cell, taken as part of the study.&lt;br&gt;2.	Judged by the treating physician to have the potential to derive clinical benefit form sunitinib treatment&lt;br&gt;3.	Male or Female, 18 years of age or older&lt;br&gt;4.	Adequate organ function as defined by the following criteria:&lt;br&gt;•	Total serum bilirubin =2 x ULN (patients with Gilbert’s disease exempt)&lt;br&gt;•	Serum transaminases &lt;5 x ULN&lt;br&gt;•	Serum creatinine =2 x ULN&lt;br&gt;•	Absolute neutrophil count (ANC) =1000/mm3 without growth factor support&lt;br&gt;•	Platelets = 75,000/mm3&lt;br&gt;5.	Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment.&lt;br&gt;6.	Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures&lt;br&gt;7.	ECOG performance status of 0,1 or 2.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Congestive heart failure, myocardial infarction or coronary artery bypass graft in the previous six months, ongoing severe or unstable arrhythmia requiring medication.&lt;br&gt;2.	Previous treatment  for renal cancer. &lt;br&gt;3.	Pregnancy or breastfeeding.  Patients must be surgically sterile or be postmenopausal, or must agree to use adequate contraception during the period of therapy.  The definition of effective contraception will be based on the judgement of the principal investigator or a designated associate.  Male patients must be surgically sterile or agree to use adequate contraception.&lt;br&gt;5.	Other severe acute or chronic medical or psychiatric condition, or laboratory abnormally that would impart, in the judgement of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgement of the investigator, would make the patient inappropriate for entry into this study&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>The current standard treatment in patients with metastatic renal cancer includes nephrectomy followed by immune therapy with either interleukin 2 (rIL-2) or interferon (IFN-a).  Unfortunately, responses occur in only approximately 15% of patients, with less than 5% benefiting from a durable remission. Treatment options for patients who progress on this treatment remain very limited. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Product Name: Sunitinib Malate&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Sutent-H-687-00-00&lt;br&gt;CAS Number: 557795-19-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 50, 25 &amp; 12.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to determine the effect of three months pre-operative treatment with SUNITINIB in patients with operable and inoperable metastatic renal cancer.;Secondary Objective: 1.	To establish if there is a correlation between PET response and overall survival in these patients.  Additionally changes in gene suppression &lt;br&gt;&lt;br&gt;2.	To investigate if changes in growth factor and growth factor receptor expression at a tissue level before and after treatment are associated response &lt;br&gt;&lt;br&gt;3.	Assess tumour response using sequential micro-array&lt;br&gt;&lt;br&gt;4.	To determine the proportion of patients that are deemed to be inoperable that will become operable with SU011248.&lt;br&gt;&lt;br&gt;5.	To evaluate the safety and tolerability profile&lt;br&gt;;Primary end point(s): The primary endpoint is time to radiological progression.  </Primary_outcome>
    <Secondary_ID>RC-2007-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470615</Internal_Number>
    <TrialID>EUCTR2006-005373-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Erythropoietin and Delayed Graft Function in Renal Allografts from Extended Criteria Donors.

 - EPO and DGF</Public_title>
    <Scientific_title>Erythropoietin and Delayed Graft Function in Renal Allografts from Extended Criteria Donors.

 - EPO and DGF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Central Manchester and Manchester Children's University Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20070530</Date_registration3>
    <Date_registration>30/05/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005373-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/07/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Men and women aged = or &gt; 18 years&lt;br&gt;2.	The subject is willing to provide signed written informed consent.&lt;br&gt;3.	The subject is the recipient of a deceased donor kidney transplant.&lt;br&gt;4.	The donor and/or donor kidney meet at least one of the following extended criteria for organ donation from either (a) or (b) as described below:&lt;br&gt;a)&lt;br&gt;&lt;br&gt;Donor condition	Donor age categories&lt;br&gt;	                 50-59 years	&gt;or=60 years&lt;br&gt;CVA+HTN+SCr&gt;1.5	eligible	eligible&lt;br&gt;CVA+HTN	                    eligible	eligible&lt;br&gt;CVA+SCr&gt;1.5	eligible	eligible&lt;br&gt;HTN+SCr&gt;1.5	eligible	eligible&lt;br&gt;CVA	                      no	eligible&lt;br&gt;HTN	                      no              eligible&lt;br&gt;SCr&gt;1.5	                      no	eligible&lt;br&gt;None 	                      no	eligible&lt;br&gt;&lt;br&gt;b)	Additional criteria&lt;br&gt;	i)	anticipated CIT  = or &gt; 24hrs&lt;br&gt;	ii)	donor with cardiac death&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Women who are pregnant or breastfeeding.&lt;br&gt;2. Women with a positive pregnancy test on enrolment.&lt;br&gt;3. Subjects with any active infection that would normally exclude &lt;br&gt;    transplantation.&lt;br&gt;4. Subjects who have used any other investigational drug within 30 days prior to &lt;br&gt;    transplantation.&lt;br&gt;5. Subjects with a haemoglobin level = or &gt; 15g/dl&lt;br&gt;6. Subjects with a diastolic blood pressure &gt; 100 mm/Hg pre-transplantation.&lt;br&gt;7. Subjects previously intolerant of NeoRecormon.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Transplantation of renal allografts from extended criteria donors</Condition>
    <Intervention>&lt;br&gt;Trade Name: NeoRecormon&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The principal objective of this study is to investigate whether giving erythropoietin (EPO) to patients at the time of kidney transplantation reduces the incidence and/or severity of delayed graft function, when compared to patients who receive a placebo.;Secondary Objective: 1.	To monitor and compare kidney function in both patient groups post-operatively and at 3, 6, 9 and 12 months&lt;br&gt;2.	To record number and severity of acute rejection episodes.     &lt;br&gt;3.	To measure biomarkers involved in ischaemia/reperfusion injury and compare the findings in the EPO group with the placebo group&lt;br&gt;4.	The longer term outcome (at 1 year and 2 years) of the patients in both groups will be followed to compare the incidence of chronic allograft nephropathy. &lt;br&gt;;Primary end point(s): The primary end point of the trial is the comparison between plasma levels and gene expression of biomarkers between the two arms of the trial at the specified time points.</Primary_outcome>
    <Secondary_ID>10322</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2470806</Internal_Number>
    <TrialID>EUCTR2007-002914-20-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Calcineurin Inhibitor Minimisation in Renal Transplant Recipients with Stable Allograft Function: A Prospective Randomised Controlled Trial - CNIM-SRT</Public_title>
    <Scientific_title>Calcineurin Inhibitor Minimisation in Renal Transplant Recipients with Stable Allograft Function: A Prospective Randomised Controlled Trial - CNIM-SRT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>University Hospital Birmingham NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20070731</Date_registration3>
    <Date_registration>31/07/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002914-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/09/2007</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;To be included in the study the patient must be an adult recipient of a first kidney transplant, and have:&lt;br&gt;•A functioning kidney allograft (with estimated (e)GFR by MDRD &gt;30ml/min/1.73m2) and be between 1 and 10 years post transplantation&lt;br&gt;•Stable allograft function, as defined by no greater than 10% rise in serum creatinine in the preceding 6 months, on ciclosporin and azathioprine immunosuppression&lt;br&gt;•Minimal proteinuria, evidenced as urine albumin:creatinine ratio &lt;50mg/mmol&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;The presence of any of the following will preclude patient inclusion&lt;br&gt;&lt;br&gt;• &lt;18 years of age&lt;br&gt;• Pregnancy or suspicion of pregnancy confirmed by positive b-HCG pregnancy test&lt;br&gt;• Female patients unwilling to take effective contraception for study duration&lt;br&gt;• Untreated ureteric obstruction on ultrasound of allograft&lt;br&gt;• Recurrent urosepsis&lt;br&gt;• Severe systemic infection&lt;br&gt;• Untreated significant (&gt;50%) renal artery stenosis on magnetic resonance       angiography performed prior to study.&lt;br&gt;• History of acute allograft rejection &lt;br&gt;• History of myocardial infarction&lt;br&gt;• History of malignancy in previous 5 years (excluding non-melanomatous tumours limited to skin)&lt;br&gt;• Symptomatic ischaemic heart disease&lt;br&gt;• Hepatitis B surface antigen positive, Hepatitis C positive or HIV positive. &lt;br&gt;• Recipient of combined organ transplantation (e.g. pancreas/kidney; liver/kidney) &lt;br&gt;• Recipient of ABO-incompatible kidney&lt;br&gt;• Greater than 1 HLA mismatch at either the “B” or “DR” locus&lt;br&gt;• Peak HLA antibody Panel Reactivity (PRA) greater than 10% &lt;br&gt;• Recipient who underwent HLA desensitisation procedure prior to transplantation&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10010185
Term: Complications of transplanted kidney
 &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10052779
Term: Transplant rejections
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Current Sponsor code: RRK3367&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Current Sponsor code: RRK3367&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Current Sponsor code: RRK3367&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865133&lt;br&gt;Current Sponsor code: RRK3367&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine whether complete calcineurin inhibitor withdrawal offers benefits over partial withdrawal (minimisation) in delaying the progression of histological graft damage, in patients with stable short-term allograft function, but who are at risk for progressive histological damage.;Secondary Objective: •To compare patient and graft survival between withdrawal and minimisation groups&lt;br&gt;•To compare renal function between groups&lt;br&gt;•To assess the incidence of allograft rejection (clinical and sub-clinical) between groups&lt;br&gt;•To evaluate effect on proteinuria, where present&lt;br&gt;•To compare changes in anti-HLA antibody profiles between groups&lt;br&gt;•To compare lymphocyte function between groups&lt;br&gt;•To compare cardiovascular risk profile between groups&lt;br&gt;•To compare the incidence of viral and bacterial infection between groups&lt;br&gt;;Primary end point(s): To compare renal allograft markers of damage and evolving injury in biopsies immediately pre study and at the end of the study. The primary tissue assessments will comprise:&lt;br&gt;&lt;br&gt;1) Index of chronic damage (an objective measure of the amount of chronic damage, shown to be a powerful indicator of prognosis in non-allograft renal biopsies )&lt;br&gt;2)Interstitial fibrosis quantification by Sirius Red staining&lt;br&gt;3)TGF-beta expression&lt;br&gt;4)P-selectin expression and leukocyte infiltration (macrophage).&lt;br&gt;5)Fibroblast function&lt;br&gt;6)Epithelial mesenchymal transformation markers&lt;br&gt;7)Markers of apoptosis&lt;br&gt;8)Electron Microscopy&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>RRK3367;ISRCTN60081949</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2471541</Internal_Number>
    <TrialID>EUCTR2008-001747-18-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude multicentrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insuffisants rénaux chroniques sous dialyse péritonéale - MISTRAL</Public_title>
    <Scientific_title>Etude multicentrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insuffisants rénaux chroniques sous dialyse péritonéale - MISTRAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>ROCHE</Primary_sponsor>
    <Date_registration3>20080513</Date_registration3>
    <Date_registration>13/05/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001747-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/06/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Relatifs à la population : &lt;br&gt;1. Patient adulte (= 18 ans) ayant délivré un consentement de participation écrit &lt;br&gt;2. Patient apte selon l’investigateur à se plier aux impératifs de l’étude &lt;br&gt;3. Patient affilié à un régime de sécurité sociale ou bénéficiaire d'un tel régime&lt;br&gt;&lt;br&gt;Relatifs à la pathologie : &lt;br&gt;4. Patient atteint d’insuffisance rénale chronique associée à une anémie, sous dialyse péritonéale depuis au moins 3 mois avant la période de sélection &lt;br&gt;5. Patient chez lequel un minimum de 36 litres de dialysat est infusé par semaine &lt;br&gt;6. Patient ayant un Kt/V total (rénal + dialytique) hebdomadaire = 1.7 et/ou une clairance hebdomadaire totale (rénale + dialytique) &gt; 50 litres &lt;br&gt;7. Patient ayant un taux moyen d’Hb compris entre [10; 12] g/dl pendant la période de sélection (moyenne de 3 valeurs d’Hb mesurées à S-4, S-2 et J0) &lt;br&gt;8. Patient recevant un traitement de maintenance continu en sous-cutané par epoetin ou darbepoetin alfa avec une fréquence d’administration identique pendant la période de sélection et pendant les 4 semaines précédentes &lt;br&gt;9. Patient ayant une dose d’ASE stable pendant la période de sélection (aucun changement de la dose hebdomadaire n’est autorisé) &lt;br&gt;10. Patient ayant un statut martial adéquat (mesuré sur une valeur durant la période de sélection): ferritine sérique &gt; 100 ng/ml et TSAT &gt; 20% (ou pourcentage de globules rouges hypochromes &lt; 10%)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Relatifs à la population : &lt;br&gt;1. Femme enceinte ou allaitant &lt;br&gt;2. Femme en période d’activité génitale sans contraception efficace &lt;br&gt;3. Patient atteint d’une déficience ne lui permettant pas une bonne compréhension des impératifs de l’essai&lt;br&gt;4. Patient ayant déjà été inclus dans le présent essai &lt;br&gt;5. Patient participant à un essai clinique, ou ayant reçu un autre médicament expérimental moins de 3 mois avant la sélection&lt;br&gt;Relatif au traitement à l’essai : &lt;br&gt;6. Au moment de la sélection : patient pour lequel un transfert en hémodialyse est prévu pendant la période de l’étude &lt;br&gt;7. Patient présentant un ou des saignements aigus ou chroniques significatifs notamment gastro-intestinaux dans les 8 semaines précédant la période de sélection &lt;br&gt;8. Patient recevant une ou plusieurs transfusions sanguines (globules rouges) pendant la période de sélection et pendant les 8 semaines précédentes &lt;br&gt;9. Patient recevant un traitement immunosuppresseur (autre que corticoïdes pour une affection chronique, cyclosporine, et anticorps monoclonaux/polyclonaux) pendant la période de sélection et pendant les 8 semaines précédentes &lt;br&gt;10. Patient recevant une dose hebdomadaire d’epoetin &gt; 16000 UI ou dose hebdomadaire de darbepoetin alfa&gt; 80 µg pendant la période de sélection et pendant les 8 semaines précédentes &lt;br&gt;11. Patient ayant un changement de voie d’administration de l’epoetin ou de la darbepoetin alfa pendant la période de sélection &lt;br&gt;12. Patient présentant une hémoglobinopathie (anémie falciforme, thalassémies) &lt;br&gt;13. Patient présentant une hémolyse &lt;br&gt;14. Patient présentant une maladie maligne active dans les 5 dernières années (excepté les cancers cutanés hors mélanome) &lt;br&gt;15. Patient présentant un déficit sérique connu en Vitamine B12 ou en acide folique 16. Patient présentant une hyperparathyroïdie secondaire non contrôlée ou symptomatique &lt;br&gt;17. Patient présentant une péritonite active ou toute autre infection sévère et/ou syndrome inflammatoire nécessitant une antibiothérapie (orale, intraveineuse ou intra péritonéale) pendant la période de sélection &lt;br&gt;18. Patient présentant une hypertension artérielle mal contrôlée, c’est-à-dire une pression artérielle (PAS/PAD) assise &gt; 170/100 mmHg et nécessitant une interruption de traitement par ASE dans les 6 mois précédant la période de sélection&lt;br&gt;19. Patient présentant une crise d’épilepsie dans les 6 mois précédant la période de sélection &lt;br&gt;20. Patient présentant un infarctus du myocarde, coronaropathie sévère ou instable, accident vasculaire cérébral, ou hépatopathie sévère survenant dans les 12 semaines précédant la période de sélection &lt;br&gt;21. Patient présentant un nombre de plaquettes &gt; 500 x 109/L ou &lt; 100 x 109/L &lt;br&gt;22. Patient présentant une insuffisance cardiaque congestive sévère (stade IV de la New York Heart Association) &lt;br&gt;23. Patient présentant ou ayant présenté une érythroblastopénie &lt;br&gt;24. Patient ayant une chirurgie planifiée pendant la durée de l’étude à l’exception d’une intervention pour : cataracte, photocoagulation laser, révision/création d’une voie d’abord vasculaire et chirurgie ambulatoire mineure ne nécessitant pas d’hospitalisation &lt;br&gt;25. Patient présentant une hypersensibilité connue à une érythropoïétine recombinante, au polyéthylène glycol ou à tout autre constituant du traitement à l’étude&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients insuffisants rénaux chroniques sous dialyse péritonéale &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10054353
Term: Chronic renal failure anemia
</Condition>
    <Intervention>&lt;br&gt;Product Code: RO503821/F03&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F04&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F05&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F21&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 120-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F06&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F07&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F08&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glycol-epoetine beta&lt;br&gt;Current Sponsor code: RO503821&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Product Code: RO503821/F23&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: methoxy polyethylene glyco</Intervention>
    <Primary_outcome>Main Objective: Evaluer le maintien du taux d'hémoglobine avec une administration sous-cutanée mensuelle de  C.E.R.A. chez des patients insuffisants rénaux chroniques sous dialyse péritonéale;Secondary Objective: Evaluer la variabilité du taux d'hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. dans cette population de patients&lt;br&gt;&lt;br&gt;Evaluer la tolérance d'une administration sous-cutanée mensuelle de C.E.R.A. dans cette population de patients&lt;br&gt;&lt;br&gt;Evaluer le statut nutritionnel des patients&lt;br&gt;&lt;br&gt;Evaluer la qualité de vie (QdV) des patients;Primary end point(s): Proportion de patients maintenant un taux moyen* d’hémoglobine dans l’intervalle cible [10; 12] g/dl pendant la période d’évaluation d’efficacité (PEE)&lt;br&gt;* Moyenne de 3 valeurs d’Hémoglobine mesurées aux semaines 16, 20 et 24</Primary_outcome>
    <Secondary_ID>ML 21421 </Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2471896</Internal_Number>
    <TrialID>EUCTR2008-008895-15-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Influence de l'introduction du sirolimus sur la balance inflammatoire chez le transplanté rénal - SIRILYGRE</Public_title>
    <Scientific_title>Influence de l'introduction du sirolimus sur la balance inflammatoire chez le transplanté rénal - SIRILYGRE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Hospices Civils de Lyon</Primary_sponsor>
    <Date_registration3>20090318</Date_registration3>
    <Date_registration>18/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008895-15                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/02/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- âge &gt; ou égale à 18 ans&lt;br&gt;- patients transplantés rénaux depuis plus de 3 mois,&lt;br&gt;- suivis dans les Centres Hospitaliers Universitaires de Lyon et Grenoble,&lt;br&gt;- pour lesquels est décidée l’introduction du sirolimus en remplacement des anticalcineurines (quelque soit la cause de ce changement thérapeutique).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- âge &lt; 18 ans, &lt;br&gt;- greffe rein-pancréas, &lt;br&gt;- date de la greffe &lt; 3 mois, &lt;br&gt;- rejet en cours ou mal contrôlé, &lt;br&gt;- suivi de 3 mois non possible, &lt;br&gt;- hypersensibilité au sirolimus ou à l’un des excipients,&lt;br&gt;- absence de contraception efficace chez la femme non ménauposée&lt;br&gt;- absence de consentement éclairé&lt;br&gt;- patient non affilié à un régime de sécurité sociale.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Transplantation rénale &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Product Name: sirolimus&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;CAS Number: 53123889&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-2&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: ;Primary end point(s): - Effets secondaires rattachés au sirolimus : &lt;br&gt;   * effets cliniques, évalués indépendamment par le médecin et par le patient à l’aide d’un questionnaire qui lui sera remis&lt;br&gt;   * effets biologiques&lt;br&gt;- Dosage de cytokines plasmatiques impliquées dans la balance pro / anti inflammatoire&lt;br&gt;- Génotypage du cytochrome P450 3A5&lt;br&gt;;Main Objective: - Déterminer le profil des manifestations inflammatoires cliniques et biologiques après conversion d’un inhibiteur de la calcineurine au sirolimus ;&lt;br&gt;- Déterminer si ces manifestations inflammatoires corrèlent avec une exposition différente à la molécule (relation dose effet, génotype du cytochrome 3A5) ;&lt;br&gt;- Valider l’hypothèse avancée chez les patients anémiques que les manifestations inflammatoires du sirolimus dépendent d’un blocage de la boucle d’autorégulation IL-10 dépendante de l’inflammation.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>HCL/P 2008.537/38</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472146</Internal_Number>
    <TrialID>EUCTR2008-007235-40-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors - VZV-specific CD4+ T cells</Public_title>
    <Scientific_title>Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors - VZV-specific CD4+ T cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Department für Pädiatrie, Medizinische Universität Innsbruck</Primary_sponsor>
    <Date_registration3>20090330</Date_registration3>
    <Date_registration>30/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007235-40                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/06/2009</Date_enrollement>
    <Target_size>180</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients listed for renal transplantation:&lt;br&gt;Patients with renal failure (meeting the criterias for transplantion listing; renal failure stage 4 or 5, glomerular filtration rate &lt; 29ml/min/1.73m2); age 24 months to 80 years; routine VZV vaccination (Varivax)&lt;br&gt;Healthy subjects (according to WHO definition): age 24 months to 80 years; routine VZV vaccination with Varivax&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients listed for renal transplantation:&lt;br&gt;Positive VZV IgG antibody levels at time point 0; immunosuppression at time of vaccinations; malignancies; rheumatic diseases; loss of immunoglobulins; proteinuria; blood transfusion or treatment with intravenous immunglobulin or plasma products in the last 6 months; pregnancy (validated by urine beta-HCG)&lt;br&gt;Healthy subjects: Positive VZV IgG antibody levels at time point 0; malignancies; rheumatic diseases; immunosuppression; cortisone therapy in the last 6 months; cytostatic therapy; blood transfusion or treatment with intravenous immunglobulin or plasma products in the last 6 months; pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients (aged 24 months to 80 years) listed for renal transplantation
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Varivax&lt;br&gt;Product Name: Varivax&lt;br&gt;Product Code: 2-00300&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The proposed study is aimed to investigate the kinetics and maintenance of CD4+ T cell memory by evaluating VZV-specific CD4+ T cells after two-dose VZV vaccination in RTX recipients compared to two control groups of healthy age-matched children after VZV wildtype infection or after VZV vaccination, prospectively. Additionally, VZV IgG antibody levels and IgG avidity are monitored over 18 months in RTX recipients and healthy age-matched controls to assess humoral immunity against VZV. &lt;br&gt;Main objective: percentage of VZV-specific CD4+ T cells;Secondary Objective: VZV-specific IgG antibodies (U/ml) and relative avidity index of VZV-specific IgG antibodies;Primary end point(s): Drop-out criteria for vaccination:&lt;br&gt;Transplantation, immunosuppression, wish of patient, wish of doctor&lt;br&gt;Drop-out criteria for blood withdrawal: &lt;br&gt;wish of patient, wish of doctor&lt;br&gt;</Primary_outcome>
    <Secondary_ID>2008-007235</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472516</Internal_Number>
    <TrialID>EUCTR2008-006772-30-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Evaluation of HCV clearance by hemodialysis</Public_title>
    <Scientific_title>Evaluation of HCV clearance by hemodialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Medical University of Graz</Primary_sponsor>
    <Date_registration3>20090204</Date_registration3>
    <Date_registration>04/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006772-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/03/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Consecutive hemodialysed patients with end-stage renal disease and documented presence of HCV RNA in serum over a period of ?6 months&lt;br&gt;- Age &gt;18 years&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- HCV/HBV or HCV/HIV co-infection&lt;br&gt;- Hematologic disease&lt;br&gt;- Sepsis&lt;br&gt;- Pregnancy&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic hepatitis C in patients with chronic renal failure &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10008912
Term: Chronic hepatitis C
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10066622
Term: Chronic hemodialysis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Pegasys&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;&lt;br&gt;Trade Name: Copegus&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine HCV RNA clearance at different time points during hemodialysis;Primary end point(s): HCV RNA level;Secondary Objective: 1. To assess cellular and humoral immunologic parameters in peripheral blood before and after hemodialysis&lt;br&gt;2. To correlate HCV RNA levels, HCV RNA clearance, and cellular and humoral immunological parameters&lt;br&gt;3. To compare different hemodialysis methods (low flux hemodialysis versus high flux hemodiafiltration) on HCV RNA levels, HCV RNA clearance, and cellular and humoral immunological parameters&lt;br&gt;4. To assess sustained virological response (SVR) to antiviral treatment with peginterferon plus ribavirin&lt;br&gt;5. To relate SVR to HCV clearance and cellular and humoral immunological parameters&lt;br&gt;</Primary_outcome>
    <Secondary_ID>20-026</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472575</Internal_Number>
    <TrialID>EUCTR2007-004590-25-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Determination of immune response after sequential pneumococcal vaccination using the 7-valent conjugate pneumococcal and the 23-valent pneumococcal polysaccharide vaccine in renal transplant recipients</Public_title>
    <Scientific_title>Determination of immune response after sequential pneumococcal vaccination using the 7-valent conjugate pneumococcal and the 23-valent pneumococcal polysaccharide vaccine in renal transplant recipients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Medical University of Vienna</Primary_sponsor>
    <Date_registration3>20090127</Date_registration3>
    <Date_registration>27/01/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004590-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/03/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Adult patients will be recruited at the transplant center of the Medical University of Vienna.&lt;br&gt;Patients will be eligable if between 6 months and 3 years had passed since their kidney transplant and if they have stable allograft function, as evidenced by creatinine level &lt; 250 µl for 1 month prior involvement&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;splenectomy, pneumococcal vaccination within preceeding 5 years, any acute febrile illness in the 2 weeks prior to or at time of enrollment, use of intravenous immunoglobulis within precceding 6 months, history of severe allergic reaction or anaphylaxis, hemoglobin value &lt; 10 g/dl at the time of inclusion &lt;br&gt;</Exclusion_Criteria>
    <Condition>Immunisation of renal transplant patients against streptococcus pneumoniae by conjugated or non conjugated pneumococcal vaccination</Condition>
    <Intervention>&lt;br&gt;Trade Name: Pneumo 23; &lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Prevenar&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To find an optimal vaccination schedule for tranplant patients;Secondary Objective: ;Primary end point(s): The aim of the study is to compare the quantitative antibody response of PPV23 with those of a sequential schedule of PCV7 followed by PPv23 12 months later in adult renal transplant recipients by measuring the concentrations of serotype-specific IgI in sera using ELISA recommended by the WHO.</Primary_outcome>
    <Secondary_ID>0/0</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472747</Internal_Number>
    <TrialID>EUCTR2008-007786-23-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO

RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA</Public_title>
    <Scientific_title>ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO

RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Pfizer, S.A.</Primary_sponsor>
    <Date_registration3>20090217</Date_registration3>
    <Date_registration>17/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007786-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/04/2009</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. CCRm confirmado mediante estudio histológico con un componente histológico de células claras.&lt;br&gt;2. Ningún tratamiento sistémico previo para el CCRm (ni ningún tratamiento adyuvante ni neoadyuvante previo)&lt;br&gt;3. Si el paciente ha recibido radioterapia o una operación quirúrgica previa, ha transcurrido al menos 1 semana desde el final de la radioterapia y al menos 4 semanas desde la cirugía mayor. Toda la toxicidad previa relacionada con el tratamiento deberá haber mejorado a un grado &lt;= de los CTCAE del NCI, versión 3.0, o hasta el valor basal, salvo la alopecia. &lt;br&gt;4. Presencia de enfermedad mensurable (es decir, &gt;= 1 masa tumoral maligna que pueda medirse exactamente en al menos 1 dimensión que tenga un tamaño  &gt;=20 mm con tomografía computadorizada [TC] convencional o resonancia magnética [RM], o  &gt;=10 mm con TC helicoidal usando un algoritmo de reconstrucción de bloques contiguos de 5 mm o más pequeños). No se consideran mensurables las lesiones óseas, ascitis, carcinomatosis peritoneal o lesiones biliares, derrames pleurales o pericárdicos, diseminación linfangítica a la piel o el pulmón, lesiones quísticas o lesiones radiadas. Se permite la radioterapia paliativa previa para las lesiones metastásicas, siempre que persista al menos una lesión mensurable que no haya sido radiada.&lt;br&gt;5. Ausencia de hipertensión no controlada, documentada por dos mediciones basales de la presión arterial obtenidas con una diferencia de al menos 1 hora: las mediciones basales de la presión arterial sistólica deben ser &lt;=140 mm Hg y las mediciones basales de la presión arterial diastólica deben ser &lt;=90 mm Hg. &lt;br&gt;6. Función orgánica adecuada según lo definido por los criterios siguientes:&lt;br&gt;? Recuento absoluto de neutrófilos (RAN)  &gt;=1.500/mm3&lt;br&gt;? Plaquetas  &gt;= 75.000 células/mm3&lt;br&gt;? Hemoglobina  &gt;= 9,0 g/dl.&lt;br&gt;? AST y ALT &lt;= 2,5 veces el límite superior de la normalidad (LSN); si existen metástasis hepáticas, AST y ALT &lt;= 5,0 x LSN;&lt;br&gt;? Bilirrubina total &lt;= 1,5 x LSN;&lt;br&gt;? Creatinina sérica &lt;= 1,5 x LSN o aclaramiento de creatinina calculado &gt;=60 ml/min;&lt;br&gt;? Proteinuria &lt;2+ medida con tira reactiva. Si la tira reactiva es &gt;=2+, se medirá la proteinuria en la orina de 24 horas y los resultados deberán mostrar &lt;2 g por 24 horas.&lt;br&gt;7. Varones o mujeres de edad  &gt;=18 años.&lt;br&gt;8. Estado funcional del ECOG de 0 ó 1.&lt;br&gt;9. Esperanza de vida &gt;= 12 semanas.&lt;br&gt;10. Las mujeres (o sus parejas) deberán estar esterilizadas por métodos quirúrgicos o ser posmenopáusicas, o deberán acceder a usar un método anticonceptivo eficaz mientras reciban el tratamiento del estudio y por lo menos durante 3 meses después (o durante 6 meses, si así lo exige la normativa local). Todas las mujeres en edad fértil deberán dar negativo en una prueba de embarazo (suero/orina) en las 72 horas anteriores al inicio del tratamiento. Los varones (o sus parejas) deberán estar esterilizados por métodos quirúrgicos o deberán acceder a usar un método anticonceptivo eficaz mientras reciban el tratamiento del estudio y por lo menos durante 3 meses después (o durante 6 meses, si así lo exige la normativa local). La definición de un método anticonceptivo eficaz deberá cumplir la normativa local y se basará en el criterio del investigador principal o de un colaborador designado. En este estudio no podrán participar las mujeres lactantes.&lt;br&gt;11. Documento de consentimiento informado firmado y fechado en el que se indique que el paciente (o su representante legal) ha sido informado de todos los aspectos pertinentes del estudio antes de su </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Uso concurrente de más de 2 antihipertensivos. &lt;br&gt;2. Uso previo de axitinib (AG-013736).&lt;br&gt;3. Alteraciones del aparato digestivo como incapacidad para tomar medicación oral; necesidad de alimentación intravenosa; procedimientos quirúrgicos previos que afecten a la absorción, incluida la resección gástrica total; tratamiento por úlcera péptica activa en los 6 meses anteriores; hemorragia digestiva activa no relacionada con el cáncer demostrada por hematemesis, hematoquecia o melena en los 3 meses anteriores sin pruebas de resolución documentada por endoscopia o colonoscopia; síndromes de malabsorción.&lt;br&gt;4. Uso actual o necesidad prevista de tratamiento con fármacos que son inhibidores potentes de la enzima CYP3A4 (p. ej., zumo de pomelo, verapamilo, ketoconazol, miconazol, itraconazol, eritromicina, telitromicina, claritromicina, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir y delavirdina).&lt;br&gt;5. Uso actual o necesidad prevista de tratamiento con fármacos que son inductores de las enzimas CYP3A4 o CYP1A2 (p. ej., carbamazepina, dexametasona, felbamato, omeprazol, fenobarbital, fenitoína, amobarbital, nevirapina, primidona, rifabutina, rifampicina e hipérico).&lt;br&gt;6. Necesidad actual o reciente (en los 10 días previos al comienzo del tratamiento) de dosis terapéuticas completas de anticoagulantes orales o parenterales o de tratamiento diario crónico con ácido acetilsalicílico (&gt;325 mg/día) o clopidogrel (&gt;75 mg/día). &lt;br&gt;7. Trastorno convulsivo o signos de metástasis cerebrales, compresión de la médula espinal o meningitis carcinomatosa. &lt;br&gt;8. Cualquiera de los trastornos siguientes en los 12 meses previos a la administración del fármaco del estudio: infarto de miocardio, angina grave o inestable, injerto de derivación de arterias coronarias o periféricas, insuficiencia cardíaca congestiva sintomática, accidente cerebrovascular o accidente isquémico transitorio, y en los 6 meses previos en caso de trombosis venosa profunda o embolia pulmonar. &lt;br&gt;9. Infección bacteriana, fúngica o vírica activa; enfermedad relacionada con el virus de la inmunodeficiencia humana (VIH) o el síndrome de inmunodeficiencia adquirida (sida). &lt;br&gt;10. Antecedentes de neoplasia maligna (diferente del cáncer de células renales) excepto en los pacientes tratados con intención curativa por cáncer de piel distinto del melanoma, cáncer de mama o cervicouterino in situ, o aquellos tratados con intención curativa por otro cáncer que no hayan tenido signos de enfermedad durante 2 años.&lt;br&gt;11. Demencia o alteración importante del estado mental que impediría la comprensión o la concesión del consentimiento informado y el cumplimiento de los requisitos de este protocolo.&lt;br&gt;12. Cualquier otro trastorno médico o psiquiátrico grave, agudo o crónico, o cualquier anomalía de laboratorio que pueda aumentar el riesgo asociado a la participación en el ensayo o a la administración del fármaco del estudio o interferir en la interpretación de los resultados del estudio y, en opinión del investigador, impedir la participación en este ensayo.&lt;br&gt;</Exclusion_Criteria>
    <Condition>CCR metastásico

Metastatic RCC &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: Axitinib&lt;br&gt;Product Code: AG-013736&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Axitinib&lt;br&gt;CAS Number: 319460-85-0&lt;br&gt;Current Sponsor code: AG-013736&lt;br&gt;Other descriptive name: Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: Axitinib&lt;br&gt;Product Code: AG-013736&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Axitinib&lt;br&gt;CAS Number: 319460-85-0&lt;br&gt;Current Sponsor code: AG-013736&lt;br&gt;Other descriptive name: Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar la tasa de respuesta objetiva (TRO) en los pacientes que reciben axitinib con o sin ajuste de la dosis (grupos A y B);Secondary Objective: Evaluar el perfil de seguridad, otros parámetros de eficacia, la farmacocinética, las relaciones entre los biomarcadores o el perfil de expresión génica con el resultado clínico o la medición de la PA en pacientes que reciben axitinib con o sin ajuste de la dosis (grupos A y B). Aunque la principal comparación del estudio se realiza entre los grupos A y B, la información adicional como la referente a la seguridad y la relación entre el perfil de biomarcadores/expresión génica y los resultados clínicos también se evaluará en el grupo no aleatorizado, el grupo C.;Primary end point(s): TRO (grupos A frente a B)</Primary_outcome>
    <Secondary_ID>A4061046</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2472802</Internal_Number>
    <TrialID>EUCTR2009-010920-24-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio para evaluar la eficacia de Rapamicina en pacientes con Poliquistosis Renal Autosómica Dominante (PQRAD)</Public_title>
    <Scientific_title>Estudio para evaluar la eficacia de Rapamicina en pacientes con Poliquistosis Renal Autosómica Dominante (PQRAD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fundación para la Investigación Biomédica del Hospital Universitario La Paz</Primary_sponsor>
    <Date_registration3>20090312</Date_registration3>
    <Date_registration>12/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-010920-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/08/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Medicación convencional&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Edad igual o mayor de 18 años.&lt;br&gt;2.	Pacientes con antecedentes familiares de PQRAD y/o diagnóstico confirmado de PQRAD tipo1.&lt;br&gt;3.	Serán incluidos los pacientes con una Tasa de Filtración Glomerular (aclaramiento de creatinina) &gt; 70 ml/min.&lt;br&gt;4.	Haber dado su consentimiento informado por escrito.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Embarazo y lactancia.   &lt;br&gt;2.	Pacientes con aclaramiento de creatinina &lt; de 70 ml/min.&lt;br&gt;3.	Pacientes con proteinuria &gt; 500 mg/ 24 h.&lt;br&gt;4.	Administración conjunta de medicamentos inductores o inhibidores del CYP 3A4.&lt;br&gt;5.	Hiperlipemia.&lt;br&gt;6.	Infección severa en el momento de entrar al estudio.&lt;br&gt;7.	Hipersensibilidad a la Rapamicina conocida.&lt;br&gt;8.	Pacientes en quienes no se haya documentado, a través de técnicas de imagen, crecimiento del volumen renal en los 6 meses previos a la aleatorización.&lt;br&gt;9.	Antecedentes de neoplasias en los últimos 2 años excepto cáncer de cérvix o cáncer cutáneo tratado.&lt;br&gt;10.	Participación en otro ensayo clínico.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Poliquistosis Renal Autosómica Dominante (PQRAD)</Condition>
    <Intervention>&lt;br&gt;Trade Name: RAPAMUNE 2 mg comprimidos recubiertos&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: SIROLIMUS&lt;br&gt;Other descriptive name: SIROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): Para evaluar la eficacia de la Rapamicina se comparará el porcentaje de variación del volumen renal (lo mismo hepático) a los 12 meses entre ambos grupos.;Secondary Objective: ?	Monitorizar la evolución de la presión arterial cada 3 meses. &lt;br&gt;?	Monitorizar la aparición de proteinuria cada 3 meses.&lt;br&gt;?	Analizar la evolución de los quistes hepáticos a lo largo del estudio.;Main Objective: Evaluar la eficacia, seguridad y tolerabilidad de Rapamicina para retrasar y/o enlentecer el crecimiento de los quistes y del volumen renal y para prevenir la pérdida de la función renal en pacientes con PQRAD con función renal conservada, midiendo los volúmenes de los riñones por RMN y la función renal durante un periodo de 1 año.</Primary_outcome>
    <Secondary_ID>FLP-RAP-2009-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473082</Internal_Number>
    <TrialID>EUCTR2008-006210-14-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma</Public_title>
    <Scientific_title>Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Amgen Inc</Primary_sponsor>
    <Date_registration3>20090324</Date_registration3>
    <Date_registration>24/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006210-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/04/2009</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sunitinib Malate historical data&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Disease Related&lt;br&gt;• Subjects must have a histologically confirmed metastatic RCC with a clear cell component&lt;br&gt;• Low or intermediate risk according to the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk classification defined as meeting between 0 and 2 of the following risk factors:&lt;br&gt;o Karnofsky performance status &lt; 80%&lt;br&gt;o Time from diagnosis of RCC to first systemic treatment &lt; 1 year&lt;br&gt;o Serum lactate dehydrogenase &gt; 1.5 x upper limit of normal (ULN)&lt;br&gt;o Serum hemoglobin &lt; lower limit of normal (LLN) for their institution&lt;br&gt;o Serum calcium (corrected) &gt; 10 mg/dL&lt;br&gt;*For the corrected calcium value, the following formula should be used:&lt;br&gt;Corrected calcium = Total serum calcium [mg/dL] + (0.8 x (4 – serum albumin [g/dL]))&lt;br&gt;Note: If the units of calcium measurement are in mmol/L (or mmoles/L or mM), then the conversion to mg/dL is as follows:&lt;br&gt;?? Calcium (mmol/L) x 4 = Calcium (mg/dL)&lt;br&gt;?? Calcium (mg/dL) x 0.25 = Calcium (mmol/L)&lt;br&gt;• Measurable disease with at least one unidimensionally measurable lesion per RECIST (see Appendix E).&lt;br&gt;• Left ventricular ejection fraction (LVEF) = 45% as measured by Muga scan or ECHO within 28 days prior to enrollment&lt;br&gt;Demographic&lt;br&gt;• Men or women &gt; 18 years old&lt;br&gt;• ECOG of 0 or 1&lt;br&gt;Laboratory&lt;br&gt;• Adequate organ and hematological function as evidenced by the following laboratory studies within 14 days of enrollment:&lt;br&gt;• Hematological function, as follows:&lt;br&gt;o Absolute neutrophil count (ANC) = 1.5 x 109/L&lt;br&gt;o Platelet count = 100 x 109/L&lt;br&gt;o Hemoglobin = 9 g/dL&lt;br&gt;• Renal function, as follows:&lt;br&gt;o Calculated creatinine clearance &gt; 50 mL/min according to the Cockcroft- Gault formula&lt;br&gt;o Urinary protein quantitative value of &lt; 30 mg in urinalysis or &lt; 1+ on dipstick, unless quantitative protein is &lt; 1000 mg in a 24 hour urine sample&lt;br&gt;• Hepatic function, as follows:&lt;br&gt;o Aspartate aminotransferase (AST) &lt; 2.5 x upper limit of normal (ULN) (if liver metastases are present, = 5 x ULN)&lt;br&gt;o Alanine aminotransferase (ALT) &lt; 2.5 x ULN (if liver metastases are present, = 5 x ULN)&lt;br&gt;o Alkaline phosphatase &lt; 2.0 x ULN (if bone or liver metastases are present, = 5 x ULN)&lt;br&gt;o Bilirubin &lt; 2.0 x ULN&lt;br&gt;• Hemostatic function, as follows:&lt;br&gt;o International Normalized Ratio (INR) &lt; 1.5 per institutional laboratory range&lt;br&gt;o Partial thromboplastin time (PTT) or activated partial thromboplastin (aPTT) = 1.5 x ULN per institutional laboratory range&lt;br&gt;General&lt;br&gt;• Able to tolerate infusions and self-administer oral medications&lt;br&gt;• Competent to comprehend, sign, and date an institutional review board (IRB)/ Independent Ethics Committee (IEC) -approved informed consent form&lt;br&gt;• Subject plans to begin protocol directed therapy within 7 days of enrollment&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Disease Related&lt;br&gt;• Primary tumor in situ&lt;br&gt;o Subjects must have their primary tumor resected to be eligible for this study&lt;br&gt;• Any existing tumor thrombus must be removed before enrollment&lt;br&gt;• Known history of central nervous system metastases. An MRI or CT scan of the brain or head will be performed within 28 days of enrollment.&lt;br&gt;• History of arterial or venous thromboembolism within 12 months prior to enrollment&lt;br&gt;• History of clinically significant bleeding within 6 months prior to enrollment&lt;br&gt;• Previous treatment (excluding surgery, prior cytokine-based immunotherapy and palliative radiotherapy) for advanced or metastatic renal cell carcinoma&lt;br&gt;• Focal radiation therapy for palliation of pain from bony metastases within 14 days of enrollment.&lt;br&gt;• Subjects who received radiation therapy must have recovered from all radiation induced toxicities prior to enrollment&lt;br&gt;Medications&lt;br&gt;• Currently or previously treated with sunitinib or other small molecule inhibitors of VEGF including, but not limited to AMG 706 (motesanib), SU11248 (sunitinib), sorafenib, PTK787 (vatalinib), AZD 2171 (recentin), AEE-788&lt;br&gt;• Currently or previously treated with agents that neutralizing VEGF such as bevacizumab, or VEGF-TRAP&lt;br&gt;• Currently or previously treated with AMG 386, or other molecules that inhibit the angiopoietins or Tie2 receptor including but not limited to, XL-820, XL-184, or CVX- 060/PF-4856884&lt;br&gt;• Currently or previously treated with agents inhibiting the mammalian target of rapamycin (mTOR)&lt;br&gt;• Current or within 30 days prior to enrollment treatment with immune modulators such as cyclosporine and tacrolimus&lt;br&gt;• Concomitant or previous use within 30 days prior to enrollment of any strong inducer of CYP3A4 including, but not limited to, rifampin, St. John’s wort, phenytoin, carbamazepine, phenobarbital and dexamethasone&lt;br&gt;• Concomitant or previous use within 30 days prior to enrollment of any strong inhibitors of CYP3A4 including, but not limited to, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit, and grapefruit juice&lt;br&gt;• Concomitant or previous use of amiodarone within 6 months prior to enrollment&lt;br&gt;General Medical&lt;br&gt;• Known ongoing pancreatitis&lt;br&gt;• Clinically significant cardiovascular disease within 12 months prior to enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication, percutaneous transluminal coronary angioplasty/stent&lt;br&gt;• History of allergic reactions to bacterially produced proteins&lt;br&gt;• Pregnant (i.e., positive beta-human chorionic gonadotropin test) or is breast feeding&lt;br&gt;• Subjects with history of prior malignancy, except:&lt;br&gt;?? Malignancy treated with curative intent and with no known active disease present for = 3 years before enrollment and felt to be at low risk for recurrence by treating physician&lt;br&gt;?? Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease&lt;br&gt;?? Adequately treated cervical carcinoma in situ without evidence of disease&lt;br&gt;?? Prostatic intraepithelial neoplasia without evidence of prostate cancer&lt;br&gt;• Major surgery within 28 days prior to enrollment or still recovering from prior surgery&lt;br&gt;• Minor surgical procedures, placement of central venous access device (except PICC or peripherally inserted central catheter), or fine needle aspiration </Exclusion_Criteria>
    <Condition>Metastatic renal cell carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: AMG 386&lt;br&gt;Product Code: AMG 386&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: AMG 386&lt;br&gt;Current Sponsor code: AMG 386&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to determine the safety and tolerability of AMG 386 in combination with sunitinib in subjects with metastatic renal cell carcinoma;Secondary Objective: • To estimate the efficacy (as measured by objective response rate [ORR], disease control rate [DCR], duration of response [DOR], progression free survival [PFS], overall survival [OS]) and change in continuous measures of tumor burden) of AMG 386 10 mg/kg IV QW in combination with sunitinib (50 mg PO QD) in subjects with metastatic renal cell cancer.&lt;br&gt;• To evaluate the pharmacokinetics (PK) of AMG 386 and sunitinib and its primary active metabolite when used in combination (only in a sub-group of subjects at selected sites outside of Europe for sunitinib and its primary active metabolite) &lt;br&gt;• To determine the incidence of occurrence of anti-AMG386 antibody formation ;Primary end point(s): The primary endpoint is safety and tolerability, as measured by the incidence of adverse events, dose interruptions due to adverse events, dose reductions of sunitinib during the first 12 weeks of study treatment and significant laboratory abnormalities.</Primary_outcome>
    <Secondary_ID>20080579</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473104</Internal_Number>
    <TrialID>EUCTR2008-006072-30-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Mycophénolate sodic in graded increased doses in the first 3 months of renal transplantation _  Pharmacokinetic descriptive Pilot study</Public_title>
    <Scientific_title>Mycophénolate sodic in graded increased doses in the first 3 months of renal transplantation _  Pharmacokinetic descriptive Pilot study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>CHU Saint-Etienne</Primary_sponsor>
    <Date_registration3>20090324</Date_registration3>
    <Date_registration>24/03/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006072-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/01/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- &gt;18 years&lt;br&gt;- Receveurs d’une greffe rénale à partir d'un donneur décédé ou vivant.&lt;br&gt;- Renal transplant from a dead or alive donor.&lt;br&gt;-  Patients treated by initial quadritherapy with basiliximab, tacrolimus, stéroïdes et mycophénolate sodique&lt;br&gt;- Test de grossesse ßHCG négatif à l’initiation du traitement Myfortic®&lt;br&gt;- Contraception efficace pendant le traitement et jusqu’à 6 semaines après le traitement par Myfortic®&lt;br&gt;&lt;br&gt;	&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Patient at high risk of rejection of a transplant&lt;br&gt;- IMC &gt; ou = 30&lt;br&gt;- Platelets &lt; 75000 / mm3 et/ou neutrophiles &lt; 1500 / mm3 et/ou leucocytes &lt; 2500/ mm3 et/ou hémoglobine &lt; 6 g/dL.&lt;br&gt;- Patient requiring a anti-CMV prophylaxis  by valganciclovir.&lt;br&gt;- Pregnant women or allaitantes.&lt;br&gt;</Exclusion_Criteria>
    <Condition>renal transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050436
Term: Prophylaxis against renal transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Product Name: MYFORTIC®&lt;br&gt;Pharmaceutical Form: Cachet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Describe the pharmacokinetics of the MYFORTIC ® ( MPA) with graded increased doses first 3 months of the renal transplantation;Secondary Objective: Determine the parameters of pharmacokinetic modelling of the MPA at renal transplanted patients treated by MYFORTIC ®.;Primary end point(s): Area under the curve (AUC0 - 12 hours) of the MPA and its métabolites MPAG and Ac-MPAG</Primary_outcome>
    <Secondary_ID>0808100</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473450</Internal_Number>
    <TrialID>EUCTR2008-008852-18-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients - PRAEMARKERAAT08</Public_title>
    <Scientific_title>Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients - PRAEMARKERAAT08                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Medizinische Universität Innsbruck Innere Medizin V</Primary_sponsor>
    <Date_registration3>20090422</Date_registration3>
    <Date_registration>22/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008852-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/06/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Histological confirmed Tumor specimen RCC, HCC, CRC or NSCLC &lt;br&gt;Measurable disease according to RECIST criteria                  &lt;br&gt;Age: 18-80 years                                                                     &lt;br&gt;Antiangiogenic Monotherapy (Avastin, Nexavar or Sutent)&lt;br&gt;WHO 0-2                                                                                 &lt;br&gt;Life expectancy of more than 3 months                                  &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Prior or concurrent antitumor therapy (&lt;3 weeks)&lt;br&gt;Pregnant or lactating patients                   &lt;br&gt;Preconditions in which MRI is contraindicated (claustrophopia, certain metal implants, others)                 &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>The present project is an academic clinical trial in which patient suffering from hepatocellular carcinoma, non-small cell lung cancer, renal cell cancer and colorectal cancer treated routinely with antiangiogenic agents. The study protocol intends to include ten patients per tumour entitity (n=40), treated either with Sorafenib (Nexavar), Bevacizumab (Avastin) or Sunitinib (Sutent), which are all approved antiangiogenic drugs in Austria in one of the cancer types defined above.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Product Name: Sutent&lt;br&gt;Product Code: H-C-687   &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Product Name: Nexavar&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;&lt;br&gt;Trade Name: Avastin&lt;br&gt;Product Name: Avastin&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Bevacizumab&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: ;Primary end point(s): Evaluation of biomarker analyses;Main Objective: Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.</Primary_outcome>
    <Secondary_ID>PRAEMARKERAAT08</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473469</Internal_Number>
    <TrialID>EUCTR2009-011497-15-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>PILOT CLINICAL TRIAL WITH MIRCERA (methoxy polyethylene glycol-epoetin beta) IN DIALYSIS UNIT OF A.O. SAN GIOVANNI BATTISTA DI TORINO - ND</Public_title>
    <Scientific_title>PILOT CLINICAL TRIAL WITH MIRCERA (methoxy polyethylene glycol-epoetin beta) IN DIALYSIS UNIT OF A.O. SAN GIOVANNI BATTISTA DI TORINO - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"</Primary_sponsor>
    <Date_registration3>20090422</Date_registration3>
    <Date_registration>22/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011497-15                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/05/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;no evidence of clinical problems with influence on blood crasis (i.e. Infections, bleedings, surgical procedures) in the last 6 months&lt;br&gt;- stable hemoglobin values into NKF-DOKI range (11-12g/dl) or more for minimum three months before study inclusion&lt;br&gt;epoetin alfa, epoetin beta, darbopoetin therapy with modifications inferior to 25% of the dose for minimum three months before study inclusion&lt;br&gt;therapy with ferrum or B12 vitamin or folinic acid administration without any modification for minimum three months before study inclusion&lt;br&gt;last available PTHi value &lt; 500pg/ml&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Drug controindications to MIRCERA: ipersensivity reactions to drug formulation or non controlled arterial hypertension&lt;br&gt;Neoplasia or drug therapy or radioteraphy for previous neoplasia&lt;br&gt;</Exclusion_Criteria>
    <Condition>End stage renal patients in hemodialysis or peritoneal dialysis treatment &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10014647
Term: End stage renal failure
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MIRCERA*IV SC FL 200MCG 1ML&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: noninferiority and safety evaluation of MIRCERA versus conventional epoetin theapy in hemodiaysis and peritoneal dialysis population in Dialysis Unit of A.O. San Giovanni Battista di Torino;Secondary Objective: evaluation of hemoglobin values stability, reticolocytes values stability, sideremia and vitamin status stability and number of therapy modification before and after shift from conventional epoetin therapy to MIRCERA;Primary end point(s): noninferiority and safety evaluation of MIRCERA versus conventional epoetin theapy in hemodiaysis and peritoneal dialysis population in Dialysis Unit of A.O. San Giovanni Battista di Torino</Primary_outcome>
    <Secondary_ID>CERA</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473554</Internal_Number>
    <TrialID>EUCTR2007-004012-31-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>The effects of improving oxygen concentration in the reduction of dialysis induced myocardial stunning – A pilot study - Oxygenation and myocardial stunning</Public_title>
    <Scientific_title>The effects of improving oxygen concentration in the reduction of dialysis induced myocardial stunning – A pilot study - Oxygenation and myocardial stunning                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Derby Hospitals NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20090416</Date_registration3>
    <Date_registration>16/04/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004012-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>06/07/2009</Date_enrollement>
    <Target_size>24</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Other specify the comparator: room air&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Patients on HD treatment at least 3times/week.&lt;br&gt;2.	Willing to provide consent.&lt;br&gt;3.	Male and female, age&gt;18 years old.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Dialysis for &lt;4 months	&lt;br&gt;2.	Unable to obtain echocardiographic data of sufficient quality to allow analysis&lt;br&gt;3.	Cardiac transplant recipients&lt;br&gt;4.	NYHA IV heart failure&lt;br&gt;5.	Chronic obstructive airway disease, other chronic/acute lung condition exacerbating hypoxia and/or unable to tolerate O2 therapy.&lt;br&gt;6.	Patients on long term oxygen therapy (LTOT).&lt;br&gt;7.      Pregnant women or female subjects in childbearing age.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure patients who are receiving haemodialysis treatment &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10066623
Term: Chronic haemodialysis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Oxygen&lt;br&gt;Product Name: Oxygen&lt;br&gt;Pharmaceutical Form: Inhalation gas&lt;br&gt;CAS Number: 7782447&lt;br&gt;Other descriptive name: OXYGEN&lt;br&gt;Concentration unit: l litre(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4 litres-per minute&lt;br&gt;&lt;br&gt;Trade Name: Oxygen&lt;br&gt;Product Name: Oxygen&lt;br&gt;Pharmaceutical Form: Inhalation gas&lt;br&gt;CAS Number: 7782447&lt;br&gt;Other descriptive name: OXYGEN&lt;br&gt;Concentration unit: l litre(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4 litres-per minute&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Test if increasing inhaled O2 concentration at 4 litre/minute via nasal cannulae, reduces dialysis related myocardial stunning.&lt;br&gt;;Primary end point(s): The response to O2 administration at 4 litre/minute during HD on the frequency and severity of myocardial stunning, measured by the number of the new Regional Wall Motion Abnormalities (RWMA) and the reduction in the myocardial contractility in each of the segment affected by RWMAs respectively ;Secondary Objective: 1.      Observe the difference in the haemodynamic variables during HD including the frequency and severity of intradislytic hypotension and pulse rate in response to inhaled O2 at 4litre/min. &lt;br&gt;2.	Observe the difference in the global left ventricular ejection fraction with and without inhaled O2 at 4litre/min, pre and post dialysis.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>RD 5130-009-07</Secondary_ID>
    <Secondary_Sponsor>The University of Nottingham-Research innovation services</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2473601</Internal_Number>
    <TrialID>EUCTR2009-011473-33-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés rénaux de novo traités par une immunosuppression sans inhibiteur de la calcineurine associant Certican® et Myfortic® versus une immunosuppression standard associant Néoral® et Myfortic® (Etude CERTITEM). - CERTITEM</Public_title>
    <Scientific_title>Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés rénaux de novo traités par une immunosuppression sans inhibiteur de la calcineurine associant Certican® et Myfortic® versus une immunosuppression standard associant Néoral® et Myfortic® (Etude CERTITEM). - CERTITEM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Novartis Pharma S.A.S.</Primary_sponsor>
    <Date_registration3>20090515</Date_registration3>
    <Date_registration>15/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011473-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/06/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: single group from transplantation to randomisation (between months 3 and 4)&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Critères d'inclusion à la transplantation:&lt;br&gt;1.Patient, homme ou femme, âgé de 18 à 70 ans.&lt;br&gt;2.Patient receveur d’une première ou deuxième greffe rénale d’un donneur décédé ou vivant apparenté ou non et devant recevoir une thérapie d’induction par basiliximab. &lt;br&gt;3.Temps d’ischémie froide &lt; 30 heures.&lt;br&gt;4.Pour les femmes en âge de procréer, test de grossesse négatif dans les 7 jours précédant la sélection ou au moment de la sélection et utilisation d’une méthode de contraception reconnue et fiable pendant toute la durée de l’étude et pendant 2 mois après l’arrêt du traitement de l’étude, même en cas d’antécédents de stérilité.&lt;br&gt;5.Patient souhaitant et étant capable de participer à l’intégralité de l’étude et ayant donné son consentement par écrit.&lt;br&gt;6.Patient affilié à un régime de sécurité sociale ou bénéficiaire d’un tel régime.&lt;br&gt;&lt;br&gt;Critères d’éligibilité à la randomisation (entre 3 et 4 mois post-tx):&lt;br&gt;1.Biopsie du greffon rénal réalisée à M3 et matériel histologique adéquat adressé pour détermination de la TEM.&lt;br&gt;2.Pour les femmes en âge de procréer, utilisation d’une méthode de contraception reconnue et fiable pendant toute la durée de l’étude et pendant 2 mois après l’arrêt du traitement de l’étude, même en cas d’antécédents de stérilité.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) &lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) &lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Critères de non inclusion à la transplantation&lt;br&gt;1.Patient receveur d’une greffe multi-organes y compris des deux reins ou ayant précédemment reçu une greffe autre que rénale.&lt;br&gt;2.Patient receveur d’un greffon d’un donneur à cœur arrêté.&lt;br&gt;3.Taux d’anticorps anti-HLA = 20% dans les 3 derniers mois précédant l’inclusion.&lt;br&gt;4.Greffon ABO incompatible ou ayant un cross match T positif.&lt;br&gt;5.Hyperlipidémie sévère : cholestérol total = 9,1 mmol/L (= 350 mg/dL) et/ou triglycérides = 8,5 mmol/l (= 750 mg/dL) malgré un traitement hypolipémiant adapté.&lt;br&gt;6.Hypersensibilité ou contre-indications connues à l’acide mycophénolique, à la ciclosporine ou au lactose.&lt;br&gt;7.Hypersensibilité ou contre-indications connues aux macrolides ou aux médicaments de la classe des inhibiteurs des m-TORs.&lt;br&gt;8.Séropositivité pour le VIH, ou hépatites B (Ag HBs) ou C chroniques actives. Les résultats obtenus au cours des 6 mois précédant l’inclusion sont acceptables. Les receveurs de donneurs positifs pour les hépatites B ou C seront exclus.&lt;br&gt;9.Patient ayant une thrombopénie (= 75 000 /mm3), une neutropénie (= 1500 /mm3), une leucopénie (= 2500 /mm3) et/ou une hémoglobine &lt; 8 g/dl à la visite d’inclusion.&lt;br&gt;10.ASAT, ALAT ou bilirubine totale = 3 LNS.&lt;br&gt;11.Infection sévère non contrôlée, allergie sévère nécessitant un traitement aigu ou chronique.&lt;br&gt;12.Patient ayant une pathologie maligne ou des antécédents de pathologie maligne au cours des 5 dernières années, à l’exception d’un carcinome basocellulaire ou spinocellulaire excisé et d’un cancer in situ du col utérin traité.&lt;br&gt;13.Condition médicale ou chirurgicale, à l'exception de la transplantation, qui pourrait exclure le patient selon l'avis de l'investigateur.&lt;br&gt;14.Femme enceinte, allaitante ou en âge de procréer et refusant ou étant incapable d’utiliser une méthode de contraception reconnue et fiable.&lt;br&gt;15.Patient présentant des symptômes de pathologie mentale ou somatique significative. Incapacité à coopérer ou à communiquer avec l'investigateur.&lt;br&gt;16.Patient sous tutelle ou curatelle ou tout patient protégé par la loi.&lt;br&gt;&lt;br&gt;Critères de non éligibilité à la randomisation&lt;br&gt;1.Rejet aigu histologiquement prouvé entre la transplantation et la randomisation (lecture locale).&lt;br&gt;2.Rejet aigu infraclinique (à l’exception d’une lésion borderline) diagnostiqué sur la biopsie de M3 (lecture locale). &lt;br&gt;3.Anticorps anti-donneur positifs à M3.&lt;br&gt;4.Débit de filtration glomérulaire estimé &lt; 30 ml/min/1,73m² (MDRDa).&lt;br&gt;5.Protéinurie = 1 g/24h.&lt;br&gt;6.Hyperlipidémie sévère : cholestérol total = 9,1 mmol/L (= 350 mg/dL) et/ou triglycérides = 8,5 mmol/l (= 750 mg/dL) malgré un traitement hypolipémiant adapté.&lt;br&gt;7.Thrombopénie (= 75 000 /mm3), neutropénie (= 1500 /mm3), leucopénie (= 2500 /mm3) et/ou hémoglobine &lt; 8 g/dl.&lt;br&gt;8.ASAT, ALAT ou bilirubine totale = 3 LNS.&lt;br&gt;9.Condition médicale ou chirurgicale qui serait apparue et pourrait exclure le patient selon l'avis de l'investigateur.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;Trade Name: Néoral&lt;br&gt;Product Name: Néoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Néoral&lt;br&gt;Product Name: Néoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Néoral&lt;br&gt;Product Name: Néoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Néoral&lt;br&gt;Product Name: Néoral&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Myfortic&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: mycophenolic acid&lt;br&gt;Current Sponsor code: ERL 080&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Myfortic&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: mycophenolic acid&lt;br&gt;Current Sponsor code: ERL 080&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentr</Intervention>
    <Primary_outcome>Main Objective: Comparer la progression de la fibrose rénale entre le 3ème et le 12ème  mois post-transplantation selon le profil de transition épithélio-mésenchymateuse (TEM) chez des patients transplantés rénaux de novo recevant soit un traitement immunosuppresseur sans inhibiteur de la calcineurine associant Certican® et Myfortic®, soit un traitement immunosuppresseur standard associant Néoral® et Myfortic®.&lt;br&gt;Cet objectif principal comportera une comparaison principale des groupes de patients TEM+ Néoral® et TEM+ Certican®. &lt;br&gt;Trois comparaisons secondaires porteront sur les paires suivantes : &lt;br&gt;- groupe de patients TEM+ Néoral® versus groupe de patients TEM- Néoral®&lt;br&gt;- groupe de patients TEM- Néoral® versus groupe de patients TEM- Certican®&lt;br&gt;- groupe de patients TEM+ Certican® versus groupe de patients TEM- Certican®&lt;br&gt;;Primary end point(s): Le critère principal est un critère histologique qui consistera à comparer la progression de la fibrose du greffon rénal sur la base du nombre de patients ayant une augmentation =1 du score de FI/AT entre 3 et 12 mois post-transplantation en tenant compte du profil TEM entre les 2 groupes de traitement. ;Secondary Objective: Histologie&lt;br&gt;•Fibrose du greffon à 3 et 12 mois post-transplantation&lt;br&gt;•TEM à 3 et 12 mois post-transplantation&lt;br&gt;•Valeur prédictive de la TEM à 3 mois sur la fibrose du greffon à 12 mois&lt;br&gt;•Incidence des rejets aigus infracliniques et borderline à 3 mois&lt;br&gt;•Autres lésions histologiques&lt;br&gt;&lt;br&gt;Efficacité&lt;br&gt;•Fonction rénale à 6 et 12 mois post-transplantation&lt;br&gt;•Echecs de traitement (RAPB, perte de greffon, perdu de vue ou décès) à 6 et 12 mois post-transplantation&lt;br&gt;•RAPB et rejets traités à 6 et 12 mois post-transplantation&lt;br&gt;•Survies du patient et du greffon à 12 mois post-transplantation&lt;br&gt;&lt;br&gt;Tolérance&lt;br&gt;•Evènements indésirables, EI graves&lt;br&gt;•Arrêts prématurés de l’étude et du traitement à l’étude et raisons d’arrêt&lt;br&gt;•Paramètres métaboliques&lt;br&gt;•Doses et concentrations résiduelles (C0) de Certican&lt;br&gt;•Doses et concentrations sanguines (C0 et C2) de Néoral&lt;br&gt;•Doses et variations de doses (réduction, augmentation, interruption) de Myfortic&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CRAD001AFR10</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473624</Internal_Number>
    <TrialID>EUCTR2006-004822-97-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - Combination Infliximab and Sorafenib in RCC</Public_title>
    <Scientific_title>A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - Combination Infliximab and Sorafenib in RCC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>The Royal Marsden NHSF Trust</Primary_sponsor>
    <Date_registration3>20090508</Date_registration3>
    <Date_registration>08/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004822-97                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>09/01/2007</Date_enrollement>
    <Target_size>51</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.&lt;br&gt;&lt;br&gt;2. The presence of one or more clinically or radiologically measurable lesions&lt;br&gt;&lt;br&gt;3. ECOG performance status 0 or 1&lt;br&gt;&lt;br&gt;4. Life expectancy greater than 12 weeks&lt;br&gt;&lt;br&gt;5. At least 21 days since major surgery and 7 days since skin/tumour biopsy&lt;br&gt;&lt;br&gt;6. The capacity to understand the patient information sheet and the ability to provide written informed consent&lt;br&gt;&lt;br&gt;7. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures&lt;br&gt;&lt;br&gt;8. Male or female, age 18 or greater&lt;br&gt;&lt;br&gt;9. Women must be postmenopausal (no menstrual period for a minimum of 1 year) or have a negative serum pregnancy test on entry in the study (even if surgically sterilized).  Men and women of childbearing potential must use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last study treatment&lt;br&gt;&lt;br&gt;10. Serum aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 x upper limit of normal (ULN) &lt;br&gt;&lt;br&gt;11. Total serum bilirubin =1.5 x ULN &lt;br&gt;&lt;br&gt;12. Serum creatinine =1.5 x ULN &lt;br&gt;&lt;br&gt;13. Haemoglobin =9.0 g/dL&lt;br&gt;&lt;br&gt;14. Absolute neutrophil count =1.5 x 109/L &lt;br&gt;&lt;br&gt;15. Platelets =100 x 109/L  &lt;br&gt;&lt;br&gt;16. Prothrombin time (PT) =1.5 x ULN &lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Previous treatment with monoclonal antibodies or antibody fragments, or known hypersensitivity to any murine proteins or other infliximab components&lt;br&gt;&lt;br&gt;2. Known infection with human immunodeficiency virus (HIV) and / or hepatitis B surface antigen or hepatitis C&lt;br&gt;&lt;br&gt;3. Known history of serious infections (e.g. hepatitis, pneumonia or pyelonephritis) in the previous 3 months&lt;br&gt;&lt;br&gt;4. Opportunistic infections (e.g. herpes zoster (shingles), cytomegalovirus, active pneumocystis carinii, aspergillosis, histoplasmosis, or atypical mycobacteria infection other than TB) within the last 6 months&lt;br&gt;&lt;br&gt;5. History of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (e.g. nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area) or splenomegaly#&lt;br&gt;&lt;br&gt;6. Current signs or symptoms of severe progressive or uncontrolled hepatic, haematologic, gastrointestinal, endocrine, pulmonary or cardiac disease other than directly related to RCC&lt;br&gt;&lt;br&gt;7. Intracranial disease, unless there has been radiological evidence of stable intracranial disease &gt; 6 months. In the case of a solitary brain metastasis, evidence of a disease-free interval of at least 3 months post surgery.  All patients previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days&lt;br&gt;&lt;br&gt;8. Previous treatment with a tyrosine kinase inhbitor or anti-angiogenic agent (licensed or investigational) such as sunitinib or bevacizumab&lt;br&gt;9. Any drug (licensed or investigational) that targets the RAS or EGFR pathway&lt;br&gt;&lt;br&gt;10. Any chemotherapy, immunotherapy or hormonal treatment over the last 4 weeks. Palliative radiotherapy to symptomatic disease sites is permitted&lt;br&gt;&lt;br&gt;11. Women who are pregnant, nursing, or planning pregnancy within 6 months after the last treatment (this includes men who plan to father a child within 6 months of the last treatment)&lt;br&gt;&lt;br&gt;12. Chest radiograph at screening that shows evidence of malignancy, infection, or any abnormalities suggestive of TB as described in Appendix C&lt;br&gt;&lt;br&gt;13. Ineligibility according to the TB eligibility assessment, screening, and early detection of reactivation rules (see Appendix C)&lt;br&gt;&lt;br&gt;14. Malignancy other that the condition being treated or a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence&lt;br&gt;&lt;br&gt;15. Use of any investigational drug within 30 days prior to screening or within 50 days of infliximab infusion&lt;br&gt;&lt;br&gt;16. Presence of a transplanted solid organ (with the exception of a corneal transplant) &gt; 3 months prior to screening&lt;br&gt;&lt;br&gt;17. History of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results&lt;br&gt;&lt;br&gt;18. Peripheral neuropathy greater than grade 1 according to the Common Terminology Criteria (CTC) criteria&lt;br&gt;&lt;br&gt;19. Concomitant diagnosis or history of congestive heart failure as assessed by the investigator&lt;br&gt;&lt;br&gt;20. Uncontrolled hypertension or hypertension treated with 2 or more anti-hypertensive agents&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic Renal Cell Carcinoma (RCC) &lt;br&gt;MedDRA version: 8.1
Level: HLT
Classification code 10038408
Term: Renal cell carcinomas
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Remicade&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): Phase I: Doses of infliximab and sorafenib in combination that are safe and tolerable&lt;br&gt;&lt;br&gt;Phase II: Proportion of patients progression free at six months&lt;br&gt;;Main Objective: This is a phase I / II design. &lt;br&gt;The objective of the phase I section is to define a safe and tolerable dose of infliximab and sorafenib in combination and to assess its pharmacokinetics and pharmacodynamics.&lt;br&gt;&lt;br&gt;The objective of the phase II section is to assess safety and efficacy of the combination in a Simon 2 stage design. The primary efficacy variable will be the proportion of patients progression free after 6 months of treatment.&lt;br&gt;;Secondary Objective: Secondary efficacy variables will be &lt;br&gt;1.  Pharmacokinetics of the combination of infliximab and sorafenib &lt;br&gt;2. Changes in predictive biomarkers and pharmacodynamic markers induced by the combination of  infliximab and sorafenib&lt;br&gt;3. Response rate at 12 weeks of treatment and best response to therapy  &lt;br&gt;4. Overall survival median and 95% Confidence Interval, CI; also PFS median and 95% CI.&lt;br&gt;5. Correlation of biological markers in original nephrectomy specimen (if available) or on-study biopsies with clinical outcome and serum biomarkers such as TNF?? IL-6 and CCL2&lt;br&gt;</Primary_outcome>
    <Secondary_ID>EU-RD-001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473732</Internal_Number>
    <TrialID>EUCTR2009-011505-16-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis</Public_title>
    <Scientific_title>Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Medizinische Universität Wien,KIM I,Klinische Abteilung für Infektionen u.Tropenmedizin</Primary_sponsor>
    <Date_registration3>20090526</Date_registration3>
    <Date_registration>26/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011505-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/01/2010</Date_enrollement>
    <Target_size>8</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Male or female, aged between 18 and 85 years&lt;br&gt;•	Patients on APD using Icodextrin (Extraneal) for the long daytime dwell &lt;br&gt;•	Willingness and ability to comply with the protocol&lt;br&gt;•	Signed informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	any systemic infection&lt;br&gt;•	peritonitis or catheter-related infection which required antibiotic treatment within 2 months prior to the start of the study .&lt;br&gt;•	Allergy or hypersensitivity against study drug.&lt;br&gt;•	Severe hepatic impairment (Child-Pugh Class C)&lt;br&gt;•	Pregnancy, or women of child bearing potential not willing to apply adequate contraception during study period&lt;br&gt;•	Any disease considered relevant for proper performance of the study or risks to the patient, at the discretion of the investigator&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>A total of 8 patients with renal insufficiency and treatment with automated peritoneal dialysis (APD) will be enrolled into this study evaluating the pharmacokinetics of fosfomycin in this special patient group. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10034660
Term: Peritoneal dialysis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fosfomycin&lt;br&gt;Product Name: Fosfomycin&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1. Determination of concentrations of fosfomycin in plasma and dialysate after single intraperitoneal or intravenous application in APD-patients&lt;br&gt;&lt;br&gt;  ;Secondary Objective: 2. Calculation of PK/PD indices to estimate target site efficacy of fosfomycin. &lt;br&gt;;Primary end point(s): AUC, Cmax, Half-life (t1/2), time to reach maximum drug concentration (tmax)</Primary_outcome>
    <Secondary_ID>3.0</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473747</Internal_Number>
    <TrialID>EUCTR2009-012010-52-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma - mRCC</Public_title>
    <Scientific_title>Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma - mRCC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Department of Oncology, Aarhus University Hospital</Primary_sponsor>
    <Date_registration3>20090528</Date_registration3>
    <Date_registration>28/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012010-52                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/08/2009</Date_enrollement>
    <Target_size>118</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Avastin, IL-2, IFN alpha vs IL-2, IFN alpha alone&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Signed written informed consent obtained prior to any study specific screening procedures.&lt;br&gt;2.	Patient must be willing and able to comply with the protocol.&lt;br&gt;3.	Age ? 18.&lt;br&gt;4.	Histologic og cytologic biopsy proven locally advanced or metastatic renal cell carcinoma, considered non-candidates for curative surgery. Nephrectomy is not mandatory.&lt;br&gt;5.	Patient with renal cell carcinoma (RCC) with a clear-cell histologic component confirmed by local pathology review. (Patient with true papillary, sarcomatoid features without any clear cell component, chromophobe, oncocytoma, collecting duct tumours, Bellini tumours and transitional cell carcinoma are not allowed.)&lt;br&gt;6.	If metastatic disease is diagnosed more than two years from the date of the initial diagnosis of RCC, histological or cytological confirmation of renal cell carcinoma (clear cell type) origin of the metastatic lesion(s) is mandatory.&lt;br&gt;7.	Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.&lt;br&gt;8.	Fertile women of childbearing potential (&lt;2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilisation).&lt;br&gt;9.	Memorial-Sloan-Kettering-Cancer-Centre favourable- and intermediate prognostic group.&lt;br&gt;10.	Measurable or non-measurable disease (as per RECIST criteria) &lt;br&gt;11.	Karnofsky Performance status ? 70%.&lt;br&gt;12.	Life expectancy greater than 4 months.&lt;br&gt;13.	The required laboratory values at baseline are as follows:&lt;br&gt;14.	Haematology: &lt;br&gt;15.	WCC = 3.0 x 109/L, Platelet count = 100 x 109/L, Haemoglobin = 6.2 mmol/l, International Normalized Ratio (INR) = 1.5, APTT = 1.5 x ULN&lt;br&gt;16.	Biochemistry:&lt;br&gt;Total bilirubin = 1.5 x upper limit of normal (ULN), AST, ALT = 2.5 x ULN in patients without liver metastases, = 5 x ULN in patients with liver metastases, Serum Creatinine  = 150 ?mol/L&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Prior systemic treatment for metastatic RCC disease (including neo-adjuvant therapy).&lt;br&gt;2.	Major surgical procedure, open surgical biopsy, or significant traumatic injury within 28 days prior to randomization.&lt;br&gt;3.	Serious non-healing wound, ulcer or bone fracture.&lt;br&gt;4.	Evidence of current central nervous system (CNS) metastases or spinal cord compression. Patient must undergo an MRI or CT scan of the brain (with contrast, if possible) within 28 days prior to randomization. &lt;br&gt;5.	Seizure(s) not controlled with standard medical therapy.&lt;br&gt;6.	Dipstick urine test of protein = 2+.&lt;br&gt;7.	Other malignancies within 5 years prior to randomization (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).&lt;br&gt;8.	Evidence of bleeding diathesis or coagulopathy.&lt;br&gt;9.	Ongoing or recent (within 10 days prior to study treatment start) need for full therapeutic dose of oral anticoagulants or chronic daily treatment with aspirin. Low molecular weight heparin are allowed&lt;br&gt;10.	Uncontrolled hypertension (? 160 mm Hg systolic and/or ? 100 mm Hg diastolic) while receiving chronic medication.&lt;br&gt;11.	Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents (= 6 months before randomisation), myocardial infarction (= 6 months before randomisation), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication.&lt;br&gt;12.	Recent (within the 30 days prior to randomization) treatment with another investigational drug or participation in another investigational study. &lt;br&gt;13.	Chronic treatment with corticosteroids (dose of = 10 mg/day methylprednisolone equivalent), excluding inhaled steroids.&lt;br&gt;14.	History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications.&lt;br&gt;15.	Known hypersensitivity to interleukin-2, Inferferon, alpha or bevacizumab.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient with previously untreated Metastatic Renal Cell Carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Avastin&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Bevacizumab&lt;br&gt;CAS Number: 216974-75-3&lt;br&gt;Current Sponsor code: RO4876646&lt;br&gt;Other descriptive name: rhuMAb VEGF, anti-VEGF &lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Avastin as monotherapy has effect in mRCC. Avastin in combination with interferon-alfa (IFN-a) has significant efficacy in mRCC and has been approved by EMEA. &lt;br&gt;The present study will assess whether the combination of Interleukin-2 (IL-2) and IFN-a with Avastin may add efficacy in patients with mRCC with a tolerable safety profile.&lt;br&gt;Progression Free Survival;Secondary Objective: Response rate, overall survival (OS), duration of response, time to progression, time to treatment failure, tolerability, frequency of surgical resection of residual disease and frequency of no evidence of disease (NED). To explore the immunomodulatory effect of therapy in serial blood samples and serial tumor core biopsies and to correlate these biomarkers with outcome. To assess dynamic contrast-enhanced imaging as a potential biomarker;Primary end point(s): Primary objective&lt;br&gt;•	To determine the efficacy of the combination of interleukin-2 / interferon alfa-2b plus bevacizumab as compared with interleukin-2 /interferon-alfa 2b in patients with metastatic RCC, based on progression free survival (PFS).&lt;br&gt;</Primary_outcome>
    <Secondary_ID>mRCC</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473764</Internal_Number>
    <TrialID>EUCTR2009-012673-35-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Etude pharmacocinétique et pharmacodynamique comparant deux posologies différentes de la Thymoglobuline® en transplantation rénale. - THYMO</Public_title>
    <Scientific_title>Etude pharmacocinétique et pharmacodynamique comparant deux posologies différentes de la Thymoglobuline® en transplantation rénale. - THYMO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>CHRU de TOURS</Primary_sponsor>
    <Date_registration3>20090528</Date_registration3>
    <Date_registration>28/05/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012673-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/07/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: 2 different doses&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-	Patient âgé(e) de plus de 18 ans,&lt;br&gt;-	Première ou seconde transplantation rénale,&lt;br&gt;-	Patient avec PRA (Panel Reactive Antibody) &lt; 20% et un cross-match négatif&lt;br&gt;-	Patient pour lequel un suivi d’au moins un an est prévu&lt;br&gt;-	Patient ayant donné son consentement éclairé et écrit pour participer à l’essai clinique.&lt;br&gt;-	Patient affilié à la sécurité sociale&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Patient ayant reçu une induction par Thymoglobuline® ou par un autre ATG lors d’une transplantation antérieure,&lt;br&gt;-	Patient ayant un poids = 50 kg ou = 85 kg&lt;br&gt;-	Temps d’ischémie froide avec un risque de reprise retardée de la fonction du greffon (DGF) (c'est-à-dire avec une IF&gt; 24 h)&lt;br&gt;-	Femme en période d’activité génitale sans contraception efficace, &lt;br&gt;-	Patient avec greffes d’organes multiples &lt;br&gt;-	Patient avec une infection active, ou avec une suspicion d’infection par VIH, VHB ou VHC, ou de tuberculose&lt;br&gt;-	Patient pour lequel est prévue une vaccination dans l'année&lt;br&gt;-	Patient atteint d’une déficience ne lui permettant pas une bonne compréhension des impératifs de l’essai, &lt;br&gt;-	Patient sous sauvegarde de justice, sous tutelle ou curatelle, &lt;br&gt;-	Patient présentant une contre-indication à la Thymoglobuline® (hypersensibilité connue aux protéines de lapin ou à l'un des composants de la préparation)&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal transplantation &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: THYMOGLOBULINE® 5 mg/ml&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparer les paramètres pharmacocinétiques et pharmacodynamiques de 2 posologies d’immunoglobulines anti-thymocytes de lapin (rATG Thymoglobuline®) à la dose standard sur 4 jours ou à dose élevée sur 2 jours, en association avec le MMF, un retrait précoce des corticoïdes et l’introduction retardée du tacrolimus, chez 2 groupes de patients transplantés rénaux.;Secondary Objective: * Évaluer l’influence du polymorphisme génétique du récepteur Fc?RIIIa sur les paramètres pharmacocinétiques et pharmacodynamiques.&lt;br&gt;* Évaluer la tolérance de l’induction par 2 posologies de Thymoglobuline® par :&lt;br&gt;•	le recours à la dialyse durant la première semaine définissant la reprise retardée de fonction du greffon&lt;br&gt;•	la créatininémie à J5, une créatininémie supérieure à 250 µmol/L en l’absence de dialyse définissant une reprise lente de fonction rénale&lt;br&gt;•	l’évolution de la fonction rénale selon Cockroft à 3 mois et à 1 an&lt;br&gt;•	le taux de rejet aigu sur les 3 premiers mois et à 1 an&lt;br&gt;•	la survie des patients et des greffons à 1 an &lt;br&gt;•	l’incidence des infections en particulier à CMV, de la maladie sérique et des syndromes lymphoprolifératifs&lt;br&gt;;Primary end point(s): - Paramètres pharmacocinétiques de la Thymoglobuline® et de la Thymoglobuline® active :&lt;br&gt;o	concentration totale et active&lt;br&gt;o	demi-vie d’élimination&lt;br&gt;o	aire sous la courbe des concentrations en fonction du temps (AUC)&lt;br&gt;o	Paramètres pharmacocinétiques correspondant à un modèle à 2 compartiments (CLc, CLp, Vc, Vp)&lt;br&gt;&lt;br&gt;- Paramètres pharmacodynamiques :&lt;br&gt;o	Évolution des numérations lymphocytaires : lymphocytes totaux CD4, CD8, CD56, CD19&lt;br&gt;o	Évolution de l’expression des marqueurs des populations de cellules T régulatrices (Treg): CD4+ CD25+ CD127- FoxP3+&lt;br&gt;o	Évolution de l’expression des marqueurs des cellules T naïves et mémoires : CD4 CD45 RA, CD4 CD45 RO, CD27, CD62L&lt;br&gt;&lt;br&gt;- Polymorphisme génétique :&lt;br&gt;o	Polymorphisme génétique du récepteur Fc?RIIIa&lt;br&gt;&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>PHAO08-YL/THYMO</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2473772</Internal_Number>
    <TrialID>EUCTR2008-006438-82-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Vitamin D og kronisk nyreinsufficiens</Public_title>
    <Scientific_title>Vitamin D og kronisk nyreinsufficiens                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Odense Universitetshospital, Nyremedicinsk Afd. Y</Primary_sponsor>
    <Date_registration3>20090602</Date_registration3>
    <Date_registration>02/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006438-82                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/06/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Chronic kidney disease (CKD 3-5 and renal transplanted patients)&lt;br&gt;- Age &gt; 18 years&lt;br&gt;- Vitamin D insufficiency or deficiency (25-OHD &lt; 50nmol/l, 3 months before project start)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Treatment with vitamin D2/D3 (dose more than 10000 IU within the last 3 months)&lt;br&gt;- hypercalcæmi (Ca-ion &gt; 1.35 mmol/L) more than 4 weeks despite missing intake of calcium containing preparations and aktivated vitamin D&lt;br&gt;- uncontrolled hyperphosphatæmia (S-phosphat &gt; 2.2 mmol/L &lt;br&gt;- Sarcoidose&lt;br&gt;- Malignant disease &lt;br&gt;- psychotic disorders&lt;br&gt;- Pregnancy and lactation&lt;br&gt;- Allergy to soya&lt;br&gt;</Exclusion_Criteria>
    <Condition>Investigating the effects of treatment with not activated vitamin D (cholecalciferol) in chronic kidney disease petients with vitamin D deficiency.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dekristol&lt;br&gt;Product Name: Cholecalciferol&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CHOLECALCIFEROL&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Pharmaceutical form of the placebo: Capsule, soft&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Purpose of the experiment is to investigate the effect of treatment with not activated vitamin D (cholecalciferol) compared with placebo in a trial including chronic kidney disease patients with vitamin D deficiency. Multible biological variables are monitored in order to assess any effect on the biological system (calcium-phosphat metabolism, bone and endotel markers, inflammation and muscle function);Secondary Objective: ;Primary end point(s): - Calcium phosphate associated metabolites&lt;br&gt;- Bone markers&lt;br&gt;- Endotel markers&lt;br&gt;- Inflammation&lt;br&gt;- Muscle function</Primary_outcome>
    <Secondary_ID>001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474119</Internal_Number>
    <TrialID>EUCTR2008-004746-81-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effect of amiloride on lithium-induced chronic nephropathy.
Comparing discontinuation of lithium treatment to adding amiloride while continuing lithium treatment.</Public_title>
    <Scientific_title>Effect of amiloride on lithium-induced chronic nephropathy.
Comparing discontinuation of lithium treatment to adding amiloride while continuing lithium treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Parnassia-BAVO groep</Primary_sponsor>
    <Date_registration3>20090213</Date_registration3>
    <Date_registration>13/02/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004746-81                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/07/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Group 1 stops lithium (control), group 2 continues lithium with amiloride added&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients are eliglible for participation in case of&lt;br&gt;&lt;br&gt;Long-term use of lithium treatment, defined as having used lithium for at least five years prior to inclusion.&lt;br&gt;progressive renal faillure defined as an increase of plasma creatinine levels of at least 10umol/l/year for at least five years. with r2 &gt;/= 0.85 and a maximal serum creatinine level of 200umol/L.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patients with either hyper or hypotension. Use of antihypertensive medication is allowed.&lt;br&gt;not being able to provide informed consent for participation&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal failure due to long-term use of lithium salts in patients with bipolar disorders. &lt;br&gt;MedDRA version: 9.1
Level: HLT
Classification code 10004938
Term: Bipolar disorders
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10009121
Term: Chronic renal failure worsened
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Modamide&lt;br&gt;Product Name: amiloride (modamide)&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AMILORIDE (Modamide)&lt;br&gt;CAS Number: 2016-88-8 &lt;br&gt;Current Sponsor code: not available&lt;br&gt;Other descriptive name: not available&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: determining the effect on kidney functioning of addition of amiloride to continuing lithium treatment in patients with lithium induced renal failure.&lt;br&gt;&lt;br&gt;&lt;br&gt;;Secondary Objective: Comparing the effect of addition of amiloride treatment to continuing lithium treatment with discontinuation of lithium treatment in patients with renal failure;Primary end point(s): a decrease in renal faillure defined as a decrease in plasma creatinine level of at least 50% in nine months.&lt;br&gt;&lt;br&gt;Creatinine clearance (estimated by using MDRD), lithium serum level, blood pressure  and potasium levels will be monitored with three month intervals during a two year follow-up period. In addition patients` psychiatric condition will be evaluated.</Primary_outcome>
    <Secondary_Sponsor>St. Elisabeth Ziekenhuis;University Medical Center Utrecht</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2474360</Internal_Number>
    <TrialID>EUCTR2009-013547-11-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sodium Bicarbonate for the prevention of Contrast Induced Nephropathy in patients undergoing CTPA - The Nephros Study</Public_title>
    <Scientific_title>Sodium Bicarbonate for the prevention of Contrast Induced Nephropathy in patients undergoing CTPA - The Nephros Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Leids Universitair Medisch Centrum</Primary_sponsor>
    <Date_registration3>20090715</Date_registration3>
    <Date_registration>15/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013547-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/07/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Doing nothing&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-estimated glomerular filtration rate (eGFR) &lt; 60 ml/min&lt;br&gt;- clinical suspected acute pulmonary embolism with an indication for CTPA with intravenous administration of iso osmolar contrast media.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Age &lt; 18 years&lt;br&gt;- Exposure to radiographic contrast media within 7 days&lt;br&gt;- Pregnancy&lt;br&gt;- Systolic bloodpressure &lt; 100 mmHg&lt;br&gt;- Allergy for contrast media&lt;br&gt;</Exclusion_Criteria>
    <Condition>The prevention of Contrast Induced Nephropathy is under investigation.
Contrast induced nephropathy (CIN) can occur after injecting radiographic iso osmolair contrast media. Patients with a renal impairment or a decreased renal function and aspecially in combination with diabetis mellitus are at risk for developing CIN.
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10037790
Term: Radiocontrast nephropathy
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Natriumwaterstofcarbonaat 1,4%&lt;br&gt;Product Name: Natriumwaterstofcarbonaat&lt;br&gt;Product Code: N.A.&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;CAS Number: 0&lt;br&gt;Other descriptive name: SODIUM HYDROGEN CARBONATE&lt;br&gt;Concentration unit: % percent&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.4-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): - Mean increase in serum creatinine 2-4 days after CTPA;Main Objective: -Evaluation of the mean increase in serum creatinine following CTPA (CT- pulmonary angiography) without prehydration compaired to a short prehydration regime with sodium bicarbonate during one hour.;Secondary Objective: -Evaluation of the incidence of CIN following CTPA without prehydration compaired to a short prehydration regime with sodium bicarbonate during one hour.&lt;br&gt;-Furthermore, the risk of developing CIN after CTPA with iso-osmolair contrast media is studied for both patient groups</Primary_outcome>
    <Secondary_ID>09-059</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474478</Internal_Number>
    <TrialID>EUCTR2008-005806-38-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with advanced solid tumors</Public_title>
    <Scientific_title>A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with advanced solid tumors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>F.Hoffmann-La Roche Ltd.</Primary_sponsor>
    <Date_registration3>20090806</Date_registration3>
    <Date_registration>06/08/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005806-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/10/2009</Date_enrollement>
    <Target_size>134</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. [Phase Ib] Patients must have histologically confirmed recurrent or refractory advanced solid malignancy with no known standard of care according to the judgment of the investigator (including Hodgkin’s and non-Hodgkin’s lymphoma)&lt;br&gt;&lt;br&gt;[Phase II] Patients must have histologically confirmed:&lt;br&gt;• Advanced metastatic renal cell carcinoma (RCC) with evidence of progressive disease despite prior VEGFr- TKI therapy.&lt;br&gt;• Advanced low- to intermediate grade metastatic or unresectable locoregional pancreatic neuroendocrine tumors (pNET) and carcinoid tumors who have failed standard therapy and have evidence of progressive disease. Patients with either carcinoid or islet cell tumors&lt;br&gt;will be included in this cohort.&lt;br&gt;&lt;br&gt;2. Measurable disease according to RECIST in Phase II&lt;br&gt;&lt;br&gt;3. Male and female patients, = 18 years age &lt;br&gt;&lt;br&gt;5. Patients with treated, asymptomatic, stable CNS metastases are eligible for enrollment only if:&lt;br&gt;• Patient has received prior treatment  to the site(s) of CNS metastatic disease at least 4 weeks prior to treatment&lt;br&gt;• Patient has no requirement for glucocorticoids (discontinued at least 3 weeks prior to treatment) &lt;br&gt;• Patient is not taking anticonvulsants (discontinued at least 3 weeks prior to treatment)&lt;br&gt;• Patient has no overt evidence of neurological deficit&lt;br&gt;&lt;br&gt;6. ECOG performance status 0-2 &lt;br&gt;&lt;br&gt;7. Patients must have adequate organ and marrow function &lt;br&gt;&lt;br&gt;8. Negative pregnancy test (serum ß-HCG) within 7 days of startingStudy treatment in women of childbearing potential (both premenopausal women and women &lt; 2 years after the onset of menopause).&lt;br&gt;&lt;br&gt;10. HbA1c = 7% at screening.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Prior treatment with agents that act via inhibition of the IGF-1R&lt;br&gt;pathway.&lt;br&gt;&lt;br&gt;2. Prior treatment with agents that act via mTOR inhibition (e.g. sirolimus, temsirolimus, everolimus) for the phase II portion only.&lt;br&gt;&lt;br&gt;3. Patients with untreated CNS metastases.&lt;br&gt;&lt;br&gt;5. Previous or current anti cancer therapy: Patients who are currently receiving any anti cancer therapy (other than those administered on this study) or who have received:&lt;br&gt;• Radiotherapy = 4 weeks prior to enrollment&lt;br&gt;• Chemotherapy (including biologic therapy) = 4 weeks prior to enrollment&lt;br&gt;• Patients who have received therapy more than 4 weeks prior to enrollment who have not recovered adverse events to = grade 1, (excluding alopecia)&lt;br&gt;&lt;br&gt;7. History of allogeneic bone marrow transplantation or organ transplantation.&lt;br&gt;&lt;br&gt;11. Patients who are pregnant or breastfeeding.&lt;br&gt;&lt;br&gt;12. Fertile men and women of childbearing potential not employing an effective method of birth control throughout the trial and for 3 months after last study drug administration in both sexes. Women of childbearing potential must have a negative pregnancy test (serum ß- HCG) within the 7 days prior to study drug administration.&lt;br&gt;&lt;br&gt;13. Known hypersensitivity to R1507 or its excipients or to RAD001 or compounds of similar chemical or biologic composition to RAD001.&lt;br&gt;&lt;br&gt;14. Any known severe and/or uncontrolled medical conditions&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>PIb: solid malignancy that is metastatic or unresectable 
PII: C 1: Advanced metastatic renal cell carcinoma 
C 2: Advanced low- to intermediate grade metastatic or unresectable locoregional pancreatic neuroendocrine tumors + carcinoid tumors &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050076
Term: Metastatic renal carcinoma
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10065147
Term: Malignant solid tumor
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10052399
Term: Neuroendocrine tumour
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10026664
Term: Malignant pancreatic islet neoplasm
</Condition>
    <Intervention>&lt;br&gt;Product Name: huMab IGF1-R&lt;br&gt;Product Code: RO4858696/F05&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;Current Sponsor code: RO4858696&lt;br&gt;Other descriptive name: R1507 (CHO)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 125-&lt;br&gt;&lt;br&gt;Trade Name: AFINITOR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Current Sponsor code: 3745429.013&lt;br&gt;Other descriptive name: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): The primary endpoints are defined according to the cohort in which a patient is entered into the study:&lt;br&gt;– Progression-free survival rate at 24 weeks after start of therapy in the advanced renal cell carcinoma cohort&lt;br&gt;– Progression-free survival rate at 24 weeks in the advanced NET cohort.&lt;br&gt;;Main Objective: P Ib:&lt;br&gt;• To characterize the safety and tolerability of R1507 administered every 3 weeks in combination with daily RAD001 and to determine the maximum-tolerated dose (MTD) of RAD001 administered orally daily, in combination with R1507 administered intravenously every 3 weeks in patients with advanced solid malignancies, and to determine the recommended dose of RAD001 for the phase II study of the combined regimen.&lt;br&gt;P II:&lt;br&gt;• To assess the clinical activity of combination R1507 and RAD001 in two cohorts of patients, defined by:&lt;br&gt;• PFS rate at 24 weeks, in a cohort of patients with advanced stage renal cell carcinoma [RCC cohort],&lt;br&gt;• PFS rate at 24 weeks, in a cohort of patients with advanced low to intermediate grade metastatic or unresectable locoregional pancreatic neuroendocrine tumors (pNET) and carcinoid tumors, [NET cohort].&lt;br&gt;• NOTE: the NET cohort will be comprised of equal numbers of patients of 2 tumor subgroups, (pancreatic islet cell tumors and carcinoid tumors);Secondary Objective: Phase Ib:  &lt;br&gt;• To describe the tolerability and adverse event profile of the combination of R1507 and RAD001 in patients with advanced solid tumors. &lt;br&gt;• To describe pharmacokinetics (PK) of the combination of RAD001 and R1507 using a population PK approach&lt;br&gt;• To evaluate preliminary anti-tumor activity of the combination.&lt;br&gt;&lt;br&gt;Phase II:  &lt;br&gt;• To determine the overall objective response rate, response duration, progression-free survival and overall survival in two cohorts of patients 1) patients with advanced stage renal cell carcinoma (RCC) cohort, and 2) patients with advanced low- to intermediate grade metastatic or unresectable locoregional neuroendocrine tumors (NET) cohort.&lt;br&gt;• To determine the tolerability and adverse event profile of combination R1507 and RAD001 in patients with advanced solid tumors. &lt;br&gt;• To describe pharmacokinetics (PK) of the combination of RAD001 and R1507 using a population PK approach.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>NO21884</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474744</Internal_Number>
    <TrialID>EUCTR2009-013541-28-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Intérêt de l’utilisation d’un inhibiteur de la mTor (everolimus) pour la minimisation des anticalcineurines dans les transplantations rénales de type « old for old » (receveur &gt; 60 ans recevant un greffon &gt; 60 ans) - EVEROLD</Public_title>
    <Scientific_title>Intérêt de l’utilisation d’un inhibiteur de la mTor (everolimus) pour la minimisation des anticalcineurines dans les transplantations rénales de type « old for old » (receveur &gt; 60 ans recevant un greffon &gt; 60 ans) - EVEROLD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>CHU de Brest</Primary_sponsor>
    <Date_registration3>20090929</Date_registration3>
    <Date_registration>29/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013541-28                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/10/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• première ou deuxième transplantation rénale d’un patient de 60 ans ou plus&lt;br&gt;• recevant un greffon rénal de 60 ans ou plus &lt;br&gt;• immunisation prégreffe &lt; 30 %&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• troisième greffe ou plus&lt;br&gt;• immunisation supérieure à 30%&lt;br&gt;• bi greffe ou greffe multiorgane&lt;br&gt;• greffe à donneur vivant&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Candidat de 60 ans et plus à une greffe rénale et bénéficiant d'un greffon de donneur de 60 ans et plus &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10038533
Term: Renal transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: SIMULECT&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for injection&lt;br&gt;&lt;br&gt;Trade Name: THYMOGLOBULINE&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;&lt;br&gt;Trade Name: NEORAL&lt;br&gt;Product Name: Ciclosporine&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;&lt;br&gt;Trade Name: CERTICAN&lt;br&gt;Product Name: Everolimus&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Primary end point(s): Fonction rénale calculée à un an par la formule MDRD simplifiée;Main Objective: Etudier l'intérêt sur la fonction rénale à un an du remplacement de la ciclosporine par Everolimus  soit d"emblée soit après un mois de greffe chez les transplantés rénaux de plus de 60 ans recevant un greffon rénal de plus de 60 ans;Secondary Objective: •	Comparer les trois stratégies immunosuppressives en terme de survie patient et greffon, incidence de rejet, sortie d’étude, effets secondaires.&lt;br&gt;•	Promouvoir un programme de greffe de type old for old sur l’ensemble du territoire français. &lt;br&gt;•	Étudier les caractéristiques immunologiques du sujet âgé.&lt;br&gt;•	Étudier la pharmacocinétique et pharmacogénétique de l’everolimus&lt;br&gt;</Primary_outcome>
    <Secondary_ID>RB 09.074</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474748</Internal_Number>
    <TrialID>EUCTR2007-006274-29-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sympathetic activation, microcirculation, haemostasis and inflammation in diabetic and non-diabetic kidney disease: disease modification by vitamin D receptor activation - VDRA and CKD</Public_title>
    <Scientific_title>Sympathetic activation, microcirculation, haemostasis and inflammation in diabetic and non-diabetic kidney disease: disease modification by vitamin D receptor activation - VDRA and CKD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Karolinska Institutet at Danderyd University Hospital</Primary_sponsor>
    <Date_registration3>20090922</Date_registration3>
    <Date_registration>22/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006274-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/11/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Man or woman above 20 years of age.&lt;br&gt;If woman in reproductive age: not nursing and not pregnant (preseting a negative pregnancy test), and on anticonception therapy.&lt;br&gt;Calculated GFR between 15-59 mL/min/1.73m2 using MDRD  &lt;br&gt;S-Ca2+ &lt;2.6 mmol/L&lt;br&gt;iPTH between 35-500 pg/mL &lt;br&gt;Serum albumin &gt; 3.0 g/dL &lt;br&gt;Signed informed consent&lt;br&gt;&lt;br&gt;For inclusion in the diabetes study group:&lt;br&gt;•	Diagnosed type II diabetes, and treated with peroral antidiabetics or insulin the last 12 months&lt;br&gt;•	HbA1c &lt;= 12% &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Changes in ACE-inhibitor medication or ARB within 8 weeks before start of the study. &lt;br&gt;&lt;br&gt;Nefrotic syndrome&lt;br&gt;Expected need for dialysis within 6 months after study start&lt;br&gt;Vitamin D treatment within 6 months before start of the study.&lt;br&gt;Poorly controlled hypertension with blood pressure &gt;150/100 mmHg (repeated measurements after 15 minutes rest)&lt;br&gt;Concomitant treatment with drugs affecting bone and calcium metabolism such as kalcitonin, cinacalcet (Mimpara or Parareg), and high dose corticosteroids. &lt;br&gt;Concomitant treatment with drugs inhibiting or inducing Cytokrom P450 3A.&lt;br&gt;Known hypersensitivity to any of the substances in study drug or placebo.&lt;br&gt;Diabetic nefropathy and concurrent glomerulonefritis or nefritis&lt;br&gt;Acute renal failure within 12 weeks before screening&lt;br&gt;Other severe chronic disease (AIDS/HIV-positive, cancer, severe heart failure etc.)&lt;br&gt;Known kidney artery stenosis&lt;br&gt;Known kidney stone disease&lt;br&gt;Intake of other investigational medicinal product within 30 days before screening.&lt;br&gt;Known alcohol or drug abuse&lt;br&gt;Known low compliance&lt;br&gt;Not suitable for participation for other reason according to investigators opinion.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with mild to moderate chronic renal failure (CRF; GFR 15-60ml/min; n=26)
Patients with mild to moderate CRF and coexisting Diabetes Mellitus (n=26)

 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10045242
Term: Type II diabetes mellitus
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zemplar&lt;br&gt;Product Name: Zemplar&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: paricalcitol&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The major goal of this study is to develop an enhanced understanding of the disturbances involved in how a progressive loss of kidney function cause increased cardiovascular disturbance, disease and ultimately death, and if some of these disturbances can be ameliorated and modified by treatment with a VDRA. Furthermore, evidence suggest that Diabetic kidney disease constitute a separate entity with certain characteristics that may respond differently to treatment with VDRA. Thus we intend to compare diabetic kidney disease with non-diabetic.&lt;br&gt;As kidney disease is characterized by increased neurohormonal activation and sympathetic overactivity, the primary outcome variable will be a change (reduction) in sympathetic activity as measured by a tungsten microelectrode inserted percutaneously into a fascicle of the peroneal nerve at the level of the fibular head (muscle sympathetic nerve activity: MSNA).&lt;br&gt;;Secondary Objective: A) 	To determine whether sympathetic overactivity cause sympathovagal imbalance, reflected in altered heart rate variability, disturbed baroreflex regulation, and altered transfer-function between blood pressure and sympathetic nerve activity? May these disturbances be ameliorated by treatment with VDRA?&lt;br&gt;B)	Endothelial dysfunction and increased arterial stiffness are common features in severe renal failure, and have been shown even before diagnosis in DM-II. To which degrees are they present in mild to moderate CKD, and how do they correlate with other physiological changes? May these disturbances be modified by treatment with VDRA?&lt;br&gt;C/	Several factors involved in haemostasis and inflammation are independent risk factors for mortality in patients with end stage renal disease. Is the haemostasis disturbed in mild to moderate CKD, and if so, is this correlated to sympathetic activation and impaired microcirculatory control? May these disturbances be ameliorated by treatment with VDRA?;Primary end point(s): Sympathetic activation measured by microneurography at the conclusion of the 12 weeks treatment period.</Primary_outcome>
    <Secondary_ID>ZEMPLAR</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2474907</Internal_Number>
    <TrialID>EUCTR2009-011236-35-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A post-marketing safety study in patients with moderate renal insufficiency who receive Omniscan (Gadodiamide Injection) for contrast enhanced magnetic resonance imaging (MRI)

Estudio de seguridad poscomercialización en pacientes con insuficiencia renal moderada a los que se les administra OMNISCAN (inyección de gadodiamida) para la adquisición de imágenes de RM (IRM) realzada con contraste.</Public_title>
    <Scientific_title>A post-marketing safety study in patients with moderate renal insufficiency who receive Omniscan (Gadodiamide Injection) for contrast enhanced magnetic resonance imaging (MRI)

Estudio de seguridad poscomercialización en pacientes con insuficiencia renal moderada a los que se les administra OMNISCAN (inyección de gadodiamida) para la adquisición de imágenes de RM (IRM) realzada con contraste.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>GE Healthcare Limited and its Affiliates</Primary_sponsor>
    <Date_registration3>20091013</Date_registration3>
    <Date_registration>13/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011236-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/10/2009</Date_enrollement>
    <Target_size>600</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;(1) The subject is 18 years of age or older at time of study entry.&lt;br&gt;(2) The subject is physically able and willing to comply with study procedures and a signed and dated informed consent is obtained.&lt;br&gt;(3) The subject has been referred for a clinically indicated MRI examination with a gadolinium-based contrast agent (GBCA).&lt;br&gt;(4) The subject has known or suspected chronic kidney disease with an eGFR &gt;30 and &lt;60 mL/min/1.73m2 as measured within 30 days prior to the planned index OMNISCAN administration.&lt;br&gt;(5) The subject agrees to be contacted for follow-up for 24 months.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;(1) Patients with known or suspected NSF based on biopsy confirmation or the onset of signs and symptoms of NSF lasting at least  7 days as follows: (a) skin - swelling, hardening and tightening; reddened or darkened patches; burning or itching ; (b) eyes - yellow raised spots on whites of eyes; or (c) bones and muscle - stiffness in joints; difficulty in moving or straightening of arms,&lt;br&gt;hands, legs or feet; bone pain especially in hips and ribs or muscle weakness.&lt;br&gt;(2) Patients allergic to any GBCA.&lt;br&gt;(3) Patients with chronic renal disease with a GFR &lt;30 mL/min/1.73m2 as measured within 30 days prior to the planned index OMNISCAN administration.&lt;br&gt; (4) Patients with acute renal insufficiency of any severity due to the hepato-renal syndrome&lt;br&gt;or in the peri-operative liver transplantation period.&lt;br&gt;(5) Patients that were exposed to any GBCA within a period of 12 months prior the planned index administration of OMNISCAN.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with moderate renal insufficiency (estimated eGFR &gt; 30 and &lt;60 mL/min/1.73m2).

Pacientes con insuficiencia renal moderada (tasa de filtración glomerular [TFG] &gt;estimada 30 y &lt;60 ml/min/1,73 m2). &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10064499
Term: Nephrogenic fibrosing dermopathy
</Condition>
    <Intervention>&lt;br&gt;Trade Name: OMNISCAN  0,5 mmol/ml solución inyectable&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: GADODIAMIDA&lt;br&gt;CAS Number: 122795-43-1&lt;br&gt;Other descriptive name: GADODIAMIDE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 287-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To capture post-marketing safety information on patients with moderate renal insufficiency (eGFR &gt;30 and &lt;60 mL/min/1.73m2) undergoing routine contrast-enhanced MRI with OMNISCAN in order to assess the risk of developing nephrogenic systemic fibrosis (NSF).;Secondary Objective: Not applicable.;Primary end point(s): The primary endpoint will be the development of NSF, whether or not confirmed histologically.</Primary_outcome>
    <Secondary_ID>GE-041-075</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475063</Internal_Number>
    <TrialID>EUCTR2009-014997-16-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Identification of patients with high probability of not or poorly responding to therapy with mycophenolic acid pro-drugs.</Public_title>
    <Scientific_title>Identification of patients with high probability of not or poorly responding to therapy with mycophenolic acid pro-drugs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Medizinische Universität Wien, Abteilung für Nephrologie und Dialyse</Primary_sponsor>
    <Date_registration3>20091021</Date_registration3>
    <Date_registration>21/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014997-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/04/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;de novo kidney graft&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;highly immunized patients (due to previous transplantations etc) with PRA levels &gt;40%&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with a de novo kidney transplantation &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic&lt;br&gt;Product Name: Mycophenolate sodium&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Detection of functionally relevant SNPs in IMPDH 2 gene.;Secondary Objective: The association of detected SNPs in inosine monophosphate dehydrogenase-2 transcript or high IMPDH 2 activity with biopsy proven rejection reactions in the first year after transplantation.;Primary end point(s): Biopsy proven rejection</Primary_outcome>
    <Secondary_ID>MPASNP1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475112</Internal_Number>
    <TrialID>EUCTR2009-016797-32-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase 2/3, twelve-month, multicenter, intra-subjectcontrolled
(retrospective-prospective), open-label,
active-treatment study to evaluate the efficacy, safety,
tolerability and pharmacokinetics of cinacalcet
hydrochloride for the treatment of secondary
hyperparathyroidism in paediatric subjects with chronic
kidney disease on dialysis, followed by 12-month study
extension. - Cinacalcet in paediatric secondary HPT due to CKD</Public_title>
    <Scientific_title>Phase 2/3, twelve-month, multicenter, intra-subjectcontrolled
(retrospective-prospective), open-label,
active-treatment study to evaluate the efficacy, safety,
tolerability and pharmacokinetics of cinacalcet
hydrochloride for the treatment of secondary
hyperparathyroidism in paediatric subjects with chronic
kidney disease on dialysis, followed by 12-month study
extension. - Cinacalcet in paediatric secondary HPT due to CKD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>ISTITUTO GIANNINA GASLINI</Primary_sponsor>
    <Date_registration3>20091102</Date_registration3>
    <Date_registration>02/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016797-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/11/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: controllo intra-paziente retrospettivo-prospettico&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Other specify the comparator: controllo intra-paziente con terapia standard&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;To be eligible for inclusion into this study, the subjects must fulfill all of the following&lt;br&gt;criteria at study entry:&lt;br&gt;- Parents/guardian written informed consent, and childs assent given before any studyrelated&lt;br&gt;procedure not part of the subjects normal medical care, with the understanding&lt;br&gt;that consent may be withdrawn by the subject at any time without prejudice to his or her&lt;br&gt;future medical care.&lt;br&gt;- Age &gt; 2 and &lt;18 years;&lt;br&gt;- A dry body weight (BW) &gt;10.49 Kg in males and &gt;9.95 Kg in females, respectively;&lt;br&gt;- Inpatient or outpatient status at the time of enrolment;&lt;br&gt;- Males or females. Female subjects sexually active must be neither pregnant nor breastfeeding,&lt;br&gt;and must lack childbearing potential from screening visit to the end of the&lt;br&gt;safety follow-up, as defined by using an effective form of contraception (i.e. condoms,&lt;br&gt;oral contraceptives or intra-uterine device-IUD). Medically approved contraception&lt;br&gt;could include abstinence. Oral contraception will be accompanied by a barrier method.&lt;br&gt;A negative serum pregnancy test is required prior to initiation of treatment with study&lt;br&gt;medication.&lt;br&gt;- On stable hemodialysis (HD) or peritoneal dialysis (PD) for their CKD for at least one&lt;br&gt;month before entering the 6-month pre-treatment period;&lt;br&gt;- Plasma iPTH levels &gt; 300 pg/mL, AND&lt;br&gt;- Plasma calcium (Ca) levels &gt; 9.4 mg/dL (with normal serum albumin level), AND&lt;br&gt;- Plasma phosphorus (P) levels &lt;6.5 mg/dL in patients younger than 6 years, or &lt;6.0&lt;br&gt;mg/dL in older patients, OR&lt;br&gt;- &amp;#61531;Ca x P&amp;#61533; product &gt; 60;&lt;br&gt;- Records availability for the following parameters 6 months prior to study entry:&lt;br&gt;demographic information, physical examination, height and dry weight,&lt;br&gt;auxological/anthropometric indices, blood pressure values, Kt/V urea, plasma iPTH,&lt;br&gt;calcium, phosphorus, and alkaline phosphatase levels, blood pH and bicarbonate,&lt;br&gt;serum creatinine/urea, C reactive protein (CRP) levels, liver function tests, blood&lt;br&gt;count, blood 25(OH) vitamin D3 level.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;To be eligible for inclusion in this study the subjects must not meet any of the following&lt;br&gt;criteria at study entry:&lt;br&gt;- The following laboratory values: Hb&lt;9.0 g/dL, WBC&lt;2000/mm3 (2x109/L), platelets&lt;br&gt;&lt;150,000/mm3 (150x109/L) only in subjects who are otherwise eligible for PK/PD&lt;br&gt;assessments; abnormal liver function, defined by a total bilirubin &amp;#8805;2 times the upper&lt;br&gt;limit of normal values, aspartate aminotransferase, alanine aminotransferase or &amp;#947; &lt;br&gt;glutamyltranspeptidase (&amp;#947;-GT) levels &amp;#8805;2 times the upper limit of normal values.&lt;br&gt;- Any other lab values that in the opinion of the investigator might place the subject at&lt;br&gt;unacceptable risk for participation in the study.&lt;br&gt;- History of malignancy (active malignancy, or off therapy since less than 1 year)&lt;br&gt;- History of diseases causing hypercalcemia (primary hyperparathyroidism; parathyroid&lt;br&gt;carcinoma; Williams syndrome; prolonged immobilization)&lt;br&gt;- Chronic inflammatory diseases (C-Reactive Protein-CRP &gt;2 times the upper limit of&lt;br&gt;normal values) requiring a concomitant corticosteroid or immunosuppressive therapy&lt;br&gt;- History of infectious diseases (including opportunistic infections) within 4 weeks&lt;br&gt;prior to study entry&lt;br&gt;- Evidence as assessed by the Investigator of active or latent bacterial, viral or fungal&lt;br&gt;infections at the time of potential enrollment, including subjects with evidence of&lt;br&gt;Human Immunodeficiency virus (HIV) infection.&lt;br&gt;- Hepatitis-B surface antigen-positive subjects only in subjects who are otherwise&lt;br&gt;eligible for PK/PD assessments&lt;br&gt;- Hepatits C antibody-positive subjects who are also PCR-positive or RIBA positive&lt;br&gt;only in subjects who are otherwise eligible for PK/PD assessments&lt;br&gt;- Use of recombinant human growth hormone therapy&lt;br&gt;- Use of tricyclic antidepressant use&lt;br&gt;- Use of drugs that interact with cinacalcet disposition, such as ketoconazole,&lt;br&gt;itraconazole, telythromycin, voryconazole, ritonavir, rifampin&lt;br&gt;- Previous use of cinacalcet&lt;br&gt;- History of hypersensitivity to any of the ingredients of the study drug.&lt;br&gt;- Use of any investigational drug, device or biologic within 4 weeks prior to study entry&lt;br&gt;or during the study.&lt;br&gt;</Exclusion_Criteria>
    <Condition>secondary
hyperparathyroidism in paediatric subjects with chronic
kidney disease &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020708
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MIMPARA&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Trade Name: MIMPARA&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;&lt;br&gt;Trade Name: MIMPARA&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 90-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: -To determine the efficacy of cinacalcet HCl plus standard therapy for SHPT in paediatric&lt;br&gt;subjects with CKD on dialysis by assessing the response to treatment (e.g., a reduction from&lt;br&gt;baseline &gt;25% in mean intact parathyroid hormone (iPTH) levels with concomitant values&lt;br&gt;for P&lt;6 mg/dL and Ca between 8.4-10.5 mg/dL or &amp;#61531;Ca x P&amp;#61533; product &lt;60) after 6 months&lt;br&gt;compared to standard therapy alone intra-subject;&lt;br&gt;AND&lt;br&gt;- To evaluate the overall safety and tolerability of cinacalcet HCl plus standard therapy for&lt;br&gt;SHPT in paediatric patients with CKD on dialysis over 6 months compared to standard&lt;br&gt;therapy alone intra-subject.;Secondary Objective: -to determine the efficacy of cinacalcet HCl plus standard therapy in the target population&lt;br&gt;by assessing the response to treatment during the induction period over 6 months, and during&lt;br&gt;the maintenance period over 12 months;&lt;br&gt;- To evaluate the overall safety and tolerability of cinacalcet HCl plus standard therapy in the&lt;br&gt;target population over 18 months;&lt;br&gt;- To evaluate the effects of cinacalcet HCl on bone growth by measuring anthropometric&lt;br&gt;indices (Height-for-Age, Weight-for-Age, Weight-for-Height, Body Mass Index-for-Age)&lt;br&gt;and subject growth velocity over 18 months;&lt;br&gt;- In a subset of adolescent subjects (12-18 yrs), to assess the pharmacokinetics&lt;br&gt;(PK)/pharmacodynamic (PD) profile of cinacalcet HCl and its correlation with iPTH target&lt;br&gt;levels and testosterone level when applicable;&lt;br&gt;- In a subset of children (2-11 yrs), to explore the population clinical pharmacology of&lt;br&gt;cinacalcet HCl.;Primary end point(s): The primary study endpoint (EP) will be the proportion of recruited patients who will have a&lt;br&gt;reduction from baseline of at least 25% in mean iPTH levels with concomitant values for&lt;br&gt;plasma P &lt;6 mg/dL and Ca between 8.4 and 10.5 mg/dL or the &amp;#61531;Ca x P&amp;#61533; product &lt;60 during&lt;br&gt;the 6-month, intra subject-controlled, efficacy-assessment phase.</Primary_outcome>
    <Secondary_ID>IGG_ev_003</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475361</Internal_Number>
    <TrialID>EUCTR2009-010827-23-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio nacuinal, multicéntrico, abierto, de tratamiento de inducción con VELCADE y Dexametasona en pacientes con mieloma múltiple e insuficiencia renal no tratados previamente</Public_title>
    <Scientific_title>Estudio nacuinal, multicéntrico, abierto, de tratamiento de inducción con VELCADE y Dexametasona en pacientes con mieloma múltiple e insuficiencia renal no tratados previamente                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fundación PETHEMA</Primary_sponsor>
    <Date_registration3>20091210</Date_registration3>
    <Date_registration>10/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-010827-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>02/02/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- El paciente se encuentra, en opinión del investigador, dispuesto y capacitado para cumplir con los requisitos del protocolo.&lt;br&gt;- El paciente o su representante legal ha otorgado voluntariamente su consentimiento informado por escrito antes de la realización de cualquiera de los procedimientos relacionados con el estudio, que no forman parte de la atención médica normal, entendiendo que dicho consentimiento puede ser retirado por parte del paciente en cualquier momento sin que ello suponga un perjuicio en su atención médica futura.&lt;br&gt;- Edad mayor o igual de 18 años.&lt;br&gt;- Se trata de un paciente con diagnóstico reciente de mieloma múltiple sintomático, según  los criterios estándar y que no ha recibido ningún tratamiento anterior con quimioterapia para el mieloma múltiple.&lt;br&gt;- El paciente presenta una enfermedad medible, definida como sigue:&lt;br&gt;          - Para el mieloma múltiple secretor, la enfermedad medible se define como  valores de proteína monoclonal cuantificables en suero de IgG&gt;10g/l o IgA&gt;5g/l  y, si procede, excreción de cadena ligera en orina mayor o igual a 200 mg/24 horas.&lt;br&gt;          - Para el mieloma múltiple oligosecretor o no secretor, la enfermedad medible se define por la presencia plasmocitomas de tejido blando (no óseo), determinados en el examen clínico o radiológico pertinente (p.ej. MRI, CT-Scan). En pacientes con mieloma múltiple oligosecretor, las mediciones de proteína M en suero y/o en orina son muy bajas y de difícil seguimiento para la evaluación de la respuesta. En los pacientes con mieloma múltiple no secretor, no se detecta proteína M en suero o en orina mediante inmunofijación.&lt;br&gt;- El paciente posee un estado funcional de ECOG menor o igual a 2.&lt;br&gt;- El paciente posee una esperanza de vida superior a 3 meses.&lt;br&gt;- Filtrado glomerular determinado por MDRD &lt;50 ml/min&lt;br&gt;- El paciente presenta los siguientes valores de laboratorio en los 14 días anteriores a la administración del fármaco en estudio:&lt;br&gt;          - Recuento plaquetario mayor o igual a 50x109/l.&lt;br&gt;          - Recuento absoluto de neutrófilos (ANC) igual o superior a 0.75 x 10 9/ L.&lt;br&gt;          - Calcio en suero corregido (ver anexo 15) menor o igual a 14mg/dl.&lt;br&gt;          - Aspartato transaminasa (AST): inferior o igual a 2,5 x el límite superior normal.&lt;br&gt;          - Alanintransaminasa (ALT): menor o igual a 2,5 x el límite superior normal.&lt;br&gt;          - Bilirrubina total: inferior o igual a 1,5 x el límite superior normal.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Filtrado glomerular determinado por MDRD &amp;#8805; 50ml/min&lt;br&gt;- MM asintomático con insuficiencia renal atribuible a otras causas&lt;br&gt;- Paciente que anteriormente ha recibido tratamiento con VELCADE&lt;br&gt;- Paciente que anteriormente ha recibido tratamiento para el mieloma múltiple&lt;br&gt;- Paciente sometido a cirugía mayor en las 4 semanas anteriores al reclutamiento.&lt;br&gt;- Paciente con recuento plaquetario menor de 50x10 9/l en los 14 días anteriores al reclutamiento.&lt;br&gt;- Paciente con recuento absoluto de neutrófilos menor de 0,75x10 9/l en los 14 días anteriores al reclutamiento. &lt;br&gt;- Paciente con neuropatía periférica mayor o igual a Grado 2 en los 14 días anteriores al reclutamiento.&lt;br&gt;- Paciente con hipersensibilidad frente a bortezomib, ácido bórico o manitol.&lt;br&gt;- Paciente que ha recibido otros fármacos en investigación en los 14 días anteriores al reclutamiento.&lt;br&gt;- Paciente con seropositividad conocida frente al virus de la inmunodeficiencia humana (VIH).&lt;br&gt;- Paciente que ha sufrido un infarto de miocardio en los 6 meses anteriores al reclutamiento o que presenta una insuficiencia cardiaca de cualquier clase (III ó IV según la Asociación de Cardiología de Nueva York &lt;NYHA&gt;), angina inestable, arritmias ventriculares graves no controladas o evidencia electrocardiográfica de isquemia aguda, anomalías del sistema de conducción activas o cualquier otra condición o dolencia cardiológica que, a juicio del especialista, suponga un factor de riesgo para desarrollar insuficiencia cardiaca, digno a tener en cuenta.&lt;br&gt;- Paciente que participa en otro estudio de investigación clínica y/o está siendo tratado con un producto en investigación por cualquier motivo.&lt;br&gt;- Paciente con enfermedad pulmonar difusa y/o enfermedad pericárdica&lt;br&gt;- Embarazo, lactancia o mujeres potencialmente fértiles que no utilizan ni utilizarán durante el estudio un método anticonceptivo efectivo aprobado médicamente desde la selección hasta al menos 30 días después de finalizar el último ciclo de tratamiento. Si es varón, el sujeto se compromete a usar un método anticonceptivo de barrera aceptable desde la selección hasta como mínimo 30 días después de recibir el último ciclo de tratamiento.&lt;br&gt;- Historia previa de otras enfermedades malignas diferentes al mieloma (excepto para carcinoma basal o escamoso de la piel, o carcinoma in situ de cérvix o mama) a menos que el paciente se encuentre libre de enfermedad más allá de 5 años&lt;br&gt;- Hipertensión arterial o diabetes mellitus mal controladas o cualquier otra enfermedad orgánica grave que suponga un riesgo excesivo para el paciente o cualquier alteración psiquiátrica que interfira con la comprensión del consentimiento informado.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Mieloma Múltiple e insuficiencia renal no tratados previamente &lt;br&gt;MedDRA version: 9
Level: LLT
Classification code 10028228
Term: Multiple myeloma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: VELCADE 3,5 mg, polvo para solución inyectable&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: BORTEZOMIB&lt;br&gt;Other descriptive name: BORTEZOMIB&lt;br&gt;Concentration unit: mg/m2 milligram(s)/square meter&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.3-&lt;br&gt;&lt;br&gt;Trade Name: FORTECORTIN 8 mg comprimidos&lt;br&gt;Product Name: FORTECORTÍN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DEXAMETASONA&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Other descriptive name: DEXAMETHASONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 8-&lt;br&gt;&lt;br&gt;Trade Name: FORTECORTIN 4 mg comprimidos&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DEXAMETASONA&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Other descriptive name: DEXAMETHASONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;&lt;br&gt;Trade Name: FORTECORTIN 1 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DEXAMETASONA&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Other descriptive name: DEXAMETHASONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Estudiar la eficacia en términos de tasa de respuesta;Secondary Objective: - Estudiar la rapidez y grado de respuesta (variación en la cuantía del componente M en suero y orina) tras cada ciclo de bortezomib/dexametasona.&lt;br&gt;- Reversibilidad de la insuficiencia renal.&lt;br&gt;- Proporción de pacientes uq epueden discontinuar la diálisis.&lt;br&gt;- Valor predictivo de la determinación de cadenas ligeras para respuesta y reversibilidad de la insuficiencia renal.&lt;br&gt;- Mortalidad precoz (menos de 2 meses).&lt;br&gt;- Supervivencia libre de progresión.&lt;br&gt;- Supervivencia global.&lt;br&gt;- Determinar la seguridad y tolerabilidad de VELCADE asociado a Dexametasona, medido en función de la incidencia de toxicidades clínicas y de laboratorio.;Primary end point(s): La variable principal de eficacia es:&lt;br&gt;- Tasa de respuesta (RC, RP) a VELCADE/DEXA.&lt;br&gt;La variable principal de seguridad es:&lt;br&gt;- Incidencias de toxicidades clínicas y de laboratorio.</Primary_outcome>
    <Secondary_ID>RENVEL</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475502</Internal_Number>
    <TrialID>EUCTR2009-014562-26-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>?Estudio multicéntrico, aleatorizado, abierto de maximización de micofenolato sódico (MFS) versus micofenolato mofetilo (MMF) para minimizar la dosis de tacrolimus en pacientes trasplantados renales en mantenimiento. Estudio Maximiza.?. - MAXIMIZA</Public_title>
    <Scientific_title>?Estudio multicéntrico, aleatorizado, abierto de maximización de micofenolato sódico (MFS) versus micofenolato mofetilo (MMF) para minimizar la dosis de tacrolimus en pacientes trasplantados renales en mantenimiento. Estudio Maximiza.?. - MAXIMIZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Novartis Farmacéuitica S.A</Primary_sponsor>
    <Date_registration3>20091223</Date_registration3>
    <Date_registration>23/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014562-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/02/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;?	Receptores de trasplante renal &amp;#8805; 1 año y &lt;5 años previos1 a la inclusión en el estudio.&lt;br&gt;?	Que estén recibiendo un régimen inmunosupresor que incluya MMF &lt;1000 mg/día y &amp;#8805;250 mg/día (mínimo durante un mes) y Prograf®1 (niveles &amp;#8805;7 ng/ml). &lt;br&gt;?	Pacientes que hayan mantenido el actual régimen de inmunosupresión con MMF a dosis estables como mínimo en los últimos 3 meses 2&lt;br&gt;?	Los pacientes incluidos deberán estar en unos niveles de Prograf &amp;#8805; 7mg/ml durante como mínimo un mes antes de su inclusión en el ensayo 2&lt;br&gt;?	Pacientes con bajo riesgo inmunológico, según criterio del investigador.&lt;br&gt;?	Pacientes con una tasa de filtrado glomerular estimado por la fórmula MDRD &gt; 30 mL/min x 1.73m2 1&lt;br&gt;?	Pacientes mayores de 18 años 1&lt;br&gt;?	Capaces de entender la información sobre el estudio y de otorgar su consentimiento informado de forma escrita.&lt;br&gt;?	Que puedan cumplir todos los requisitos del estudio incluyendo la realización de los cuestionarios y la asistencia a las visitas del estudio.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;?	Que se conozca o asuma que tiene síntomas GI no causados por el tratamiento con ácido micofenólico (MPA) (por ejemplo, diarrea infecciosa inducida por bisfosfonatos orales).&lt;br&gt;?	Pacientes con enfermedad inflamatoria intestinal crónica.&lt;br&gt;?	Pacientes diabéticos.&lt;br&gt;?	Rechazo agudo &lt; 1 mes previo a la inclusión en el estudio. &lt;br&gt;?	Pacientes con leucopenia (&lt;3.500 cel/mm3) o plaquetopenia (&lt;100.000 cel/mm3)&lt;br&gt;?	Mujeres físicamente fértiles que tengan previsto quedarse embarazadas, estén embarazadas y/o en periodo de lactancia, o bien que no deseen utilizar un método anticonceptivo eficaz [anticonceptivos hormonales (implantación, parches, oral), y métodos de doble barrera (cualquier combinación doble de: DIU, profilácticos masculinos o femeninos con gel espermicida, diafragma, esponja anticonceptiva, capuchón cervical)]. &lt;br&gt;?	Presencia de enfermedad psiquiátrica (como esquizofrenia, depresión mayor) que, a juicio del investigador, pudiese interferir con los requerimientos del estudio.&lt;br&gt;?	Que estén siendo sometidos a intervención médica por patología aguda o que estén hospitalizados.&lt;br&gt;?	Cualquier otra condición médica que, a juicio del investigador basándose en el recuento o en la revisión de historiales clínicos, pudiese afectar a la realización del estudio, incluyendo, pero no limitado a problemas visuales o deterioro cognitivo.&lt;br&gt;?	Que estén recibiendo cualquier fármaco en investigación o lo hayan recibido durante los 30 días previos a la inclusión en el estudio.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Profilaxis del rechazo agudo en trasplante alogénico renal. Minimizar la dosis de tacrolimus en pacientes trasplantados renales en mantenimiento &lt;br&gt;MedDRA version: 9
Level: LLT
Classification code 10000952
Term: Acute on chronic renal failure
 &lt;br&gt;MedDRA version: 9
Level: LLT
Classification code 10001041
Term: Acute renal failure
</Condition>
    <Intervention>&lt;br&gt;Trade Name: MYFORTIC 180 mg comprimidos gastrorresistentes recubiertos con película&lt;br&gt;Pharmaceutical Form: Gastro-resistant tablet&lt;br&gt;INN or Proposed INN: MICOFENOLICO ACIDO&lt;br&gt;Other descriptive name: MYCOPHENOLIC ACID&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: El objetivo principal demostrar que Myfortic&amp;#61650; permite una dosis óptima más alta que MMF lo que conduce a una minimización de Prograf®1 en el mantenimiento de los pacientes con trasplante renal.;Secondary Objective: ?	Comparar la eficacia entre los dos grupos de tratamiento en función de BPAR, pérdida de injerto, muerte y pérdida de seguimiento.&lt;br&gt;?	Comparar la calidad de vida entre los dos regimenes inmunosupresores en función del impacto de los síntomas GI, mediante la escala SIGIT-QoL. Asimismo, se evaluará la gravedad de los síntomas utilizando la escala de clasificación de síntomas gastrointestinales (GSRS).&lt;br&gt;?	Comparar la seguridad entre los dos regimenes inmunosupresores mediante la evaluación de acontecimientos adversos (AAs), exploración física, constantes vitales y los resultados de los análisis de laboratorio y del PRA;Primary end point(s): La variable principal será la proporción de pacientes que alcanzan al menos dos dosis mayores de MPA y consiguen reducir la dosis de Prograf®1 al finalizar el estudio (visita final) con respecto a la dosis basal.</Primary_outcome>
    <Secondary_ID>CERL080AES08</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475506</Internal_Number>
    <TrialID>EUCTR2009-014268-20-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>VZV vaccination to prevent herpes zoster after transplantation - Vaccination to prevent herpes zoster</Public_title>
    <Scientific_title>VZV vaccination to prevent herpes zoster after transplantation - Vaccination to prevent herpes zoster                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Erasmus MC</Primary_sponsor>
    <Date_registration3>20090721</Date_registration3>
    <Date_registration>21/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014268-20                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/12/2009</Date_enrollement>
    <Target_size>80</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: same VZV vaccin&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Age of patient and donor is 50 years or older&lt;br&gt;- Patients on waitinglist for living-related kidney transplantation and their donors&lt;br&gt;- Patients at least 1 month prior to to kidney transplantation&lt;br&gt;- Patient is VZV seropositive before vaccination&lt;br&gt;- Patient is capable of understanding the purpose and risks of the study, fully informed and given written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Use of immunosuppresion (inhalation corticosteroids are allowed)&lt;br&gt;- Neomycine allergy&lt;br&gt;- Fever&lt;br&gt;- Immunodeficiency due to e.g. acute/chronic, lymphoma or HIV&lt;br&gt;- Active tuberculosis&lt;br&gt;</Exclusion_Criteria>
    <Condition>Herpes Zoster &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10019974
Term: Herpes zoster
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10036897
Term: Prophylactic vaccination
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zostavax&lt;br&gt;Product Name: Zostavax&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: shingles (herpes zoster) vaccine (live)&lt;br&gt;CAS Number: 0&lt;br&gt;Other descriptive name: VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED)&lt;br&gt;Concentration unit: ml millilitre(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.65-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To study if there is a role for prophylactic VZV vaccination prior to transplantation to boost the patients B- and T-cell repertoire and thereby reducing the incidence and morbidity associated with herpes zoster.;Secondary Objective: none;Primary end point(s): VZV-specific IgG and IgM levels from baseline to endpoint (1 year after vaccination).&lt;br&gt;VZV-specific T-cell reactivity using flow cytometry specific from baseline to endpoint.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>VZV01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475528</Internal_Number>
    <TrialID>EUCTR2007-006198-98-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pain management in renal colic; The efficacy of continuous intravenous administration of tramadol versus butylscopolamine. A double blinded, randomized placebo controlled, prospective multicenter trial. - TraBu-trial</Public_title>
    <Scientific_title>Pain management in renal colic; The efficacy of continuous intravenous administration of tramadol versus butylscopolamine. A double blinded, randomized placebo controlled, prospective multicenter trial. - TraBu-trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Isala klinieken Zwolle</Primary_sponsor>
    <Date_registration3>20090901</Date_registration3>
    <Date_registration>01/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006198-98                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/10/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;The participants are 18 years and older and are able to make a will. Participants presenting with clinical signs and symptoms of renal colic, as ajudged by a urologist or resident in urology, are included after oral an written informed consent.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-pregnancy or lactation&lt;br&gt;-chronic tramadol use&lt;br&gt;-severe renal failure, GFR less than 10 ml/min&lt;br&gt;-severe hepatic failure&lt;br&gt;-allergic reactions to opioids / NSAID's&lt;br&gt;-concommitent use of MAO-inhibitor, or less than 2 weeks after stop MAO-inhibitor&lt;br&gt;-narrow-angle glaucoma&lt;br&gt;-use of NSAID's 8 hours before admittance&lt;br&gt;-use of drugs or alcohol 8 hours before admittance&lt;br&gt;-hydronephrotic kidney combined with fever&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal colic pain based on kidney or ureteric stones in patients of 18 years and older.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Tramadol&lt;br&gt;Product Name: Tramadol&lt;br&gt;Product Code: Tramadol&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Buscopan&lt;br&gt;Product Name: Buscopan&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Can a difference between the change in the perception of pain over time(0-60minutes) between tramadol and butylscopolamine in renal colic be proven?;Secondary Objective: -Can a difference in the decline in VAS-score over time (0-240min) between the tramadol group and the butylscopolamine group be proven?&lt;br&gt;-Can the therapeutic efficacy of butylscopolamine compared to placebo over time (0-240min) be proved?&lt;br&gt;-Can the therapeutic efficacy of tramadol compared to placebo over time (0-240min) be proved?&lt;br&gt;-What are the side effects of continuous intravenous administered tramadol and to what extend do they occur?&lt;br&gt;-Is a difference in the need for of rescue-medication seen between the tramadol and butylscopolamine group?;Primary end point(s): Efficacy of treatment is defiend as a decline of 10mm or more on the horizontal Visual Analogue Scale. Differences between the tramadol and butylscopolamine groups wil be calculated with change in VAS-score between T0 and T3 ( 60min ).</Primary_outcome>
    <Secondary_ID>99976</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475603</Internal_Number>
    <TrialID>EUCTR2009-014436-38-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A prospective, open, randomized, single center study comparing the effects of duo therapy with Everolimus and steroids versus triple treatment of low dose calcineurin inhibitor, low-dose MMF and steroids at least one year after renal transplantation.
Effects on renal function, tolerability, chronic allograft damage, cardiovascular parameters and malignancies.
 - STER</Public_title>
    <Scientific_title>A prospective, open, randomized, single center study comparing the effects of duo therapy with Everolimus and steroids versus triple treatment of low dose calcineurin inhibitor, low-dose MMF and steroids at least one year after renal transplantation.
Effects on renal function, tolerability, chronic allograft damage, cardiovascular parameters and malignancies.
 - STER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>UMCG</Primary_sponsor>
    <Date_registration3>20090713</Date_registration3>
    <Date_registration>13/07/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014436-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/09/2009</Date_enrollement>
    <Target_size>130</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Female or male, aged between 18 and 70 years.&lt;br&gt;•	Recipient of a kidney graft from a deceased donor or living (non-HLA identical) donor.&lt;br&gt;•	The patient understands the purpose and risks of the study and has given written informed consent to participate in the study.&lt;br&gt;•	Acceptable renal function, eGFR &gt; 40 ml/min, Proteinuria = 1, 0   g/24hr. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Patients with multi-organ transplants.&lt;br&gt;•	Patients who have been receiving a second or subsequent transplant.&lt;br&gt;•	Patients with very low function at 1 year post-transplant, GFR &lt; 40.&lt;br&gt;•	Proteinuria &gt; 1, 0   g/24 hr.&lt;br&gt;•	Patients with a screening/baseline total white blood cell count  &lt; 2,0 10Eg/l or ANC &lt; 1,0 10Eg/l,  platelet count &lt; 100 10Eg/l.&lt;br&gt;•	Patients with baseline fasting triglycerides &gt; 4.5 mmol/l or fasting total cholesterol  &gt; 7.8 mmol/l despite optimal lipid-lowering therapy.&lt;br&gt;•	Presence of sub clinical rejection (Borderline or Banff score &gt;1a) in biopsy taken at approximately month 12&lt;br&gt;•	Vascular or Acute rejection (Banff score = 2a) six months preceding randomization.&lt;br&gt;•	Female patients who are pregnant or unwilling to use adequate contraception during the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal transplantation.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Neoral&lt;br&gt;Product Name: Neoral&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;Trade Name: Prograft&lt;br&gt;Product Name: Prograft&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;Trade Name: Mycofenolaat mofetil CF 500&lt;br&gt;Product Name: Mycofenolaat mofetil&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;Trade Name: Prednisolon 5 PCH&lt;br&gt;Product Name: Prednisolon 5 PCH&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: ;Primary end point(s): •	Renal function&lt;br&gt;•	The percentage of patients that need reconversion to their original therapy (tolerability).&lt;br&gt;&lt;br&gt;;Main Objective:  &lt;br&gt;To investigate the safety and efficacy of a therapy consisting Everolimus and &lt;br&gt;corticosteroids maintenance immunosuppressive regime twelve months after renal transplantation &lt;br&gt;in recipients of donor kidney graft on graft function and acute rejection rates. The other group will&lt;br&gt;receive a low-dose regimen consisting a low-dose calcineurin inhibitor, low dose MMF and corticosteroids. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>2009/07</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475607</Internal_Number>
    <TrialID>EUCTR2009-015558-40-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Abatacept treatment in patients with primary Sjögren’s syndrome</Public_title>
    <Scientific_title>Abatacept treatment in patients with primary Sjögren’s syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>University Medical Center Groningen</Primary_sponsor>
    <Date_registration3>20091223</Date_registration3>
    <Date_registration>23/12/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015558-40                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/07/2010</Date_enrollement>
    <Target_size>15</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;?	pSS according to the revised European – U.S. criteria(22).&lt;br&gt;?	Male or female  ? 18 years.&lt;br&gt;?	Stimulated whole saliva secretion ? 0.15 ml/min. &lt;br&gt;?	Positive autoantibodies (IgM-Rf ?10 and SS-A and/or SS-B).&lt;br&gt;?	Parotid gland biopsy  (paraffin material and fresh frozen tissue) with characteristic features of SS performed at time of inclusion (no longer than 12 months ago).&lt;br&gt;?	In female patients: use of reliable method of contraception during the study and at least until 14 weeks after the last infusion, in women of child bearing potential. &lt;br&gt;?	In male patients: use of reliable method of contraception during the study and at least until 14 weeks after the last infusion by partner of patient, in case the partner of the patient is a female of child bearing potential.&lt;br&gt;?	Written informed consent.&lt;br&gt;?	Patients are allowed to continue artificial tears and/or artificial saliva provided that the dosage and schedule regime are stable, and that the usage will be stopped one day prior to each evaluation. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;?	Disease duration ? 5 years.&lt;br&gt;?	The presence of any other connective tissue disease.&lt;br&gt;?	Clinically significant serious abnormalities on electrocardiography or chest X ray.&lt;br&gt;?	Lab abnormalities:&lt;br&gt;o	Serum creatine &gt; 2.8 mg/dl (250 ?mol/l);&lt;br&gt;o	ASAT or ALAT outside 1.5 x upper normal range of the laboratory;&lt;br&gt;o	Hb &lt; 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females;&lt;br&gt;o	Neutrophil granulocytes less than 0.5 x 109/l;&lt;br&gt;o	Platelet count less than 50 x 109/l.&lt;br&gt;?	Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions, chronic or latent infectious diseases (e.g., patients with hepatitis B or C, patent tuberculosis or latent tuberculosis non-adequately treated) or immune deficiency which places the patient at an unacceptable risk for participation in the study. &lt;br&gt;?	History of cancer, including mucosa associated lymphoid tissue (MALT) lymphoma in the preceding 5 years (except adequately treated basal cell carcinoma of the skin and carcinoma in situ of the skin).&lt;br&gt;?	Positive pregnancy test or breast-feeding.&lt;br&gt;?	Planned major surgery (e.g. joint replacement) within the duration of the treatment period of the study. &lt;br&gt;?	Serious infections in the preceding month. &lt;br&gt;?	Opportunistic infection in the preceding 3 months.&lt;br&gt;?	Subjects with evidence of active or latent bacterial infections at the time enrollment, including subjects with evidence of Human Immunodeficiency Virus (HIV) infection.&lt;br&gt;?	Subjects with current clinical or laboratory evidence of active tuberculosis (TB).&lt;br&gt;?	Subjects with a history of active TB treated within the last 3 years.&lt;br&gt;?	Subjects who received treatment for active TB greater than 3 years ago may be eligible for inclusion in this study if there is documentation of the prior anti-TB treatment confirming that it was appropriate in duration and type. &lt;br&gt;?	Subjects with latent TB which was not successfully treated.&lt;br&gt;?	Subjects with a positive TB screening test indicative of latent TB will not be eligible for this study unless active TB infection has been ruled out and they have been initiated treatment for latent TB with isoniazid (INH) for at least 4 weeks prior to dosing of Abatacept and they have a negative chest x-ray for  active TB at enrollment. Such subjects should complete 9 months of INH treatment.&lt;br&gt;?	Subjects with herpes zoster that resolved less than 2 months prior to enrollment.&lt;br&gt;?	Preceding treatment with anti-TNF, rituximab or other monoclonal antibodies&lt;br&gt;?	Use of prednisone and/or pilocarpine less than 2 weeks ago&lt;br&gt;?	The use of hydroxychloroquine, azathioprine, cyclofosphamide, cyclosporine, MTX and other DMARDs should be discontinued at least 1 month prior to the first infusion of abatacept.&lt;br&gt;?	History of alcohol or drug abuse.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Sjögren’s syndrome (SS) is a chronic, systemic, lymphoproliferative autoimmune disease affecting the exocrine glands. The salivary and lacrimal glands are most commonly affected, resulting in dry mouth and dry eyes. Extraglandular involvement can occur in SS, and includes, amongst others, pulmonary disease, renal disease and vasculitis. Moreover, almost all patients suffer from restricting fatigue. &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10040767
Term: Sjogren's syndrome
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Orencia&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluation of efficacy (as assessed by the stimulated whole saliva flow rate at 24 weeks) and safety of abatacept treatment in 15 patients with pSS. &lt;br&gt;;Secondary Objective: Evaluation of efficay of abatacept treatment in 15 patients with pSS on objective signs and subjective complains.;Primary end point(s): primary endpoint:&lt;br&gt;- Stimulated whole salivary gland function at week 24&lt;br&gt;&lt;br&gt;secundary endpoints:&lt;br&gt;- functional parameters (clinical glandular and extraglandular examination)&lt;br&gt;- laboratory parameters (e.g. B and T cell subsets, IgM-Rf)&lt;br&gt;- subjective parameters (VAS scores, MFI, SF-36)&lt;br&gt;- histological/molecular parameters</Primary_outcome>
    <Secondary_ID>ABACEPT1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475617</Internal_Number>
    <TrialID>EUCTR2009-016159-23-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study - ViRTUE</Public_title>
    <Scientific_title>Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study - ViRTUE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>University Medical Center Groningen (UMCG)</Primary_sponsor>
    <Date_registration3>20091008</Date_registration3>
    <Date_registration>08/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016159-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/10/2011</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Male and female patients&lt;br&gt;- Non-diabetic renal disease as established by history, serum biochemistry tests and/or renal biopsy&lt;br&gt;- Age = 18 and = 75 years &lt;br&gt;- Residual proteinuria &gt; 1,0 g/day and &lt; 8 g/day during conventional treatment of at least 8 weeks with ACE-inhibitor or ARB  at the maximum recommended dose &lt;br&gt;- Stable renal function (creatinine clearance of &gt; 30 ml/min/1.73m2; with &lt; 6 ml/min per year decline)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Inability to meet inclusion criteria&lt;br&gt;- uncontrolled hypertension, hyperkalemia (potassium &gt;6.0 mmol/l, cardiovascular disease (myocardial infarction, unstable angina, percutanous transluminal coronary angioplasty, coronary artery bypass grafting, or stroke within last 6 months, heart failure NYHA III-IV), Diabetes Mellitus &lt;br&gt;- epilepsy&lt;br&gt;- liver disease resulting in liverfunction aberrations (zemplar bevat ethanol))&lt;br&gt;- Previously treated (within 3 months of screening) with paricalcitol or vitamin D&lt;br&gt;- contraindication to ACEi, high/low sodium diet or paricalcitol&lt;br&gt;- medication interacting with ACEi or paricalcitol &lt;br&gt;- frequent NSAID use (&gt;2 doses/week)&lt;br&gt;- Immunosuppressive medication&lt;br&gt;- Digoxine use&lt;br&gt;- secondary or tertiary hyperparathyreoidie &lt;br&gt;- active malignancy &lt;br&gt;- any bowel disorder resulting in fat malabsorption&lt;br&gt;- Pregnant or nursing (lactating) women, where pregnancy is defined as a state of a female after conception and until the termination of gestation, confirmed by a positive ß-hCG laboratory test (&gt;5 mIU/ml).&lt;br&gt;- incompliance with diet or study medication&lt;br&gt;- any psychiatric condition or psychofarmacon use&lt;br&gt;- drug or alcohol abuse&lt;br&gt;</Exclusion_Criteria>
    <Condition>chronic kidney disease &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10064848
Term: Chronic kidney disease
</Condition>
    <Intervention>&lt;br&gt;Trade Name: paricalcitol&lt;br&gt;Product Name: paricalcitol&lt;br&gt;Product Code: RVG 100436&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Pharmaceutical form of the placebo: Capsule*&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: ramipril&lt;br&gt;Product Name: ramipril&lt;br&gt;Product Code: RVG28004&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Does paricalcitol have an additive antiproteinuric respons to RAAS blockade and low sodium diet?;Secondary Objective: Does paricalcitol prevent the reactive rise in renin during RAAS-blockade?;Primary end point(s): proteinuria</Primary_outcome>
    <Secondary_ID>ViRTUE-2009</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475621</Internal_Number>
    <TrialID>EUCTR2008-004548-35-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER
 - Phase II Lutetium</Public_title>
    <Scientific_title>PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER
 - Phase II Lutetium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Radboud university nijmegen medical centre</Primary_sponsor>
    <Date_registration3>20091130</Date_registration3>
    <Date_registration>30/11/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004548-35                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/08/2010</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with proven advanced and progressive renal cell carcinoma of the clear cell type&lt;br&gt;At least one evaluable lesion less than 5 cm&lt;br&gt;Performance status: Karnofsky &gt; 70 % &lt;br&gt;Laboratory values obtained less than 14 days prior to registration:&lt;br&gt;White blood cells (WBC) &gt; 3.5 x 109/l&lt;br&gt;Platelet count &gt; 100 x 109/l&lt;br&gt;Hemoglobin &gt; 6 mmol/l &lt;br&gt;Total bilirubin &lt; 2 x upper limit of normal (ULN) &lt;br&gt;ASAT, ALAT &lt; 3 x ULN (&lt; 5 x ULN if liver metastases present)&lt;br&gt;Serum creatinine &lt; 2 x ULN&lt;br&gt;Negative pregnancy test for women of child¬bearing potential (urine or serum)&lt;br&gt;Age over 18 years &lt;br&gt;Ability to provide written informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Known metastases to the brain&lt;br&gt;Untreated hypercalcemia&lt;br&gt;Metastatic disease limited to the bone&lt;br&gt;Pre-exposure to murine/chimeric antibody&lt;br&gt;Chemotherapy, external beam radiation, immunotherapy or angiogenesis inhibitors within 4 weeks prior to study. Limited field external beam radiotherapy to prevent pathological fractures is allowed, when unirradiated, evaluable lesions elsewhere are present.&lt;br&gt;Cardiac disease with New York Heart Association classification of III or IV &lt;br&gt;Patients who are pregnant, nursing or of reproductive potential and are not practicing an effective method of contraception&lt;br&gt;Any unrelated illness, e.g. active infection, inflammation, medical condition or laboratory abnormalities, which in the judgment of the investigator will significantly affect patients’ clinical status &lt;br&gt;Life expectancy shorter than 6 months&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with metastatic clear cell renal cell carcinoma &lt;br&gt;MedDRA version: 9.1
Level: PT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: cG250&lt;br&gt;Product Code: cG250&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the clinical efficacy of multiple doses of 177Lu-DOTA-cG250 at MTD in patients with advanced renal cancer using RECIST criteria;Secondary Objective: To determine the toxicity of the treatment as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE v3.0)&lt;br&gt;To determine the targeting and dosimetry of 111In-DOTA-cG250 in patients with advanced renal cancer, as a surrogate for 177Lu-DOTA-cG250 &lt;br&gt;;Primary end point(s): After all 9 patients have finished the study (up to three treatment cycles) the efficacy of the treatment will be determined.</Primary_outcome>
    <Secondary_ID>15081982</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2475872</Internal_Number>
    <TrialID>EUCTR2006-002420-41-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Randomized, Open-Label Study to Compare the Safety and Efficacy of Conversion
From a Calcineurin Inhibitor to Sirolimus Versus Continued Use of a Calcineurin
Inhibitor in Cardiac Transplant Recipients With Mild to Moderate Renal Insufficiency</Public_title>
    <Scientific_title>A Randomized, Open-Label Study to Compare the Safety and Efficacy of Conversion
From a Calcineurin Inhibitor to Sirolimus Versus Continued Use of a Calcineurin
Inhibitor in Cardiac Transplant Recipients With Mild to Moderate Renal Insufficiency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Wyeth Research, Division of Wyeth Pharmaceuticals, Inc.</Primary_sponsor>
    <Date_registration3>20060811</Date_registration3>
    <Date_registration>11/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002420-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/09/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Cardiac transplant recipients aged = 18 years. &lt;br&gt;2. Receiving CsA or TAC as part of the maintenance immunosuppressive regimen since the time of transplantation.  &lt;br&gt;3. = 12 Months after cardiac transplantation but = 96 months after transplantation at the time of screening.&lt;br&gt;4. GFR &gt; 40 mL/min but &lt; 90 mL/min/1.73m2 (calculated by the Cockcroft-Gault equation and adjusted for body surface area [BSA] using the Mosteller formula) with stable renal function (as defined by no decrease in &gt; 20% of GFR) over the previous 3 months.&lt;br&gt;5. Left ventricular ejection fraction by echocardiogram (ECHO) = 40%.&lt;br&gt;6. Women of childbearing potential (CBP) must have a negative urine pregnancy test before randomization.&lt;br&gt;7. Women of CBP and men with sexual partners of CBP must agree to use a medically acceptable method of contraception throughout the treatment period.  &lt;br&gt;8. Women of CBP and men with sexual partners of CBP must agree to use a medically acceptable method of contraception for 3 months after discontinuation of assigned treatment. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Secondary cardiac transplant recipients (subjects who have lost 1 or more previous cardiac transplant).&lt;br&gt;2. Multiple-organ transplant recipients (such as heart-lung, heart-kidney, or heart-after-kidney transplant recipients).&lt;br&gt;3. Treatment of acute rejection within 3 months.&lt;br&gt;4. Evidence of active systemic or localized major infection at the time of randomization.&lt;br&gt;5. Evidence of infiltrate, cavitation or consolidation on chest x-ray film obtained within 3 months before or at the time of the screening evaluation.&lt;br&gt;6. Use of any investigational drug or treatment up to 4 weeks before random assignment.&lt;br&gt;7. Spot urine protein-to-creatinine ratio &gt; 0.5 or proteinuria &gt; 500 mg/day.&lt;br&gt;8. Subjects maintained on CNI monotherapy.&lt;br&gt;9. Prior or current use of mammalian target of rapamycin (mTOR) inhibitors unless administration was part of a "CNI holiday" (a planned temporary switch from a CNI to an mTOR inhibitor to limit exposure to CNIs) lasting no more than 10 days.&lt;br&gt;10. Known hypersensitivity to sirolimus or its derivatives or macrolide antibiotics.&lt;br&gt;11. Treatment with voriconazole, cisapride, or ketoconazole, which are all known to interact with sirolimus, that is not discontinued before randomization.&lt;br&gt;12. Treatment with aminoglycosides, amphotericin B, cisplatin, or other drugs associated with renal dysfunction that is not discontinued before randomization.&lt;br&gt;13. Subjects with screening baseline white blood cell (WBC) count &lt; 3000/mm3, platelet count &lt; 100,000/mm3, fasting triglyceride level &gt; 400 mg/dL (4.5 mmol/L), or total cholesterol level &gt; 300 mg/dL (7.6 mmol/L).&lt;br&gt;14. History of malignancy within 3 years before enrollment (except for adequately treated basal-cell or squamous-ell carcinoma of the skin).&lt;br&gt;15. Planned used of agents with a known major interaction with sirolimus or CNIs.&lt;br&gt;16. Subjects who are known to be positive for human immunodeficiency virus (HIV).&lt;br&gt;</Exclusion_Criteria>
    <Condition>Cardiac transplant recipients with mild to moderate renal insufficiency. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050432
Term: Prophylaxis against heart transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Product Code: Rapamune&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Product Code: Rapamune&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate the superiority of converting from CNI therapy to sirolimus therapy to continuing CNI therapy with respect to renal function in cardiac transplant recipients with mild to moderate renal dysfunction.;Secondary Objective: To evaluate the safety of conversion from CNI therapy to sirolimus therapy in this patient population.&lt;br&gt;To explore the effect of conversion from CNI therapy to sirolimus therapy on surrogate markers of cardiovascular risk.;Primary end point(s): Change from baseline calculated creatinine clearance (using the Cockcroft-Gault equation and adjusted for BSA using the Mosteller formula) at 52 weeks. </Primary_outcome>
    <Secondary_ID>0468E7-408</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2476533</Internal_Number>
    <TrialID>EUCTR2007-003847-66-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma - N/A</Public_title>
    <Scientific_title>Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma - N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </Scientific_title>
    <Primary_sponsor>Eli Lilly and company</Primary_sponsor>
    <Date_registration3>20080108</Date_registration3>
    <Date_registration>08/01/2008</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003847-66                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/03/2008</Date_enrollement>
    <Target_size>122</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Part 1 of the trial : Open   /// Part 2 of the trial : Randomised, Double Blind, Parrallel group&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;[1]	Patients with metastatic RCC who have not received prior treatment with systemic (adjuvant or neoadjuvant) therapy for RCC (including targeted therapy such as tyrosine kinase inhibitors or bevacizumab, immunotherapy, chemotherapy, hormonal, or investigational therapy)&lt;br&gt;[2]	Histologically confirmed RCC with metastases with a component of clear (conventional) cell histology&lt;br&gt;[3]	Evidence of unidimensionally measurable disease (=1 malignant tumor mass that can be accurately measured in at least 1 dimension =20 mm with conventional computed tomography (CT) or magnetic resonance imaging (MRI) scan, or =10 mm with spiral CT scan.  (If spiral CT scan is used, minimum lesion size should be twice the reconstruction interval used.  For example, if reconstruction size is 7 mm, lesion size should be =14 mm).  CT/MRI should be performed within 4 weeks prior to study entry&lt;br&gt;Note:  Bone lesions, ascites, peritoneal carcinomatosis or miliary lesions, pleural or pericardial effusions, lymphangitis of the skin or lung, cystic lesions, or irradiated lesions are not considered measurable.&lt;br&gt;[4]	Primary tumor has been surgically removed by nephrectomy or nephron-sparing surgery&lt;br&gt;[5]	ECOG performance status score of 0 or 1 (see Protocol Attachment S061.5)&lt;br&gt;[6]	Have adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements, to be conducted within 7 days prior to treatment:  (ULN/LLN = upper/lower limit of normal)&lt;br&gt;?	Hemoglobin &gt;9.0 g/dL&lt;br&gt;?	Absolute neutrophil count (ANC) =1.5 x 103 µL&lt;br&gt;?	Platelet count =100 x 103/µL&lt;br&gt;?	Total bilirubin =1.5 x ULN&lt;br&gt;?	Serum calcium within 10% of normal range?&lt;br&gt;?	Serum creatinine =2 x ULN&lt;br&gt;?	Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3 x ULN (or &lt;5 x ULN for patients with liver involvement of their cancer)&lt;br&gt;?	Prothrombin Time (PT) or International Normalized Ratio (INR) and activated Partial Thromboplastin Time (aPTT) = 1.5 x ULN&lt;br&gt;?	Left ventricular ejection fraction (LVEF) = LLN as defined by the institution performing the scan, as assessed by Multiple Gated Acquisition (MUGA) scan, or from echocardiogram&lt;br&gt;[7]	Estimated life expectancy of at least 12 weeks&lt;br&gt;[8]	Patient compliance and geographic proximity that allow for adequate follow-up&lt;br&gt;[9]	Patients must sign an informed consent document&lt;br&gt;[10]	Patients must be at least 18 years of age&lt;br&gt;[11]	Women of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) must test negative for pregnancy within 7 days prior to or at the time of enrollment, based on either a serum or urine pregnancy test.  Both male and female patients of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and his or her health-care team, during the study and for 3 months following the last dose of study treatment&lt;br&gt;[12]	No prior malignancies for =5 years with the exception of cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively treated =5 years prior to study entry.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;[13]	Have received prior treatment with sunitinib or enzastaurin&lt;br&gt;[14]	Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry&lt;br&gt;[15]	Have had any of the following within 12 months prior to study drug administration:  myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (CHF), cerebrovascular accident, transient ischemic attack, or pulmonary embolism&lt;br&gt;Note:  Ongoing treatment with therapeutic doses of Coumadin? (warfarin) or a derivative of Coumadin or phenprocoumon is not allowed, but prophylactic, low-dose Coumadin (= 2 mg daily) for deep vein thrombosis is allowed.  In such cases, PT/INR should be very closely monitored as clinically indicated.&lt;br&gt;[16]	Ongoing cardiac arrhythmias &gt;New York Health Association Class II (Protocol Attachment S061.6), atrial fibrillation of any grade, or prolongation of the QTc interval to &gt;450 msec for males or &gt;470 msec for females&lt;br&gt;[17]	Have uncontrolled hypertension (&gt;150/100 mm/Hg despite optimal medical therapy), or history of poor compliance with antihypertensive treatment&lt;br&gt;[18]	Have active, clinically serious bacterial or fungal infection more than NCI CTCAE Grade 2 &lt;br&gt;[19]	Have known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B/C&lt;br&gt;[20]	Have history of or known brain metastases, spinal cord compression, carcinomatous meningitis, or evidence of brain or leptomeningeal disease on screening CT or MRI scan&lt;br&gt;[21]	Have history of documented central nervous system disease unrelated to cancer; for example, uncontrolled seizures, unless adequately treated with standard medical therapy&lt;br&gt;[22]	Have evidence of bleeding diathesis, NCI CTCAE Grade 3 hemorrhage &lt;4 weeks of starting the study treatment, coagulopathy, or thromboembolic event&lt;br&gt;[23]	Have medical, psychological, or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results or have a history of substance abuse&lt;br&gt;[24]	Have known or suspected allergy to any agent given in association with this trial&lt;br&gt;[25]	Have any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study (for example, uncontrolled diabetes mellitus, pancreatitis, acute or chronic liver disease), and preexisting thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication&lt;br&gt;[26]	Require concomitant use of potent CYP3A4 inducer, for example, rifampicin or potent CYP3A inhibitors, such as ketoconazole.&lt;br&gt;Note:  Protocol Attachment S061.4 provides an extensive list of CYP3A4 inhibitors or inducers&lt;br&gt;[27]	Significant surgery or radiation therapy &lt;4 weeks of starting study treatment.  Prior palliative radiotherapy to metastatic lesion(s) is/are permitted, provided there is at least 1 measurable lesion that has not been irradiated&lt;br&gt;[28]	Patients who are pregnant or breast feeding&lt;br&gt;[29]	Have impairment of the gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug&lt;br&gt;[30]	Current or recent (within 10 days of first dose of study treatment) daily use of aspirin (&gt;325 mg/day)&lt;br&gt;[31]	Have serious nonhealing wounds, acute or nonhealing ulcers, or bone fractures&lt;br&gt;[32]	Are unable or unwilling to discontinue use of carbamazepine, phenobarbital, or phenytoin at least 14 days prior to study therapy&lt;br&gt;[33]	Are unable to swallow tablets.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal cell carcinoma</Condition>
    <Intervention>&lt;br&gt;Product Name: enzastaurin&lt;br&gt;Product Code: LY317615&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Enzastaurin Hydrochloride&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 125-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Product Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sunitinib&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50 mg -&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this Phase 2 study is to compare the progression-free survival in enzastaurin and sunitinib therapy versus sunitinib and placebo in the first-line setting for patients with metastatic clear-cell RCC;Secondary Objective: The secondary objectives of the study are:&lt;br&gt;•	to compare the following time-to-event efficacy variables between treatment arms: &lt;br&gt;-	time to tumor progression (TTP)&lt;br&gt;-	overall survival (OS)&lt;br&gt;-	to estimate duration of overall response in each treatment arm &lt;br&gt;•	to compare the objective response rate (complete response [CR] + partial response [PR]) between treatment arms&lt;br&gt;•	to compare the rate of clinical benefit (CR + PR + stable disease [SD]) between treatment arms&lt;br&gt;•	to assess the safety and adverse events in both treatment arms&lt;br&gt;•	to characterize the pharmacokinetics (PK) of enzastaurin and sunitinib when administered in combination&lt;br&gt;•	to assess biomarkers (for example, PKCß, GSK3ß, S6K, PTEN, CREB) relevant to enzastaurin and disease state, and their correlation to clinical outcome.&lt;br&gt;;Primary end point(s): The primary endpoint for Part 1 (Safety lead in) is to evaluate the safety of the combination of enzastaurin plus sunitinib.&lt;br&gt;The primary endpoint for Part 2 is to compare progression-free survival (PFS) between the two arms of treatment. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>H6Q-MC-S061</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2477363</Internal_Number>
    <TrialID>EUCTR2007-005721-30-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency - POSEIDON</Public_title>
    <Scientific_title>A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency - POSEIDON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>Biogen Idec</Primary_sponsor>
    <Date_registration3>20090611</Date_registration3>
    <Date_registration>11/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005721-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/10/2009</Date_enrollement>
    <Target_size>300</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Must give written informed consent and any authorizations required by local law (e.g., Protected Health Information).&lt;br&gt;2. Must be 18 years of age or older.&lt;br&gt;3. Must have a previous diagnosis of HF with symptoms of HF present at screening (i.e., subjects must be graded as NYHA Class II, III, or IV).&lt;br&gt;4. Must meet the following criteria (subjects graded as NYHA Class III or IV at screening must meet one of the following, while subjects graded as NYHA Class II at screening must meet both of the following):&lt;br&gt;• history of hospitalization for HF &gt;1 month and =12 months prior to the screening&lt;br&gt;visit, or documented, unscheduled outpatient treatment with intravenous (IV)&lt;br&gt;diuretics, IV vasodilators, or IV inotropic medications &gt;1 month and =12 months&lt;br&gt;prior to the screening visit&lt;br&gt;• documented BNP =150 pg/mL, or NTproBNP =500 pg/mL, within the 12 months&lt;br&gt;prior to Day 1.&lt;br&gt;5. Must have renal insufficiency as defined by a reduced estimated glomerular filtration rate (eGFR) at the time of screening =20 and =70 mL/min/1.73 m2, as determined by the Modification of Diet in Renal Disease (MDRD) equation (abbreviated version).&lt;br&gt;6. Must be on an oral loop diuretic for at least the 4 weeks prior to Day 1. Dose&lt;br&gt;adjustments are allowed within the 4 weeks prior to Day 1, but the dose on Day 1 must be within 50% to 200% of the dose the subject was receiving at 4 weeks prior to Day 1.&lt;br&gt;The introduction or withdrawal of any other class of diuretic (i.e., thiazide diuretics) is&lt;br&gt;not allowed within the 4 weeks prior to Day 1&lt;br&gt;7. Subjects with a reduced LVEF (=40%) documented during screening must be on a&lt;br&gt;pharmacological treatment regimen for HF for at least the 4 weeks prior to Day 1. The&lt;br&gt;HF regimen must include:&lt;br&gt;• treatment with a beta-blocker, unless contraindicated due to intolerance, and&lt;br&gt;• treatment with an angiotensin converting enzyme (ACE) inhibitor or angiotensin&lt;br&gt;receptor blocker (ARB), unless contraindicated due to intolerance.&lt;br&gt;Note: The dose of any of the HF medications listed above may be adjusted once within the 4 weeks prior to Day 1. This restriction also applies to subjects with LVEF &gt;40% if they are receiving treatment with beta-blockers, ACE inhibitors, and/or ARBs.&lt;br&gt;8. Women of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 2 months after their last dose of study treatment. For further details of contraceptive requirements for this study, please refer to Section 15.5.3. All female subjects of childbearing potential must have a negative pregnancy test on Screening Day and Day 1.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. History of an allergic reaction to any xanthine-containing compound.&lt;br&gt;2. History of seizure within the past 10 years or use of any medication for the suppression of seizures within the past 5 years.&lt;br&gt;3. Within the past 2 years, history of head injury with loss of consciousness, stroke, or transient ischemic attack.&lt;br&gt;4. History of multiple sclerosis, Alzheimer’s disease, mental retardation,&lt;br&gt;meningitis/encephalitis, brain surgery, or penetrating head trauma.&lt;br&gt;5. History of, or prior neuroimaging evidence of, intracranial pathology known to increase the risk of seizure such as brain tumors of any kind (including meningioma),&lt;br&gt;arteriovenous malformation, cerebral cavernous malformation, hydrocephalus, or&lt;br&gt;encephalomalacia.&lt;br&gt;6. History consistent with illicit use of drugs or alcohol abuse within 6 months prior to&lt;br&gt;Day 1.&lt;br&gt;7. Hospitalization for HF within 30 days of Day 1.&lt;br&gt;8. Myocardial infarction (MI) within 30 days of Day 1.&lt;br&gt;9. Hemodynamically destabilizing arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation) within 30 days of Day 1.&lt;br&gt;10. Cardiac surgery within 60 days prior to Day 1.&lt;br&gt;11. Uncorrected hemodynamically significant primary valvular disease.&lt;br&gt;12. Known obstructive or restrictive cardiomyopathy.&lt;br&gt;13. Currently receiving chronic renal replacement therapy (e.g., hemodialysis or peritoneal dialysis).&lt;br&gt;14. Receiving adenosine or xanthine-based agents (e.g., aminophylline, theophylline,&lt;br&gt;pentoxifylline, or dyphylline).&lt;br&gt;15. Receiving clozapine or metronidazole within 5 days of screening, during the screening period, or anticipated use during study drug treatment.&lt;br&gt;16. Regular consumption of excessive amounts of caffeinated beverages (e.g., &gt;72 ounces [2.13 liters or 9 cups] of coffee/day).&lt;br&gt;17. Initiation of cardiac resynchronization treatment within 30 days prior to Day 1.&lt;br&gt;18. Serious systemic infection (e.g., septicemia) or major surgical procedures within the 30 days prior to Day 1.&lt;br&gt;19. Fever, with body temperature &gt;38oC, within the 48 hours prior to first dose.&lt;br&gt;20. Evidence of malignancy within 6 months prior to Day 1. Subjects with a history of&lt;br&gt;stable prostate cancer, basal cell carcinomas, or fewer than 3 squamous cell carcinomas are eligible.&lt;br&gt;21. Likelihood, in the Investigator’s opinion, of undergoing cardiac transplantation, left ventricular assist device (LVAD) or other device implantation, or other cardiac surgerywithin next 3 months; or of requiring continuous IV inotropic treatment, or referral for hospice or end of life treatment.&lt;br&gt;22. Sustained systolic blood pressure &gt;170 or &lt;90 mmHg at Screening Day or Day 1.&lt;br&gt;23. Screening laboratory findings as follows (Screening laboratory tests should be&lt;br&gt;performed at the central laboratory):&lt;br&gt;• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =3 times the&lt;br&gt;upper limit of normal, or&lt;br&gt;• Total bilirubin &gt;2.0 mg/dL.&lt;br&gt;24. Nursing mothers, pregnant women, or women planning on becoming pregnant during&lt;br&gt;the study.&lt;br&gt;25. Participation in any other investigational study of drugs or devices within 30 days prior&lt;br&gt;to Day 1.&lt;br&gt;26. Unwillingness to comply with protocol-required procedures.&lt;br&gt;27. Presence of any clinically significant (as determined by the Investigator)&lt;br&gt;endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,&lt;br&gt;neurologic, dermatologic, psychiatric, and/or other major disease that might interfere&lt;br&gt;with optimal safe participation in this study.&lt;br&gt;28. Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject un</Exclusion_Criteria>
    <Condition>Heart Failure and Renal Insufficiency. &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038474
Term: Renal insufficiency
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10019279
Term: Heart failure
</Condition>
    <Intervention>&lt;br&gt;Product Name: Adentri&lt;br&gt;Product Code: Tonapofylline&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 340021-17-2&lt;br&gt;Current Sponsor code: Tonapofylline&lt;br&gt;Other descriptive name: Adentri&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 7.5-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Product Name: Adentri&lt;br&gt;Product Code: Tonapofylline&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 340021-17-2&lt;br&gt;Current Sponsor code: Tonapofylline&lt;br&gt;Other descriptive name: Adentri&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 37.5-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to assess the safety and tolerability of Tonapofylline administered to subjects with heart failure and renal insufficiency;Secondary Objective: The secondary objectives of this study are to assess the effect of Tonapofylline on the following in subjects with heart failure and renal insufficiency:&lt;br&gt;• Quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ)&lt;br&gt;• Exercise capacity as measured by 6-minute walk distance&lt;br&gt;• Renal function as assessed by serum creatinine and Cystatin-C&lt;br&gt;• Concomitant medications used to treat heart failure;Primary end point(s): The safety and tolerability of Tonapofylline administered to subjects with stable heart failure and renal insufficiency. This objective will be evaluated by the incidence of AEs and SAEs, clinically abnormal physical examinations and vital signs, shifts to outside the normal ranges in laboratory parameters, and electrocardiogram results.</Primary_outcome>
    <Secondary_ID>161HF201</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2477996</Internal_Number>
    <TrialID>EUCTR2008-008676-13-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer - SUN-CYCL (Sunitinib + Cyclophosphamide in RCC)</Public_title>
    <Scientific_title>A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer - SUN-CYCL (Sunitinib + Cyclophosphamide in RCC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>The Royal Marsden NHS Foundation Trust</Primary_sponsor>
    <Date_registration3>20090626</Date_registration3>
    <Date_registration>26/06/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008676-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/08/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients with advanced renal cell carcinoma suitable for 1st line therapy with sunitinib&lt;br&gt;2. Histologically or cytologically confirmed advanced renal cell carcinoma&lt;br&gt;3. The presence of one or more clinically or radiographically measurable lesions&lt;br&gt;4. ECOG performance status 0 or 1&lt;br&gt;5. Life expectancy greater than 12 weeks&lt;br&gt;6. At least 14 days since major surgery and 7 days since skin/tumour biopsy&lt;br&gt;7. The capacity to understand the patient information sheet and the ability to provide written informed consent&lt;br&gt;8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures&lt;br&gt;9. Male or female, age 18 or greater&lt;br&gt;10. Women must be postmenopausal (no menstrual period for a minimum of 1 year) or have a negative serum pregnancy test on entry in the study (even if surgically sterilized).  Men and women of childbearing potential must use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last study treatment&lt;br&gt;11. Serum aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 x upper limit of normal (ULN) &lt;br&gt;12. Total serum bilirubin =1.5 x ULN &lt;br&gt;13. Serum creatinine =1.5 x ULN &lt;br&gt;14. Haemoglobin =9.0 g/dL&lt;br&gt;15. Absolute neutrophil count =1.5 x 109/L &lt;br&gt;16. Platelets =100 x 109/L  &lt;br&gt;17. Prothrombin time (PT) =1.5 x ULN &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Current signs or symptoms of severe progressive or uncontrolled hepatic, haematologic, gastrointestinal, endocrine, pulmonary or cardiac disease other than directly related to RCC&lt;br&gt;2. Intracranial disease, unless there has been radiological evidence of stable intracranial disease &gt; 6 months. In the case of a solitary brain metastasis, evidence of a disease-free interval of at least 3 months post surgery.  All patients previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days&lt;br&gt;3. Previous systemic treatment for metastatic renal cell carcinoma.  Palliative radiotherapy to symptomatic disease sites is permitted&lt;br&gt;4.  Women who are pregnant, nursing, or planning pregnancy within 6 months after the last treatment (this includes men who plan to father a child within 6 months of the last treatment) &lt;br&gt;5. Malignancy other than the condition being treated or a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence&lt;br&gt;6. Use of any investigational drug within 30 days prior to screening &lt;br&gt;7. History of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results &lt;br&gt;8. Uncontrolled hypertension or hypertension treated with 2 or more anti-hypertensive agents&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic Renal Cell Carcinoma &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;CAS Number:  341031-54-7&lt;br&gt;Current Sponsor code: Sunitinib&lt;br&gt;Other descriptive name: Sutent&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Cyclophosphamide&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CYCLOPHOSPHAMIDE&lt;br&gt;CAS Number: 50180&lt;br&gt;Current Sponsor code: CYCLOPHOSPHAMIDE&lt;br&gt;Other descriptive name: CYCLOPHOSPHAMIDE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50.0-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;CAS Number:  341031-54-7&lt;br&gt;Current Sponsor code: Sunitinib&lt;br&gt;Other descriptive name: Sutent&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 12.5-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Sunitinib&lt;br&gt;CAS Number:  341031-54-7&lt;br&gt;Current Sponsor code: Sunitinib&lt;br&gt;Other descriptive name: Sutent&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Maximum tolerated dose (MTD) of the combination of sunitinib and cyclophosphamide and response rate (complete and partial response);Secondary Objective: 1) Toxicity of treatment&lt;br&gt;2) Progression-free and overall survival&lt;br&gt;3) Correlation between biological markers in original nephrectomy specimen (if available) or on-study biopsies with clinical outcome and serum biomarkers including circulating tumour cells&lt;br&gt;4) CT and PET assessment of tumour blood flow / disease activity&lt;br&gt;5) Recrudescence of symptoms/signs during the 2 week interval off sunitinib&lt;br&gt;;Primary end point(s): Maximum tolerated dose (MTD) of the combination of sunitinib and cyclophosphamide and response rate (complete and partial response)</Primary_outcome>
    <Secondary_ID>CCR3164</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478268</Internal_Number>
    <TrialID>EUCTR2009-009516-44-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomised, open label, parallel group Phase II study comparing the
efficacy and tolerability of BIBF 1120 versus sunitinib in previously
untreated patients with Renal Cell Cancer. - BIBF 1120 in 1st line Renal Cell Carcinoma</Public_title>
    <Scientific_title>A randomised, open label, parallel group Phase II study comparing the
efficacy and tolerability of BIBF 1120 versus sunitinib in previously
untreated patients with Renal Cell Cancer. - BIBF 1120 in 1st line Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Boehringer Ingelheim</Primary_sponsor>
    <Date_registration3>20090901</Date_registration3>
    <Date_registration>01/09/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009516-44                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>27/10/2009</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Patients with unresectable or metastatic Renal Cell Cancer, who have &lt;br&gt;                received no previous systemic anti-cancer treatment.&lt;br&gt;•	Histological-confirmed diagnosis of renal cell cancer with clear cell &lt;br&gt;                component.&lt;br&gt;•	Age = 18 years.  &lt;br&gt;•	ECOG Performance Score 0 or 1.&lt;br&gt;•	Life expectancy of at least 3 months&lt;br&gt;•	Must have measurable disease according to RECIST, i.e. presence of at &lt;br&gt;                least  one target lesion according to RECIST criteria in a previously &lt;br&gt;                non-irradiated area&lt;br&gt;•	Serum creatinine &lt; 2 x ULN.&lt;br&gt;•	Written informed consent consistent with ICH-GCP guidelines.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Serious illness or concomitant non-oncological disease such as neurologic, &lt;br&gt;                psychiatric, infectious disease or active ulcers (gastro-intestinal tract, &lt;br&gt;                skin) or laboratory abnormality that may increase the risk associated with &lt;br&gt;                study participation or study drug administration and in the judgment of     &lt;br&gt;                the investigator would make the patient inappropriate for entry into the &lt;br&gt;                study.&lt;br&gt;•	Major injuries, bone fracture and/or surgery within past 4 weeks or/ and &lt;br&gt;                planned surgical procedures during the study period.&lt;br&gt;•	Hypersensitivity to BIBF 1120, sunitinib or the excipients of the study &lt;br&gt;                drugs.&lt;br&gt;•	Significant cardiovascular diseases (i.e. uncontrolled hypertension, &lt;br&gt;                unstable angina, history of infarction within past 12 months, congestive &lt;br&gt;                heart failure &gt; NYHA II, serious cardiac arrhythmia).&lt;br&gt;•	LV-EF (left ventricular ejection fraction) by ECHO or MUGA below local &lt;br&gt;                 limits of normal.&lt;br&gt;•	Hepatic function: total bilirubin outside of normal limits; ALT and &lt;br&gt;                AST &gt; 1.5x upper limit of normal (ULN) in patients without liver metastasis.&lt;br&gt;                For patients with liver metastasis: total bilirubin outside of normal &lt;br&gt;                limits, ALT and AST &gt; 2.5x ULN.  &lt;br&gt;•	Coagulation parameters: international normalised ratio (INR) &gt; 2,&lt;br&gt;                prothrombin time (PT) and partial thromboplastin time (PTT) &gt; 50% of &lt;br&gt;                deviation of institutional ULN. &lt;br&gt;•	Absolute neutrophil count (ANC) &lt; 1500/ml, Platelets &lt;100000/ml, &lt;br&gt;                Haemoglobin &lt;9.0 g/dl.  &lt;br&gt;•	History of clinically significant haemorrhagic or thromboembolic event in  &lt;br&gt;                the past 6 months. &lt;br&gt;•	Known inherited predisposition to bleeds or to thrombosis.&lt;br&gt;•	History of clinically significant haemoptysis within the last 3 months (more&lt;br&gt;                than one tea-spoon of fresh blood per day)&lt;br&gt;•	Therapeutic anticoagulation (except low-dose heparin and/or heparin flush &lt;br&gt;                as needed for maintenance of an in-dwelling intravenous device) or anti-&lt;br&gt;                platelet therapy (except for low-dose therapy with acetylsalicylic acid &lt;br&gt;                &lt; 325mg per day).&lt;br&gt;•	Previous treatment for RCC with targeted agents (in particular including &lt;br&gt;                any antibody and any VEGF/VEGFR, EGFR and mTOR inhibitors), &lt;br&gt;                immunotherapy [Interferon (IFNa) or Interleukin-2 (IL-2)] or chemotherapy.&lt;br&gt;•	Treatment with other investigational drugs or participation in another &lt;br&gt;                clinical study within the past 4 weeks before start of therapy or &lt;br&gt;                concomitantly with this study.&lt;br&gt;•	Patients unable to comply with the protocol.&lt;br&gt;•	Pregnancy or breast feeding.&lt;br&gt;•	Active alcohol or drug abuse.&lt;br&gt;•	Women of child bearing potential, or men who are able to father a child, &lt;br&gt;                unwilling to use a medically acceptable form of contraception during the &lt;br&gt;                study period.&lt;br&gt;•	Symptomatic central nervous system (CNS) metastatis or leptomeningeal &lt;br&gt;                disease as documented by CT, MRI or analysis of cerebrospinal fluid &lt;br&gt;                requiring radiotherapy, steroids or anticonvulsive treatment.&lt;br&gt;•	Radiotherapy within the previous 4 weeks.&lt;br&gt;•	QTcF interval &gt; 500 ms at screening&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced unresectable or metastatic Renal Cell Cancer in patients who have received no previous systemic anti-cancer treatment. &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: N/A&lt;br&gt;Product Code: BIBF 1120&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;CAS Number: 656247-18-6&lt;br&gt;Current Sponsor code: BIBF 1120&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Code: BIBF 1120&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;CAS Number: 656247-18-6&lt;br&gt;Current Sponsor code: BIBF 1120&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: SUNITINIB&lt;br&gt;CAS Number: 557795-19-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 12.5-&lt;br&gt;&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: SUNITINIB&lt;br&gt;CAS Number: 557795-19-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the efficacy and safety of BIBF 1120 and sunitinib to treat patients with Renal Cell Cancer. An additional objective of the 1199.26 study is to assess the effects of BIBF 1120 treatment on the QTcF interval.&lt;br&gt;&lt;br&gt;;Secondary Objective: Efficacy&lt;br&gt;- Progression Free Survival.&lt;br&gt;- Objective tumour response.&lt;br&gt;- Duration of Objective Response.&lt;br&gt;- Overall Survival.&lt;br&gt;- Time to treatment failure.&lt;br&gt;- Time to progression.&lt;br&gt;&lt;br&gt;ECG - BIBF 1120 patients only&lt;br&gt;- Change of the QTcF interval from baseline to each patients maximum dose of BIBF 1120 concentration.&lt;br&gt;- Time averaged QTcF interval over 1 to 12 hours.&lt;br&gt;&lt;br&gt;Safety&lt;br&gt;- Frequency of all Adverse Events, including laboratory parameters, graded by NCI-CTCAEv3.&lt;br&gt;- Dose related dose reductions and discontinuation rates.&lt;br&gt;- Number and duration of hosptal stays due to Adverse Events.&lt;br&gt;&lt;br&gt;Pharmacokinetics&lt;br&gt;- PK characteristics of BIBF 1120 after a single dose and at steady state (Day 15).;Primary end point(s): 1. Progression Free Survival in patients treated with either sunitinib or BIBF 1120.&lt;br&gt;&lt;br&gt;2. For patients treated with BIBF 1120 only - Change from baseline to endpoint (day 15) of the QTcF interval at each point in time.</Primary_outcome>
    <Secondary_ID>1199.26</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478421</Internal_Number>
    <TrialID>EUCTR2009-013219-37-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma</Public_title>
    <Scientific_title>A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>AVEO Pharmaceuticals, Inc.</Primary_sponsor>
    <Date_registration3>20091013</Date_registration3>
    <Date_registration>13/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013219-37                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>02/02/2010</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. = 18-years of age.&lt;br&gt;&lt;br&gt;2. Subjects with recurrent or metastatic RCC.&lt;br&gt;&lt;br&gt;3. Subjects must have undergone prior nephrectomy (complete or partial) for excision of the primary tumor.&lt;br&gt;&lt;br&gt;4. Histologically or cytologically confirmed RCC with a clear cell component (subjects with pure papillary cell tumor or other non-clear cell histologies, including collecting duct, medullary, chromophobe, mixed tumor containing predominantly sarcomatoid cells, and unclassified RCC are excluded).&lt;br&gt;&lt;br&gt;5. Measurable disease per the RECIST criteria Version 1.0 (see Appendix A). Measurable disease must be verified by an independent radiologist prior to randomization.&lt;br&gt;&lt;br&gt;6. Treatment naïve subjects or subjects who have received no more than one prior systemic treatment (immunotherapy, including interferon-alfa or interleukin-2 based therapy, chemotherapy, hormonal therapy or an investigational agent) for metastatic RCC. Postoperative or adjuvant systemic therapy will not be counted as a prior therapy unless recurrence is detected within 6 months of completion of treatment, in which case it will be counted as a prior therapy for metastatic disease.&lt;br&gt;&lt;br&gt;7. ECOG performance status of 0 or 1, and life expectancy = 3 months (see Appendix B).&lt;br&gt;&lt;br&gt;8. If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.&lt;br&gt;&lt;br&gt;9. Ability to give written informed consent and comply with protocol requirements.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Any prior VEGF-directed therapy including VEGF antibody (eg, bevacizumab), VEGF receptor tyrosine kinase inhibitor (eg, sunitinib, sorafenib, axitinib, pazopanib, etc.), VEGF trap (eg, aflibercept), or any other agent or investigational agent targeting the VEGF pathway.&lt;br&gt;&lt;br&gt;2. Any prior therapy with an agent targeting the mTOR pathway (eg, temsirolimus, everolimus, etc)&lt;br&gt;&lt;br&gt;3. Primary CNS malignancies or symptomatic CNS metastases; subjects with previously treated brain metastasis will be allowed if the brain metastasis have been stable without steroid treatment for at least 3 months following prior treatment (radiotherapy or surgery).&lt;br&gt;&lt;br&gt;4. Any listed hematologic abnormalities&lt;br&gt;&lt;br&gt;5. Any listed serum chemistry abnormalities&lt;br&gt;&lt;br&gt;6. Significant cardiovascular disease&lt;br&gt;&lt;br&gt;7. Non-healing wound, bone fracture, or skin ulcer.&lt;br&gt;&lt;br&gt;8. Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug&lt;br&gt;&lt;br&gt;9. Serious/active infection or infection requiring parenteral antibiotics.&lt;br&gt;&lt;br&gt;10. Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug.&lt;br&gt;&lt;br&gt;11. Significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug, including but not limited to: Deep vein thrombosis Pulmonary embolism Cerebrovascular accident (CVA) or transient ischemic attach (TIA) Peripheral arterial ischemia &gt; Grade 2 Coronary or peripheral artery bypass graft.&lt;br&gt;&lt;br&gt;12. Significant bleeding disorders within 6 months prior to administration of first dose of study drug, including but not limited to. Hematemesis, hematochezia, melena or other gastrointestinal bleeding Grade =2 Hemoptysis or other pulmonary bleeding Grade =2 Hematuria or other genitourinary bleeding Grade =2&lt;br&gt;&lt;br&gt;13. Currently active second primary malignancy, including hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer and ductal or lobular carcinoma in situ of the breast. Subjects are not considered to have a currently active malignancy if they have completed anti-cancer therapy and have been disease free for &gt;2 years.&lt;br&gt;&lt;br&gt;14. Pregnant or lactating females.&lt;br&gt;&lt;br&gt;15. History of genetic or acquired immune suppression disease such as HIV; subjects on immune suppressive therapy for organ transplant.&lt;br&gt;&lt;br&gt;16. Life-threatening illness or organ system dysfunction compromising safety evaluation.&lt;br&gt;&lt;br&gt;17. Requirement for hemodialysis or peritoneal dialysis.&lt;br&gt;&lt;br&gt;18. Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of tivozanib or sorafenib, major resection of the stomach or small bowel, or gastric bypass procedure.&lt;br&gt;&lt;br&gt;19. Psychiatric disorder or altered mental status precluding informed consent or necessary testing.&lt;br&gt;&lt;br&gt;20. Sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures, while on study and for at least 50 days after the last dose of study drug. Sexually active male subjects must use adequate contraceptive measures, while on study and for at least 90 days after the last dose of study drug. All fertile male and female subjects must agree to use a h</Exclusion_Criteria>
    <Condition>Advanced Renal Cell Carcinoma &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10038410
Term: Renal cell carcinoma recurrent
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10050513
Term: Metastatic renal cell carcinoma
</Condition>
    <Intervention>&lt;br&gt;Product Name: AV-951&lt;br&gt;Product Code: Tivozanib&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 682745-41-1&lt;br&gt;Current Sponsor code: Tivozanib (AV-951)&lt;br&gt;Other descriptive name: KRN951&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Product Name: Tivozanib (AV-951)&lt;br&gt;Product Code: 1.5 mg&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 682745-41-1&lt;br&gt;Current Sponsor code: Tivozanib (AV-951)&lt;br&gt;Other descriptive name: KRN951&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.5-&lt;br&gt;&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Product Name: Nexavar&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: SORAFENIB&lt;br&gt;CAS Number: 284461-73-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the progression-free survival (PFS) of subjects with advanced renal cell cancer (RCC) randomized to treatment with tivozanib or sorafenib;Secondary Objective: To compare the overall survival (OS) of subjects randomized to treatment with tivozanib or sorafenib &lt;br&gt;&lt;br&gt;To compare objective response rate (ORR) and duration of response (DR) of subjects randomized to treatment with tivozanib or sorafenib &lt;br&gt;&lt;br&gt;To compare the safety and tolerability of tivozanib and sorafenib &lt;br&gt;&lt;br&gt;To compare kidney-specific symptoms and health outcome measurements in subjects randomized to treatment with tivozanib or sorafenib &lt;br&gt;&lt;br&gt;To evaluate the pharmacokinetics (PK) of tivozanib;Primary end point(s): To compare the progression-free survival (PFS) of subjects with advanced renal cell cancer (RCC) randomized to treatment with tivozanib or sorafenib</Primary_outcome>
    <Secondary_ID>AV-951-09-301</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2478483</Internal_Number>
    <TrialID>EUCTR2009-016088-13-FI</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pregabaliinin vaikutus leikkauskipuun ja toipumiseen munuaisensiirtopotilailla</Public_title>
    <Scientific_title>Pregabaliinin vaikutus leikkauskipuun ja toipumiseen munuaisensiirtopotilailla                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>Kirurgisen sairaalan munuaisensiirtoihin liittyvän kivun hoidon tutkimusryhmä</Primary_sponsor>
    <Date_registration3>20091020</Date_registration3>
    <Date_registration>20/10/2009</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016088-13                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>31/12/2009</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Kaikkien tutkimuksen aikana munuaisensiirtoleikkausta varten HYKS Kirurgisen sairaalan osastolle 9 kutsuttujen potilaiden mahdollinen sopivuus tutkimuspotilaiksi arvioidaan.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Krooninen opioidilääkitys, krooninen gabapentinoidien käyttö, kyvyttömyys kommunikoida suomen tai ruotsin kielellä, anestesialääkärin arvioima potilaan kyvyttömyys käyttää PCA (patient controlled analgesia) kivunhoitomenetelmää leikkauksen jälkeen, kyvyttömyys käyttää NRS (numeral rating scale) kivunmittausmenetelmää, allergia pregabaliinille, oksikodonille, propofolille tai remifentaniilille, tai potilaan paino &lt; 40 kg tai &gt; 120 kg.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients who receive kidney transplant &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10023438
Term: Kidney transplant
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10054711
Term: Postoperative pain
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10054048
Term: Postoperative ileus
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10028818
Term: Nausea postoperative
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10061243
Term: Post procedural nausea
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10036238
Term: Postoperative vomiting
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10047707
Term: Vomiting postoperative
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10039897
Term: Sedation
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10040760
Term: Situational anxiety
 &lt;br&gt;MedDRA version: 12.0
Level: LLT
Classification code 10002855
Term: Anxiety
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Lyrica&lt;br&gt;Product Name: Lyrica&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 148553-50-8&lt;br&gt;Other descriptive name: PREGABALIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-300&lt;br&gt;&lt;br&gt;Trade Name: Diapam&lt;br&gt;Product Name: Diapam&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;CAS Number: 439-14-5&lt;br&gt;Other descriptive name: DIAZEPAM&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 7,5-15&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Tämän prospektiivisen, randomisoidun, kaksoissokkoutetun tutkimuksen tarkoituksena on tutkia pregabaliiniesilääkityksen vaikutusta opioidin kulutukseen 24 tuntia leikkauksen jälkeen, mikä on tutkimuksen päälopputulosmuuttuja. Hypoteesina on että pregabaliinia esilääkkeeksi saaneet potilaat tarvitsevat vähemmän opioideja postoperatiivisesti kuin diatsepaamilla esilääkityt, jolloin opioidien sivuvaikutukset kuten pahoinvointi ja ummetus vähenevät.;Secondary Objective: Lisäksi tutkitaan pregabaliinin vaikutusta jännittyneisyyteen ja väsymykseen ennen leikkausta sekä kipuun, pahoinvointiin, oksenteluun, huimaukseen, väsymykseen, toimin-takykyyn, mielialaan, katetrin aiheuttamaan virtsarakon ärsytykseen ja suolen toimintaan leikkauksen jälkeen. Koska pregabaliini eliminoituu normaalisti munuaisten kautta, määritetään lisäksi sen pitoisuus annostelun jälkeen sen farmakokinetiikan muutosten selvittämiseksi. Hypoteesina on että pregabaliinia esilääkkeeksi saaneet potilaat tarvitsevat vähemmän opioideja postoperatiivisesti kuin diatsepaamilla esilääkityt, jolloin opioidien sivuvaikutukset kuten pahoinvointi ja ummetus vähenevät. Näiden esiintymistä seurataan 14 vuorokauden ajan.;Primary end point(s): Opioidin (PCA-laitteella annostellun oksikodonin) kulutus 24 tuntia leikkauksen jälkeen.</Primary_outcome>
    <Secondary_ID>Kirkipu 09-1</Secondary_ID>
  </Trial>
</Trials_downloaded_from_ICTRP>